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Abstract 
The retroviral structural proteins (encoded by gag) are not merely the architecture of the 
virus but carry out a diverse set of functions throughout the viral life cycle. Initially 
translated as a polyprotein, the Gag protein functions to encapsidate the genome and 
assemble retroviral particles at the budding sites. This polyprotein is then cleaved into 
the mature proteins: matrix (MA), capsid (CA) and nucleocapsid (NC) upon viral 
release. Most retroviruses also contain a small protein between MA and CA of unknown 
function. In Moloney murine leukaemia virus (Mo-MLV) this protein is p12. p12 
contains the late-domain, required for recruiting ESCRT machinery to promote virus 
budding, but also contains regions that have been shown to be important during the 
early stages of infection  
The aim of my PhD project was to establish the function of p12 during the early stages 
of infection and, in doing so, shed some light on the enigmatic processes occurring 
during these stages. Initially, the phenotypes of Mo-MLV virus-like particles (VLPs) 
containing previously identified p12 mutations were further characterised. Importantly, 
we found that these p12 mutations were clustered into two domains, both of which are 
required for Mo-MLV infectivity. Using genetic approaches, the order in which these 
domains act during infection was established. Furthermore, individual alanine mutants 
highlighted the residues within these domains that are essential for Mo-MLV 
infectivity. 
The conservation of p12 function was analysed by creating analogous p12 mutations in 
other gammaretroviruses. While the whole C-terminal domain was essential, some 
viruses contained dispensable portions of the N-terminal domain. Chimeric viruses were 
constructed between Mo-MLV and Gibbon ape leukemia virus (GaLV) to further assess 
the conservation of p12 function. 
Using biochemical, genetic and microscopic approaches, potential functions have been 
ascribed for the N- and C-terminal domains, allowing a model to be postulated for p12 
function during the early stages of infection. This model proposes that the N-terminal 
domain of p12 binds to a virus specific factor which ties it to the pre-integration 
complex (PIC) and also stabilises the CA core. The C-terminal domain then comes into 
play during mitosis, tethering the PIC to the chromosomes and aiding integration. 
Therefore, the last gammaretroviral Gag protein to be given a functional name has a 
large role to play in replication. Further understanding of p12, building on the work 
presented in this thesis, could aid in the design of gene transfer vectors with more 
precise integration targeting, and potentially will lead to improved understanding of 
early replication events that could enhance therapeutics against more complex 
retroviruses that cause human disease. 
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Chapter 1.  
Introduction 
Many viruses pose a significant health risk for both humans and animals, being the 
cause some of the largest epidemics in recent history. Viruses are completely reliant on 
a host for replication and have evolved to hijack various cellular processes to 
manipulate the host into producing progeny virus. Viral proteins mediate essential 
interactions between the virus and proteins of the host to carry out replication. A fuller 
understanding of the interactions between the host and virus can lead to the 
development of novel therapeutics against human disease. Furthermore, as many 
pathways exploited by viruses are essential for the cell, information on vital cellular 
processes can be derived from the study of virus replication. 
 
1.1 An historical introduction to retrovirology 
The discovery of retroviruses 
The first isolation of a retrovirus came at the turn of the twentieth century, when 
Ellerman and Bang isolated a 'filterable agent' as the cause of a transmissible chicken 
leukosis (reviewed in (Coffin, Hughes, and Varmus, 1997b)). At the time, however, 
their work was largely ignored as the scientific community did not recognise leukaemia 
as a neoplastic disease until the 1930s (Van Epps, 2005). Similarly, the description by 
Peyton Rous, of a filterable agent capable of transmitting a neoplasmic disease between 
chickens was not widely regarded as having relevance to human disease (Rous, 1910; 
Van Epps, 2005). However, Rous was later vindicated as his discovery of 'tumour-
inducing viruses' earned him a share of the Nobel Prize in Physiology or Medicine in 
1966. As cell culture techniques improved (Temin and Rubin, 1958), additional 
oncogenic viruses were discovered, including those responsible for mammalian diseases 
(Bittner, 1936; Gross, 1957). 
 
The proviral hypothesis and reverse transcriptase (RT) 
Molecular characterisation of these filterable agents revealed them to be single stranded 
RNA viruses, although their replication was unlike other RNA viruses, known at the 
time. No double-stranded RNA was detected during infection and replication was found 
to be sensitive to inhibitors of DNA synthesis (Bader, 1965; Temin, 1963). Howard 
Temin proposed the proviral hypothesis, controversial at the time, stating that these 
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RNA viruses replicated through a DNA copy of their RNA genome (Temin, 1964). This 
hypothesis went against the popular central dogma of molecular biology, proposed by 
Francis Crick, that genetic information flows from DNA, to RNA, to protein. Temin's 
proviral hypothesis was corroborated and generally accepted upon the discovery of the 
virally encoded RNA-dependant DNA polymerase, reverse transcriptase (RT) 
(Baltimore, 1970; Temin and Mizutani, 1970).   
 
Retroviruses and human disease 
The first human oncogenic retrovirus discovered was human T-cell leukaemia virus 
(HTLV-1), found to be the cause of an abnormally high incidence of adult T-cell 
leukaemia on two islands in Japan (Poiesz et al., 1980). Not long after, the virus with 
causative links to the acquired immunodeficiency syndrome (AIDS) epidemic was 
isolated, originally known as LAV, HTLV-3 or ARV, but now known as human 
immunodeficiency virus 1 (HIV-1) (Barre-Sinoussi et al., 1983; Gallo et al., 1984; Levy 
et al., 1984). Since then much research has been devoted to HIV-1 replication and has 
led to the development of a therapy, called highly active anti-retroviral treatment 
(HAART) (Montagnier, 2010; Richman et al., 2009). Unfortunately, this treatment is 
life-long and cessation of HAART results in the rebound of viral titres (Chun et al., 
2000). Access to HAART has improved since its introduction but the number of new 
HIV infections each year remains high. The search for an HIV-1 vaccine remains a high 
priority, however, despite much research no successful candidates have reached the 
clinic. 
 
Retroviral vectors and gene therapy 
Many congenital diseases are caused by the loss of a single gene product. The most 
straightforward approach to curing these types of genetic disease is by introduction of a 
functional copy of the defective gene into the individual. Retroviral based vectors hold 
great promise for gene therapy due to the fact that they stably integrate their genome 
into host chromosomes, although significant safety issues remain regarding their use in 
humans (Naldini et al., 1996). This issue was highlighted by the use of a 
gammaretroviral vector to supply a γC cytokine receptor subunit to patients with severe 
combined immunodeficiency X1, an inherited immune disease where T-cell and NK 
cells are absent in the affected individuals (Cavazzana-Calvo et al., 2000). While the 
treatment restored T-cells and NK cells in 9/10 patients, two patients developed 
leukaemia due to integration adjacent to the LM02 proto-oncogene promoter (Hacein-
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Bey-Abina et al., 2003). Two further cases of leukaemia in patients from this trial have 
now been described, as well as cases from other similar gene therapy trials (Hacein-
Bey-Abina et al., 2008; Howe et al., 2008). Interestingly, in all cases the mutagenesis 
causing the activated proto-oncogene expression is accompanied by an array of other 
genetic rearrangements (not directly caused by the gammaretroviral vector), which in 
combination have led to the development of leukaemia (Hacein-Bey-Abina et al., 2008; 
Howe et al., 2008).  
 
Newer generations of gene transfer vectors (self-inactivating, SIN) containing deletions 
in the enhancer/promoter regions of the long terminal repeats (LTRs) have been created. 
In SIN vectors the therapeutic gene is driven from an internal cellular promoter, which 
reduces the chances of proto-oncogene activation (Montini et al., 2006). Insulator 
sequences can also be inserted before the cellular promoter to further reduce the chances 
of enhanced local proto-oncogene transcription (Ramezani, Hawley, and Hawley, 
2008). While the new vector designs have increased the safety of retroviral-based 
vectors, further insight into integration targeting mechanisms of retroviruses will aid in 
the design of safer site-specific gene therapy vectors. 
 
1.2 Retrovirus classification 
The retrovirus family is divided into two subfamilies: the orthoretroviridae and the 
spumretroviridae. Orthoretroviridae are further divided into six genera: alpha-, beta-, 
gamma-, delta-, epsilon- retrovirus and lentivirus (Figure 1.1). The spumaretroviridae 
contain one genus named spumavirus, viruses from which are genetically and 
phenotypically very distinct from any genus of the orthoretroviridae, and will not form a 
focus of this study. Retroviruses are grouped into their genera based on a range of viral 
characteristics including: the physical morphology of the virus, genomic sequence and 
structure, tRNA species used for reverse transcription, the presence of accessory 
proteins and the site of virus assembly. The terms simple and complex retroviruses are 
often used to broadly subcategorise retroviruses, where the genomes of simple 
retroviruses lack accessory genes (see section 1.4.4). 
  
The majority of the work described in this introduction derives from work on three 
prototypic retroviruses murine leukaemia virus (MLV, gammaretrovirus), Rous sarcoma 
virus (RSV, alpharetrovirus) and HIV (lentivirus). While these represent examples from 
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different genera and are thus somewhat divergent, there are similarities between many 
of their replication strategies. 
 
Figure 1.1: Phylogeny of retroviruses. Phylogenetic tree highlighting all seven retroviral 
genera from the Retroviridae family (adapted from (Weiss, 2006)). 
 
1.3 Genome organisation 
Retroviruses contain a dimer of viral RNA (gRNA) with a sedimentation coefficient of 
70S (Fu, Gorelick, and Rein, 1994; Mangel, Delius, and Duesberg, 1974), which is 
specifically packaged into the virus during assembly. Similar to eukaryotic mRNA, the 
viral genome contains a 5' cap (Furuichi et al., 1975) and a 3' polyadenylyl tail (poly-A-
tail) (Lai and Duesberg, 1972). During infection viral RNA is reverse transcribed into 
DNA, which is then integrated into the host DNA, to form the provirus. The genome is 
composed of non-coding regulatory sequences and sequences coding for the viral 
proteins (Figure 1.2).   
 
1.3.1 Non-coding regions 
The un-translated regions of the viral RNA include the unique 5' region (U5), unique 3' 
region (U3), repeated region (R), 5' gag leader (including the primer binding site, PBS) 
and the sequence 3' of env including the poly purine tract (ppt). These elements play 
roles in reverse transcription of the viral RNA into viral cDNA and transcription from 
the provirus (Gilboa et al., 1979). HIV-1 also contains an additional ppt called the cPPT 
(not shown in Figure 1.2), which is involved in synthesis of the plus-sense DNA during 
reverse transcription (Charneau and Clavel, 1991; Wain-Hobson et al., 1985). Reverse 
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transcription is initiated from a tRNA molecule bound to the PBS, which is tRNAPro for 
MLV and tRNALys for HIV-1 (Harada, Peters, and Dahlberg, 1979; Peters et al., 1977; 
Ratner et al., 1985). After reverse transcription the viral DNA product contains identical 
U3-R-U5 regions at both ends (Shank et al., 1978), referred to as the LTRs. Post-
integration the viral DNA remains flanked by the LTRs (Hughes et al., 1978), which 
contain promoter and enhancer sequences, important for transcription (Graves, 
Eisenman, and McKnight, 1985; Laimins et al., 1984; Ostrowski, Berard, and Hager, 
1981). 
 
 
Figure 1.2: Structure of the gammaretroviral genome and provirus. The structure of the 
MLV provirus is shown above the genomic RNA. Below are the protein products from the two 
spliced RNAs. 'Glyco-Gag', initiated from a CUG start codon in the 5' gag leader sequence, not 
shown. (Adapted from (Petropoulos, 1997)). 
 
1.3.2 Coding regions 
All retroviruses contain the three main genes gag, pol and env, arranged in this order 
from 5' to 3' in the genome (Coffin and Billeter, 1976; Coffin, Hughes, and Varmus, 
1997a). The gag gene encodes the structural proteins of the virus; pol encodes the viral 
enzymes and env, the components of the envelope glycoprotein complex. In 
gammaretroviruses translation of mRNA for pol is carried out by read-through of the 
stop codon at the end of gag (Yoshinaka et al., 1985a; Yoshinaka et al., 1985b). Thus 
the number of Gag molecules considerably outnumber that of Pol (Jamjoom, Naso, and 
Arlinghaus, 1977). Other retroviruses, like HIV-1, generate Pol via a ribosomal 
frameshift (Jacks et al., 1988). In contrast to Gag and Pol, Env is translated from a 
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spliced mRNA. Genetically complex retroviruses also contain additional genes that 
code for regulatory and accessory proteins. These are generally situated either between 
pol and env, 3' to env (including the U3 region) or a combination joined by splicing of 
these regions (Coffin, Hughes, and Varmus, 1997a). 
 
1.4 Viral proteins 
This next section will briefly introduce the viral proteins. p12 is intentionally omitted 
from this section and will be described in greater detail in a later section. 
 
1.4.1 Gag  
The most abundant viral proteins in the particle derive from the gag gene.  Retroviral 
Gag is synthesised on the ribosome as a polyprotein, which contains all the functions 
required to drive formation of virus-like particles (VLPs) (Gheysen et al., 1989). After 
viral release, protease (PR) cleaves Gag during maturation of the virus to produce the 
mature proteins: matrix (MA), capsid (CA) and nucleocapsid (NC) (Figure 1.2). 
Additionally, many retroviruses also contain other Gag cleavage products situated 
between the protein domains of Gag. Cleaved proteins between MA and CA are the 
largest of the additional Gag proteins and some retroviral genomes encode multiple 
proteins at this location (described in section 1.8).  
 
In Gag at least three functional domains have been described as essential for production 
of VLPs: membrane binding-domain (M-domain), interaction domain (I-domain) and 
late-domain (L-domain). MA contains the M-domain and drives localisation of Gag to 
the plasma membrane. For many retroviruses, like MLV and HIV, this is done via a co-
translational addition of a myristoyl group to the N-terminal glycine in MA (Bryant and 
Ratner, 1990; Gottlinger, Sodroski, and Haseltine, 1989; Henderson, Krutzsch, and 
Oroszlan, 1983; Rein et al., 1986). This modification is essential and mutation of the N-
terminal glycine blocks MLV release and Gag accumulates in the cytoplasm (Rein et 
al., 1986). However, additional sequences in MA are also important for the stabilisation 
of the MA association with the plasma membrane (Ono and Freed, 1999; Spearman et 
al., 1994; Zhou et al., 1994). RSV is different from MLV and HIV in this regard, while 
MA is still the M-domain it does not require myristoylation (Schultz and Oroszlan, 
1983; Verderame, Nelle, and Wills, 1996; Wills et al., 1991). After virus fusion and 
entry of the core to the cytoplasm, it is assumed that the majority of mature MA will 
remain with the virion membrane. 
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CA is the major structural protein for retroviruses and is composed of an N-terminal 
domain (NTD) and a C-terminal domain (CTD) connected by a linker. In Gag, CA 
contains part of the sequence making up the vital I-domain, important for Gag-Gag 
multimerisation. This sequence maps to the CTD, although some retroviruses do not 
require CA-CA contacts in Gag for assembly (Franke et al., 1994; Mammano et al., 
1994; von Poblotzki et al., 1993; Weldon and Wills, 1993). Little sequence homology 
exists between CA proteins from different retroviruses and the most conserved region is 
the major homology region (MHR) in the CTD (Mammano et al., 1994). Despite the 
lack of sequence homology between retroviral CA, the NTDs all contain a remarkably 
similar tertiary structure (Gamble et al., 1996; Gitti et al., 1996; Mortuza et al., 2008; 
Mortuza et al., 2009). Structural conservation has even been observed in the CA NTD 
from resurrected ancient endogenous lentiviruses RELIK and PSIV, highlighting this 
structure has been highly conserved in the evolution of retroviruses (Goldstone et al., 
2010). One major structural difference between gammaretroviral CA proteins and those 
from most lentiviruses is the absence of the so-called cyclophillin binding loop (Gamble 
et al., 1996). This loop is situated between helix 4 and 5 in the CA NTD and is extended 
in HIV-1 compared to MLV (Mortuza et al., 2004). Mature CA forms the core 
surrounding the ribonucleoprotein complex (RNP), which is released into the target 
cells. 
 
The last core Gag protein is NC that also functions as the part of the I-domain during 
virus assembly. NC contains one (gammaretroviruses) or two (lentiviruses) conserved 
zinc-finger domains, which are required for packaging the viral RNA (Aldovini and 
Young, 1990; Gorelick et al., 1988; Henderson et al., 1981; Thomas and Gorelick, 
2008). Deletion of NC causes a defect in virus release due to aberrant assembly of viral 
particles (Gheysen et al., 1989; Muriaux et al., 2004). Experiments have been performed 
on MLV that have shown that the NC and RNA interaction enables Gag multimerisation 
using the RNA as a scaffold (Muriaux et al., 2001). Moreover, replacement of NC 
function for virus release can be achieved, in an RNA-independent manner, by the 
addition of a multimerisation domain, like a leucine zipper (Accola, Strack, and 
Gottlinger, 2000; Johnson et al., 2002; Zhang et al., 1998). Therefore as a part of Gag, 
NC is a key driving force for Gag-Gag interactions essential for assembly. After 
maturation NC coats the viral RNA and is beneficial for reverse transcription through its 
nucleic acid chaperone activities (Thomas and Gorelick, 2008).  
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1.4.2 Pol 
The Pol proteins are the virally encoded enzymes namely: protease (PR), reverse 
transcriptase (RT) and integrase (IN) (Figure 1.2). The translation of Pol is tightly 
regulated by retroviruses by mechanisms mentioned earlier. This results in a roughly 
20:1 excess of translated Gag -to- Gag-Pol molecules (Jamjoom, Naso, and Arlinghaus, 
1977). All the retroviral enzymes are therapeutic targets against HIV infection and 
inhibitors to each Pol protein have been approved for use in patients.  
 
PR is an aspartic protease essential for triggering the maturation of the virus after 
budding. Mutation of the residues in the PR active site or deletion of PR results in 
viruses with an immature morphology, which as a result cannot establish an infection in 
target cells (Crawford and Goff, 1985; Katoh et al., 1985; Kohl et al., 1988). For 
cleavage, PR recognises diverse cleavage motifs between Gag and Pol proteins, and 
work from HIV-1 PR has indicated that this is through recognition of a conserved 
structure at the cleavage sites (Prabu-Jeyabalan, Nalivaika, and Schiffer, 2002).  
 
RT was discovered independently by David Baltimore and Howard Temin in 1970 
(Baltimore, 1970; Temin and Mizutani, 1970). It is an RNA-dependent DNA 
polymerase with RNase H activity, which can utilise an RNA or DNA template to 
synthesise DNA (Baltimore, 1970; Telesnitsky and Goff, 1993; Temin and Mizutani, 
1970). For HIV-1 and HIV-2 the enzyme is active as a heterodimer composed of p66 
and p51 subunits, with the RNase H domain present in the larger p66 subunit 
(Kohlstaedt et al., 1992; Rodgers et al., 1995). However, the gammaretroviral RT is 
active as a monomer (Das and Georgiadis, 2004; Nowak et al., 2013). RT is both 
necessary and sufficient for the synthesis of the retroviral DNA from the RNA genome 
(described later). 
 
Integrase is essential for the establishment of the provirus in infected cells (reviewed in 
(Krishnan and Engelman, 2012)). This enzyme forms an intasome complex (dimer of 
IN dimers) with the viral LTR ends (Hare et al., 2010; Maertens, Hare, and Cherepanov, 
2010) and provides two essential enzymatic activities: (i) 3' processing of the viral 
LTRs (Roth, Schwartzberg, and Goff, 1989) and (ii) the strand transfer catalysis (Brown 
et al., 1989; Fujiwara and Mizuuchi, 1988). Lentiviral IN complexes also form vital 
contacts with lens epithelium derived growth factor (LEDGF), important for integration 
site selection (detailed in a later section). 
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1.4.3 Env 
The Env proteins are translated from a spliced full length mRNA and are trafficked to 
the endoplasmic reticulum (ER). The Env polyprotein contains two components: the 
surface (SU) and transmembrane (TM) domains. Within the ER the Env proteins form 
the Env glycoprotein complex, which is a trimer of Env for RSV, MLV and HIV 
(Einfeld and Hunter, 1988; Forster et al., 2005; Liu et al., 2008). Env is cleaved and 
then transported to the plasma membrane via the golgi apparatus. Functionally the SU 
component is required for Env-receptor interactions and the TM subunit is vital for 
membrane fusion.  
 
1.4.4 Accessory proteins 
Complex retroviruses, like those from the lentivirus genus, code for other proteins in 
addition to Gag, Pol and Env. Simple retroviruses like the gammaretroviruses do not 
code any accessory proteins (barring glyco-Gag) and thus the accessory proteins of 
HIV-1 will only be briefly mentioned.  
 
Firstly, the gammaretroviral glyco-Gag protein is initiated from a CUG codon upstream 
of the Gag initiation codon (Prats et al., 1989). Not all gammaretroviruses encode 
glyco-Gag and it is not essential for replication in cell culture but appears essential for 
MLV infection in vivo (Low et al., 2007). In line with this, all the gammaretroviral 
vectors utilised in this thesis do not encode Glyco-Gag. Glyco-Gag has been implicated 
in directing viral assembly at lipid rafts through the cellular protein La and has been 
implicated in protecting MLV from APOBEC3 (Nitta et al., 2011; Stavrou et al., 2013). 
Additionally, it has been reported that glyco-Gag can substitute for Nef in HIV-1 
suggesting it has a Nef like function for HIV-1 (Pizzato, 2010). 
 
HIV-1 encodes the regulatory proteins Tat and Rev and the accessory proteins Vif, Vpr, 
Vpu and Nef. Tat increases proviral expression by binding to the transcribed RNA 
transactivating response (TAR) region from the viral promoter and enhances 
transcription (Berkhout and Jeang, 1989; Feng and Holland, 1988; Ott, Geyer, and 
Zhou, 2011). Rev binds to the Rev-response element (RRE) on the viral RNA and 
facilitates export of the unspliced viral RNA from the nucleus (Felber et al., 1989). 
  
The accessory proteins are required in vivo but are generally dispensable for replication 
in many cell culture systems (Mustafa and Robinson, 1993). Vif has an important 
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function in counteracting the restriction factor apolipoprotein B mRNA-editing enzyme-
catalytic polypeptide-like 3G (APOBEC3G) by binding and targeting it for proteasomal 
degradation (Conticello, Harris, and Neuberger, 2003; Sheehy et al., 2002; Sheehy, 
Gaddis, and Malim, 2003). Vpr is incorporated into virions and induces G2/M cell cycle 
arrest in the target cells and has also has been linked to nuclear import of the pre-
integration complex (PIC), although the latter role has been refuted (Heinzinger et al., 
1994; Sharifi, Furuya, and de Noronha, 2012)). Vpu has been shown to counteract the 
late restriction factor tetherin, which prevents particle release, by down regulating 
tetherin cell surface expression (Neil et al., 2006; Neil, Zang, and Bieniasz, 2008; Van 
Damme et al., 2008). Vpu also degrades CD4 trapped in intracellular complexes with 
Env (Willey et al., 1992). Nef has multiple roles including down regulation of CD4 and 
MHC class I molecules. Additionally Nef is able to enhance viral DNA synthesis 
among other functions (reviewed in (Laguette et al., 2010)). 
 
1.5 The retroviral life cycle 
The retroviral life cycle is broadly separated into two parts, the early and late stages of 
infection. The early stages of infection comprise all the steps from virus binding to the 
target cell up to integration of the viral DNA. The late stages include transcription of the 
provirus through to budding and maturation (see Figure 1.3). 
 
Figure 1.3: Schematic detailing the life cycle of a retrovirus. The main steps are written in 
bold with the early steps of the life cycle highlighted in orange. RTC- reverse transcription 
complex, PIC- pre-integration complex.   
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1.5.1 Retroviral entry 
The major determinant of viral tropism is the receptor usage by the envelope 
glycoprotein complex on the surface of the virus. The tropism of the MLVs from 
laboratory mice are traditionally categorised in one of three classes: ecotropic, 
xenotropic or polytropic. Ecotropic MLVs have a host range that is restricted to host 
cells (murine and rat cells) and utilise mCAT1, a cationic amino acid transporter, for 
entry (Kim et al., 1991; Wang et al., 1991). Xenotropic MLVs are unable to infect the 
host cells of murine origin but are able to infect cells from other mammals (Levy, 
1973). Xpr1 is the receptor molecule for MLV with the xenotropic envelope 
glycoprotein complex (Battini, Rasko, and Miller, 1999; Tailor et al., 1999). The last 
class, polytropic, have a wide host range and are able to infect both murine and non-
murine cells also by exploiting the Xpr1 molecule for entry (Battini, Rasko, and Miller, 
1999; Fischinger, Nomura, and Bolognesi, 1975; Tailor et al., 1999). 
 
The initial binding of a virus to a target cell is mediated by non-specific interactions 
between the virion membrane and the membrane of the cell (Beer and Pedersen, 2007). 
Specific interactions between the Env glycoprotein complex and the receptor(s), triggers 
a cascade of steps leading to fusion and release of the core into the target cell. 
Engagement of the SU domain with the receptor isomerises the SU-TM disulphide bond 
resulting in the displacement of the SU subunit of the Env complex (Wallin, Ekstrom, 
and Garoff, 2004) This exposes the fusion peptide in the N-terminus of TM, which 
inserts into the host cell membrane. Insertion of TM into the host membrane triggers 
conformational changes in TM where the C-terminal heptad repeat folds against the N-
terminal heptad repeat bringing the host and virion membrane into close proximity 
allowing fusion to occur (Fass, Harrison, and Kim, 1996). 
   
For HIV-1, two cell surface molecules are utilised to gain entry to cells, CD4 and a co-
receptor, either CXCR4 or CCR5, depending on the specific tropism of the virion Env 
complex (Dalgleish et al., 1984; Dragic et al., 1996; Feng et al., 1996). Interaction of 
the Env complex with CD4 induces conformational changes which expose the 
CCR5/CXCR4 binding pocket (Liu et al., 2008). Binding of the co-receptor leads to 
further changes and the gp41 (TM) inserts its fusogenic peptide into the cell membrane 
(Blumenthal, Durell, and Viard, 2012). A pore is formed which is widened to allow 
delivery of the viral core. 
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Retroviruses can also be pseudotyped with a variety of heterologous glycoproteins to 
broaden cell tropism. One that has been of particular use has been the vesicular 
stomatitis virus glycoprotein (VSV-G) (Naldini et al., 1996). VSV-G allows entry to a 
wide range of cells, as the receptor is thought to be a factor ubiquitously expressed in 
most cells (Cronin, Zhang, and Reiser, 2005).   
 
1.5.2 Uncoating, reverse transcription, and the path to the nucleus 
After release of the retroviral core into the cytoplasm a set of essential processes must 
occur before insertion of the viral genome into the host chromosomes. These processes 
are dynamic and evidence is beginning to suggest that they are all inter-connected. This 
next section will detail some of the key events occurring on transit to the nucleus. 
 
Uncoating 
Uncoating is a poorly understood step of the viral life cycle, where CA is lost from the 
retroviral reverse transcription complex (RTC)/PIC during trafficking to the 
chromosomes. When uncoating occurs, its kinetics and how much CA is actually lost 
during uncoating remain debated topics. Unfortunately, due to the difficulties in 
isolation and experimental manipulation of RTC/PICs these questions have not been 
very amenable to in vitro studies. Data have highlighted, however, that the rate of 
uncoating varies between cell types, indicating that uncoating is influenced by host 
factors (Arfi et al., 2009). 
  
Different retroviruses appear to uncoat at varying rates. Early biochemical data 
suggested that the kinetics of HIV-1 uncoating was very fast and no CA could be 
detected with isolated RTCs very early after infection (Bukrinsky et al., 1993b; Fassati 
and Goff, 2001). On the other hand, in the case of MLV, CA was readily detected with 
the RTC/PIC during infection using the same biochemical techniques (Fassati and Goff, 
1999). However, uncoating does eventually occur for MLV as little CA could be 
detected in nuclear fractions of infected cells or in the nucleus of mitotic cells by 
immunofluorescence (Elis et al., 2012; Fassati and Goff, 1999; Prizan-Ravid et al., 
2010). 
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Despite evidence suggesting the rapid uncoating of the HIV-1 RTC, it seems likely that 
some CA does remain with the PIC until a later stage in the infection process. The 
evidence for this is: (i) immunofluorescence and EM showing CA associated with 
active RTCs and CA cores present at/around the nuclear pores during infection (Arhel et 
al., 2007; McDonald et al., 2002), (ii) CA appears to be the determinant of nuclear entry 
for HIV-1 and interacts with transportin 3 (TNP03) and a component of the nuclear pore 
complex, Nup358 (RANBP2) (Krishnan et al., 2010; Schaller et al., 2011; Yamashita 
and Emerman, 2004; Yamashita et al., 2007), (iii) CA can be detected in the nucleus of 
fractionated infected cells (Zhou et al., 2011) and (iv) the rapid uncoating induced by 
TRIM5alpha aborts infection before reverse transcription (Stremlau et al., 2006; Towers 
et al., 2000). The reason why CA is not biochemically isolated with HIV-1 RTCs is 
likely linked to RTC isolation protocols disrupting the CA core (McDonald et al., 
2002). 
 
The actual trigger for uncoating remains unknown. No CA-interacting molecules have 
been described for simple retroviruses that regulate/trigger uncoating. However, the host 
molecule cyclophilin A (CypA) could play a role in HIV-1 uncoating. CypA binding 
occurs on the CypA binding loop of the CA NTD for a range of lentiviral CA molecules 
(Gamble et al., 1996; Lin and Emerman, 2006). It was originally thought to be essential 
in HIV-1 producer cells, but now the general consensus is that CypA is required in the 
target cells (Hatziioannou et al., 2005; Luban et al., 1993; Thali et al., 1994). CypA is a 
peptidyl prolyl cis/trans isomerase that catalyses the cis-trans conformation of the G89-
P90 bond in HIV-1 CA (Bosco et al., 2002). It has been speculated that CypA could 
cause uncoating by either (i) cis/trans isomerisation of the G89-P90 bond or (ii) 
destabilise the CA core by high levels of CypA binding (Gamble et al., 1996). Indeed, 
high levels of CypA can dismantle CA-tubes in vitro (Grattinger et al., 1999). However 
the precise role of CypA in HIV-1 infection and uncoating remains unknown. 
 
Recent experiments have linked the process of uncoating to reverse transcription. 
Mutations or drugs blocking RT activity increase the stability of the HIV-1 CA core and 
the time required to uncoat (Hulme, Perez, and Hope, 2011; Yang, Fricke, and Diaz-
Griffero, 2013) Likewise, mutations altering the stability of the CA core alter reverse 
32 
 
transcription, indicating they likely occur concomitantly and exert an influence on each 
other (Arfi et al., 2009; Forshey et al., 2002). 
  
Reverse transcription 
Formation of the viral cDNA is an essential step in the retroviral life cycle. RT catalyses 
the conversion of viral RNA to the linear double stranded DNA and exposure to higher 
levels of dNTPs is believed to be the trigger for reverse transcription to begin. Indeed, 
retroviruses can synthesise viral DNA if the virus is permeablised and exposed to 
dNTPs (Haseltine et al., 1976). 
  
Synthesis of the negative strand begins from the incorporated tRNA bound to the PBS 3' 
to the R-U5 region of the viral RNA (Harada, Peters, and Dahlberg, 1979; Ratner et al., 
1985). During synthesis of this so-called strong-stop DNA, the RNase H activity of RT 
digests the RNA template. Detection of the strong stop DNA species in infected cells is 
often used to quantify the amount of early reverse transcription products formed and has 
been used in this thesis. Next a translocation event occurs, referred to as minus-strand 
transfer, where the synthesised R-U5 region anneals to the 3' R region of the RNA. 
Minus strand DNA is synthesised up to the end of the RNA template (PBS region). The 
RNase H activity of RT digests the RNA template apart from a resistant stretch called 
the polypurine tract (ppt). Unlike MLV, HIV and some other lentiviruses have an 
additional ppt called the central ppt (cPPT). The cPPT seems to enhance the ability of 
HIV RT by acting as an additional priming site for plus strand DNA synthesis although 
it is not essential for replication (Charneau, Alizon, and Clavel, 1992; Charneau and 
Clavel, 1991).  
 
The synthesis of the plus-strand DNA is initiated from the ppt and extends the U3-R-
U5-tRNA region. RNase H activity degrades the tRNA molecule and the second 
translocation event occurs (plus-strand transfer), annealing the PBS of the plus-strand 
U3-R-U5-PBS to the minus-strand PBS. The plus and minus strands are then extended 
to completion so that both ends of the viral DNA are flanked by the identical LTR 
sequence. This forms the DNA 3' to the LTR which is used to detect late RT products as 
so-called second strand extension products. RT is both necessary and sufficient for in 
vitro reverse transcription, although other viral proteins and cellular factors have roles 
in the reverse transcription reaction in vivo (Hu and Hughes, 2012).  
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Figure 1.4: Reverse transcription of viral RNA to DNA. (A) Reverse transcription is initiated 
from the tRNA primer bound to the primer binding site (pbs). (B) RT catalyses the R-U5 of the 
minus strand (called strong stop DNA, written in red). The RNA template (baring the pbs) is 
degraded by the RNase H domain in RT. (C) Minus-strand transfer anneals the newly 
synthesised R region to the complementary R region at the 3' end of the RNA. (D) The minus 
strand is synthesised to the end of the pbs and the RNA template is degraded except for a 
resistant patch at the 3' end called the poly purine tract (ppt). (E) The ppt is then used to prime 
the synthesis of the plus strand LTR replicating the tRNA to produce the pbs. The tRNA 
molecule is then degraded. (F) The plus strand translocation event occurs annealing the plus 
strand and minues strand pbs. (G) RT completes synthesis of the plus and minus strands 
forming the double stranded DNA (forming a DNA detected by primers used in this thesis for 
second strand extension products, written in red). Figure adapted from (Hu and Hughes, 2012). 
 
 
Trafficking 
RTC/PICs must navigate through the relatively busy environment of the cell to reach 
the nucleus for viral DNA integration. These movements require active transport. 
Association of HIV-1 RTCs with the microtubule network has been shown using live 
immunofluorescence and correlative EM, revealing that RTCs use microtubule based 
transport for long distance movements (McDonald et al., 2002). Additionally, blocking 
dynein-mediated transport before core entry to the cell resulted in the peripheral 
localisation of the RTCs, further implicating microtubule based transport in movements 
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of the PIC (McDonald et al., 2002). One report suggested that MA is involved in the 
HIV-1 RTC transport by interaction with the actin network, which was blocked by 
inhibiting actin polymerisation. However, this effect was lost when virus was 
psuedotyped with VSV-G, suggesting actin may be involved in Env-specific entry 
events (Bukrinskaya et al., 1998). A more recent detailed study using FlAsH labelled 
HIV-1 IN described four types of movement, indicating HIV-1 was utilising both 
microtubule and actin based transport. This has implied that there may be some 
functional redundancy in the trafficking mechanisms utilised by retroviruses (Arhel et 
al., 2006).  
 
Restriction factors targeting the early stages of infection 
The early stages of infection are a particularly vulnerable time for retroviruses and 
many antiretroviral drugs target these early steps. Indeed, cells have evolved five main 
restriction factors targeting these stages, namely: tripartite-motif-containing 5 alpha 
(TRIM5alpha), Friend virus susceptibility gene 1 (Fv1), Friend virus susceptibility gene 
4 (Fv4), APOBEC3G and SAM domain and HD domain-containing protein 1 
(SAMHD1). Both Fv1 and TRIM5alpha were utilised as CA-core sensors in this thesis 
and their mechanism of action is described in more detail. 
 
TRIM5alpha was discovered as a HIV-1 restriction factor from a screen of rhesus 
macaque genes, and blocks infection before reverse transcription (Stremlau et al., 2004; 
Stremlau et al., 2006). TRIM proteins come from a family with about 70 members, all 
which contain a similar domain architecture (Nisole, Stoye, and Saib, 2005). The N-
terminus consists of a RING domain, either one of two B-boxes and a coiled-coil 
domain followed by a range of C-terminal domains depending on the TRIM protein 
(Figure 1.5A) (Nisole, Stoye, and Saib, 2005). TRIM5alpha has a PRYSPRY (or B30.2) 
in the C-terminus heavily involved in specifying the CA core recognised by the 
particular TRIM5alpha protein (Song et al., 2005; Stremlau et al., 2006; Yap, Nisole, 
and Stoye, 2005). The PRYSPRY contains three hypervariable loops (V1-V3) of 
different sizes and sequence depending on the TRIM5alpha species (Sawyer et al., 
2005; Stremlau et al., 2005). These loops are important in the specificity of 
antiretroviral activity of TRIM5alpha and likely map key interfaces between the CA 
core and TRIM5alpha (Perez-Caballero et al., 2005; Sawyer et al., 2005; Stremlau et al., 
2005; Yap, Nisole, and Stoye, 2005). The human TRIM5alpha is unable to restrict HIV-
1 but is active against a range of retroviruses including N-tropic MLV. The viral 
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determinants of restriction map to the CA protein, although TRIM5alpha does not 
interact with monomeric CA proteins and requires a core-like structure (Cowan et al., 
2002; Stremlau et al., 2006). Poor solubility has precluded structural analysis of 
theTRIM5alpha-CA interaction, however mapping of escape mutants has highlighted 
the interaction between CA and TRIM5alpha likely occurs over the entire outer face of 
the CA protein (Ohkura et al., 2011; Ohkura and Stoye, 2013). 
 
A variant of TRIM5alpha, called TRIMcyp, has arisen from two independent 
retrotransposition events in owl monkeys and certain macaque species, where the 
PRYSPRY has been replaced by CypA (Brennan, Kozyrev, and Hu, 2008; Newman et 
al., 2008; Sayah et al., 2004; Virgen et al., 2008; Wilson et al., 2008). TRIMcyp 
therefore interacts with CA at the CypA binding loop and is a potent inhibitor of HIV-1 
infection. 
 
The exact mechanism behind TRIM5alpha's restriction activity remains poorly 
understood. Within the cell TRIM5alpha associates with the incoming core rapidly (<30 
mins) and has been shown to prematurely uncoat the core, suggesting this causes the 
block to infection (Perez-Caballero et al., 2005; Stremlau et al., 2006). However, it has 
been shown in cells treated with proteasome inhibitors disassembly does not occur, 
reverse transcription proceeds but infection is aborted before nuclear entry (Diaz-
Griffero et al., 2007; Wu et al., 2006). This has indicated that either TRIM5alpha has 
more than one mechanism of restriction or loss of the proteasome results in a kinetically 
slowed restriction, allowing reverse transcription to occur. Additionally, TRIM5alpha 
has been shown to act as a pattern recognition receptor for the retroviral CA lattice. 
Where association with the CA core increases the E3 ubiquitin ligase activity of the 
TRIM5alpha RING domain and with the UBC13–UEV1A complex forms free K63 
ubiquitin chains, activating a cascade of downstream events and leading to AP-1 and 
NFκB activation (Pertel et al., 2011). However, it has been shown that the E3 ubiquitin 
ligase activity is not required for restriction (Perez-Caballero et al., 2005). Thus far the 
only aspects of TRIM5alpha action essential for restriction are: recognisation of the CA 
core through the PRYSPRY/CypA domain and multimerisation through the RING, B-
box and coiled-coil domains. The B-box is important for higher order association of 
TRIM5alpha, which increases the efficiency of TRIM5alpha recruitment to the core 
(Diaz-Griffero et al., 2009; Li and Sodroski, 2008). Consistent with this notion, 
cryogenic electron microscopy (cryo-EM) images of a chimeric TRIM5alpha protein 
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(with the RING domain from TRIM21) formed on HIV-1 CA tubes have shown the 
formation of a superlattice over the CA hexagonal array, with the SPRY/B30.2 domain 
spread across the CA surface (Figure 1.5B) (Ganser-Pornillos et al., 2011).  
 
 
Figure 1.5: TRIM5alpha association on the CA core. (A) Schematic detailing the domains 
present in TRIM5alpha and TRIMcyp. Adapted from (Malim and Bieniasz, 2012). (B) Diagram 
displaying a proposed model of TRIM5alpha higher order association over the HIV-1 CA core. 
Adapted from (Ganser-Pornillos et al., 2011).  
 
Fv1 was the first CA interacting restriction factor to be cloned but less is known about 
its mechanism of restriction than is known for TRIM5alpha. Fv1 was cloned in 1996 
and is derived from the gag of an endogenous retrovirus (Best et al., 1996). It is a 
mouse gene and has two major alleles, Fv1n and Fv1b. Cells expressing the former 
restrict B-tropic MLV and the expression of the latter restricts N-tropic MLV infection. 
Restricted viruses are blocked at a stage after reverse transcription but before integration 
(Jolicoeur and Baltimore, 1976). Viral determinants of restriction map to the CA protein 
(specifically amino acid 110) (Kozak and Chakraborti, 1996; Stevens et al., 2004) and 
the specificity of Fv1 restriction maps to the C-terminal domain (Bishop et al., 2001). 
Similar to TRIM5alpha, the N-terminal domain of the protein contains a predicted 
coiled-coil domain, has been shown to dimerise and this region is essential for 
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restriction activity (Bishop et al., 2006). Artificial restriction factors, where the N-
terminal portion of Fv1 replaces the N-terminal part of TRIMcyp, are competent to 
restrict HIV-1 suggesting that Fv1 multimerisation in a fashion similar to TRIM5alpha 
is also essential for restriction (mentioned above) (Yap et al., 2007). The half-life of one 
of these restricting Fv1-Cyp proteins is much longer than TRIMcyp, indicating that the 
slower removal of Fv1-cyp may be what allows viruses restricted by Fv1 to reverse 
transcribe (Schaller et al., 2007). However, at present, poor solubility of the Fv1 protein 
means limited structural information exists and the exact mechanism of restriction 
remains ill-defined. 
  
Both Fv1 and TRIM5alpha have been utilised as retroviral core sensors in cells due to 
the fact that restriction can be saturated by infecting with a high MOI of virus (Bassin et 
al., 1978; Besnier, Takeuchi, and Towers, 2002; Boone, Innes, and Heitman, 1990; 
Cowan et al., 2002; Duran-Troise et al., 1977; Towers, Collins, and Takeuchi, 2002), 
and have been utilised in this study. 
 
Fv4 blocks infection with ecotropic MLV at the stage of viral entry to target cells 
(Suzuki, 1975). Fv4 is an endogenous gp70 molecule that is believed to compete with 
the viral Env glycoprotein for the ecotropic receptor mCAT1 (Ikeda et al., 1985; Ikeda 
and Odaka, 1984; Inaguma et al., 1991). However, the molecular mechanism behind the 
Fv4 and the mCAT1 interaction remains to be resolved. 
 
APOBEC3G is specifically packaged into the HIV-1 virions (lacking Vif) during 
assembly through contacts between its N-terminal domain with RNA and NC (Malim 
and Bieniasz, 2012; Sheehy et al., 2002). Its action results in G-to-A hypermutation on 
the cDNA plus strand (Bishop et al., 2004) in addition to inhibition of cDNA synthesis 
by RT (Bishop et al., 2008). 
   
Finally, the recently discovered restriction factor from monocytic cells, SAMHD1 
(Laguette et al., 2011; St Gelais and Wu, 2011). The mechanism of action for SAMHD1 
appears to be its enzymatic breakdown of dNTPs, depleting cellular levels of dNTPs 
and preventing reverse transcription, although the finer details of SAMHD1 restriction 
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remain under investigation (Goldstone et al., 2011; Kim et al., 2012; Lahouassa et al., 
2012)  
 
1.5.3 Nuclear entry and integration 
Entry to the nucleus is a necessary step for retroviral replication and occurs by distinct 
methods for complex and simple retroviruses. The most commonly used nuclear entry 
marker is the presence of two-LTR circles in infected cells, which are believed to be 
formed by the non-homologous DNA end joining pathway (NEHJ) in the nucleus (Li et 
al., 2001; Shoemaker et al., 1981). Simple retroviruses, such as MLV, fail to infect non-
cycling cells (Roe et al., 1993; Suzuki and Craigie, 2007). Mitosis and break down of 
the nuclear envelope is required for these viruses to access the host chromatin (Roe et 
al., 1993). Live microscopy of MLV PICs labelled with GFP-p12 have shown that  a 
breach in the nuclear envelope is required for the MLV PIC to enter the nucleus (Elis et 
al., 2012). Complex retroviruses, however, are able to pass across an intact nuclear 
envelope, enabling infection of chemically arrested or terminally differentiated cells 
(Lewis, Hensel, and Emerman, 1992). Four HIV-1 viral factors were originally 
implicated as being the determinants allowing infection of non-dividing cells: MA, IN, 
Vpr and the central ppt (Arhel, Souquere-Besse, and Charneau, 2006; Bukrinsky et al., 
1993a; Gallay et al., 1997; Heinzinger et al., 1994; Lu, Spearman, and Ratner, 1993; 
von Schwedler, Kornbluth, and Trono, 1994; Zennou et al., 2000). However, removal of 
all of these factors did not render HIV-1 unable to infect non-dividing cells (Yamashita 
and Emerman, 2005) and the current consensus is that HIV-1 CA is the determinant of 
nuclear entry (Yamashita and Emerman, 2004). 
 
The HIV-1 PIC is believed to access the nucleus via the nuclear pore complex (NPC) 
which is composed of nuclear pore proteins (nucleoporins or NUPs). Two RNAi screens 
looking for host co-factors for HIV-1 infection identified a set of nucleoporins as 
essential for infection. Two nucleoporins were common to both studies: Nup153 and 
RanBP2 (Nup358) and additionally, a karyopherin TNP03 (Brass et al., 2008; Konig et 
al., 2008), but many others were also implicated between the two studies. It is becoming 
apparent that lentiviruses can use more than one configuration of NPC for nuclear entry 
and mutations to CA alter the NPC utilised (Lee et al., 2010; Schaller et al., 2011). This 
notion is consistent with CA being the main determinant for HIV-1 nuclear entry 
(Yamashita and Emerman, 2004; Yamashita et al., 2007), but suggests a substantial 
proportion of CA must remain with the PIC. One electron microscopy study and a 
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recent super resolution imaging study have shown what appear to be intact CA cores 
at/near the NPC and have suggested a major uncoating event occuring in/at the NPC 
(Arhel et al., 2007; Lelek et al., 2012). However, whether the core remains more or less 
intact until it reaches the NPC is widely debated.  
 
TNPO3 was of particular interest from the RNAi screens as it is a karyopherin that 
transports proteins from the cytoplasm to the nucleus. Initially it was shown that HIV-1 
IN was the interacting partner for TNPO3 but later the important viral interaction was 
shown to be with CA (Christ et al., 2008; Krishnan et al., 2010). The story of TNPO3 in 
HIV-1 infection has become more complicated. TNPO3 knock down does not 
significantly block nuclear entry but a stage after nuclear entry and before integration 
(Zhou et al., 2011). It has been hypothesised that TNPO3 may act as an export factor for 
residual CA that enters the nucleus with the PIC, and that not removing this residual CA 
interferes with integration (Zhou et al., 2011). The interference to integration when 
TNPO3 is depleted requires another CA interacting molecule cleavage and 
polyadenylation specific factor 6 (CPSF6), but the mechanism behind this is not fully 
understood (Fricke et al., 2013; Price et al., 2012). 
 
Once inside the nucleus the HIV-1 PIC makes important contacts with the host factor 
LEDGF, which has been intentionally omitted from this section and will be described 
later. The actual catalysis of integration is performed by IN, which removes a 
dinucleotide from the 3' ends of the LTRs (Roth, Schwartzberg, and Goff, 1989) and 
mediates the strand transfer reaction, inserting the viral DNA ends into the host 
chromosomes (Brown et al., 1989; Fujiwara and Mizuuchi, 1988). 
 
1.5.4 The late stages of the life cycle: from transcription to virus assembly 
These steps of the life cycle are not particularly relevant to this thesis and will be briefly 
mentioned. The provirus is transcribed by the cellular RNA polymerase II through 
promoter and enhancer elements in the LTR (Laimins et al., 1984; Laimins, Tsichlis, 
and Khoury, 1984; Ostrowski, Berard, and Hager, 1981). In the nucleus the various 
spliced products of the viral RNA are generated via interactions with the splicing 
machinery. Export of the RNA from the nucleus occurs by different methods depending 
on the RNA species and on the virus. Fully spliced RNAs are transported constitutively 
as they resemble cellular RNAs, however, intron-containing viral RNAs must be 
actively exported (Cullen, 2003). Different retroviruses utilise different methods to 
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export the unspliced RNA from the nucleus. Simple retroviruses, like Mason-Pfizer 
monkey virus (MPMV), contain cis-acting elements in the 3' untranslated part of the 
viral RNA called constitutive transport elements (CTE) which drive the export of the 
unspliced RNA via the Tap/NXF1 export pathway (Bray et al., 1994; Ernst et al., 1997; 
Pasquinelli et al., 1997). Whereas complex retroviruses code for a regulatory protein 
(called Rev for HIV-1), which interacts with a cis-acting element in the viral RNA (rev 
response element (RRE) in HIV-1), and directs active transport via the CRM1 export 
pathway (Cullen, 2003; Felber et al., 1989). The mechanism behind the export of MLV 
viral RNA remains poorly defined but also likely requires a cis-acting CTE, potentially 
overlapping the packaging sequence (Basyuk et al., 2005; Smagulova et al., 2005). 
 
Translation of the viral proteins occurs on the ribosomes and the gRNA is selected for 
encapsidation by the NC domain of Gag either during translation or soon after (Aldovini 
and Young, 1990; Berkowitz et al., 1995; Dorman and Lever, 2000; Jouvenet, Simon, 
and Bieniasz, 2009). From work on HIV-1 it appears as though assembly initiates in the 
cytoplasm where small Gag/gRNA complexes are formed (Jouvenet, Simon, and 
Bieniasz, 2009; Kutluay and Bieniasz, 2010). These Gag molecules and complexes 
traffic to portions of the plasma membrane and bind via interaction between MA and the 
phospholipid phosphatidylinositol-(4,5)-bisphosphate (PI(4,5)P2) (Ono et al., 2004). 
This interaction also changes the conformation of MA, exposing the myristate for 
insertion into the plasma membrane (Saad et al., 2006). Multimerisation of Gag through 
NC and CA domains of Gag drives assembly around the gRNA and nucleates the 
formation of a bud to protrude from the cell membrane (Jouvenet, Bieniasz, and Simon, 
2008; Jouvenet, Simon, and Bieniasz, 2009). 
 
1.5.5 Virus budding and release from the cell 
The final intracellular stages of retroviral replication require the L-domain in Gag. 
Three types of retroviral L-domain have been described (i) PPxY (Wills et al., 1994), 
(ii) PTAP (Gottlinger et al., 1991) and (iii) LYPxnL (Puffer et al., 1997). MLV and RSV 
contain the PPxY type L-domains present in p12 and p2b, respectively, and the function 
of this L-domain will be described in detail later. The central responsibility of the L-
domains is in recruiting members of the endosomal sorting complex for transport 
(ESCRT) pathway to excise the budding virus from the cell membrane (Figure 1.6).  
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It has been shown that the HIV-1 L-domain, which resides in the p6 portion of Gag, 
interacts with the ESCRT-I protein TSG101 (Garrus et al., 2001). This interaction is 
essential for HIV-1 budding and knock down of TSG101 significantly reduced virus 
release (Garrus et al., 2001). Interestingly, HIV-1 also contains another L-domain (also 
in p6) of the LYPxnL type that interacts with the ESCRT accessory protein ALIX 
(Strack et al., 2003). Interactions between Gag and the ESCRT-I factors serve to recruit 
other members of the ESCRT pathway, leading to downstream recruitment of ESCRT-
III members to the budding site. Charged multivesicular body proteins (CHMPs) are the 
components of the ESCRT-III that are needed for the scission event, and co-depletion of 
CHMP4B and CHMP2A blocks HIV-1 release (Morita et al., 2011). The CHMP 
proteins are believed to form a protruding dome structure that pulls the membrane 
inwards, tightening the neck of the viral bud, promoting scission and release of the virus 
(Guizetti et al., 2011; Hanson et al., 2008).  
 
Figure 1.6: Retroviral L-domains and the ESCRT pathway. Diagram detailing how the three 
L-domains (in the red box) hijack the ESCRT pathway to direct the ESCRT machinery to the 
virion budding site. The Ub target of the Nedd4-like Ub ligases remains unknown. Adapted 
from (Chen and Lamb, 2008). 
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1.6 Maturation and formation of the retroviral CA core 
Immediately after release from the cell, retrovirus particles undergo an essential 
maturation event. Triggered by PR, this transition can be observed by transmission EM 
(TEM), where an electron-lucent viral core surrounded by a 'train-track'-like 
organisation of Gag changes to an electron dense core of a defined shape (depending on 
the species of retrovirus) (Figure 1.7). Loss of PR activity blocks this conversion and 
renders the virus non-infectious (Crawford and Goff, 1985; Katoh et al., 1985; Kohl et 
al., 1988). Thus, maturation is an important therapeutic target and PR inhibitors (PI) 
have been in use for a number of years in the treatment of HIV-1 infection (Waheed and 
Freed, 2012). A new breed of antiretrovirals are currently under investigation, which 
instead of targeting PR activity, block maturation via alternative targets such as 
blocking the PR cleavage sites. One such drug is bevirimat (BMV), which blocks HIV-1 
CA-SP1 cleavage by restricting PR access to the CA-SP1 junction (Waheed and Freed, 
2012). Bevirimat blocks a late step in maturation and thin section EM of the virions 
display a phenotype similar to CA-SP1 cleavage mutants, where a dense RNP is seen, 
but the immature core does not dismantle for the subsequent core rearrangement (de 
Marco et al., 2010b; Li et al., 2003). 
  
1.6.1 The immature Gag lattice 
Original studies looking at the morphology of immature particles by EM showed a 
'train-track'-like organisation of Gag under the virion membrane, projecting inwards 
from MA to the C-terminus of Gag (Figure 1.7) (Fuller et al., 1997; Wilk et al., 2001; 
Yeager et al., 1998). Estimates on the number of Gag molecules incorporated into virus 
particles vary considerably, with the most recent estimates being about 5000 molecules 
of Gag making up an immature HIV-1 virion (Briggs et al., 2004). However, these large 
values are likely to be overestimates as evidence is beginning to mount suggesting 
immature virus particles do not consist of a full sphere of Gag molecules (Briggs et al., 
2009; Wright et al., 2007). The methods used to create immature Gag/CA shells range 
from in vitro forms of tubular or spherical CA to virions with inactive PR. These 
immature core structures have then been studied using cryo-EM. Due to the repeating 
nature of the immature core, averaging of the repeating units can form reasonably high 
resolution reconstructions of the immature lattice. 
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Hints that the immature CA core consisted of an ordered hexagonal lattice came from 
cryo-EM analysis of Moloney (Mo)-MLV PR negative particles (Yeager et al., 1998), 
as well as immature HIV-1 particles (Fuller et al., 1997). Immature lattices formed of 
CA-NC tubes have been created by preventing the formation of the β-hairpin in HIV-1, 
Mason-Pfizer monkey virus (MPMV) and RSV (de Marco et al., 2010a). The structures 
of these immature lattices have a similar hexameric form, which appear to arise from 
the ordered CA-NTD (de Marco et al., 2010a). However, differences do exist between 
different retroviral genera due the size of the spacer peptides in Gag and the 
spacing/distance to the nucleic acid (de Marco et al., 2010a). Recently, higher resolution 
cryo-EM reconstructions of MPMV immature CA-NC lattices have enabled fitting of 
known atomic structures of MPMV and HIV-1 CA domains into the electron densities, 
suggesting an immature hexamer of CA dimers (Bharat et al., 2012). This work has 
highlighted the potential interfaces within and between hexamers in the immature CA 
lattice, with the CA NTD-NTD interfaces important for inter-hexameric interactions and 
the CA CTD-CTD interfaces important for intra-hexameric interactions (Bharat et al., 
2012). 
  
Interestingly, recent in vitro studies on immature cores from a gammaretrovirus 
(XMRV) display a striking difference to other retroviruses (HIV-1 MPMV and RSV) in 
that the CA-NTD in the immature lattice appears to be more disordered (lacking 
hexameric order) and the hexameric order of the lattice comes from CA-CTD and NC 
(de Marco et al., 2010a; Hadravova et al., 2012). This implies that the interfaces 
supporting the immature Gag lattice in gammaretroviruses are likely to differ from 
those shown by Bharat et al. for MPMV immature CA-NC tubes.  
 
1.6.2 The process of maturation and formation of the mature core 
Upon Gag cleavage a huge rearrangement occurs inside the core of the virus (Figure 
1.7) as highlighted in the models by Bharat et al.. Interestingly, only a fraction of the 
CA in the virus actually forms the mature core and for HIV-1 it has been estimated that 
the number is ~1500 CA molecules form the mature core (Briggs et al., 2003). 
 
Mutations of the Gag PR cleavage sites in MLV and HIV-1 have demonstrated that the 
kinetics and efficiency of cleavage are important for the formation of the mature core 
(de Marco et al., 2012; Oshima et al., 2004). Studies into the cleavage rates of HIV-1 
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Gag in vitro have provided an estimation of the likely order of Gag cleavage (Pettit et 
al., 2002; Pettit et al., 2005; Pettit et al., 1994). Initially MA-CA-SP1 is cleaved from 
NC-SP2-p6, followed by NC-SP2 from p6, then MA from CA-SP1 and finally, CA 
from SP1 (Pettit et al., 2002; Pettit et al., 1994). Cleavage rates vary considerably for 
different sites where the cleavage of SP1 from NC-SP2-p6 is 400-fold faster than CA 
from SP1 (Pettit et al., 2002; Pettit et al., 1994). In MLV, the cleavage order appears to 
be different and p12 is separated from CA first (Naso et al., 1979). Release of the N-
terminus of CA is an important step in maturation and results in the formation of the 
conserved β-hairpin by generating a salt bridge between the P1 and a conserved 
aspartate residue further downstream in CA (Gitti et al., 1996; Mortuza et al., 2004; 
Tang, Ndassa, and Summers, 2002; von Schwedler et al., 1998).  
 
 
Figure 1.7: Maturation of retroviruses. Schematic showing the morphological transition 
between the immature and mature retroviral cores: The virion (immature virion (MLV)) on the 
left is an averaged cryo-EM image of an immature MLV virion displaying the domains in Gag 
(immature HIV-1 virions have a similar 'train track' like organisation of Gag). A schematic of 
MLV and HIV-1 Gag is shown with scissors marking the PR cleavage sites. The images on the 
right show EM micrographs of mature MLV and HIV-1 virions. (Images adapted from 
(Auerbach, Brown, and Singh, 2007; Briggs et al., 2006; Yeager et al., 1998)). 
 
The mechanism behind formation of the mature core currently remains ill defined, but 
blocking the Gag cleavage sites in HIV-1 has enabled the analysis of potential 
maturation intermediates by cryo-EM. The processing of MA-CA-SP1 from NC-SP2-p6 
allows condensation of the RNP (de Marco et al., 2010b) and based on the in vitro Gag 
processing kinetics and the in vitro condensation ability of the cleaved NC-containing 
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Gag products, suggests the condensation of the RNP is likely an initial stage in the 
maturation process (Mirambeau et al., 2007; Pettit et al., 2002). The cleavage of CA-
SP1 from MA allows disassembly of the immature lattice but the mature CA lattice only 
forms when SP1 is cleaved from CA (de Marco et al., 2010b). 
 
High resolution crystal structures of the hexameric CA-NTD of MLV and full-length 
HIV-1 CA (stabilised by thiol-linkages) have been reported (Mortuza et al., 2004; 
Pornillos et al., 2009). These high resolution structures have helped in delineating the 
intermolecular interactions between CA molecules which support the hexameric 
building blocks of the core. Interactions between residues in the β-hairpin and α helices 
1-3 form a large intra-hexameric interface between neighbouring CA monomers, which 
stabilises the hexamers (Mortuza et al., 2004). Similarly, the cross-linked HIV-1 CA 
hexamer also contains this large intra-hexameric interface (Li et al., 2000; Pornillos et 
al., 2010; Pornillos et al., 2009). Adjacent hexamers were linked by CA CTD-CTD 
dimerisation interfaces, as have been seen in crystal structures of the CA CTD and cryo-
EM reconstructions of retroviral CA lattices formed in vitro (Bharat et al., 2012; 
Gamble et al., 1997; Li et al., 2000; Pornillos et al., 2009).  
 
One of the complexities of HIV-1 core formation, compared to formation of the MLV 
core, is the requirement to create a conical core. The formation of the CA cone is 
believed to be achieved by the insertion of 12 CA pentamers at the ends of the conical 
core. The structure of the HIV-1 CA pentamers have been solved, using a similar cross-
linking strategy utilised for the HIV-1 CA hexamers, and a model of the HIV-1 conical 
core has been proposed (Pornillos, Ganser-Pornillos, and Yeager, 2011). In this model, 
it is proposed that the flexibility at the CA interfaces allows formation of the defined 
HIV-1 core shape. Recently it has been proposed that the pentamers of hexamers (a 
central CA pentamer surrounded by 5 hexamers) forms a more angular 'dome' surface 
which contributes to the formation of the conical ends of the HIV-1 CA core (Zhao et 
al., 2013). This study also highlighted the importance of the hydrophobic trimeric 
interface between the α helix 10 of the CA CTDs (Zhao et al., 2013), and this interface 
was necessary for the formation of the correct morphology of mature core. While our 
understanding of the interfaces important for the formation of the CA core have 
improved, the mechanism behind the formation of the mature core remains elusive.  
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1.6.3 Mutations and alterations affecting mature CA core formation 
Many mutations have been described that have an effect on the formation of the mature 
retroviral CA core. Unsurprisingly, mutations in CA can affect the formation of 
retroviral cores. A whole range of mutations in Mo-MLV CA have been shown to be 
detrimental to the early stages of infection without significantly altering virus release, 
although the morphology of the CA core (by EM) has not always been assessed (Alin 
and Goff, 1996; Auerbach, Brown, and Kaplan, 2006; Auerbach, Brown, and Singh, 
2007; Auerbach et al., 2003). Interestingly, one study showed that a range of insertions 
into the NTD of Mo-MLV CA had effects on the formation of a mature core with 
minimal affects on virus release (Auerbach, Brown, and Singh, 2007). Specifically, 
insertions in the β-hairpin caused an immature core morphology for many particles 
(many also displayed an aberrant core morphology), whereas mutations further 
downstream caused almost all virions to contain aberrant cores (Auerbach, Brown, and 
Singh, 2007). Similarly with HIV-1, when mutations were made in the N-terminal β-
hairpin no conical cores were formed and many of these HIV-1 CA mutants displayed a 
condensed mass, likely the RNP, with no surrounding core (von Schwedler et al., 1998). 
Furthermore, similar aberrant core morphologies were also seen with deletion and 
insertion mutants in the NTD of HIV-1 CA (Dorfman et al., 1994; Reicin et al., 1996). 
 
Some mutations in HIV-1 NC, in the zinc fingers, have also been reported to cause core 
morphology defects, although this is combined with significant defects in gRNA 
packaging, assembly and virus release (Grigorov et al., 2007). Moreover, mutation of 
the NC basic patch (Δ16-23 NC amino acids), N-terminal to the MLV zinc finger, also 
resulted in aberrant core morphologies where some particles even contained multiple 
cores (Muriaux et al., 2004). However, as with HIV-1 this mutant had a defect in gRNA 
packaging, assembly and release, indicating these mutations could potentially be 
affecting the formation of the immature Gag lattice during assembly.  
 
Currently no host or viral factors have been described that actively participate in 
formation of the mature core. Very recently it has been shown that LEDGINs, which 
block the HIV-1 IN-LEDGF interaction, cause a late maturation defect where the 
majority of particles contain either: the RNP outside a formed core or no formed core 
(Desimmie et al., 2013). These drugs are able to induce multimerisation of Pol and the 
authors suggest that the drug influences the equilibrium of IN multimers within the 
virion, causing a defect in core formation (Desimmie et al., 2013). However, although 
unlikely, it was noted that the late effect of LEDGINs could be caused by inhibiting the 
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IN-LEDGF interaction at a late stage of infection (Desimmie et al., 2013). Interestingly, 
mutations in HIV-1 IN have also been described that cause a similar aberrant core 
morphology to the ones caused by LEDGINs (Engelman et al., 1995). Taken together 
this data suggests that alterations to IN can have detrimental effects on mature core 
formation, although whether the IN mutation causes a similar multimerisation of IN is 
currently unknown. 
 
1.6.4 Stability of the CA core 
The formation of a CA core of optimal stability has been shown to be essential for the 
early stages of infection. Mutations altering the stability of HIV-1 have significant 
effects on the ability to reverse transcribe in cells (Forshey et al., 2002). The CA 
mutations E45A and E128A/E132A both increase the stability of the HIV-1 CA core 
and result in a reduced ability to reverse transcribe in infected cells. Other mutations in 
CA were found to decrease the in vitro stability of the HIV-1 core and these also 
impacted on the ability to reverse transcribe or its kinetics in vivo (Forshey et al., 2002). 
A similar effect has also been reported for RSV. Certain mutations in RSV CA MHR 
caused a reduction in virus release. However, more conservative amino acid changes, 
like the L117I mutant, caused a remarkably different phenotype, where virus was 
released but had problems with reverse transcription in vitro and in vivo (Cairns and 
Craven, 2001; Craven et al., 1995). Analysis of the resistance to detergent treatment of 
these RSV cores revealed that the mutations had made the core unstable (Craven et al., 
1995). This again suggests that the formation of a core of optimal stability is essential 
for the early stages of infection. 
 
1.7 Integration targeting 
The design of effective and safe retroviral-based gene therapy vectors requires defined 
integration targeting. This was exemplified in human gene therapy trials utilising 
gammaretroviral-based vectors, which led to patients developing leukaemia 
(Cavazzana-Calvo et al., 2000; Hacein-Bey-Abina et al., 2003). Retroviral DNA 
integration into the host genome is not random and different retroviruses display 
preferences towards particular regions of the chromatin. MLV integrates close to 
transcriptional start sites around CpG islands (Mitchell et al., 2004; Wu et al., 2003), 
whereas HIV-1 has a preference for integration into actively transcribed genes 
(Schroder et al., 2002). Interestingly, the alpharetroviruses are the least selective and 
display only a weak preference for actively transcribed genes (Mitchell et al., 2004). 
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1.7.1 LEDGF and integration targeting 
The targeting of the lentiviral intasome to chromosomal integration sites has been an 
area of intense investigation over the past decade. Biochemical pull down of a FLAG-
tagged HIV-1 IN expressed in cells, isolated an important HIV-1 co-factor, LEDGF 
(Cherepanov et al., 2003). Inside the nucleus, HIV-1 IN binds to LEDGF via its 
integrase binding domain (IBD) (Cherepanov et al., 2004; Cherepanov et al., 2003; 
Maertens et al., 2003) and LEDGF then acts as a vital tether between IN and the host 
chromatin (Astiazaran et al., 2011; Busschots et al., 2005). The LEDGF interaction has 
been shown to occur with a variety of lentiviral IN proteins but not those from simple 
retroviruses like MLV (Busschots et al., 2005; Cherepanov, 2007).  
 
LEDGF, through its interaction with IN and the host chromatin directly influences the 
integration pattern of lentiviruses, and lentiviruses infecting LEDGF-depleted cells 
display a different pattern of integration (Ciuffi et al., 2005; Llano et al., 2006; Marshall 
et al., 2007). One study has shown that the integration pattern of HIV-1 correlated with 
the majority of LEDGF chromatin binding sites, indicating that HIV-1 integration 
occurs near to the LEDGF chromatin docking sites (De Rijck et al., 2010). Interestingly, 
in cells depleted of LEDGF, integration targeting did not become random and another 
host factor with an IBD, called heptoma-derived growth factor-related protein 2 
(HRP2), can drive the integration targeting in these cells when over-expressed 
(Cherepanov et al., 2004; Schrijvers et al., 2012; Vandegraaff et al., 2006). However, 
endogenous levels of HRP2 were unable to rescue the infectivity of HIV-1 in LEDGF 
knock down cells, suggesting its contribution in natural HIV-1 integration is minimal 
(Schrijvers et al., 2012). 
 
No chromatin tethering factors for the MLV PIC had been described at the start of this 
project, although this has now changed and will be discussed in the light of my results 
in the following chapters. Previous work on HIV/MLV chimeras had, however, shown 
that inclusion of the MLV IN protein could change the HIV-1 integration pattern to one 
that is more similar to MLV (Lewinski et al., 2006). This suggested that the IN portion 
of MLV is a major driving force behind integration site selection. Interestingly, addition 
of the MLV Gag proteins into the HIV/MLV-IN chimera produced an integration 
pattern even closer to that of MLV, indicating that MLV Gag proteins are also involved 
in integration site selection (Lewinski et al., 2006). No further characterisation of the 
regions of Gag involved in MLV integration site selection has been performed. 
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A bioinformatics study had also revealed that MLV integration sites are areas of 
transcription factor binding (Felice et al., 2009). This suggested that transcription 
factors could be involved in MLV integration targeting. Moreover thirteen DNA-
binding cellular factors have been shown to interact with MLV IN in yeast-two-hybrid 
screens including, amongst others, a panel of transcription factors TFIIE-β, B-ATF, 
Znfp15, Znfp38, Ankrd49 and AF9 (Studamire and Goff, 2008). However, little work 
has been performed on the effect of these transcription factors on MLV integration. 
 
1.8 Gag proteins between MA and CA 
Almost all genera of orthoretroviruses contain proteins between the MA and CA 
domains of Gag (Figure 1.8). These proteins often contain the L-domain and many have 
roles in viral assembly or influence the morphology of the CA core. 
 
RSV is the prototypic alpharetrovirus and contains three proteins cleaved out from Gag 
between MA and CA: p2a, p2b and p10. p2b carries the RSV PPxY late domain and if 
removed results in a significant reduction in released virus (Xiang et al., 1996). The p10 
domain of RSV Gag can convert in vitro assembled CA-NC tubes into spherical 
particles, indicating it is involved in particle morphology (Campbell and Vogt, 1997). In 
vivo p10 is involved in nuclear export of the RSV genome for packaging into 
assembling virions (Scheifele, Ryan, and Parent, 2005), but certain mutations in p10 
also cause defects in core morphology (Scheifele et al., 2007).  
 
The prototypic betaretrovirus mouse mammary tumour virus (MMTV) contains four 
proteins between MA and CA of Gag, namely: p21, p8, p3 and n (Hizi et al., 1989). 
Deletion of the MMTV p8 domain of Gag results in a lack of assembling virus in the 
cytoplasm (Zabransky et al., 2010). Deletion of the n domain of MMTV Gag results in 
the formation of tube-like structures in the cytoplasm and released from cells, 
suggesting it has a role in the morphology of particles during assembly (Zabransky et 
al., 2010). MPMV, another betaretrovirus, has three additional Gag proteins between 
MA and CA: p24/p16 (p24 is additionally cleaved to p16) and p12. Deletion of the 
p24/p16 region of MPMV Gag results in a budding defect as the two L-domains are 
positioned within p16 (PPPY and PSAP) (Gottwein et al., 2003; Yasuda and Hunter, 
1998). The p12 protein is positionally analogous to p8/p3/n region of MMTV Gag 
(Sommerfelt, Rhee, and Hunter, 1992), and deletion of the p12 domain in MPMV Gag 
resulted in a defect in virus release (Sommerfelt, Rhee, and Hunter, 1992). Moreover, 
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betaretroviral particles initially assemble in the cytoplasm before trafficking to the 
membrane for release, and p12 mutant MPMV intracellular particles biochemically 
isolated from cells were unstable (Sommerfelt, Rhee, and Hunter, 1992). This indicated 
that the MPMV p12 protein is important for Gag-Gag multimerisation during assembly. 
This has also been shown with purified MPMV p12, which forms stable multimers in 
vitro (Knejzlik et al., 2007; Knejzlik et al., 2004) and is able to interact with itself in 
yeast-two-hybrid experiments, something that was not seen for the p8/p3/n protein for 
MMTV (Zabransky, Sakalian, and Pichova, 2005). All of which highlights a role for 
MPMV p12 in assembly.  
 
The prototypic epsilon retrovirus walleye dermal sarcoma virus (WDSV) also contains a 
protein between MA and CA called p20 (which is also processed to p10), although 
currently little is known about the functions of Gag in this retrovirus (Holzschu et al., 
1995).   
 
 
Figure 1.8: Gag protein composition. A diagram illustrating the protein domain structure for 
orthoretroviral Gag proteins, which are cleaved out during maturation. 
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1.8.1 p12 
The protein situated between MA and CA in gammaretroviruses is the primary focus of 
this thesis, p12 (Figure 1.8). The mature p12 protein is a small polypeptide with high 
proline content (~20%). Nuclear magnetic resonance data suggests that p12 remains 
highly flexible when expressed as a fusion to the NTD of CA, suggesting it is unlikely 
to adopt a highly ordered structure in isolation (Kyere, Joseph, and Summers, 2008). 
Mutagenesis of p12 has revealed an essential requirement for this part of Gag during, 
both, the late and early stages of infection (Auerbach et al., 2003; Yuan et al., 2002; 
Yuan, Li, and Goff, 1999; Yueh and Goff, 2003). 
 
1.8.2 p12 and the late stage of infection 
L-domains are involved in recruiting members of the ESCRT pathway essential for 
virus release from the cell, as detailed earlier. MLV p12 contains the L-domain motif 
PPxY, which is utilised by a number of retroviruses (Bieniasz, 2006; Martin-Serrano et 
al., 2005; Yuan, Li, and Goff, 1999) and functions independent of its position in Gag 
(Yuan et al., 2000). Indeed, other retroviral L-domains can replace the MLV p12 L-
domain function when inserted into p12 or other parts of Gag, suggesting it is a 
commonly utilised pathway by all retroviruses (Yuan et al., 2000). The L-domain in p12 
has been shown to interact with the WW domain of cellular HECT ubiquitin ligases 
WWP1, WWP2, Itch and Nedd4 (Martin-Serrano et al., 2005), and MLV Gag has been 
shown to recruit WWP1 to the plasma membrane in an L-domain dependant fashion 
(Martin-Serrano et al., 2005). No interaction between WWP1 and WWP2 with members 
of the ESCRT pathway was seen in yeast-two-hybrid experiments, but indirect evidence 
for an interaction could be seen by analysing the localisation of WWP1, WWP2 and 
Itch in the presence of a dominant negative form of VPS4, a core component of the 
ESCRT pathway (Martin-Serrano et al., 2005). The budding of MLV via the PPxY L-
domain interaction with WW domain proteins requires the HECT ubiquitin ligase 
activity, although the target of the ubiquitination is not a viral protein and currently 
remains unknown (Figure 1.6) (Martin-Serrano, 2007; Martin-Serrano et al., 2005; 
Zhadina et al., 2007). 
 
1.8.3 The discovery of a role for MLV p12 during the early stages of infection 
The first hint that p12 was involved in the early stages of MLV infection came from a 
study in 1984, when a deletion removing 48 amino acids in MLV Gag, 23 from the C-
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terminus of MA and 25 from the N-terminus of p12, blocked infection at an early stage 
(Crawford and Goff, 1984). This mutant had reduced levels of linear viral DNA and no 
LTR circles in vivo, indicating a block affecting the efficiency of reverse transcription 
and entry of the viral DNA to the nucleus (Crawford and Goff, 1984). The in vitro 
endogenous RT activity assay indicated that the RNA genome was present and this 
mutant was competent for reverse transcription (Crawford and Goff, 1984). At the time, 
the effects on MA or p12 function could not be separated due to the nature of the 
deletion spanning MA and p12 sequence. However, subsequent mutagenesis 
experiments revealed that p12 does indeed have a function during the early stages of 
infection. Seven p12 mutants, four in the N-terminus (mutants 5-8) and three in the C-
terminus (mutant 13-15), were blocked at an early stage of infection before entry to the 
nucleus, as determined by a lack (or severe reduction) of two-LTR circles in infected 
cells (Yuan, Li, and Goff, 1999).  
 
Later experiments also found these regions of p12 were sensitive to insertions, with the 
N-terminal region slightly more sensitive than the C-terminus (Auerbach et al., 2003). 
Two p12 mutants in the N-terminus of p12 (mutant 6 and 8) also displayed a reduced 
ability to synthesise linear viral DNA in vivo, indicating that these mutants contain a 
slightly earlier block, reducing the efficiency of reverse transcription (Yuan, Li, and 
Goff, 1999). Mutant 6 packaged gRNA at levels equivalent to wild type, suggesting that 
RNA is available for reverse transcription in vivo, and this is not the defect with these 
mutants (Yuan, Li, and Goff, 1999).  
 
1.8.4 p12 and nuclear entry of the MLV PIC 
All the p12 mutants described by Yuan et al. were unable to access/remain in the 
nucleus based on a lack of two-LTR circles. Biochemical analysis of MLV p12 mutant 
14 PICs isolated from cells has shown that this mutant is not significantly different from 
wild type PICs, indicating that mutation in the C-terminus of p12 does not affect the 
gross composition of the PIC (Yuan et al., 2002). Interestingly, PICs from the p12 
mutant 14 are competent for integration in vitro, leading the authors to conclude that 
mutations in p12 are likely involved in localisation of the PIC to the nucleus or the 
specific sub-nuclear environment (Yuan et al., 2002). Furthermore, during the period of 
my PhD study, data has come to light stressing a role for MLV p12 in tethering the 
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MLV PIC to chromatin. This more recent data will be discussed in the context of my 
own work in the following chapters.   
 
1.8.5 Interactions of p12 with host and viral factors 
Nucleic acid 
Purified MLV p12 has been shown to bind specifically to MLV RNA and not RNA 
from other retroviruses (Sen, Sherr, and Todaro, 1976; Sen and Todaro, 1977). 
Interestingly, the interaction of purified p12 did not alter the velocity sedimentation of 
the viral RNA, indicating the conformation of the RNA was not significantly altered by 
p12 binding (Sen, Sherr, and Todaro, 1976). The extent of p12-RNA binding was low 
with little p12 bound to the RNA, in the in vitro binding assays, with the authors 
calculated ratio of less than 15 p12 molecules per 70S dimeric genome (Sen, Sherr, and 
Todaro, 1976). Another study by the same group has also shown that the extent of 
phosphorylation of p12 dictates its affinity for RNA, where phosphorylated p12 had a 
higher affinity for RNA than unphosphorylated p12 or p12 saturated by phosphorylation 
(Sen, Sherr, and Todaro, 1977). Furthermore, it has been highlighted that the N-terminal 
sequence of MLV p12 has sequence homology with histone H5, which also binds to 
nucleic acid in a manner regulated by phosphorylation (Henderson, Gilden, and 
Oroszlan, 1979). However, the majority of p12 phosphorylation has been shown to be 
dispensable for the early function of p12 (Yueh and Goff, 2003).  
 
Capsid 
CA and p12 have been shown to colocalise in infected cells and immunoprecipitation of 
p12, from infected cells, can also co-precipitate CA, albeit at a low level compared to 
the total CA in the cells (Prizan-Ravid et al., 2010). However, work in our laboratory 
has so far not found a direct interaction between purified p12 and CA in vitro (Nader, 
M. unpublished data). Regardless, there is good genetic evidence to suggest that the 
function of p12 is linked to CA during the early stages of infection. Chimeric viruses 
constructed from spleen necrosis virus (SNV) and MLV could only infect cells if the 
CA and p12 (p18 in the case of SNV) were from the same species of virus (Lee and 
Nagashima, 2005). Therefore, while limited evidence for a direct interaction between 
p12 and CA exists, the chance that these proteins interact remains a possibility based on 
the genetic evidence from Lee et al. 
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Clathrin 
Recently MLV has been shown to specifically incorporate clathrin via a DLL motif in 
p12 (Zhang et al., 2011). Knock down of clathrin using RNA interference reduced the 
infectivity of MLV by three-fold, whereas mutation of the DLL motif reduced 
infectivity by greater than 100-fold, indicating a large discrepancy between the effect of 
the mutation and of clathrin depletion (Zhang et al., 2011). However, the clathrin levels 
were only depleted to 20% of the wild type levels so this may explain the discrepancy. 
The authors observed a loss of mature p12 by immunoblotting when the DLL motif was 
mutated, and a reduced ability to saturate TRIM5alpha restriction (Zhang et al., 2011). 
This indicated that there was a morphological defect of the core combined with a loss of 
mature p12, when MLV was unable to incorporate clathrin (Zhang et al., 2011). A 
variety of retroviruses have now been shown to incorporate clathrin via motifs situated 
in varying positions in Gag and Pol (Popov et al., 2011; Zhang et al., 2011). However 
prevention of clathrin incorporation by removal of clathrin, or mutation of sequences 
driving incorporation, had varied effects on infectivity depending on the virus. Thus the 
exact function of clathrin incorporation is currently poorly understood. 
 
1.8.6 Phosphorylation of p12 
Some Gag proteins are phosphorylated by host proteins during infection. The function 
of these phosphorylation events remain poorly understood. p12 is the major 
phosphoprotein of MLV and phosphorylation is thought to mainly occur on serine 
residues (Ikuta and Luftig, 1988; Naso et al., 1979; Sen, Sherr, and Todaro, 1977). 
Mutation of S61 in p12 to alanine resulted in virus with significantly reduced levels of 
phosphorylation (~15% of wild type) and caused a block to infection at an early stage 
(Yueh and Goff, 2003). Mutation of other serines in p12 did not significantly reduce the 
levels of p12 phosphorylation, indicating that S61 is the major site of p12 
phosphorylation (Yueh and Goff, 2003). Replacement of S61 with aspartic acid, to 
mimic the negative charge of phosphoserine, was unable to rescue the infectivity defect, 
and importantly revertant viruses derived from the S(61,65)A MLV mutant did not have 
an increase in phosphorylation (Yueh and Goff, 2003). This has been taken to indicate 
that the majority of p12 phosphorylation, per se, is not essential for p12 function during 
the early stages of infection.  
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A subset of the revertant viruses arising from the S(61,65)A p12 mutant contained 
additional positively charged residues in the C-terminus of p12 (mainly arginines) 
(Yueh and Goff, 2003). The authors decided to individually mutate the natural basic 
arginine patch in p12 (R66, R68, R70 and R71), which produced a mutants with a 
phenotype similar to the p12 mutants 13-15 (Yueh and Goff, 2003). Interestingly, the 
similar basic amino acid lysine could not replace the arginine, highlighting the 
importance of this C-terminal arginine patch for p12 function (Yueh and Goff, 2003). 
 
1.9 Aims and Findings 
The primary aim of this PhD project was to investigate the role of the gammaretroviral 
Gag protein p12 during the early stages of infection, and in doing so add to our 
understanding of the dynamic processes that occur during the early steps of the 
retroviral life cycle. 
 
Mutations exhibiting a potent block to Mo-MLV infection during the early stages of 
infection have been previously described (Yuan, Li, and Goff, 1999). This project began 
by characterising these p12 mutants in an Mo-MLV vector system. Chapter 3 describes 
the phenotype of these Mo-MLV p12 mutant VLPs using a variety of assays. 
Importantly, Mo-MLV p12 was found to have two functional domains, which act in a 
non-independent manner during the early stages of infection. Additionally, the amino 
acids essential for function of these N- and C-terminal domains in Mo-MLV p12 were 
established. 
 
Little is known about the function of p12 in other gammaretroviruses and chapter 4 
details the analysis of the conservation of p12 function within the gammaretroviral 
genus. Similar assays to those utilised in chapter 3 have revealed that all 
gammaretroviruses require p12 during the early stages of infection. Closer analysis of 
gibbon ape leukaemia virus (GaLV) p12 revealed that it also contains two functional 
domains in the N- and C-terminus. Chimeras between Mo-MLV and GaLV were then 
generated to test if the N- and C-terminal domains serve common functions between 
gammaretroviruses.  
 
Much work had been done by this point on p12 function and Chapter 5 details various 
experiments designed to establish the function of the N- and C-terminal domains of p12. 
56 
 
Importantly, functions were assigned to both domains based on the results of these 
experiments. To compliment the work carried out in the first three chapters, Chapter 6 
details microscopy-based studies probing the localisation of p12 expressed in cells or as 
part of the retroviral PIC.  
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Chapter 2.  
Materials and Methods 
 
2.1 Recombinant DNA 
2.1.1 Plasmid amplification in chemically competent cells 
Plasmid DNA (<1μg) was transformed into chemically competent TOP10 E.coli cells 
and heat shocked for 30 s at 42 oC, then they were allowed to recover for 1 hr and plated 
on Lysogeny Broth (LB)-agar containing the selective antibiotic (either kanamycin 30 
μg/ml [Sigma Aldrich] or ampicillin 50 μg/ml [Sigma Aldrich]). Plates were then 
incubated at 37 oC for >16hrs. A single clone was selected from the plate and grown in 
LB media containing the selective antibiotic at 37 oC for >16hrs. 
 
2.1.2 Plasmid DNA purification 
Purification of plasmid DNA from small bacterial cultures (2-3ml) was carried out by 
alkaline lysis followed by ethanol precipitation using the buffers (P1, P2 and P3) of the 
Plasmid Midi Kit (QIAGEN). Bacteria were pelleted and re-suspended in buffer P1 
(100 µl). Cells were then lysed with buffer P2 (100 µl) and neutralised by incubation on 
ice for 10 min with buffer P3 (150 µl). Lysates were centrifuged at 13,000 xg for 5min,  
the supernatant transferred into 1 ml of pre-chilled 100 % ethanol and placed at -20 oC 
for 10 min. Samples were then centrifuged at 13,000 xg for 7 min and the supernatant 
aspirated. The pellet was washed with 70 % ethanol, centrifuged at 13,000 xg for 8 min 
and the supernatant aspirated. The pellet was air dried and re-suspended in dH2O (50 
µl). 
  
Purification of plasmid DNA from larger bacterial cultures (50-100 ml) was carried out 
using the Midi Plasmid Purification kits (QIAGEN) according to the accompanying 
protocol. Plasmid DNA was resuspended in 100-200 µl of TE buffer (10 mM Tris-HCl 
[Fisher Scientific], 1 Ethylenediaminetetraacetic acid mM [EDTA, Sigma Aldrich] pH 
8). DNA concentrations were determined by measuring the absorbance at 260 nm on a 
spectrophotometer (WPA). A list of all the plasmids utilised in this study can be seen in 
Appendix B. 
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2.1.3 Restriction enzyme digest 
To verify the presence of the correct plasmid after purification, the DNA was digested 
with restriction endonucleases (New England Biolabs). Plasmid DNA (1μg) was 
digested with the selected restriction endonuclease in a 15 μl reaction containing the 
optimal buffer and at the optimal temperature for the enzyme for 1 hr. DNA loading dye 
(30 % glycerol, 0.25 % bromophenol blue 0.25% xylene cyanol [Sigma Aldrich], 3 μl) 
was added to the reaction and the DNA was separated by electrophoresis on a 1% 
agarose gel (Fisher Scientific) containing 0.5 μg/ml ethidium bromide (Bio-Rad). The 
gel was visualised using a UV transilluminator equipped with a digital camera (Bio-
Rad). 
 
2.1.4 Polymerase chain reaction (PCR) 
Amplification of DNA plasmid fragments was carried out by PCR using Phusion DNA 
polymerase (Finnzymes). Typically, 5-10ng of plasmid DNA was subjected to PCR in a 
50μl volume with the final concentrations of: 1X HF buffer (Finnzymes); 0.5 μM each 
primer (Sigma and Eurofins); 200 μM dNTPs (Roche); 1 U polymerase. The PCR was 
performed in a DNA engine thermal cycler (Bio-Rad) with the following cycling 
conditions: 98 oC for 30 s; 98 oC for 10 s; 65-72 oC for 20 s; 72 oC for 20s per kb and 
cycled 28 times with a final extension of 10 min. Amplified DNA fragments were 
purified using the QIAquick PCR purification kit (QIAGEN) according to the 
accompanying protocol and eluted in 30-50 μl dH2O. 
 
2.1.5 Cloning by restriction digest and DNA ligation 
To clone DNA fragments into plasmids, the vector and DNA insert were digested with 
0.8 μl of each restriction endonuclease (New England Biolabs) for 3 hr at the optimal 
temperature. The vector was additionally treated with 0.6 μl of alkaline phosphatase 
(Roche) for 30 min at 37 oC and another 0.6 μl for 30 min at 50 oC. Digested DNAs 
were separated on a 1 % agarose gel containing 0.5 μg/ml ethidium bromide and the 
required fragments of DNA excised on a UV transilluminator (UVP). Fragments were 
purified using the QIAquick Gel Extraction Kit (QIAGEN) according to the 
accompanying protocol. The digested insert was then ligated into the vector using the 
Rapid DNA ligation Kit (Roche) with the following protocol: 7 μl insert DNA; 1 μl 
vector DNA; 2 μl 5x DNA dilution buffer; 10 μl 2x T4 DNA ligation buffer and 1 μl T4 
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DNA ligase (5 U/μl). The reaction was then incubated at 20 oC for 10 min. Ligated 
plasmid DNA (2-4 μl) was then amplified in E.coli as in section 2.1.1. 
 
2.1.6 Site-directed mutagenesis (SDM) 
Substitutions and deletions were introduced into plasmids by extension of 
complementary oligonucleotides containing the desired changes using the Stratagene 
XL site directed mutagenesis kit (Aligent). Briefly, 30-50 ng of parental plasmid was 
amplified using 125 ng of each mutagenic primer (See Appendix A). The parental 
plasmid was removed by digestion with Dpn I (10 U, Roche) for 1 hr at 37 oC adding 
the same amount of enzyme after 1 hr. SDM product (2-8 μl) was amplified in E.coli as 
described in section 2.1.1. For reactions with a low yield of modified plasmid DNA, 
XL-10 gold cells (Aligent) were used due to their greater transformation capacity. 
Multiple clones from one transformation were grown in 2 ml of selective LB media for 
>16 hr at 37 oC and plasmid DNA was then prepared as in section 2.1.2. The resulting 
plasmid DNA was assessed by restriction enzyme digest and sequencing to confirm the 
presence of the desired change (for details of all the plasmids produced by SDM see 
Appendix B).   
 
2.1.7 Production of chimeric Mo-MLV/GaLV plasmids by overlapping extension 
PCR 
Chimeric p12 sequences were constructed by overlapping PCR from three DNA 
fragments amplified from either pKB4 (for Mo-MLV sequence) or pczGaLVgp (for 
GaLV sequence). All DNA fragments were amplified using Phusion DNA polymerase 
(Finnzymes) according to the manufacturer's instructions. 
 
The amino acid sequences at the crossover junctions in the Mo-MLV based chimeras 
are as follows (i) Mo-MLV/Ga-p12: Mo-MLV MA(...SSLY/PALTDD…)GaLV p12 and 
GaLV p12(…DSTVIL/PLRA…)Mo-MLV CA; (ii) Mo-MLV/Ga-Np12: Mo-MLV 
MA(…SSLY/PALTDD…)GaLV p12 and GaLV p12(...LLSEPT/PPPY...)Mo-MLV 
p12; (iii) Mo-MLV/Ga-Cp12: Mo-MLV p12(...PPPY/PAALPP...)GaLV p12 and GaLV-
p12(...DSTVIL/PLRA...)Mo-MLV CA. The final PCR fragments were amplified with 
primers for 5'-ccgcatggacacccagacca-3', and rev 5'-tggggcttctgcccgcgttt-3', and inserted 
into pKB4 between the BsrGI and XhoI sites. 
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The amino acid sequence at the crossover junctions in the GaLV based chimeras are as 
follows: (i) GaLV/Mo-p12: GaLV MA(..PPIY/PALTPS..)Mo-MLV p12 and Mo-MLV 
p12-(..TTSQAF/PLRA..)GaLV CA; (ii) GaLV/Mo-Np12: GaLV 
MA(..PPIY/PALTPS..)Mo-MLV p12 and Mo-MLV p12(..EDPPPY/PAAL..)GaLV 
p12; (iii) GaLV/Mo-Cp12: GaLV p12(..SEPT/PPPYRD..)MoMLV p12 and Mo-MLV 
p12(..TTSQAF/PLRA..)GaLV CA. Due to the lack of suitable restriction sites in 
pczGaLVgp, a BsrGI site was introduced into this plasmid 5' of gag, and an XhoI site 3' 
of pol was removed, both by site directed mutagenesis. The final chimeric fragments 
were amplified using primers, for 5'-gcagatatccagcacagtgg-3', and rev 5'-
cagaagacgctccctacctg-3', and inserted into pczGaLVgp between the introduced BsrGI 
site and a now unique XhoI site. The BsrGI site was then removed by site directed 
mutagenesis. 
 
2.1.8 DNA sequencing 
All DNA sequencing was performed by Source Bioscience using ABI 3730 DNA 
sequencing technology. Sequencing primers used are listed in Table 2.1. 
  
Table 2.1: Sequencing primers 
Primer name Plasmid DNA target Sequence (5'-3') 
oKB128 pKB4 or derivatives of 
pKB4 
p12 caagccctttgtacaccctaagcc 
oKB129 pKB4 or derivatives of 
pKB4 
p12 tctgggcgctcgaggggaaaagcg 
oDW202 pKB4 or derivatives of 
pKB4 
p12 atggacacccagaccaggtc 
oVBrev1 pKB4 or derivatives of 
pKB4 
CA tctgctcatcctctgtcc 
oDW203III pcFeLVdw or pcFeLVgp p12 accttatgtgaggccgaatg 
oGaLVp12 pcGaLVgp p12 caaggtcgctgttgtctctg 
oXMRVp12 pHG1 p12 ctaaaccccctctcttaccg 
oKB136 pCI3GN/B p12 ggctattgcctatgaacc 
oKB137 pCI3GN/B p12 cagtttacctggatcctc 
 
2.2 Cell culture and virus production 
2.2.1 Cell culture 
293T, D17, HeLa, Mus dunni (M. dunni), NIH3T3 (N-3T3), TE671, Balb/c 3T3 (B-
3T3), U20S and U/R cells were maintained in Dulbecco’s modified eagle medium 
(DMEM, Gibco) supplemented with 10 % fetal calf serum (FCS, BioSera) and 100 
61 
 
U/ml penicillin and 100 µg/ml streptomycin (Sigma) (from now on referred to as 
DMEM complete). U/R cells (a gift from Eran Bacharach) express mCAT-1, the 
ecotropic MLV receptor, under zeocin selection and were passaged with 0.1 mg/ml 
zeocin (Invitrogen). Cells were grown on 10 cm plates and were passaged every 48-72hr 
into fresh DMEM complete for a maximum of 28 passages. Cell stocks were stored in 
liquid nitrogen and were passaged 5-7 times after thawing before they were used in any 
assays.  
 
2.2.2 Blocking the cell cycle in the Mitotic (M)-phase 
To block at mitosis, cells were washed with DMEM complete and fresh DMEM 
complete with of nocodazole (0.4 μg/ml, Sigma) was added for 18 hr. To check the 
percentage of cells blocked in mitosis, cells were fixed with 4 % paraformaldehyde 
(Alfa Aesar) PBS for 20 min, washed three times with PBS and mounted on slides with 
vectashield (Vector labs) with 4',6-diamidino-2-phenylindole (DAPI, 1.5 µg/ml). Cells 
were imaged with a fluorescent microscope and the proportion of cells with condensed 
chromatin counted. 
 
2.2.3  Transfection of cells with mCherry-p12 expression vectors 
To express the mCherry-p12 fusion proteins, mammalian cells were transiently 
transfected using Turbofect in Vitro transfection reagent (Fermentas) according to the 
accompanying protocol. 293T, HeLa or M. dunni cells were seeded at 1x105 cells per 
well, in a 12 well plate (Corning) containing a sterile 12 mm circular coverslip (VWR). 
The following day, 1-2 μg of mCherry-p12 expression plasmid (or control) was added 
to 180 μl of serum-free DMEM with 12 μl Turbofect (Fermentas), incubated for 20 min 
and added drop-wise onto the cells. After at least 16 hr cells were fixed and imaged 
using a fluorescent microscope (see section 2.8.7), or trypsinised, pelleted and prepared 
for western blotting as described in section 2.6.1. 
 
2.2.4 Virus-like particle (VLP) production 
Virus-like particles of Mo-MLV, N-MLV, B-MLV, XMRV, FeLV, GaLV and HIV-1 
were prepared by co-transfection of 293T cells with a 1:1:1 ratio (2:1:1 for FeLV and 
3:1:1 for GaLV) of three plasmids encoding the appropriate wild type or mutant Gag-
Pol protein, VSV-G, and a reporter gene (β-galactosidase or GFP) respectively, using 7 
µl (in 6-well plate) or 35 µl (for 10cm plate) polyethylenimine (PEI, PolySciences) as a 
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transfection reagent. To produce mixed viral particles, wild type and mutant Gag-Pol 
expression plasmids (or two different mutants) were added to the transfection mix at 
different ratios, keeping the total concentration of the Gag-Pol plasmid constant. After 
24 hr, cells were washed and fresh DMEM complete was added for a further 16 hr. 
Virus-containing supernatants were harvested, passed through a 0.45 um filter 
(Sartorius), aliquoted and stored at -80 oC. In the abrogation assays, Turbofect 
(Fermentas) was used as transfection reagent. Approximately 18 hr post-transfection, 
cells were washed and sodium butyrate media (0.02 M sodium butyrate in DMEM 
complete) added for 6 hr before replacing it with fresh DMEM complete. VLPs were 
harvested after 16hr, as above. 
 
2.2.5 Quantification of VLP reverse transcriptase activity 
The reverse transcriptase (RT)-activity present in the harvested cell supernatant from 
VLP producer cells was quantified using the C-type RT activity Kit (CaVIDI) according 
to the accompanying protocol. 
 
2.3 Infectivity assays 
2.3.1 X-Gal staining of infected cells 
To establish the infectious titre of LacZ-encoding VLPs, X-gal staining of infected cells 
was performed. Cells were seeded at 5x104 cells per well in a 12-well plate (Corning). 
Cells were infected 24 hr later with 0.5 ml of a ten-fold dilution series of virus. The 
standard conditions for infection were 2 hr at 37 oC but for synchronised infections 2 hr 
at 4 oC or spinoculation (1000 xg) at 4 oC was used. After the infection, cells were 
washed three times with DMEM complete and incubated for 48-72 hr 37 oC. After the 
incubation, cells were washed once with PBS, fixed for 10 min in 2 % formaldehyde, 
0.2% gluteraldehyde (Fisher Scientific and Sigma Aldrich, respectively) and stained 
overnight with the staining solution (0.4 mg/ml X-gal (5-bromo-4-chloro-3-indolyl- 
beta-D-galactopyranoside, [Sigma Aldrich]), 4 mM K3Fe(CN)6 (Sigma Aldrich), 4mM 
K4Fe(CN)6ˑ3H2O (Sigma Aldrich), 2mM MgCl2 (Fisher Scientific) in PBS). The 
following day the number of blue LacZ+ clones (groups of cells) were counted using a 
light microscope (Olympus). The titre in infectious units per ml (I.U./ml), was 
calculated by multiplying the number of clones by the dilution factor and then by 2 (to 
account for the fact that 0.5 ml virus was used in the infections). 
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2.3.2 Chemiluminescent detection of beta-galactosidase activity in infected cells 
To determine the infectivity of LacZ-encoding VLPs a chemiluminescent assay for the 
presence of beta-galactosidase was used. D17 cells were seeded at 4x103 cells per well 
in a 96-well plate (Corning). The cells were infected 24hr later with virus, normalised 
by their RT activity (infection was with 75 - 600 mU/ml virus). Infected cells were 
lysed 48-72 hr post-infection in 20 μl Tropix Lysis Buffer (Invitrogen) and stored at -20 
oC. To assess the level of beta-galactosidase activity in the infected cell lysate 5 μl 
lysate was added to a white 96-well plate (Corning) and 50 μl of Tropix Galactostar 
reaction mixture (50:1 dilutent-to-substrate [Applied Biosciences]) added. The 
luminescence was measured every 10 min for  1 hr on a Tecan Safire2 plate reader 
(Tecan Group Ltd) with an integration time of 1000 ms. For the luminescence readout a 
time point was selected from the kinetic run where the luminescence was still increasing 
exponentially to ensure that the chemiluminescent substrate was not limiting the 
enzymatic reaction. The mean luminescence from at least two uninfected controls was 
subtracted from the sample values to account for the background. 
 
2.3.3 Quantification of GFP-encoding VLP infectivity by flow cytometry 
VLPs encoding GFP were generated as described in section 2.2.4. M.dunni cells were 
plated at 5x104 cells per well in a 24 well plate. The following day a 2-fold dilution 
series of the VLPs was added to the cells. Three days later the cells were trypsinised and 
transferred into flow cytometry tubes (BD Biosciences) with 3 % formaldehyde PBS 
(Fisher Scientific) and centrifuged at 530 xg for 10 min in a J6-MI centrifuge (Beckman 
Coulter). The supernatant was removed and the cells re-suspended by vortexing in 50μl 
of PBS 3mM Sodium azide (Sigma Aldrich). Infected GFP+ cells were quantified on a 
FACS Calibur flow cytometer (BD Biosciences). Single cells were gated on in the 
forward scatter (FSC) versus side scatter (SSC) plot (G1). Fluorescence intensity 
detected in FL1 (excitation laser 488nm and emission filter 530/30nm) was plotted 
versus the cell count on a histogram and a second gate was set for GFP positive cells 
(G2). At least 10,000 events in G1 were recorded per sample. The percentage of 
infected cells for each sample was calculated in the Cell Quest software with the 
following formula: % of infected cells=	 
  
  
  × 100. The same gating and instrument 
settings (gains on detectors, thresholds, number of cells counted, etc) were used for all 
experiments.  
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2.4 Abrogation assay 
The abrogation assay was used to test for the presence of the 'intact' CA core within 
cells infected with MLV VLPs. Tester VLPs were produced as described in section 
2.2.4. The day before harvest of the VLPs, either TE671 or Balb/c3T3 cells, which 
express the restriction factors human TRIM5alpha and Fv1b, respectively, were plated 
in 24 well plates (Corning) at 5x104 cells per well. VLPs were harvested through sterile 
0.45μm Minisart filters (Sartorius) and a 2-fold dilution series was made in DMEM. 
The dilutions of tester VLPs, from 1/2 to 1/128, were added to TE671 or B-3T3 cells 
and incubated for 4hr. Subsequently, cells were infected with a fixed volume of GFP-
encoding indicator N-tropic MLV VLPs. The indicator GFP-encoding VLPs were 
titrated on M.dunni cells and the volume required to infect ~30% (~MOI 1) was used to 
infect the TE671 or B-3T3 cells, pre-infected with the tester VLPs. After 72 hr of 
infection the cells were prepared for flow cytometry as in section 2.3.3.. 
 
2.5 Isolation of MLV cores from virions (detergent layer gradient) 
VLPs, from two 10 cm plates of 293T cells, were produced as described in section 
2.2.4. The VLP containing cell supernatant was concentrated in a 14x89 mm 
polyallomer ultracentrifuge tube (Beckman Coulter), underlayed with a 2.5 ml 20 % 
(w/v) sucrose (VWR) cushion and by centrifuging in an SW41 rotor (Beckman Coulter) 
at 100,000 xg for 90 min using an Optima L-90K ultracentrifuge (Beckman Coulter) 
cooled to 4 oC. The supernatant and sucrose were aspirated and the viral pellet drained 
by placing the tube upside down on tissue paper for 10 min. The viral pellet was then 
re-suspended in 250 μl PBS on ice for 4-5 hr. Linear 10-42% (w/w) sucrose gradients 
were poured in 14x89mm polyallomer ultracentrifuge tubes using a Gradient Master 
108 (BioComp Instruments, Inc). Layered on top of each gradient was 250 μl of 1 % 
Triton X-100 in 5 % (w/w) sucrose PBS or just 5 % (w/w) sucrose PBS (for VLP 
analysis) followed by 250 μl of 2.5 % (w/w) sucrose PBS. The re-suspended virus was 
gently layered on top (5 μl was kept for the input sample). The gradients were then 
centrifuged in an SW41 rotor at 100,000 xg for 16 hr using an Optima L-90K 
ultracentrifuge cooled to 4 oC. The next day the gradients were fractionated into 1 ml 
volumes using a BR-186 gradient fractionator with syringe pump (Brandel) connected 
to a RediFrac fraction collector (Pharmacia Biotech). For viral RNA analysis, fractions 
were collected in RNase-free tubes (Eppendorf) and 100 μl aliquots were treated and 
analysed as described in section 2.7.2 and 2.7.3, respectively. For protein analysis, 300 
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μl of each fraction was diluted in 100 μl 4X sodium dodecyl sulphate (SDS) loading dye 
(40 % (v/v) glycerol [Fisher Scientific], 12% SDS [Bio-Rad], 240 mM Tris pH 6.8 
[Fisher Scientific], 0.4 M dithiothreitol [DTT, Sigma Aldrich], 0.0125 % bromophenol 
blue [Sigma Aldrich]). All samples were heated for 8 min at 100 oC and then analysed 
by SDS polyacrlyamide gel electrophoresis (PAGE) as described in section 2.6.3. 
 
2.6 Protein analysis 
2.6.1 Preparation of cell lysate for protein analysis 
Cells were trypsinised from plates and transferred to 1.5 ml eppendorf tubes, 
centrifuged at 16,000 xg for 5 min. The supernatant was removed, the volume of the 
pellet was estimated and an equal volume of PBS added and vortexed. An equal volume 
of 0.3 M DTT (Sigma Aldrich) was added to the cell/PBS mixture and vortexed. 
Finally, one volume of 3x SDS loading dye was added (30 % (v/v) glycerol, 9 % SDS, 
180 mM Tris pH 6.8, 0.0125 % bromophenol blue) and vortexed again. Samples were 
boiled at 100 oC for 10 min and analysed by SDS-PAGE as described in section 2.6.3. 
 
2.6.2 Preparation of viral lysate for protein analysis 
VLPs were harvested in the cell supernatant of transfected cells and passed through a 
0.45 μm filter to remove cellular debris. For 6-well plate viruses: 1ml of VLP 
containing media was, underlayed with 200 μl 20 % (w/v) sucrose PBS and centrifuged 
at 16,000 xg for 2 hr at 4 oC. For larger volumes of virus (2-9 ml): VLP containing 
media was placed in a 14x89 mm polyallomer ultracentrifuge tube (Beckman Coulter), 
underlayed with 2.5 ml 20 % (w/v) sucrose PBS and centrifuged in an SW41 rotor 
(Beckman Coulter) at 28,500 rpm (~100,000 xg) using an Optima L-90K ultracentrifuge 
(Beckman Coulter) for 90 min at 4 oC. For the largest volumes of virus (10-30 ml): VLP 
containing media was placed in a 25x89 mm Ultra-Clear ultracentrifuge tube (Beckman 
Coulter), underlayed with 7.5 ml 20 % (w/v) sucrose PBS and centrifuged in an SW32 
rotor at 28,600 rpm (100,000 xg) using an Optima L-90K ultracentrifuge (Beckman 
Coulter) for 90 min. After centrifugation the media and the sucrose cushion were 
aspirated and the viral pellet was left to dry up-side-down for 15 min. The virus pellet 
was re-suspended and lysed in 1X SDS loading dye (10 % (v/v) glycerol 3 % SDS, 60 
mM Tris pH 6.8, 0.1 M DTT, 0.0125 % bromophenol blue). Virus lysate was boiled at 
100 oC for 10 min and separated by SDS-PAGE as described in section 2.6.3. 
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2.6.3 Protein separation by SDS PAGE - Novex system 
Samples were prepared as described in section 2.6.1 and 2.6.2 and then loaded on either 
a 10 % or 12 % acrylamide Novex NuPAGE gel (Invitrogen). Benchmark protein ladder 
(10µl, Invitrogen) was loaded as a molecular weight ladder. Gels were run at 180 V for 
40 min in  1X MES running buffer (Invitrogen) in an XCell SureLock Mini-Cell 
(Invitrogen). To stain gels, 30 ml of SimplyBlue SafeStain (Invitrogen) was added, the 
gel was heated in a microwave for 30 s and was destained for 10-30 min with dH2O. 
Gels were scanned with an Epson V700 scanner (Epson). For immunoblotting, proteins 
were transferred to either Immobilon-FL polyvinylidene difluoride (PVDF) or an 
Immobilon-P PVDF membrane (Millipore) for use with infrared labelled secondary 
antibodies or horseradish peroxidase (HRP) labelled secondary antibodies, respectively. 
Membranes were prepared by soaking briefly in methanol (Fisher Scientific) and rinsing 
in dH2O. The wet blotting transfer was carried out in a Mini Trans-Blot Cell (Bio-Rad) 
in transfer buffer (25 mM Tris, 192 mM glycine [Sigma Aldrich], 30 % methanol) for 
either 60 min at 100 V or overnight (16 hr) at 16 V. 
 
2.6.4 Protein separation by SDS PAGE - mini-PROTEAN 3 system 
Tris-glycine gels containing 10 % or 12 % acrylamide resolving gel were poured into 
the mini-PROTEAN 3 gel casting system. Recipe of SDS-PAGE resolving gel: 12 % 
gel (12% acrylamide/bis 29:1 [Bio-Rad], 375 mM Tris pH 8.8, 0.1 % SDS, 0.1% 
ammonium persulfate [Bio-Rad], 0.04% Tetramethylethylenediamine [TEMED, Bio-
Rad]) or 10 % gel (10% acrylamide/bis 29:1, 375 mM Tris pH 8.8, 0.1 % SDS, 0.1 % 
ammonium persulfate, 0.04 % TEMED). After the resolving gel had set a stacking gel 
was poured and a well comb inserted. Recipe of stacking gel: 5.1 % acrylamide/bis 
29:1, 125 mM Tris pH 6.8, 0.1 % SDS, 0.1% ammonium persulfate, 0.1 % TEMED. 
Samples were loaded into wells on the gel with 10 µl of Benchmark (Invitrogen) 
molecular weight marker. SDS-PAGE was carried out for 60 min in running buffer (25 
mM Tris, 192 mM glycine, 0.1 % SDS) buffer at 23 mA. Proteins were then transferred 
onto a PVDF membrane as in section 2.6.3. 
 
2.6.5 Immunoblotting 
After transfer onto a PVDF membrane (see section 2.6.3 and 2.6.4) the membrane was 
blocked in 1 % milk (Marvel) in PBS for 60 min. Primary antibodies were diluted in the 
antibody solution (1 % milk, 0.001 % Tween20 Sigma PBS) and membranes were 
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incubated in 4-5 ml of diluted antibody in a 50 ml falcon tube (Corning) on a roller 
mixer for 60 min (for antibody dilutions see Table 2.2). Membranes were then washed 
in PBS 0.001 % Tween20 four times (10 min each). Secondary antibodies were diluted 
in 5-10 ml of antibody solution (in a fresh 50 ml falcon tube) and the membrane was 
placed inside and incubated on a roller mixer for 60 min (for dilutions of secondary 
antibodies see Table 2.3). The membrane was washed four times with PBS 0.001 % 
tween20 (10 min each). For membranes probed with the secondary antibodies 
conjugated to infrared dyes, the bands were visualized using the Li-COR Odyssey 
imaging and quantitation system (LI-COR Bioscience). For membranes probed with 
secondary antibodies conjugated to horseradish peroxidase (HRP), the membranes were 
treated with Immobilon Western Chemiluminescent substrate (Millipore) for 1 min, 
then exposed on X-ray film (Scientific Laboratory Supplies). The X-ray film was 
processed with a Fujifilm FPM-3800A developer. 
 
Table 2.2: Primary antibodies utilised in immunoblotting 
Antibody Source Target Host 
species 
Dilution 
anti-p12 
monoclonal 
Hybrodoma CRL- 
1890 (ATCC) 
MLV p12 mouse 1:1,000 
anti-p12 
polyclonal 
Gift from Jonathan 
Stoye 
MLV p12 goat 1:2,000 
anti-CA Hybrodoma CRL-
1912 (ATCC) 
MLV CA rat 1:5,000 
anti-NC Gift from Jonathan 
Stoye 
MLV NC goat 1:1,000 
anti-MA Gift from Alan Rein MLV MA rabbit 1:500,000 
anti-FLAG Sigma-Aldrich FLAG epitope rabbit 1:1,000 
anti-dsRed Clonetech dsRed/mCherry/RFP mouse 1:400 
 
Table 2.3: Secondary antibodies utilised in immunoblotting 
Antibody Source Host species Dilution 
anti-mouse 
IRDye800CW 
LI-COR 
Bioscience 
goat 1:5,000 
anti-mouse HRP Pierce goat 1:20,000 
anti-rat IRDye800CW LI-COR 
Bioscience 
goat 1:5,000 
anti-rat HRP Pierce goat 1:20,000 
anti-goat IRDye800CW LI-COR 
Bioscience 
donkey 1:5,000 
anti-goat HRP Vector 
Laboratories 
Horse 1:20,000 
anti-rabbit 
IRDye800CW 
LI-COR 
Bioscience 
goat 1:5,000 
anti-rabbit HRP Thermo Scientific goat 1:10,000 
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2.7 Viral RNA and cDNA analysis 
2.7.1 DNA isolation from infected cells 
VLPs used for infections where the viral DNA was to be isolated were produced as 
described in section 2.2.4 with the following modification. The morning after 
transfection, the 293T cells were treated with 100 U of RQ1 RNase-free DNase 
(Promega) in the presence of 10 mM MgCl2 (Fisher Scientific) for at least 6 hr. The 
DNase was washed away and fresh DMEM placed on the cells for the VLP harvest. For 
the infections, D17 cells were seeded at 3.5x105 cells per well in a 6-well plate 
(Corning). The following day the virus was normalised by RT-activity, treated with 100 
U of RQ1 RNase-free DNase in the presence of 10 mM MgCl2 for 30 min at 37 
oC, 
cooled to 4 oC for 10 min (as were the cells). The cells were then infected for 2 hr at 4 
oC with gentle shaking allowing  attachment of virions to the cells, but not entry. Cells 
were then washed with pre-warmed DMEM complete (apart from the 0 hr time point 
which washed with 4 oC DMEM complete) and replaced in the incubator. At various 
time points post-infection, cells were washed with PBS, flushed off the wells with PBS 
and pelleted at 10,000 xg for 5 min. The supernatant was aspirated and the pellet re-
suspended in 200 μl PBS by vortexing and stored at -80 oC. The total DNA from 
infected cells was then isolated using the DNeasy Blood and tissue Kit (QIAGEN) 
according to the accompanying protocol.  
 
2.7.2 Viral RNA isolation 
To isolate viral RNA from sucrose gradients, a double phenol-chloroform extraction 
based protocol was adopted. To 100 μl of sample 10μl of RNase-free proteinase K 
(QIAGEN) was added and the sample was incubated at 56 oC for 15 min. Trizol reagent 
(1 ml, Invitrogen) was added and the sample vortexed. Chloroform (200 μl, Fisher 
Scientific) was then added and the tubes were mixed vigorously by hand for 15 s. The 
tubes were incubated at room temperature for 3 min and phase separation was 
performed by centrifugation at 12,000 xg at 4 oC. The aqueous phase, containing the 
RNA, was carefully removed and placed in a fresh 1.5 ml RNase/DNase-free eppendorf 
tube (Eppendorf). RNase-free glycogen (10μg, Invitrogen) was added as a carrier for the 
RNA and the sample vortexed. To precipitate the RNA, 500μl of propan-2-ol was 
added, the sample vortexed and centrifuged at 12,000 xg for 10 min at 4 oC. The 
supernatant was removed and the pellet was washed with 500 μl of 75 % ethanol (Fisher 
Scientific). The RNA was then pelleted at 7500 xg for 5 min at 4 oC. The ethanol was 
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aspirated and the RNA pellet air-dried for 10-15 min. The pellet was re-suspended in 50 
μl of PCR grade H2O by heating at 60 
oC for 10 min. To remove the co-precipitated 
DNA, the sample was treated with 1 U of RQ1 RNase-free DNase (Promega) in RQ1 
DNase 1X Reaction Buffer (40 mM Tris-HCl (pH 8.0), 10 mM MgSO4 and 1 mM 
CaCl2) at 37 
oC for 30 min. Trizol reagent (500μl) was added and the phenol-
chloroform extraction repeated, as above, with half the volumes of reaction components. 
The final air-dried RNA pellet was re-suspended in 25 μl of PCR-grade H2O at 60 
oC 
for 10 min. The RNA was then stored at -80 oC. To prepare the RNA for detection by 
quantitative PCR it was reverse transcribed using the High-capacity RNA-to-cDNA Kit 
(Applied Biosciences). Briefly, 9 μl of RNA was reverse transcribed in a 20 μl reaction 
at 37 oC for 60 min followed by 95 oC for 5 min and then 4 oC for 10 min using a DNA 
engine thermal cycler (Bio-Rad). The reverse transcribed viral cDNA was then stored at 
-20 oC. 
 
2.7.3 Quantitative real time PCR for viral cDNA 
To quantify the copy number of isolated viral cDNA products in infected cells or in the 
reverse transcribed viral RNA extracted from gradients, quantitative real time PCR was 
performed on samples generated from section 2.7.1 and 2.7.2. Minus strand strong stop 
reverse transcription products (Early RT product) were detected by amplification of the 
R-U3 region of Mo-MLV corresponding to nucleotides 997-1126 of the pLacZ-LTR 
plasmid using the primers oJWB45 (5’-gcgccagtcctccgatagactga-’3) and oJWB47 (5’-
ctgacgggtagtcaatcactcag-’3) with probe oJWB38 (5’-FAM-atccgactcgtggtctcgctgttc-
TAMRA-’3). This primer set was also used for detection of the reverse transcribed viral 
RNA, extracted from gradients. Second strand extension reverse transcription products 
(Late RT product) were detected by amplification of the R-gag region corresponding to 
the nucleotides 997-1240 of the pLacZ-LTR plasmid using the same forward primer, 
oJWB45, and probe oJWB38 but with the reverse primer oJWB48 (5’- 
acaatcggacagacacagataagttg-’3). Reactions were performed in triplicate on 2 μl of DNA 
in TaqMan Gene Expression Master Mix (Applied Biosystems) using 900 nM of each 
primer and 250 nM of probe. Quantitative real time PCR was performed on a Fast 7500 
PCR system (Applied Biosystems) in 96-well plates (Applied Biosystems) using 
standard cycling conditions of 50 °C for 2 min, 95 °C for 10 min followed by 40 cycles 
of 95 °C for 15 s and 60 °C for 1 min. To form a standard curve the pLacZ-LTR 
plasmid was diluted into purified gDNA from the target cell line (or PCR-grade H2O for 
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the RNA isolated from gradients) to create a dilution series of samples that were used to 
calculate relative cDNA copy numbers and confirm the linearity of the assay. 
 
2.7.4 MLV integration site sequencing 
Integration sites, from cells infected with MLV based VLPs, were sequenced and 
annotated in Rick Bushman's laboratory. The infectious titre of the VLPs was 
established as in section 2.3.1 and HeLa cells were infected with an MOI  of 
approximately 1.5 (or neat virus for p12 mutant 6 and mutant 14). Cells were harvested 
48 hr later and the total DNA isolated as in section 2.7.1. DNA samples were then 
sequenced in the Bushman laboratory. Briefly, DNA samples were fragmented using 
Fragmentase (New England Biosciences) and DNA was purified using QiaQuick PCR 
purification kit (QIAGEN). The ends of the fragmented samples DNA were blunted and 
a polyA-tail added using Klenow 3'-5' exo- (New England Biolabs). Linkers were then 
ligated onto the fragmented sample DNA using T4 DNA ligase (New England 
Biosciences), purified using QiaQuick PCR purification kit and digested with Dpn I to 
remove vector DNA contamination. Nested PCR was performed to amplify LTR-
genome DNA sequences, which were then gel purified and AMPure bead (New 
England Biolabs) -purified. The purified amplified DNA fragments were then analysed 
using 454 pyrosequencing. All sample handling, after the total DNA isolation from 
infected cells, and annotation to the human genome were performed by members of 
Rick Bushman's laboratory. 
 
2.8 Microscopic analysis 
2.8.1 Indirect immunofluorescence of VLPs fixed on coverslips 
To detect viral proteins in VLPs bound to glass coverslips using indirect 
immunofluorescence, 300 μl of VLP containing media was placed on top of 12 mm #1.5 
glass coverslips (VWR) in 24-well plates (Corning). The 24-well plate was spun at 1000 
xg, 20 oC for 2 hr in a Legend RT centrifuge (Sorvall). Coverslips were gently washed 
with 500 μl PBS and then fixed with 500 μl of either (i) 3.7 % formaldehyde (Fisher 
Scientific) in piperazine-N,N′-bis(2-ethanesulfonic acid) buffer (PIPES,[Sigma 
Aldrich]) pH 6.7 for 10 min, (ii) 4 % paraformaldhyde (Alfa Aesar) in PBS for 20 min 
both at room temperature or (iii) 4 % paraformaldehyde for 5 min followed by -20 oC 
100 % methanol (Fisher Scientific) for 5 min at -20 oC. For fixation (i) and (ii) the 
VLPs were permeabilised with 0.1 % Triton PBS for 10 min at room temperature. 
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Coverslips were washed twice with PBS 50 mM glycine (Fisher Scientific) and once 
with PBS followed by blocking with 5 % normal donkey serum (NDS) (Source 
Bioscience) in PBS for 30 min at room temperature. VLPs were then treated for 45 min 
with 400 μl primary antibody (Table 2.4) diluted in 1 % normal donkey serum (NDS, 
Source Bioscience) PBS. Coverslips were then washed three times with PBS and treated 
for 45 min with 400 μl of the secondary antibodies (Table 2.5) diluted in 1 % NDS PBS. 
The coverslips were kept in the dark as much as possible from here on. Coverslips were 
then washed three times and post-stain fixed with 400 μl 3.7 % formaldehyde in PIPES 
pH 6.7 for 10 min at room temperature. Coverslips were washed twice with PBS 50 mM 
glycine and once with PBS before being mounted in Prolong Gold mounting media 
(Invitrogen) on glass slides (Menzel-Gläser). The coverslips were finally sealed with 
clear nail varnish. 
 
Table 2.4: Primary antibodies utilised for indirect Immunofluorescence. 
Antibody Source Target Host Species Dilution 
anti-p12 monoclonal Hybridoma CRL- 
1890 (ATCC) 
MLV p12 mouse 1:1,500 
anti-p12 polyclonal Gift from 
Jonathan Stoye 
MLV p12 goat 1:2,000 
anti-CA Hybridoma CRL-
1912 (ATCC) 
MLV CA rat 1:1,500 
anti-NC Gift from 
Jonathan Stoye 
MLV NC goat 1:2,000 
anti-p24 ARP3243.3 (NIH 
AIDS Reagents 
program) 
HIV CA 
(p24) 
mouse 1:400 
anti-myc 9E10 Gift from Eran 
Bacharach 
c-Myc 
epitope 
mouse 1:6 
(hybridoma 
supernatant) 
anti-CA polyclonal Gift from Eran 
Bacharach 
MLV CA goat 1:1000 
 
Table 2.5: Secondary antibodies utilised for indirect Immunofluorescence 
Antibody Source Host Species Dilution 
Alexa Fluor 488 anti-mouse IgG (H+L) Invitrogen Donkey 1:2,000 
Alexa Fluor 594 anti-mouse IgG (H+L) Invitrogen Donkey 1:2,000 
Alexa Fluor 488 anti-rat IgG (H+L) Invitrogen Donkey 1:2,000 
Alexa Fluor 594 anti-rat IgG (H+L) Invitrogen Donkey 1:2,000 
Alexa Fluor 488 anti-goat IgG (H+L) Invitrogen Donkey 1:2,000 
Alexa Fluor 594 anti-goat IgG (H+L) Invitrogen Donkey 1:2,000 
 
2.8.2 Indirect Immunofluorescence in infected cells 
Cells were seeded on sterile 13 mm coverslips (VWR) in a 12-well plate at 5x104 cells 
per well. Cells were infected as specified in the text. The cells were then washed once 
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gently with PBS and fixed by either: (i) 4 % paraformaldehyde (AlfaAesar) for 20 min 
at room temperature or (ii) 4 % paraformaldehyde 5 min at room temperature followed 
by ice-cold methanol at -20 oC for 5 min. Cells were permeablised with 0.1 % Triton in 
PBS for 10 min and washed three times with PBS with 50 mM glycine. Cells were then 
stained as in section 2.8.1, except all antibodies were left on the cells for 1 hr and 
Prolong Gold (Invitrogen) with DAPI was used for mounting.  
 
2.8.3 Labelling p12 with the biarsenical dye ReAsH 
To follow p12 within infected cells, a tetracysteine tag (TC, sequence- CCPGCC) was 
cloned into the central portion of p12 to be stained with a biarsenical dye, FlAsH or 
ReAsH (Invitrogen). Two methods were used to label p12 containing the TC tag 
(referred to as p12-TC from now on): an in vitro cell-free labelling method and an in 
vivo labelling method. For the in vitro method, 1 ml of VLP containing media was 
treated with 50 μl of 1 M 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid  (HEPES 
[Sigma Aldrich]) pH 7.5, 10 μl of 0.1 M β-mercaptethanol (Sigma Aldrich), 10 μl of 0.1 
M tris(2-carboxyethyl)phosphine (TCEP [Sigma Aldrich]) and 10 μl of 1 mM 1,2-
ethanedithiol (EDT [Sigma Aldrich]). After briefly mixing, 10 μl of 50 μM ReAsH-
EDT2 (Invitrogen) was added, mixed and incubated at room temperature for 2 hr. To 
clear the labelled VLPs from the free dye, VLPs were pelleted in an SW55 rotor 
(Beckman Coulter) at 40,000 rpm using an Optima L-90K ultracentrifuge (Beckman 
Coulter) for 30 min at 4 oC. The supernatant was then removed and the virus re-
suspended in 50 μl (for staining on coverslips) or 500 μl for infections. For in vivo 
labelling VLPs were labelled in the producer cells. 16 hr post-transfection with the VLP 
plasmids the producer cells were washed twice with serum-free Opti-MEM I 
(Invitrogen) media. Serum-free Opti-MEM media containing 2.5 μM ReAsH-EDT2 was 
added to the cells and labelled VLPs were harvested the next morning (>16 hr). 
 
2.8.4 Detection of viral DNA by Fluorescent in situ hybridisation (FISH) combined 
with indirect immunofluorescence 
D17 cells were seeded on sterile 13mm coverslips in the bottom of a 12-well plate at 
5x104 cells per well. The cells were then infected as specified in the text. Cells were 
fixed with 4 % paraformaldehyde for 10 min at room temperature, washed once with 
PBS and stored overnight in fresh PBS at 4 oC. The following day cells were 
permeabilised with 0.1 % Triton X100 in PBS for 10 min with gentle shaking. Then 
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they were washed in 0.1 M Tris buffer pH 7.4 and incubated in 20 % glycerol PBS for 
20 min. Excess glycerol was removed by gently blotting the edge of the coverslip on 
tissue paper. Cells were dipped into liquid nitrogen three times for 10 s, transferred to a 
fresh 12 well plate and was washed with 0.1 % Triton X100 in PBS for 5 min. Cells 
were then blocked with 10% normal goat serum (NGS [Fisher Scientific]) in PBS for 30 
min with gentle shaking. Primary antibodies were diluted in 25 mM Tris-buffered saline 
(TBS, Sigma Aldrich) and incubated on the cells for 1 hr with gentle shaking. Cells 
were washed with once with TBS and twice with PBS for 5 min each. Secondary 
antibodies were diluted in TBS and added to the cells for 40 min (all subsequent steps 
were carried out in the dark). Cells were washed again with TBS and PBS followed by a 
second fixation with 4 % paraformaldehyde for 1 min at room temperature. Cells were 
then washed twice with PBS and stored overnight in 70 % ethanol at 4 oC. The 
following day, the coverslips were removed, dried face up on tissue paper and placed in 
6 well plates with 0.1 M HCl (Fisher Scientific) for 10 min. HCl was removed and 
replaced with 0.5 % Triton X100 in PBS for 10 min at 37 oC. The cells were then 
washed with ice-cold PBS three times for 5 min each and 1 ml fresh ice-cold PBS was 
added to the cells. Ice-cold fixer (1ml, 3:1 methanol:acetic acid [Fisher Scientific]) was 
dropped onto the cells and incubated for 20 min on ice. Fixer was removed and replaced 
with fresh ice-cold fixer for 15 min on ice. This replacement of fixer step was repeated 
four times in total. Coverslips were removed and left to air dry cell-side up on tissue 
paper. The coverslips were fixed to glass slides and left to air-dry overnight. 
  
Biotin labelled probe was prepared using a nick translation kit (Roche) on a DNA 
fragment excised from pLacZ-LTR using the restriction endonucleases NheI and XmnI. 
The probe was labelled for 90 min at 15 oC then placed on ice. Labelled probe was 
confirmed by denaturing a small fragment for 3 min at 95 oC and run on an agarose gel 
as in section 2.1.3. Probe (50ng per cell sample) was precipitated in a reaction 
containing: 20 μl dH2O,  1 μl shredded (by pipetting up and down) salmon sperm 
(Roche), 1/10th of total volume with 3 M sodium acetate (Sigma Aldrich) and 2.5 
volumes of ethanol. Precipitation was carried out at -70 oC for 1 hr. The probe was 
pelleted at 16,000 xg for 30 min at 4 oC, washed with 70 % ethanol and pelleted at 
16,000 xg for 15 min at room temperature. The probe was allowed to air dry for 5 min 
and re-suspended in 4 μl (per 50ng probe) deionised formamide (Sigma Aldrich) for 10 
min with constant agitation. Then 4 μl (per 50ng probe) of 2X hybridisation buffer (2% 
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dextral sulfate in 2X SSC buffer) was added and the reaction agitated for a further 10 
min. The slides were then dehydrated using an series of ethanols (70 %, 90 % and 100 
%) for 5 min each on a mixer. Slides were then dried at 37 oC and denatured in 70 % 
deionised formamide diluted in 2X SSC buffer (30 mM trisodium citrate, 0.3 M NaCl, 
pH 7) for 5 min at 75 oC. Slides were then dehydrated again (as above) and the probe 
denatured for 5 min at 75 oC followed by incubation on ice for 3 min. A Gene Frame 
(Thermo Scientific) was placed around the coverslips on the slides and 8 μl probe was 
spotted on to the cells. A clean coverslip was placed on top and the Gene Frame sealed. 
Hybridisation was carried out overnight at 37 oC in a moist chamber. 
 
The following day, the Gene Frame was removed and the slides incubated in 50 % 
formamide 2X SSC to remove the top coverslips. Slides were washed three times with 
50 % formamide 2X SSC (pre-warmed to 42 oC) for 5 min each. Then they were 
washed three times with 0.1 % SSC (pre-warmed to 60 oC) for 5 min each. Slides were 
blocked with 3  % BSA/4X SSC for 1 hr at 37 oC. To block non-specific avidin binding, 
cells were incubated with 1 mg/ml avidin (Sigma Aldrich) in 1X SSC buffer at 37 oC 
for 1 hr followed by three washes in 4X SSC 0.1 % Tween20 (pre-warmed to 42 oC). 
Circles were drawn around the coverslips using a hydrophobic barrier pen and a 1:1000 
dilution of Streptavidin-AlexaFluor488 (Invitrogen) in 1 % BSA/4X SSC/0.1 % 
Tween20 was added for 30 min at 37 oC. The slides were then washed three times with 
4X SSC/0.1% Tween20 (pre-warmed to 42 oC) for 5 min each. A drop of vectashield 
(Vector Laboratories) containing DAPI (1.5 μg/ml) was placed on top of the cells and a 
fresh coverslip was used to seal the cells. 
 
2.8.5 Live imaging of cells infected with VLPs containing eGFP-p12 
To visualise the movements of the Mo-MLV PIC, the PIC was labelled with eGFP-p12 
or CA-YFP (Elis et al., 2012). Labelled Mo-MLV VLPs for these experiments were 
synthesised as described in section 2.2.4, but with a percentage of the Gag from 
pcDNA-GFP-p12 (30% of total Gag plasmids) or pB30Y (10 % of total Gag plasmids), 
which express cleavable GFP-p12 or CA-YFP fusions in Gag. These experiments were 
carried out in Eran Bacharach's laboratory at Tel Aviv University. 
 
U/R H2A-RFP cells were seeded at 5x104 cells per well on 4-chamber coverglass 
bottomed tissue culture dishes. Cells were either used 16 hr after seeding for infections 
75 
 
or 2 hr after seeding they were transfected with 1 μg S15mCherry using Polyjet DNA In 
Vitro Transfection Reagent (SignaGen Laboratories) according to the manufacturer's 
instructions. Fluorescent VLPs were diluted to the correct MOI (either 5 or 8, specified 
in the text) in DMEM complete containing 20 mM HEPES (Sigma) and warmed to 37 
oC. The cells were then infected on the microscope and imaged through a x100 NA1.45 
objective lens (Carl Zeiss Germany) using a Zeiss Axiovert 200 M microscope (Carl 
Zeiss Germany) with a Yokogawa CSU-22 spinning disk confocal head connected to an 
Evolve EMCCD camera (Photometrics). All images were recorded using the same 
exposure settings for GFP or YFP between the samples. After imaging, infected cells 
were washed with DMEM complete (2 hr post-infection) and returned to the incubator 
over night. Cells were then imaged again between 20-25 hr post-infection. Images were 
deconvolved using the No Neighbours algorithm in SlideBook 5 (3i) and exported as 
tiffs. GFP or YFP signal was scaled to emphasise the signal as appropriate for each 
experiment.  
 
2.8.6 Immunofluorescence time-course of cells infected with N-terminal p12 
mutants 
Mo-MLV mutant VLPs containing a myc tag in p12 were synthesised as in section 
2.2.4. U/R cells were seeded at 2x104 cells per well on glass coverslips in 12 well 
plates. Cells were infected with Mo-MLV VLPs (MOI of 3, based on the RT-activity 
for p12 mutants) by spinoculation at 1000 xg for 2 hr at 4 oC. Cells were washed three 
times with cold DMEM complete and returned to the incubator at 37 oC. The cells were 
fixed at various times post-infection for 20 min using 4 % paraformaldehyde. Cells 
were then processed for indirect immunofluorescence as in section 2.8.2 with the 
following modifications: (i) samples were permeabilised  for 2 min, (ii) samples were 
blocked in 3 % BSA in PBS, (iii) antibody solutions contained 1 % BSA instead of 
NDS, (iv) the myc antibody and CA antibody were applied sequentially rather than 
together and (v) no post-staining fixation was performed. Cells were imaged through a 
x100 NA1.45 objective lens (Carl Zeiss Germany) using a Zeiss Axiovert 200 M 
microscope (Carl Zeiss Germany) with a Yokogawa CSU-22 spinning disk confocal 
head connected to an Evolve EMCCD camera (Photometrics). Cells were chosen 
randomly based on the DAPI staining and a Z-stack was recorded through the imaged 
cells. All images were recorded using the same exposure settings for each fluorescent 
dye. The fluorescent signal was scaled by the same values for each fluorescent dye 
when constructing images from different samples. 
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2.8.7 Microscopy, image acquisition and analysis 
Imaging of fixed mCherry-p12 transfected cells 
Microscopy was performed using a DeltaVision Core widefield microscope with the 
x100 NA1.4 objective (Olympus). Images were recorded on an QuantEM EMCCD 
camera (Photometrics) using the same exposure settings for the mCherry signal. 
Excitation/emission filter wavelengths were: mCherry Ex555/25 nm Em605/52 nm and 
DAPI Ex360/40 nm Em455/50 nm. A Z-stack of images was taken at intervals of 0.2 
μm and all images were analysed using Fiji (ImageJ). Images shown in this thesis show 
one Z-plane and fluorescent intensities are scaled by the same values for each sample. 
 
Live imaging of mCherry-p12 transfected cells 
Microscopy was performed using a DeltaVision Core widefield microscope with x63 
NA1.4 objective (Olympus). Images were recorded every 5 min on an QuantEM 
EMCCD camera (Photometrics) using the same exposure settings for the mCherry 
signal. Excitation/emission filter wavelengths were: mCherry Ex555/25 nm Em605/52 
nm and Hoechst 33342 Ex360/40 nm Em455/50 nm. All images were analysed using 
Fiji (ImageJ). Movies shown in this thesis are from one Z-plane and fluorescent 
intensities are scaled to emphasise the signal. 
 
Imaging of VLPs on coverslips and infected cells 
Microscopy was performed using a Deltavision core widefield micoscope with x100 
NA1.4 objective (Olympus). Images were recorded on an QuantEM EMCCD camera 
(Photometrics) using the same exposure settings for each fluorescent dye between 
samples in an experiment. Excitation/emission filter wavelengths were: DAPI Ex 
Ex360/40 nm Em 455/50 nm; AlexaFluor488, GFP and YFP Ex490/20 nm Em525/36 
nm and AlexaFluor594 Ex555/25 nm Em605/52 nm. For VLPs: eight simultaneous 
images were taken for each fluorescent channel. Images shown in the thesis are an 
average projection of the eight frames. For infected cells: A Z-stack of images were 
taken at intervals of 0.2 μm from the top to the bottom of the cell. Images shown in this 
thesis show one Z-plane and fluorescent intensities are scaled by the same values for 
each sample. All images were analysed by Fiji (ImageJ). Co-localisation analysis of 
VLPs on coverslips was carried out using the 'Co-localization finder' Plugin in Fiji, 
followed by manual counting of the co-localised puncta.  
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2.9 Electron Microscopy 
2.9.1 VLP sample preparation for thin-section electron microscopy 
Serum-free media containing VLPs (228ml) was produced in as in section 2.2.4. Six 
sets of 38 ml VLP containing media was pelleted in 14x89 mm polyallomer 
ultracentrifuge tubes (Beckman Coulter) at 100,000 xg for 60 min at 4 oC. Each pellet 
was re-suspended in 50 μl PBS for 30 min on ice. Re-suspended viral pellets (300μl 
total) were pooled and 300 μl of 5 % gluteraldehyde/0.2 M sodium cacodylate buffer 
(Fisher Scientific and Sigma Aldrich, respectively) was added, mixed and fixed for 60 
min on ice. Virus was pelleted at 17,800 xg for 60 min at room temperature. The 
fixative was removed and 250 μl warm (37 oC) 2 % low melting point agarose (Fisher 
Scientific) placed on top and mixed. Virus was then centrifuged at 16,200 xg for 20 min 
in a centrifuge heated to 38 oC immediately followed by incubation on ice. After 30 
min, ice-cold 2.5 % gluteraldehyde/0.1 M sodium cacodylate buffer was layered on top 
of the solid agarose (up to the top of the tube). This was left overnight on ice to 
completely set the agar. 
 
2.9.2 Thin sectioning of VLPs and staining for transmission electron microscopy 
The solid agarose containing the VLP pellet was removed from the eppendorf tube and 
washed with 0.1 M sodium cacodylate buffer for 10 min. The sample was post-fixed 
with 1 % osmium tetroxide for 90min, washed in 0.1 M sodium cacodylate buffer for 10 
min and stained with 1 % aqueous uranyl acetate for 90 min. The samples were then 
dehydrated in an ethanol series (50 %, 75 %, 90 %, three times in 100 %, 5 min each) 
and twice in propylene oxide for 15 min each. Samples were embedded in medium Agar 
100 resin and polymerised overnight at 70 oC. 50 nm-thick sections were cut from the 
resin block, placed on microscopy grids and stained with saturated ethanolic uranyl 
acetate and Reynold's lead citrate. After fixation, the sectioning and staining of the 
samples was performed by Liz Hirst in the Electron Microscopy department. 
 
2.9.3 Transmission electron microscopy (TEM) and image acquisition 
TEM micrographs of thin sectioned and stained VLPs were viewed at 20,000x 
magnification using a JOEL 1200EX transmission electron microscope (JOEL Ltd) 
operating at 82 kV. Images were captured on an Orius CCD camera (Gatan) using the 
auto-exposure mode. TEM micrographs were taken with the help and supervision of Liz 
Hirst. 
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Chapter 3.  
Further investigations into the function of Mo-
MLV p12 and the identification of early acting 
domains within p12 
 
The importance of the MLV Gag protein, p12, during the early stages of retroviral 
infection has been known for over a decade (Yuan, Li, and Goff, 1999). The original 
study describing a role for p12 in the early stages of infection utilised a proviral Mo-
MLV construct, expressing an infectious clone of Mo-MLV. Seven p12 mutants, four in 
the N-terminus and three in the C-terminus, were found to produce virus but were 
unable to cause a productive infection in susceptible cells (Yuan, Li, and Goff, 1999). 
Other studies have also found that these N- and C-terminal regions of p12 are intolerant 
to mutation (Auerbach et al., 2003; Yueh and Goff, 2003). 
  
Mo-MLV single cycle vectors, encoding a reporter gene, offer a rapid and sensitive tool 
to assess the viability of mutant viruses during the early stages of infection (Soneoka et 
al., 1995). As Mo-MLV vectors can be easily pseudotyped using an envelope with a 
broad cell tropism, like the vesicular stomatitis virus glycoprotein (VSV-G), the 
phenotype of the p12 mutant virus like particles (VLPs) could be assessed in a range of 
different cellular contexts. 
 
To validate the use of Mo-MLV VLPs, this chapter contains further analysis of the 
existing seven Mo-MLV p12 mutants, in a single cycle vector system. Importantly this 
analysis revealed the presence of two domains which function during the early stages of 
replication. Using genetic approaches, the relationship between these two domains was 
investigated and the residues essential for their function identified. 
 
3.1 Investigating the effect of p12 mutations in an Mo-MLV vector system 
All of the viruses used in this study are single cycle vectors pseudotyped with VSV-G 
and encoding the bacterial LacZ gene. A chemiluminescent substrate for the LacZ 
product, β-galactosidase, was used to assess the infectivity of Mo-MLV VLP mutants. 
Initially, the phenotype of the existing seven p12 mutants in Mo-MLV VLPs was 
investigated, to validate their use in place of viruses derived from the proviral vectors. 
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3.1.1 The phenotype of p12 mutants in an Mo-MLV vector system 
The Mo-MLV Gag-Pol expression plasmid used here was produced by cloning the gag-
pol region from pMD-MLV Gag-Pol into pcDNA3.1. The seven p12 mutant Gag-Pol 
expression plasmids were then generated by exchanging the BsrGI-XhoI fragment of 
gag from pNCS-PM5, -PM6, -PM7, -PM8, -PM13, -PM14, -PM15, -FLAG and -L-
domain. The map and the position of these alterations in p12 are shown in Figure 3.1A. 
 
 
 
Figure 3.1: Production of Mo-MLV p12 mutant VLPs and assessment of their infectivity. 
(A) Position of p12 within the translated Gag polyprotein from the CMV-driven Mo-MLV Gag-
Pol plasmid utilised in this study. Below the primary amino acid sequence of p12, the position 
of the existing p12 mutants and the FLAG tag in Mo-MLV p12 are shown (Yuan, Li, and Goff, 
1999). (B) Schematic detailing how LacZ-encoding Mo-MLV VLPs were produced and their 
infectivity tested. 
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Mo-MLV VLPs were generated by transiently transfecting 293T cells with pMo-MLV 
Gag-Pol, pVSV-G and pLacZ-LTR (Figure 3.1B). After at least 36 hours, VLPs were 
harvested in the cell supernatant. To assess VLP production, a modified ELISA for 
reverse transcriptase activity (from now on called 'RT-ELISA') was performed on the 
harvested producer cell supernatant. The infectivity of the VLPs were determined by 
infecting target cells with equal RT-units of VLPs, incubating for 48-72 hours, followed 
by measuring the level of β-galactosidase activity in the cell lysate using a 
chemiluminescent substrate (Figure 3.1B). None of the existing p12 mutants, in this 
vector system, had a dramatic effect on VLP release (Figure 3.2A). This included the 
Mo-MLV VLPs with the FLAG-tagged wild type p12 (for the position of FLAG see 
Figure 3.1A). Consistent with the previous report using proviral constructs, mutant 8 
had a minor effect (three-fold reduction compared to wild type) on VLP release (Figure 
3.2A, dark green bar), likely due to its proximity to the Late(L)-domain (Yuan, Li, and 
Goff, 1999). Mutation of the L-domain itself affects the ability of Mo-MLV to recruit 
members of the ESCRT pathway required for efficient budding, and this mutant 
displayed a more significant (35-fold) reduction in VLP release (Figure 3.2A, grey bar) 
(Martin-Serrano et al., 2005; Martin-Serrano, Zang, and Bieniasz, 2003; Rauch and 
Martin-Serrano, 2011).  
 
To gauge the effect of the p12 mutations on Gag polyprotein cleavage, immunoblotting 
was performed on VLPs using antibodies against CA and p12 (Figure 3.2B). All p12 
mutants contained equal amounts of the cleaved CA protein (Figure 3.2B, top panel). 
Interestingly, the p12 monoclonal antibody recognised mutants 5 and 8 poorly, and 
could not recognise mutants 6 and 7 at all (Figure 3.2B, middle panel). This antibody 
was used in a previous publication to show that mature p12 was missing from viral 
particles containing mutations in the 'DLL' motif, which is mutated in mutant 8 (Zhang 
et al., 2011). Using both the monoclonal antibody and a polyclonal antibody against 
p12, it was shown that all the p12 mutants did, in fact, contain detectable mature p12 
(Figure 3.2B, middle and bottom panel). Therefore the Mo-MLV VLPs containing 
alterations in p12 had no defect in Gag polyprotein processing by the viral PR. 
Interestingly the cleavage of MA-p12 appeared to be inefficient, even for wild type Mo-
MLV, with a sizable proportion of the p12 present as the uncleaved MA-p12 fusion 
(Figure 3.2B, middle and bottom panel). This suggested that liberation of all p12 during 
maturation was not essential for infectivity. 
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Figure 3.2: VLP release and Gag cleavage of Mo-MLV VLPs containing mutations in p12. 
(A) LacZ-encoding Mo-MLV VLPs were produced by transient transfection in 293T cells and 
VLP synthesis was measured by the viral reverse transcriptase activity quantified using an RT-
ELISA. The histogram shows the mean RT activity of the harvested p12 mutant VLPs and the 
error bars indicate the range. (B) Equal RT-units of Mo-MLV VLPs were analysed by 
immunoblotting using anti-CA (top panel), anti-p12 monoclonal (middle panel) and anti-p12 
polyclonal (bottom panel) antibodies. 
 
To test the infectivity of the p12 mutant VLPs, D17 cells were infected with equal RT-
units of mutant VLPs and the infectivity was determined using the chemiluminescent β-
galactosidase assay. VLPs containing the FLAG-tagged wild type p12 were as 
infectious as wild type VLPs (Figure 3.3, orange bar), but the infectivity of the other 
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p12 mutants were reduced by 84-to-760-fold (Figure 3.3). This indicated that p12 
mutants 5-8 and 13-15 in the Mo-MLV vector system recapitulated the potent 
infectivity defect seen for MLV p12 mutants derived from the proviral vectors. 
 
 
Figure 3.3: Infectivity of Mo-MLV VLPs bearing mutations in p12. D17 cells were infected 
with equal RT-units of p12 mutant VLPs and productive infection was quantified after at least 
48 hours. The infectivity is displayed as a percentage of wild type Mo-MLV infectivity with the 
mean and range (highest and lowest values) of three independent experiments shown.    
 
3.1.2 The cell species dependence of the p12 mutant infectivity phenotype 
Many viral proteins have functions that are required in certain cellular environments, to 
counteract negative factors or provide functions that cannot be supplied by the host. As 
the Mo-MLV vector system is pseudotyped with VSV-G, this system allows 
observation of the p12 mutant phenotype in a range of cell species or types. A panel of 
cell lines, of different types and from different species, were infected with equal RT-
units of Mo-MLV VLPs containing either wild type p12 or p12 mutant 5, 6, 8 or 13. 
The p12 mutants all showed a decrease in infectivity, when compared to the wild type, 
for all the cell lines tested (Figure 3.4). The smallest reduction in infectivity, between 
wild type and the most infectious mutant, was observed in CHO cells, where the 
reduction in infectivity was just six-fold. The largest difference was seen in the canine 
D17 cell line, where the infectivity was reduced by greater than 100-fold. The 
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preservation of the infectivity defect, over a wide range of cells, indicated that p12 did 
not function in a cell-specific manner. 
 
 
 
Figure 3.4: Activity of p12 mutants in a panel of cell lines. Equal RT-units of VLPs were 
used to challenge a panel of cell lines from different species of either (A) epithelial or (B) 
fibroblastic origin and productive infection was measured after 48 hours. Infectivity is displayed 
as luminescence counts per second (cps) with the mean and range of three independent 
experiments shown. (Data courtesy of Virginie Boucherit). 
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3.1.3 The ability of p12 mutants to reverse transcribe in infected cells 
One of the hallmarks of retroviral infection is the reverse transcription of the viral RNA 
genome into double stranded viral DNA, which is then integrated into the host 
chromatin. To assess the ability of p12 mutants to reverse transcribe in vivo, D17 cells 
were infected with p12 mutant VLPs and total DNA was isolated from infected cells, at 
various time points post-infection. Quantitative PCR to detect both early (minus strand 
strong stop) and late (second strand extension) reverse transcription products was then 
performed.  
 
For wild type VLPs, the presence of strong stop and second strand extension reverse 
transcription products appeared very early (~3 hours post infection) and peaked at 
around 6 hours post-infection (Figure 3.5, red line). The levels remained high 
throughout the time-course and were still present at two weeks post infection, indicating 
that the viral DNA had stably integrated into the host chromosomes. 
  
All of the p12 mutants, barring mutant 6, synthesised both early and late viral DNA 
products with kinetics equivalent to that seen for wild type (Figure 3.5 A and B). 
However, two weeks after infection, viral DNA levels for all the p12 mutants were 
reduced to background levels, indicating they all failed to integrate (Figure 3.5 A and B, 
last points). As seen in NIH-3T3 cells (Yuan, Li, and Goff, 1999), mutant 6 failed to 
accumulate high levels of early, and subsequently late, reverse transcription products in 
D17 cells, implying this mutant has a defect in reverse transcription. Interestingly, 
mutant 8 was competent to reverse transcribe in D17 cells, in contrast to what has been 
described for mutant 8 in NIH-3T3 cells (Yuan, Li, and Goff, 1999). Unfortunately, a 
high background prevented the accurate measurement of viral DNA synthesis in NIH-
3T3 cells infected with our mutant p12 VLPs (Virginie Boucherit, personal 
communication). The fact that mutant 8 could reverse transcribe in some cells and not in 
others suggested that the block with this mutant is probably concomitant with reverse 
transcription. Taken together, these results show that the Mo-MLV VLPs, generated 
from a Gag-Pol vector, have a phenotype that was comparable to that seen with mutant 
viruses derived from a proviral vector. 
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Figure 3.5: Ability of Mo-MLV p12 mutant VLPs to synthesise viral cDNA in infected 
cells. D17 cells were infected with equal RT-units of wild type or mutant VLPs and total DNA 
was isolated at various times post infection, as indicated. The relative amounts of (A) minus 
strand strong stop or (B) second strand extension reverse transcription products were measured 
by qPCR. Results are representative of at least three independent experiments. 
 
3.2 Identification of two early acting domains in Mo-MLV p12 
It had been assumed that the two regions, in the N- and C-terminus of p12, perform the 
same function and most of the published data concerns only alteration of the C-terminal 
86 
 
region of p12. No studies have addressed whether the N- and C-terminal regions of p12 
carry out independent functions during the early stages of life cycle. Mutations to the N-
terminal region of p12 have been shown to affect reverse transcription (Figure 3.5), but 
mutations to the C-terminus did not, therefore it is possible that these regions perform 
independent functions. This idea was investigated using genetic approaches. 
 
3.2.1  Production of VLPs containing different p12 molecules from two separate 
plasmid sources 
The p12 protein exists within the virion at an equimolar ratio with all of the other Gag 
proteins (MA, CA and NC), as Gag is incorporated into particles prior to cleavage and 
maturation. This does not necessarily mean that all of the packaged p12 molecules are 
needed by the virus for full infectivity. Therefore to establish how much wild type p12 
was required in a virion for full infectivity, mixed VLPs were synthesised (Figure 3.6). 
  
 
 
Figure 3.6: Producing mixed Mo-MLV VLPs with p12 from two Gag-Pol plasmid sources. 
To make Mo-MLV VLPs, which contain a mixture of wild type and mutant p12 (or two 
mutants), two Mo-MLV Gag-Pol expression plasmids (containing two different p12 species) 
were transfected into 293T cells along with the LacZ-LTR and VSV-G expression plasmids. 
VLPs were then harvested and the infectivity tested as detailed earlier. 
 
 
In this case, instead of the Gag-Pol proteins coming from one plasmid source (as in 
Figure 3.1B), they come from two plasmid sources, one containing wild type p12 and 
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the other mutant p12 (or two p12 mutants). Theoretically, the ratio of different Gag 
proteins in the particles should reflect the ratio of the plasmids transfected. To test this, 
mixed Mo-MLV VLPs were synthesised containing wild type FLAG-tagged p12 and 
untagged mutant 6 p12 (Figure 3.7A). Equal RT-units of VLPs were analysed by 
immunoblotting using the anti-CA (Figure 3.7A, top panel) and anti-FLAG (Figure 
3.7A, bottom panel) antibodies. The percentage of Mo-MLV Gag-Pol vector, containing 
the FLAG-tagged p12, in the transfection mixture is indicated below the immunoblot. 
For all of the mixed particles, the CA signal in the western blot remained constant 
(Figure 3.7A top panel), whereas the signal from the FLAG-tagged p12 decreased as the 
percentage of the Mo-MLV Gag-Pol, containing FLAG-tagged p12, decreased in the 
transfection mix (Figure 3.7A, bottom panel). This showed that the p12 present in the 
mixed VLPs came from the plasmids in a dose-dependent manner. Unfortunately this 
analysis cannot resolve between the following scenarios: (i) VLPs assembling with an 
actual mixture of Gag-Pol from the two plasmids transfected or (ii) two separate 
populations of non-mixed VLPs, each arising from one of the transfected Gag-Pol 
plasmids.  
 
To distinguish between these two possibilities an experiment was devised to trans-
complement the early defect induced by the p12 mutations using the p12 L-domain 
mutant. The L-domain function of p12 is completely independent of the early function 
of p12, as all of the p12 mutants exhibiting an early block in the life cycle can 
efficiently bud from the cell (Figure 3.2A). Therefore if true mixed particles were 
formed, the p12 mutant 6 should rescue budding and the L-domain mutant should 
rescue the early defect. This is indeed what was seen (Figure 3.7B). Mixed VLPs 
containing the p12 L-domain mutant and p12 mutant 6, were synthesised and D17 cells 
infected with equal RT-units of VLPs. The absence of the grey dashed line indicates 
that not enough VLPs were produced to test the infectivity, due to the L-domain defect. 
Therefore this synthesis protocol generated truly mixed particles containing Gag-Pol 
from the two transfected plasmids, in a dose-dependent manner.   
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Figure 3.7: Gag protein contribution to mixed Mo-MLV VLPs made from two plasmid 
sources. (A) Mixed Mo-MLV VLPs were produced from two Gag-Pol expression plasmids, 
containing FLAG-tagged wild type p12 or untagged mutant 6 p12, and were analysed by 
immunoblotting with antibodies against CA (top panel) or FLAG (bottom panel). (B) Mixed 
Mo-MLV particles containing wild type FLAG-tagged p12 or L-domain mutant p12, mixed 
with mutant 6 p12 were produced. D17 cells were infected with equal RT-units of mixed Mo-
MLV VLPs and productive infection was quantified after at least 48 hours. (Note: the absence 
of the grey dashed line indicate points where a lack of VLPs were produced for the infectivity to 
be tested). Infectivity is displayed as the percentage of wild type Mo-MLV infectivity and data 
is representative of at least three independent experiments. 
 
 
3.2.2 The phenotype of mixed VLPs containing wild type and mutant p12 
To establish the amount of wild type p12 required in MLV for full infectivity, mixed 
particles were synthesised with wild type and the p12 mutants. The infectivity of the 
resulting VLPs were assessed in D17 cells (Figure 3.8). 
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The infectivity of the p12 mutant mixed particles fell into two groups, with the 
exception of p12 mutant 5. The N-terminal mutants (except mutant 5) all maintained 
wild type levels of infectivity until over 90% of the p12 in the particle was mutant, after 
which the infectivity decreased sharply (Figure 3.8, light green, dark blue and dark 
green lines). In contrast to this, the C-terminal mutants exhibited a dramatic decline in 
infectivity, until they were completely non-infectious before 50% of the p12 in the 
particle was mutant (Figure 3.8, pink, purple and magenta lines). 
 
 
Figure 3.8: Infectivity of Mo-MLV mixed particles containing a mixture of wild type and 
mutant p12. Mo-MLV mixed particles, containing wild type p12 and a p12 mutant (see 
legend), were generated by transient transfection in 293T cells. (Note: the 'mix control' is not a 
mixed particle but a mixture of VLPs containing either all wild type p12 or mutant 6 p12, mixed 
at the percentages indicated by the x-axis.) D17 cells were infected with equal RT-units of VLPs 
and productive infection was quantified after at least 48 hours. Infectivity is displayed as the 
percentage of wild type Mo-MLV infectivity and data is representative of at least three 
independent experiments. 
 
 
The p12 mutant 5 mixed particles remained as infectious as wild type until 60% of the 
p12 was mutant, then it fell until 80% of the p12 was mutant, and the particle was no 
longer infectious (Figure 3.8, light blue line). Therefore the N- and C-terminal p12 
mutants have very differing effects on the infectivity of mixed particles. This has 
highlighted that only a small proportion of the p12 in the particle was required for full 
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infectivity and that the C-terminal p12 mutants were able to act as dominant negative 
mutants, interfering with wild type function. 
 
3.2.3 The functional relationship between the N- and C-terminal regions of p12 
The fact that the N- or C-terminal p12 mutants had such distinct phenotypes in mixed 
particles (Figure 3.8), and that the central portion of p12 was tolerant to mutation, 
suggested that p12 contains two functional domains (Auerbach et al., 2003; Yuan, Li, 
and Goff, 1999; Yueh and Goff, 2003). 
  
To test if the N- and C-terminal regions of p12 acted independently, with regard to the 
infectivity of Mo-MLV, mixed particles were synthesised containing either p12 mutant 
6 (N-terminal mutant) or 13 (C-terminal mutant) with all the other mutants. The 
infectivity of this panel of mixed VLPs was quantified and expressed as a percentage of 
wild type (Figure 3.9). When the p12 mutant 6 was mixed with FLAG-tagged wild type 
p12, the same phenotype was seen as when it was mixed with the untagged wild type 
p12 (compare: Figure 3.9A, orange line and Figure 3.8, light green line). Mixing any of 
the other p12 mutants with p12 mutant 6 in the mixed particles did not rescue infectivity 
(Figure 3.9A). Likewise, when p12 mutant 13 was mixed with FLAG-tagged wild type 
p12, the same dominant negative effect on infectivity was seen as when mixed with 
untagged wild type p12 (compare Figure 3.9B, orange line and Figure 3.8, pink line). 
Again, mixing any of the other p12 mutants with p12 mutant 13 failed to rescue the 
infectivity defect (Figure 3.9B). This suggested that the two domains did not function 
independently of each other and both were required on a single molecule of p12 for Mo-
MLV infectivity.  
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Figure 3.9: Infectivity of Mo-MLV mixed particles containing mixtures of two p12 
mutants. Mixed Mo-MLV VLPs were produced by transient transfection with mixtures of (A) 
p12 mutant 6 or (B) p12 mutant 13 with all the other p12 mutants (see legend). (Note- The p12 
L-domain mutant is mixed with wild type p12 as a control (A and B, black lines) and the 
percentage plasmid transfected, along the x-axis, in this case relates to wild type p12 plasmid 
transfected and not mutant 6 (A) or mutant 13 (B)). D17 cells were infected with equal RT-units 
of p12 mutant VLPs and productive infection was quantified after at least 48 hours. Infectivity 
is displayed as a percentage of wild type Mo-MLV and the data is representative of at least three 
independent experiments. Wt- wild type. 
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3.2.4 The effect of mutating both N- and C-terminal domains in p12 
To assess which of the mixed particle phenotypes was dominant, two point mutations 
were introduced into p12 that knocked out the N- and C-terminal domain functions (as 
assessed by the infectivity of the point mutants, Figure 3.15 and Figure 3.18). 
  
Mixed particles were synthesised and the infectivity quantified in D17 cells. Both the 
L16A and R66A point mutants infectivity phenotypes mirrored that of the larger 
substitution mutants where these residues reside, mutant 6 and 14 respectively (Figure 
3.10, compare light green line and grey dashed line with green triangles, and purple line 
and grey dashed line with purple triangles). Interestingly, the phenotype of the p12 
double mutant mixed particles, LR(16,66)AA, clearly resembled that of the N-terminal 
domain mutants (Figure 3.10, yellow line). Hence for the dominant negative effect to 
occur in mixed particles, p12 must contain an active N-terminal domain. This suggests 
that the N-terminus must interact with a limiting factor and/or its activity must precede 
that of the C-terminus. 
 
 
 
Figure 3.10: Infectivity of Mo-MLV mixed particles containing mutations in both the N- 
and C-terminal domains of p12. D17 cells were infected with equal RT-units of mixed VLPs 
and productive infection was quantified after at least 48 hours. Infectivity is displayed as a 
percentage of wild type Mo-MLV infectivity and the data is representative of at least three 
independent experiments. 
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3.2.5 The spatial and/or conformational requirements of the linker between the 
domains 
The regions identified by mutation as the N- and C-terminal domains of Mo-MLV p12 
are separated by 29 amino acids which, barring the L-domain (PPPY), have been shown 
to be tolerant to mutagenesis (Auerbach et al., 2003; Yuan, Li, and Goff, 1999; Yueh 
and Goff, 2003). This 'linker sequence' is a sizable proportion of the total protein length 
(>34% of the total amino acids), and it is possible that this stretch of amino acids is 
important for the optimal spacing and/or conformation of these two domains. To alter 
the size of the 'linker sequence' between these two domains two types of cloning were 
utilised (i) sequence excision by site-directed mutagenesis, and (ii) introduction of a 
unique AscI endonuclease restriction site into p12 of the Gag-Pol vector, to introduce 
sequence into p12 (see Figure 3.11).  
 
 
 
Figure 3.11: Generating large insertions in the central portion of Mo-MLV p12. An AscI 
restriction endonuclease site was introduced into the central region of p12 by site directed 
mutagenesis (AscI p12). Complementary oligonucleotides, including the desired sequence 
flanked by AscI sites (Insert oligo), were annealed and digested with AscI restriction 
endonuclease. The insert was then ligated into the AscI digested Mo-MLV Gag-Pol plasmid 
containing the AscI-p12 (Insert in AscI-p12) using T4 DNA ligase. 
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Two deletions, of 11 and 21 amino acids, plus two insertions of 18 and 20 amino acids 
were generated using these methods. LacZ-encoding Mo-MLV VLPs containing the 
deletions or insertions in p12 were synthesised and the infectivity quantified. Neither 
insertion nor deletion of sequence between the N- and C-terminal domains of wild type 
p12 significantly reduced the infectivity of Mo-MLV (Figure 3.12). This indicated that 
the length of the 'linker sequence' after the L-domain in p12, but before the C-terminal 
domain, could be extended or shortened without affecting p12 function. 
 
 
Figure 3.12: Infectivity of Mo-MLV containing insertions or deletions in the central 
portion of p12. Deletions or insertions were cloned into the central portion of p12, in the Mo-
MLV Gag-Pol expression plasmid. D17 cells were infected with equal RT-units of VLPs and 
productive infection was quantified after at least 48 hours. The infectivity is displayed as a 
percentage of wild type Mo-MLV infectivity with the mean and range of three independent 
experiments shown. 
 
 
A short peptide from GFP (sGFP11, RDHMVLHEYVNAAGIT) has been described as 
a genetic tag for expressed proteins, which when co-expressed with the non-fluorescent 
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remaining proportion of GFP (sGFP1-10) will self-complement to form the fluorescent 
GFP molecule (Cabantous, Terwilliger, and Waldo, 2005). In an attempt follow p12 
movements in infected cells, the sGFP11 tag was cloned into p12 using the introduced 
AscI restriction endonuclease site (Figure 3.11). Frustratingly, but interestingly, this 
sGFP11 tag in p12 decreased the infectivity of Mo-MLV by >1000-fold (Figure 3.13). 
This potent block to infectivity demonstrated that some sequences were not tolerated 
within this 'linker' region of p12. The disruption was likely due to the structure of this 
peptide compared to a string of alanines, as the sequence codes for a beta-strand from 
GFP (Kent, Childs, and Boxer, 2008). 
 
 
 
Figure 3.13: Infectivity of Mo-MLV containing the sGFP11 peptide in the central portion 
of p12. The 16 amino acid sGFP11 peptide (RDHMVLHEYVNAAGIT), which is part of the 
split GFP system (Cabantous, Terwilliger, and Waldo, 2005), was inserted into the central 
portion of p12 via the AscI site. D17 cells were infected with a two-fold dilution series of the 
VLPs, based on RT activity, and productive infection was quantified after at least 48 hours. 
Infectivity is expressed as the luminescence counts per second (cps) for each dilution of VLPs. 
Data is representative of three independent experiments. 
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Therefore, although the 'linker region' of p12 was not sensitive to alanine mutagenesis 
and could be extended or cut in length, insertion of the sGFP11 has emphasised that 
some compositions of the linker were toxic to p12 function.  
 
3.3 Identifying the essential residues within the early acting domains of p12 
The two previous sections have built on previously published data on p12 function and 
have revealed that p12 contains two early acting domains that are functionally 
dependant. To date some isolated individual substitution mutants have been described, 
however not all of the amino acids in these domains have been assessed (Yueh and 
Goff, 2003). 
  
3.3.1 The effect of individual alanine substitutions in p12 on Mo-MLV VLP release 
To investigate which amino acids in the N- and C-terminal domains of p12 were 
essential for function, individual alanine mutations were generated in all the residues 
covered by the p12 mutations 5-8 and 13-15. All these p12 point mutant viruses 
produced similar levels of RT activity (data not shown), consistent with what was seen 
for the larger substitution mutants in p12. While p12 mutant 8 had a three-fold reduction 
in VLP production (Figure 3.2), this effect was not seen with any of the point mutants in 
this region of p12.  
 
To assess the effect of the p12 mutations on Gag cleavage, a panel of p12 point mutant 
VLPs were concentrated and analysed by immunoblotting with a set of anti-MLV 
antibodies (Figure 3.14). None of the p12 point mutations in the N-terminal domain 
(Figure 3.14A) or the C-terminal domain of p12 (Figure 3.14B) affected the cleavage of 
Gag by the viral protease during maturation. The subtle changes in mobility of p12 (and 
MA-p12) reflected the changes in charge caused by the mutations. Thus, the point 
mutations in Mo-MLV p12 did not affect VLP release or Gag cleavage, indicating that 
these mutant viruses did not have major defects in the late stages of the viral life cycle. 
97 
 
 
Figure 3.14: The effect of individual alanine mutations in p12 on Gag cleavage during 
virus maturation. A panel of Mo-MLV p12 mutant VLPs, with point mutations in the (A) N-
terminus or (B) C-terminus of p12,  were analysed by immunoblotting with anti-CA (A and B, 
top panel), anti-p12 polyclonal (A and B, middle panel), anti-MA (A, bottom panel) or anti-NC 
(B, bottom panel) antibodies. 
 
98 
 
3.3.2 Mapping the essential residues in the N-terminus of p12 
The infectivity of Mo-MLV with point mutations in the N-terminal domain of p12 was 
assessed (Figure 3.15). Of the 21 amino acids mutated to alanines, only six reduced the 
infectivity by greater than 10-fold. These were V15 (19-fold), L16 (73-fold), L23 (15-
fold), D25 (114-fold), L26 (14-fold) and L27 (36-fold). Nine mutations had negligible 
effect on the infectivity of Mo-MLV and the remaining seven mutations reduced the 
infectivity by 2-to-10-fold. 
  
The fact that many of the mutations had minor effects on infectivity, suggested that the 
residues comprising the N-terminal domain of p12 contribute as a whole to the function 
of the domain. This was backed up by the mutations: K10A, K12A or Q14A which each 
reduced the infectivity by 2-to-10-fold, but when all three were mutated together the 
infectivity was reduced by greater than 100-fold compared to wild type (similar to the 
infectivity defect of p12 mutant 5) (Figure 3.15). 
 
To investigate further the amino acid requirements in the N-terminal domain of p12, 
three amino acids in the mutant 6 region of p12 were chosen for further mutation to 
residues other than alanine. L16, S17 and D18 when mutated to alanine had a large, 
negligible and minor effect on infectivity, respectively. Therefore these three amino 
acids were mutated to a panel of residues with differing biochemical properties (F, K, 
L/V, Q and D/E) (Figure 3.16). None of the S17 changes had any effect on infectivity, 
indicating that this amino acid is not essential for Mo-MLV infectivity. When L16 was 
changed to valine or aspartic acid the infectivity defect was the same as seen for the 
alanine mutant (Figure 3.16). Interestingly, a change to phenylalanine, lysine or 
glutamine had less of an effect on infectivity (4-fold, 15-fold and 7-fold reduction 
compared to wild type, respectively).  
 
The changes at position D18 fell into two groups: (i) mutations that had a greater effect 
on infectivity than the D18A change (F= 83-fold, K= 233-fold, and L= 286-fold 
reductions) and (ii) mutations that could function in the place of D18 (Q and E). Taken 
together this data suggests that some of the residues in the N-terminal domain (like 
S17), could accommodate a range of amino acids in their place with no detrimental 
effect on infectivity, whereas more critical residues (like L16 and D18) have some 
fundamental properties that could, to some degree, be mimicked by other amino acids. 
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Figure 3.15: Infectivity of Mo-MLV containing individual alanine mutations in the N-
terminal domain of p12. Individual alanine mutations in the N-terminal domain of p12 were 
generated and D17 cells were infected with equal RT-units of mutant VLPs. Productive 
infection was quantified after at least 48 hours. The infectivity is displayed as a percentage of 
wild type with the mean and range of three independent experiments shown. 
 
 
 
Figure 3.16: Infectivity of Mo-MLV containing expanded individual mutations in the 
mutant 6 region of p12. Individual mutations in the mutant 6 region of p12 were generated and 
D17 cells were infected with equal RT-units of mutant VLPs. Productive infection was 
quantified after at least 48 hours. The infectivity is displayed as a percentage of wild type with 
the mean and range of three independent experiments shown. 
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3.3.3 Investigating the role of p12 in Mo-MLV reverse transcription 
Mo-MLV p12 mutant 6 was the only p12 mutant VLP that had a reduced ability to 
reverse transcribe in infected D17 cells (Figure 3.5). Three of the point mutants residing 
in the region covered by p12 mutant 6 had an effect on the infectivity of Mo-MLV. 
Therefore it seemed logical to investigate if these point mutations affected reverse 
transcription in infected cells. D17 cells were infected with equal RT-units of VLPs and 
the total DNA isolated at various times post-infection. Strong stop (Figure 3.17A) and 
second strand extension (Figure 3.17B) reverse transcription products were detected by 
qPCR.  
 
Mutant 6 failed to accumulate significant levels of viral DNA products, as seen earlier 
(Figure 3.17). The three p12 point mutants V15A, L16A and D18A were all able to 
reverse transcribe in D17 cells with similar kinetics to wild type. The amounts of viral 
DNA synthesised by the V15A and L16A mutants were slightly reduced when 
compared to wild type across the time-course, but they were almost 10-fold higher than 
p12 mutant 6 levels (Figure 3.17). The level of viral DNA that was observed at the two 
week time point was significantly reduced for all the mutants (on a par with the 
infectivity defect of the mutants). In conclusion, the reduced ability to reverse transcribe 
only occurred when the larger mutant 6 region of p12 was altered, suggesting that the 
larger mutation increased the severity of the mutant phenotype. 
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Figure 3.17: Ability of Mo-MLV VLPs containing individual alanine mutations in the 
mutant 6 region of p12 to synthesise viral cDNA in infected cells. D17 cells were infected 
with equal RT-units of wild type or mutant VLPs and total DNA was isolated at various times 
post infection, as indicated. The relative amounts of (A) minus strand strong stop or (B) second 
strand extension reverse transcription products were measured by qPCR. Results are 
representative of multiple independent experiments. 
 
 
3.3.4 Mapping the essential residues in the C-terminus of p12 
To complete the finer mutagenesis of Mo-MLV p12, all of the amino acids comprising 
the C-terminal domain of p12 were mutated individually to alanine. LacZ-encoding p12 
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point mutant Mo-MLV VLPs were synthesised and their infectivity quantified (Figure 
3.18). 
 
Of the 15 amino acids in the C-terminal domain (14 mutated as residue 64 is an 
alanine), six had no effect on the infectivity of Mo-MLV when mutated to alanine. 
Eight had an effect on the infectivity of Mo-MLV, and remarkably all inhibited the 
infectivity by greater than 100-fold, when compared to wild type infectivity (Figure 
3.18). The least affected was the S61A mutant, although its infectivity was still reduced 
by 115-fold. In stark contrast to what was seen for the N-terminal domain, none of the 
mutations produced an in-between effect on infectivity. This indicated that a motif of 
eight essential amino acids were required for the function of the p12 C-terminal domain. 
 
Of the amino acids mentioned above, mutation of the four arginines (R66, R68, R70 and 
R71) along with serine 61 have previously been shown to block replication of Mo-MLV 
at an early stage in the life cycle (Yueh and Goff, 2003). Attempts to rescue the block to 
replication caused by the S61A mutant included mutation to aspartic acid, to mimic the 
negative charge of phosphoserine (Yueh and Goff, 2003). This was unsuccessful, but 
could a similar phosphorylatable amino acid, threonine, function in the place of serine? 
A p12 S61T mutant was synthesised and the VLPs were also found to be non-infectious 
(Figure 3.19). This indicated that a phosphorylatable residue could not necessarily 
function in place of the serine at position 61, although the level of p12 phosphorylation 
was not quantified.  
 
Revertant viruses from an Mo-MLV p12 S(61,65)A mutant were found to contain extra 
positive charges (mainly arginines), leading to the discovery that the four arginines in 
the C-terminus of p12 were essential for Mo-MLV infectivity (Yueh and Goff, 2003). 
These arginines in p12 could not be replaced by another positively charged amino acid, 
lysine (Yueh and Goff, 2003). To test if the other positively charged amino acid, 
histidine, could replace the arginines in the C-terminus of p12, R66 and R70 were 
mutated to histidine. In line with the lysine changes, histidine could not replace the 
function of the arginine residues (Figure 3.19). Therefore the charge alone was not the 
essential feature of these residues for the p12 C-terminal domain function. It is possible 
that these eight essential residues form a motif recognised by a cellular factor, and 
hence alterations to the motif affect this essential interaction. 
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Figure 3.18: Infectivity of Mo-MLV containing individual alanine mutations in the C-
terminal domain of p12. Individual alanine mutations in the C-terminal domain of p12 were 
generated and D17 cells were infected with equal RT-units of VLPs. Productive infection was 
quantified after at least 48 hours. The infectivity is displayed as a percentage of wild type with 
the mean and range of three independent experiments shown. 
 
 
Figure 3.19: Infectivity of Mo-MLV containing extended individual mutations in the C-
terminal domain of p12. Individual mutations in the C-terminal domain of p12 were generated 
and D17 cells were infected with equal RT-units of VLPs. Productive infection was quantified 
after at least 48 hours. The infectivity is displayed as a percentage of wild type with the mean 
and range of three independent experiments shown. 
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3.4 Summary 
The experiments detailed here have shown that the p12 mutant Mo-MLV VLPs, 
synthesised from the Mo-MLV Gag-Pol vector system, have phenotypes reminiscent of 
those derived from the proviral plasmids (Yuan, Li, and Goff, 1999). The p12 mutants 
5-8 and 13-15 were all blocked before integration of the viral DNA into the host 
chromosomes. Interestingly, the timing of the block, with regard to the synthesis of viral 
DNA in infected cells, varied between the experiments presented here and in the 
literature (Yuan, Li, and Goff, 1999). While the only p12 mutant VLP that failed to 
accumulate viral cDNA in infected cells was mutant 6, a previous study on the p12 
mutants concluded that in addition to mutant 6, mutant 8 was unable to synthesise viral 
cDNA (Yuan, Li, and Goff, 1999). The viral cDNA in these former experiments was 
quantified from a different cell line, NIH-3T3, to the D17 cells used here. 
Unfortunately, a high background in the qPCR precluded the analysis of these cells 
infected with our p12 mutant VLPs (Virginie Boucherit, personal communication). The 
fact that p12 mutant 8 could reverse transcribe in D17 cells and not in N3T3 cells, 
indicates that reverse transcription occurs differently in different cells, which has also 
been reported for HIV-1 (Arfi et al., 2009).  
 
Most importantly, the analysis of Mo-MLV mixed particles containing mixtures of wild 
type p12 and mutant p12, or two mutants, showed that the N- and C-terminal regions of 
p12 are actually two separate functional domains. Analysis of purified GST-tagged p12 
by analytical ultracentrifugation (AUC) and multi-angle laser light scattering (MALLS) 
has shown that p12 is monomeric over a wide range of concentrations (Wight et al., 
2012). Thus the dominant negative effect observed in mixed particles, containing wild 
type p12 and a C-terminal p12 mutant, was unlikely to be caused by inhibition of p12 
multimerisation (with the caveat that the concentrations of p12 tested are probably 
below the levels present inside a virion). As Mo-MLV mixed particles containing a 
mixture of N- and C-terminal p12 mutants were non-infectious, the N- and C-terminal 
domains do not function independently of each other. For infectious particles, both 
domains must be unaltered on the same molecule of p12. Simultaneous mutation of both 
domains of p12 has shown that the N-terminal domain is required for the dominant 
negative effect of the C-terminal p12 mutants in mixed particles. Thus the N-terminus 
of p12 must function first and/or interact with a limiting factor. 
  
The inhibition of MLV infectivity, in mixed particles composed of a C-terminal p12 
mutant and wild type p12, occurred when very little C-terminal mutant p12 was in the 
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virus, indicating that the C-terminal mutant p12 molecule was more efficient than wild 
type p12 at carrying out the N-terminal domain interaction/activity. This suggests that 
the C-terminal domain of p12 has an inhibitory effect on the N-terminal domain of p12, 
although the significance of this inhibition for the virus is currently unknown. 
  
Mutation of the 'linker' region, between the N- and C-terminal domains of p12, has 
revealed that it can be significantly shortened or increased in size without an impact on 
p12 function. Surprisingly, inclusion of the sGFP11 sequence was shown to be toxic to 
p12 function. The reason why this sequence is detrimental to p12 function is unclear, 
but potentially, due to the structure of the sGFP11 peptide, it may indicate that the 
central 'linker' region of p12 needs to remain flexible for p12 function. However other 
possibilities exist, for example the addition of extra charged residues into the 'linker' 
region may be detrimental p12 function. 
 
A closer examination of the amino acids that were essential for the domain functions 
revealed a stark contrast between the N- and C-terminal domains. The C-terminal 
domain contained eight amino acids all of which are essential for infectivity, whereas 
the N-terminal domain contained a few essential amino acids (notably leucines and 
aspartic acids) surrounded by others that contributed to the optimal function of the 
domain (i.e. mutating them had a smaller but notable effect on infectivity). The C-
terminal domain contains a motif of essential amino acids based around arginine 
residues, which could not be changed to residues with similar biochemical properties. 
  
The N-terminal domain is more complicated: the larger substitution mutants, composed 
of five or six alanines, had a greater effect on the infectivity of Mo-MLV than many of 
the point mutants. It is entirely possible that the residues in the N-terminal domain may 
contribute to an optimal conformation and/or spacing within the domain. Therefore, the 
residues that reduce the infectivity of Mo-MLV by 2-to-10 fold when mutated to alanine 
may promote optimal conditions for domain function. Considering that alanine and 
valine, two small non-polar amino acids similar to leucine, could not function in place 
of the essential L16, showed that there is something special about this leucine residue. 
Interestingly, the larger non-polar amino acid phenylalanine could function (to some 
degree) in place of L16. One similarity between these two amino acids is the length of 
their side chains and the other two amino acids that could partly function in place of 
L16 also have longer side chains (although not the same as leucine) with one being 
polar (glutamine) and the other positively charged (lysine). Recently, the interaction of 
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TRIM5alpha with the CA core has been described as a poly-valent interaction, where 
multiple weak interactions combine to make a strong binding to the core surface 
(Ohkura et al., 2011). Could a similar principle be true for the N-terminal domain of 
p12? Identification of an interacting partner of the N-terminal domain of p12 would 
certainly help to answer this question.  
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Chapter 4.  
The conservation of p12 function within the 
gammaretrovirus family 
 
Almost all retroviruses contain some sequence between MA and CA in their gag gene, 
although it does not always code for a functional protein. In the case of HIV-1, a small 
(~16 amino acid) spacer peptide exists between MA and CA of no known function. 
Retroviruses from other genera, like the alpha-retrovirus RSV code for three peptides, 
p2a, p2b and p10, which serve functions in particle budding and morphology of the CA 
core (Scheifele et al., 2007; Spidel et al., 2004). All gammaretroviruses contain a 'p12-
like' protein coded between MA and CA, which carries the 'PPPY' late-domain motif. 
 
Experiments in the previous chapter have established that the p12 protein in Mo-MLV 
contains two functional domains that are essential for the early stages of infection. The 
requirement for p12 during this part of the viral life cycle in other gammaretroviruses 
has not been established. Therefore, this chapter describes investigations into the 
conservation of p12 function in gammaretroviruses. Importantly, the requirement for 
p12 function, during the early stages of infection, was shown to be conserved in the 
gammaretroviridae.  
 
4.1 The effect of mutations in p12 on a panel of gammaretroviruses 
A panel of gammaretroviral Gag-Pol vectors were available for this study: N-tropic 
MLV (N-MLV), B-tropic MLV (B-MLV), xenotropic MLV-related virus, feline 
leukaemia virus (FeLV) and gibbon ape leukaemia virus (GaLV). All the synthesised 
gammaretroviral VLPs contain the MLV LTR-driven LacZ reporter genome and were 
psuedotyped with VSV-G. Both, the FeLV and GaLV, have previously been assessed to 
ensure they can package the reporter genome from MLV (Melvyn Yap, personal 
communication). Therefore, the effect of p12 mutations in this panel of gammaretroviral 
VLPs could be investigated. 
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4.1.1 The conservation of p12 sequence within the gammaretroviral genera 
Before generating mutations, the p12 sequences from the panel of gammaretroviruses 
were aligned using Clustal X2 (Larkin et al., 2007) (Figure 4.1). Manual fine-tuning of 
the outputs were made to ensure the most accurate alignments were constructed. 
 
 
Figure 4.1: Alignment of Mo-MLV p12 with the p12 sequences from other 
gammaretroviruses. The Mo-MLV p12 amino acid sequence (GenBank: J02255.1) was 
aligned with other retroviruses using Clustal X2 (Larkin M. A. et al. 2007). (A) Alignment of 
Mo-MLV p12, with p12 from: GaLV (M26927.1), KoRV ([Koala retrovirus] AF151794.2), 
FeLV (M18247.1), N-MLV (K01203.1) and XMRV (EF185282.1). Positions of the p12 
mutations 5-8 and 13-15 are shown by the coloured boxes. 
 
 
The most similar p12 sequences to Mo-MLV p12 were the other MLV sequences. N-
MLV (and B-MLV, the p12 sequence is identical) and XMRV p12 had 64.7% and 
71.4% sequence identity when compared to Mo-MLV p12, respectively. FeLV p12 
contained an 11 amino acid deletion in the centre of p12 and an overall 55.7% identity 
with Mo-MLV p12. The two most distantly related gammaretroviruses to Mo-MLV, 
GaLV and KoRV, had large deletions in the N-terminus of p12 and a low sequence 
identity with Mo-MLV p12 of 25.7% and 32.4%, respectively. The N-terminal domain 
of p12 had a high degree of similarity between the gammaretroviruses (barring GaLV 
and KoRV) and contained many leucines and aspartic acids (Figure 4.1A, green and 
blue boxes). The residues in the C-terminal domain of p12 appeared less well conserved 
(Figure 4.1A, pink and purple boxes). However, some arginines, which were shown to 
be essential for Mo-MLV infectivity, were preserved, although their position within the 
C-terminal domain varied.  
 
4.1.2 VLP release from a panel of gammaretroviruses carrying mutations in p12 
Similar p12 mutations were introduced into a panel of gammaretroviruses based on the 
sequence alignment in Figure 4.1A (see coloured boxes). As GaLV has a small N-
terminal region, only two mutants were made in this region, mutant 8 and one called 
mutant N (TDDLL/AAAAA). LacZ-encoding gammaretroviral VLPs were synthesised 
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and VLP production was assessed by the level of RT activity. None of the 
gammaretroviral p12 mutants had a major defect in VLP production (Figure 4.2). Mo-
MLV mutant 8 had a minor (three-fold) reduction in VLP release, which was also seen 
for N-MLV and B-MLV (~five-fold reduction, Figure 4.2 B and C, dark green bars), 
although not for FeLV and GaLV. Unfortunately, despite our best efforts, XMRV p12 
mutant 8 could not be cloned (Virginie Boucherit, personal communication).  
 
 
Figure 4.2: The effect of p12 mutations on VLP release for a panel of gammaretroviruses. 
The amount of (A) Mo-MLV, (B) N-MLV, (C) B-MLV, (D) XMRV, (E) FeLV and (F) GaLV 
VLPs released was quantified by measuring the RT activity using the RT-ELISA. The graphs 
show the percentage of p12 mutant VLPs released relative to wild type for each virus (based on 
the determined RT activity). The bars represent the mean and the range of three independent 
experiments. *ND- not determined. 
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4.1.3 The effect of p12 mutations on the infectivity of a panel of 
gammaretroviruses 
To assess the effect of the p12 mutations on the ability of the gammaretroviruses to 
progress through the early stages of infection, the infectivity of our panel of p12 
mutants were tested in D17 cells. All the gammaretroviruses tested were sensitive to 
alterations to the C-terminal region of p12 and these mutant viruses were non-infectious 
(Figure 4.3). The N-terminal domain was different in this regard: The p12 mutants 6 or 
8 were non-infectious in all gammaretroviral backgrounds, but both N-MLV and B-
MLV carrying p12 mutant 5 and 7 were much more infectious than Mo-MLV carrying 
these p12 mutations (Figure 4.3 A versus B and C, light and dark blue bars). The 
infectivity of these mutants was only reduced by 3-to-8.5-fold compared to wild type. 
This is interesting for p12 mutant 7 as the primary amino acid sequence in the p12 
mutant 7 region is the same between these three MLVs (Figure 4.3A).  
 
FeLV p12 mutant 5 was also infectious compared with Mo-MLV mutant 5, having only 
~2-fold reduction in infectivity when compared to wild type FeLV (Figure 4.3E). Both 
the XMRV p12 mutants 5 and 7, while greater than 10-fold more infectious than 
XMRV p12 mutant 6 (Figure 4.3D blue bars versus light green bar), were still relatively 
non-infectious. Finally, mutation of the short N-terminal domain of GaLV p12 (mutant 
N) also rendered the virus non-infectious (Figure 4.3F, peach bar). Therefore, all of the 
gammaretroviruses analysed required p12 function during the early stages of infection, 
although some portions of the N-terminal region were less sensitive to mutation in 
certain gammaretroviruses. 
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Figure 4.3: The infectivity of a panel of gammaretroviruses carrying mutations in p12. 
Equal RT-units of: (A) Mo-MLV, (B) N-MLV, (C) B-MLV, (D) XMRV, (E) FeLV and (F) 
GaLV VLPs were used to infect D17 cells. Productive infection was measured after at least 48 
hours. The graphs show the mean infectivity, as a percentage of wild type, from three 
independent experiments with the error bars displaying the range. *ND-  not determined. 
 
4.2 Identifying the early acting domains in GaLV p12 
From the panel of gammaretroviruses analysed, GaLV is the most distantly related to 
Mo-MLV. The p12 of GaLV has an interesting short N-terminal region, which, just like 
in Mo-MLV, was required during the early stages of replication (Figure 4.3F). 
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Therefore, to test the conservation of p12 function in the gammaretroviral genera 
further, a closer analysis of GaLV p12 function was undertaken. 
 
4.2.1 The N- and C-terminal domains in GaLV p12 
To assess if GaLV p12 also contained two functional domains, LacZ-encoding mixed 
GaLV particles containing wild type and mutant p12 were synthesised and the 
infectivity was quantified (Figure 4.4). 
 
Figure 4.4: Infectivity of GaLV particles containing mixtures of wild type and mutant p12. 
D17 cells were infected with equal RT-units of mixed particles and productive infection was 
measured after at least 48 hours. Infectivity is displayed as a percentage of wild type GaLV 
infectivity and the data is representative of at least two independent experiments. 
 
The GaLV N-terminal p12 mutant mixed particles displayed a phenotype similar to the 
N-terminal p12 mutants in Mo-MLV mixed particles (Figure 3.8). Little wild type p12 
(~10-20%) was required in the mixed particles to preserve infectivity (Figure 4.4, dark 
green and peach lines). The C-terminal p12 mutants 13 and 14 (Figure 4.4, pink and 
purple lines) displayed the dominant negative effect seen with Mo-MLV C-terminal p12 
mutants mixed particles, although the magnitude of the effect was reduced (the 
infectivity did not decrease sharply until 50% of p12 in the particle was mutant) (Figure 
4.4, pink and purple lines). Furthermore, GaLV p12 mutant 15 showed no dominant 
negative effect and its phenotype resembled that of the N-terminal p12 mutant mixed 
particles (Figure 4.4, magenta line). Thus, the GaLV mixed particles showed that GaLV 
also likely contained two domains in p12, but there were differences. (i) The dominant 
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negative effect of the C-terminal mutants was restricted to mutant 13 and 14 and (ii) the 
strength of the dominant negative effect was less in GaLV compared to Mo-MLV. 
  
To confirm the loss of the dominant negative effect, GaLV mixed particles were 
synthesised with wild type and a p12 point mutant in the mutant 15 region, R56A (that 
reduced the infectivity of GaLV by 71-fold, Figure 4.7B). As a control, mixed particles 
containing p12 mutant 14 and a point mutant in the mutant 14 region, R51A (Figure 
4.7B), were synthesised (Figure 4.5). As expected, the phenotype of the point mutant, 
R51A, mirrored the dominant negative phenotype of the larger p12 mutant 14 (Figure 
4.5, purple line and black dashed line with purple triangles), whereas the R56A point 
mutant mixed particles did not show a dominant negative effect, just like p12 mutant 15 
(Figure 4.5, pink line and black dashed line with pink triangles). Therefore, mutation of 
this region of p12 disrupted p12 function, but additionally removed the dominant 
negative activity in GaLV mixed particles. 
 
Figure 4.5: Infectivity of GaLV mixed particles containing mixtures of wild type and C-
terminal p12 point mutants. D17 cells were infected with equal RT-units of mixed particles 
and productive infection was measured after at least 48. Infectivity is displayed as a percentage 
of wild type GaLV. 
 
4.2.2 The essential residues in the N-terminal domain of GaLV p12 
Individual point mutants in Mo-MLV p12 revealed the essential amino acids in the N- 
and C-terminal domains of p12. Thus, the same approach was taken with GaLV p12. 
Alanine substitutions were generated for the residues in the N-terminal domain of p12 
(barring S8, E9, P10 and T11), LacZ-encoding VLPs were synthesised and their 
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infectivity was tested (Figure 4.6B). As a point of reference, the Mo-MLV N-terminal 
p12 sequence has been aligned with that of GaLV (Figure 4.6A). 
  
Only one mutant displayed a major effect on infectivity and one had a minor effect 
(Figure 4.6B). Interestingly, these residues were leucine (600-fold reduction in 
infectivity) and aspartic acid (three-fold reduction). Therefore, as was seen with the N-
terminal domain of Mo-MLV p12, leucine and aspartic acid residues were important for 
domain function. The larger p12 mutant N reduced the infectivity of GaLV by greater 
than 100-fold, but none of the point mutants in this region (mutant N) recapitulated this 
phenotype. This suggested that, as with Mo-MLV, the residues in the N-terminal 
domain of GaLV p12 were all contributing to an optimal conformation and/or spacing 
to the domain.  
 
Figure 4.6: Infectivity of GaLV containing individual alanine mutations in the N-terminal 
domain of p12. (A) Primary amino acid sequence of the N-terminal domain of Mo-MLV p12 
aligned with the corresponding amino acids of GaLV p12. Bold red amino acids indicate 
residues that when mutated to alanine, reduce the infectivity of Mo-MLV by greater than 10-
fold. (B) D17 cells were infected with equal RT-units of VLPs and productive infection 
quantified after at least 48 hours. Infectivity is displayed as a percentage of wild type GaLV 
infectivity with the mean and range of three independent experiments shown. *ND- not 
determined. 
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4.2.3 The essential residues in the C-terminal domain of GaLV p12 
To investigate which amino acids in the C-terminal domain of GaLV p12 were essential 
for function, individual alanine mutations were generated in GaLV p12 and the 
infectivity of the resulting VLPs tested (Figure 4.7). For comparison, the Mo-MLV p12 
C-terminal domain sequence is aligned with that of GaLV p12 (Figure 4.7A). 
  
Seven amino acid, when mutated to alanine, reduced the infectivity of GaLV by greater 
than 10-fold, namely: G45, P46, G49, T50, R51, R53 and R56 (Figure 4.7B). S52A had 
a minor effect on the infectivity of GaLV, reducing the infectivity by 7.3-fold (Figure 
4.7B). Interestingly, unlike Mo-MLV, only three out of the four arginines in the C-
terminus were essential for GaLV infectivity. Therefore, while the essential amino acids 
in the C-terminal domain of p12 were not conserved in position between Mo-MLV and 
GaLV, there were similarities. 
 
Figure 4.7: Infectivity of GaLV containing individual alanine mutations in the C-terminal 
domain of p12. (A) Primary amino acid sequence of the C-terminal domain of Mo-MLV p12 
aligned with the corresponding amino acids of GaLV p12. Bold red amino acids indicate 
residues that when mutated to alanine reduce the infectivity of Mo-MLV by greater than 10-
fold. (B) D17 cells were infected with equal RT-units of VLPs and the productive infection was 
quantified after at least 48 hours. Infectivity is displayed as a percentage of wild type GaLV 
infectivity with the mean and range of three independent experiments shown. 
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4.3 Investigating the conservation of the p12 domain function(s) between 
gammaretroviruses 
The GaLV p12 protein is interesting in the fact that it contains a very short N-terminal 
domain when compared to MLVs or FeLV. The results from the p12 alanine 
mutagenesis highlighted similar essential amino acids between GaLV and Mo-MLV 
p12. Experiments were therefore designed to test if the p12 proteins could be swapped 
between the viruses. 
 
4.3.1 The effect of GaLV p12 in Mo-MLV on VLP release 
To test whether the GaLV p12 can function in the Mo-MLV background, a panel of 
chimeras were constructed, containing either the whole GaLV p12, or N- or C-terminal 
regions. (Figure 4.8A, Mo-MLV/Ga-p12, Mo-MLV/Ga-Np12 and Mo-MLV/Ga-Cp12, 
respectively). To restore the Mo-MLV MA-p12 protease cleavage site, a leucine was 
inserted between the A2 and T3 of the Mo-MLV/Ga-p12 and Mo-MLV/Ga-Np12 
chimeras (Figure 4.8A, Mo-MLV/Ga-p12-CL and Mo-MLV/Ga-Np12-CL). 
 
All the Mo-MLV chimeras released wild type amounts of VLPs (Figure 4.8B). Equal 
RT-units of chimeric VLPs were analysed by immunoblotting with antibodies against 
CA (Figure 4.8C, top left panel), MA (Figure 4.8C, top right panel) and two antibodies 
against p12 (monoclonal in Figure 1.8C bottom right panel and a polyclonal in Figure 
4.8C, bottom left panel). All chimeric VLPs contained mature CA, but mature MA was 
not seen for the Mo-MLV/Ga-p12 and Mo-MLV/Ga-Np12 chimeras, indicating that the 
cleavage between MA-p12 had been disrupted (Figure 4.8C). When the Mo-MLV MA-
p12 cleavage site was restored, mature MA was detected in the chimeras, indicating the 
processing defect had been reversed (Figure 4.8C). Using a combination of the p12 
monoclonal and polyclonal antibodies (Figure 4.8C, lower panels), it could be seen that 
the Mo-MLV/Ga-Np12-CL and Mo-MLV/Ga-Cp12 contained mature p12. 
Unfortunately, the p12 antibodies did not cross react to GaLV p12, but as mature MA 
could be detected, it was assumed Mo-MLV/Ga-p12-CL must contain mature p12 
(Figure 4.8C, top right panel). Therefore, the Gag polyprotein in the Mo-MLV chimeras 
was processed by the viral PR. However, cleavage between MA and p12 required the 
natural Mo-MLV p12 sequence (PALT). 
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Figure 4.8: Mo-MLV chimeric VLPs containing GaLV p12. (A) Schematic detailing the 
regions of p12 swapped between Mo-MLV and GaLV (Asterisks- Mo-MLV/Ga-p12-CL and 
/Ga-Np12-CL contain a leucine inserted between the second alanine and third threonine of the 
GaLV p12, to restore the Mo-MLV protease cleavage site). (B) The level of VLPs released was 
measured by quantifying the RT activity by the RT-ELISA and is shown as the percentage of 
the wild type. The bars represent the mean and range of three independent experiments. (C) 
Equal RT-units of VLPs were analysed by immunoblotting with anti-CA (top left panel), anti-
MA (top right panel), anti-p12 polyclonal (bottom left panel) and anti-p12 monoclonal (bottom 
right panel) antibodies. 
 
4.3.2 The functionality of GaLV p12 domains in the Mo-MLV background 
The ability of the Mo-MLV/Ga-p12 chimeras to pass through the early stages of the life 
cycle was assessed by quantifying their infectivity in D17 cells (Figure 4.9). Mo-MLV 
chimeras containing the N-terminal region of GaLV p12 were 833-fold less infectious 
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than wild type Mo-MLV (Figure 4.9, Mo-MLV/Ga-Np12). This reduction in infectivity 
remained even when the MA-p12 protease cleavage site in the chimera had been 
restored (Figure 4.9, Mo-MLV/Ga-Np12-CL). Unsurprisingly, the same reduction in 
infectivity was seen when the whole GaLV p12 was introduced into the Mo-MLV 
background (Figure 4.9, Mo-MLV/Ga-p12 and Mo-MLV/Ga-p12-CL). Interestingly, 
Mo-MLV containing the C-terminal region of GaLV p12 was infectious (Figure 4.9, 
Mo-MLV/Ga-Cp12). Therefore the C-terminal domain of GaLV p12, but not the small 
N-terminal domain of p12, was able to function in the Mo-MLV background. 
 
 
Figure 4.9: Infectivity of Mo-MLV chimeric VLPs with GaLV p12. D17 cells were infected 
with equal RT-units of chimeric VLPs and the infectivity was quantified. The Infectivity is 
displayed as a percentage of wild type infectivity with the mean and range of three independent 
experiments shown. 
 
4.3.3 The effect of Mo-MLV p12 in GaLV on VLP release 
As the N-terminus of GaLV p12 could not function in the Mo-MLV background, it was 
important to assess the inverted chimeras. To do this, GaLV chimeras were constructed 
with the full Mo-MLV p12, N-terminus of Mo-MLV p12 (N-terminal to PPPY) or C-
terminus of Mo-MLV p12 (C-terminal to PPPY) (Figure 4.10A). 
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The GaLV chimera containing the C-terminus of Mo-MLV p12 did not have a defect in 
VLP release (Figure 4.10B, GaLV/Mo-Cp12). However, unlike the Mo-MLV chimeras, 
when GaLV contained the N-terminus of Mo-MLV p12 there was a dramatic reduction 
in the amount of chimeric VLPs released (Figure 4.10B, GaLV/Mo-Np12). 
Unsurprisingly, this was also seen with the chimera containing the entire Mo-MLV p12, 
although the effect was slightly less severe (Figure 4.10B, GaLV/Mo-p12). A BsrGI 
restriction endonuclease site was cloned into the GaLV Gag-Pol vector, 5' to the start of 
gag, to enable cloning of the chimeric fragments into the Gag-Pol vector. The reversion 
of this modification to the original sequence did not increase VLP production (data not 
shown).  
 
To assess the Gag processing in the GaLV chimeras, VLPs were concentrated and 
analysed by immunoblotting with p12 monoclonal and polyclonal antibodies (Figure 
4.10C, left and right panels, respectively). As mentioned above, neither antibody 
recognised the GaLV p12. Both the GaLV/Mo-p12 and GaLV/Mo-Np12 chimeras 
contained many bands, which likely represented Gag processing intermediates or 
processing errors (Figure 4.10C, left panel). The prominent band for 'mature' p12 in 
both these chimeras was slightly larger than that of Mo-MLV p12 in size. This was 
unexpected as the p12 amino acid sequence in Mo-MLV and GaLV/Mo-p12 is exactly 
the same. In addition, the p12 species in the GaLV/Mo-Np12 chimera has the same 
theoretical size as Mo-MLV p12 (8.7kDa). An explanation for this could be that the 
very faint bands, equal and smaller than Mo-MLV p12 (for GaLV/Mo-p12 and 
GaLV/Mo-Np12, respectively), represent the mature p12 species in these chimeras 
(Figure 4.10C, left and right panel, between 6kDa and 15kDa). In this scenario, the p12 
species in the GaLV/Mo-Np12 must migrate slightly faster than the Mo-MLV p12 due 
to charge differences between the proteins.  
 
The GaLV chimera with the C-terminus of Mo-MLV p12 had less processing 
intermediates than the other chimeras (Figure 4.10C, right panel). Again the size of the 
prominent band for 'mature' p12 in this GaLV/Mo-Cp12 was larger than would be 
expected based on a theoretical size of 7kDa, indicating that the mature protein may be 
the smaller faint p12 species on the immunoblot (Figure 4.10C, right panel, faint band 
between 6kDa and 15kDa). In summary, all of the chimeras did produce some form of 
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'mature' p12 separated from MA, but there were obvious processing defects, especially 
when the N-terminus of Mo-MLV p12 was in the GaLV background. 
 
Figure 4.10: GaLV chimeric VLPs containing Mo-MLV p12. (A) Schematic detailing the 
regions of p12 swapped between GaLV and Mo-MLV. (B) The level of VLPs released was 
measured by quantifying the RT activity by the RT-ELISA and is shown as the percentage of 
the wild type. The bars represent the mean and range of three independent experiments. (C) 
Equal RT-units of VLPs were analysed by immunoblotting with anti-p12 polyclonal (right 
panel) and p12 monoclonal (left panel) antibodies. 
 
4.3.4 The functionality of Mo-MLV p12 domains in the GaLV background 
Despite the processing defects observed in this set of chimeras, all of the chimeras were 
relatively infectious compared to wild type GaLV (Figure 4.11). The GaLV chimera 
with the C-terminus of Mo-MLV p12 had an infectivity that was reduced by 3.3-fold 
compared to the wild type GaLV (Figure 4.11, GaLV/Mo-Cp12). Unsurprisingly, the 
GaLV chimera containing the whole Mo-MLV p12 displayed the same reduction in 
infectivity (Figure 4.11, GaLV/Mo-p12). Interestingly, the GaLV containing the N-
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terminus of p12, which had an inhibitory effect on VLP release, was as infectious as 
wild type (Figure 4.11 GaLV/Mo-Np12). Thus, despite the chimeras having defects in 
VLP assembly/release and Gag cleavage, the released chimeric VLPs were infectious. 
Therefore, as was seen with the Mo-MLV chimeras, the C-terminus of p12 could 
function in the GaLV background, but, in contrast to the Mo-MLV chimeras, the Mo-
MLV p12 N-terminus could also function in the GaLV background.  
 
 
Figure 4.11: Infectivity of GaLV chimeric VLPs with Mo-MLV p12. D17 cells were 
infected with equal RT-units of chimeric VLPs and the infectivity was quantified. The 
infectivity is displayed as a percentage of wild type infectivity with the mean and range of three 
independent experiments shown. 
 
4.4 Summary 
This chapter looked at the function of p12 in other gammaretroviruses to establish if the 
function of p12 in early infection is conserved. By introducing p12 mutations, 
positionally analogous to those in Mo-MLV p12, into a panel of gammaretroviruses, the 
early function of p12 was shown to be conserved. Interestingly, while the whole C-
terminal region was required for all of the gammaretroviruses analysed, some 
gammaretroviruses had portions of the N-terminal region which could be altered with 
minor effects on infectivity. 
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To test the conservation of p12 further, I looked closer at the GaLV p12. This p12 
molecule is the most divergent from Mo-MLV p12 in the panel of viruses studied here, 
and it contains a very small N-terminal region when compared to the MLVs and FeLV. 
GaLV mixed particles showed that the N- and C-terminal p12 mutants acted in a similar 
way to the Mo-MLV mixed particles with the following differences: (i) the dominant 
negative effect of GaLV p12 mutants 13 and 14 was less severe when compared with 
Mo-MLV mutant 13 and 14, and (ii) GaLV p12 mutant 15 had no dominant negative 
activity in mixed particles. The lack of a dominant negative effect of p12 mutant 15 was 
confirmed using the point mutant R56A in mixed particles, which also lacked dominant 
negative activity. 
  
The essential residues in the N- and C-terminal domains of GaLV p12 were similar to 
those in Mo-MLV p12. The N-terminal domain contained only one essential residue (a 
leucine) and an aspartic acid that was found to have a minor effect on infectivity when 
mutated to alanine. Interestingly, leucines and aspartic acids were the essential residues 
in the N-terminal domain of Mo-MLV. This suggests the possibility that the N-terminus 
of p12 is interacting with a similar factor between the two viruses. The C-terminal 
domain of GaLV p12, like with Mo-MLV, contained a run of essential amino acids. 
While the amino acid composition of these motifs varied between Mo-MLV and GaLV, 
some features were shared. (i) Both contained arginines that were essential (Mo-MLV 
four versus GaLV three), (ii) both had an essential proline at the N-terminus of the 
motif and (iii) a phosphorylatable residue was amongst the essential residues in the 
motif (Mo-MLV S61 and GaLV T50). 
  
Using chimeric Mo-MLV or GaLV viruses it was shown that the C-terminus of p12 
could be swapped between these viruses, whereas the N-terminal domain of GaLV was 
unable to function in the Mo-MLV background. This implied that the C-terminal 
domains of gammaretroviral p12 proteins serve a common function between viruses, 
and as speculation, the C-terminal domain may interact with some essential host factor. 
As the small N-terminus of GaLV p12 was unable to function in the Mo-MLV 
background, this pointed towards the N-terminus of p12 having a virus specific 
function, although other explanations exist. The fact that the Mo-MLV p12 N-terminus 
can function in the GaLV background would argue against this notion. However, due to 
the sheer size of the Mo-MLV p12 N-terminal domain, it could possibly adapt to 
provide the required function in GaLV. 
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It should be noted that there were assembly/release defects when GaLV contained the 
N-terminus of Mo-MLV p12. This potentially implicates the N-terminus of GaLV p12 
as important during the late stages of the life cycle. However, it is entirely possible that 
this is merely a knock on effect of introducing extra sequence into the GaLV Gag. For 
example it was recently published that the runs of prolines in the C-terminus of MA and 
p12 produced an extended conformation of the MLV Gag poly-protein in vitro (Datta et 
al., 2011). The significance of this observation in vivo remains to be confirmed, but it is 
entirely possible that the added prolines (four extra) from the N-terminus of Mo-MLV 
p12 may affect the Gag polyprotein and thus assembly/release. 
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Chapter 5.  
Investigations into the functions' of the early 
acting domains of the gammaretroviral protein 
p12 
 
Indications towards the function of p12 have been around for some time. Mutation of 
the C-terminal domain of p12 results in PICs, which are biochemically identical to wild 
type, but are unable to physically integrate their viral genome during infection (Yuan et 
al., 2002; Yuan, Li, and Goff, 1999). In addition, mutation of the C-terminal domain of 
p12 does not affect the ability of the mutant PICs to integrate in vitro (Yuan et al., 
2002). Therefore localisation to the chromosomal DNA appeared to be defective with 
these mutants. This idea was taken further using immunofluorescence. It was shown 
that, during mitosis, p12 was localised to the condensed chromatin in infected cells, 
something that was not seen for the C-terminal p12 mutant 14 (Prizan-Ravid et al., 
2010). 
 
It had been assumed, for a long time, that both the N- and C-terminal p12 mutants have 
a similar defect, and thus little work has been done on the N-terminal domain of p12. 
There does appear to be an alteration to core morphology (or stability) based on the 
inability of the 'DLL' mutant to be recognised by TRIM5alpha in infected cells (Zhang 
et al., 2011). Thus, the N-terminal domain of p12 may have a role in the morphology of 
the CA core. Additionally, the function of p12 has been genetically linked to CA by 
studying the infectivity of chimeras between MLV and spleen necrosis virus (SNV) 
(Lee and Nagashima, 2005). 
 
This chapter describes various manipulations and assays to gain insight into the 
functions of the N- and C-terminal domains of p12. Importantly, a different function has 
now been assigned to each domain with the N-terminal domain of p12 participating in 
the formation of the mature retroviral core and the C-terminal domain playing a 
tethering function retaining the PIC on the condensed chromatin during infection. 
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5.1 Detecting the CA core within cells infected by p12 mutant VLPs 
After fusion of the virion membrane and host cell membranes, the retroviral core, 
composed of a fullerene arrangement of CA hexamers, is released into the cytoplasm 
(Briggs et al., 2003; Mortuza et al., 2004). The CA core-recognising restriction factors, 
TRIM5alpha and Fv1, are believed to interact with the 'intact' CA core of incoming 
retroviruses, blocking replication before and after reverse transcription respectively 
(Cowan et al., 2002; Hofmann et al., 1999; Jolicoeur and Baltimore, 1976; Munk et al., 
2002; Stremlau et al., 2006; Towers et al., 2000; Wu et al., 2006). Both these restriction 
factors interact with an 'intact' CA core very soon after its release into the cytoplasm and 
can be used as sensors for the correctly processed and formed mature retroviral core. 
 
5.1.1 Abrogation of restriction factor activity by p12 mutant N-tropic MLV 
Fv1 and TRIM5alpha can be saturated when a cell, expressing either factor, is infected 
with a high MOI of virus, blocking the restriction factor activity (Bassin et al., 1978; 
Boone, Innes, and Heitman, 1990; Duran-Troise et al., 1977; Towers, Collins, and 
Takeuchi, 2002). These cells can then be productively infected with a second 
(restriction factor-sensitive) virus, within a short time frame (4-6 hours) (Besnier, 
Takeuchi, and Towers, 2002; Boone, Innes, and Heitman, 1990; Hatziioannou et al., 
2003). This phenomenon has been used to develop an assay to test for the correctly 
processed CA core early after infection, called the abrogation assay (Bassin et al., 1978; 
Besnier, Takeuchi, and Towers, 2002; Cowan et al., 2002; Duran-Troise et al., 1977), 
and was used to test the p12 mutants.  
 
Mo-MLV is an NB-tropic virus and is not restricted by Fv1 or human TRIM5alpha thus 
the N-tropic virus N-MLV with the p12 mutants were tested (Hartley, Rowe, and 
Huebner, 1970; Towers et al., 2000). Balb/c 3T3 (B3T3, expressing Fv1b) or TE671 
(expressing human TRIM5alpha) cells were infected with a two-fold dilution series of 
the N-MLV VLPs. After 4 hours, the cells were infected with the second virus at a fixed 
dose (~MOI 1 in M.dunni cells) of GFP-encoding N-MLV. After 72 hours, the 
percentage of GFP+ cells was quantified using flow cytometery. Infection of B3T3 cells 
with wild type N-MLV resulted in the abrogation of Fv1b activity and permitted 
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infection of the cells by the second indicator virus (Figure 5.1A, black line and 
triangles). In contrast, infection with the unrestricted B-MLV resulted in no abrogation 
and restriction of the indicator virus (Figure 5.1A, black line and squares). This 
represented a greater than 10-fold reduction in abrogation ability of B-MLV compared 
to N-MLV. The two C-terminal p12 mutants, mutant 13 and 15, displayed an abrogation 
profile similar to that of wild type N-MLV (Figure 5.1A, pink and magenta lines). 
Therefore the C-terminal p12 mutants in N-MLV contained CA cores that were 
recognised by Fv1. Two N-terminal p12 mutants, mutant 5 and 7, have a partial 
abrogation phenotype, reduced by 2.6-fold and 1.7-fold when compared to wild type N-
MLV (Figure 5.1A, light blue and dark blue lines, respectively). This is not surprising 
as in N-MLV both these p12 mutants were relatively infectious compared to the other 
p12 mutants (Figure 4.3 B and C). Thus based on their infectivity, it would be expected 
that these mutant viruses would abrogate restriction, albeit at a slightly reduced level. In 
contrast, the two remaining N-terminal p12 mutants, mutant 6 and 8, are non-infectious 
and were unable to abrogate Fv1 restriction (Figure 5.1A, light and dark green lines). 
The same pattern was observed with the other core-targeting restriction factor, human 
TRIM5alpha (Figure 5.1B). This suggests that the CA cores from C-terminal p12 
mutant N-MLV were processed correctly and available to restriction factors during 
infection, whereas the non-infectious N-terminal p12 mutant CA cores were not. 
 
Mo-MLV p12 mutants 6 and 8 have been shown to have defects in reverse transcription 
(Chapter 3 and (Yuan, Li, and Goff, 1999)), and the inability to abrogate restriction 
factors could be linked to an inability to reverse transcribe in infected cells. 
Unfortunately, a high background prevented the measurement of viral DNA products in 
B3T3 or TE671 cells (Virginie Boucherit, personal communication). Therefore the 
ability of the N-MLV p12 mutants to reverse transcribe in D17 cells was assessed. 
Quantitative PCR on total DNA isolated from infected cells was performed as 
mentioned in chapter 3. All of the N-MLV p12 mutants were competent to reverse 
transcribe in D17 cells (Figure 5.2 A and B). (Note- a high background with mutant 8 
was observed and thus a conclusion could not be made regarding this mutants ability to 
reverse transcribe). Hence it's less likely that the inability of the N-terminal p12 mutants 
6 and 8 to abrogate restriction factors is linked to their ability to reverse transcribe in 
vivo. 
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Figure 5.1: Abrogation of Fv1 and TRIM5alpha restriction factor activity by N-tropic 
MLV carrying mutations in p12. (A) Balb/c 3T3 cells, expressing Fv1b, or (B) TE671 cells, 
expressing human TRIM5alpha, were infected with a two-fold dilution series of the tester VLPs 
(see key). Four hours later, cells received a second infection with a fixed volume of GFP-
encoding N-MLV. The percentage of GFP+ cells is plotted for each volume of tester virus. The 
graphs are representative of at least three independent experiments. 
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Figure 5.2: The ability of p12 mutant N-MLV VLPs to synthesise viral cDNA in infected 
cells. D17 cells were infected with equal RT-units of N-MLV VLPs containing mutations in p12 
(see key). At various times post infection, DNA was isolated from the infected cells. The 
relative amounts of viral reverse transcription products (A) strong stop (Early product) and (B) 
second strand extension (Late product) were measured by qPCR. The graphs are representative 
of multiple independent experiments. Note- mutant 8 has been omitted due to a high 
background in the assay. (Data courtesy of Virginie Boucherit). 
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5.1.2 Abrogation of human TRIM5alpha activity by Mo-MLV with an altered 
restriction factor tropism 
Due to the relatively high infectivity of the p12 mutants 5 and 7 in the N-MLV 
background, a general conclusion regarding the ability of the N-terminal p12 mutants to 
abrogate restriction factors could not be made. In an attempt to resolve this, mutations 
were made in the CA region (D82N, A110R and H117L) of the Mo-MLV Gag-Pol 
vectors to make the resulting VLPs (designated 'N/Mo') sensitive to restriction by Fv1b 
and human TRIM5alpha (Stevens et al., 2004). 
 
To quantify the infectivity of the N/Mo VLPs, D17 or TE671 cells were infected with 
equal RT-units of VLPs (Figure 5.3). The N/Mo VLPs carrying mutations in p12 had a 
similar infectivity defect as seen for the Mo-MLV p12 mutants. Interestingly in D17 
cells, N/Mo mutant 5 had an infectivity that was 40-fold reduced compared to wild type, 
which is considerably smaller than the infectivity defect of Mo-MLV p12 mutant 5 
(Figure 5.3 and Figure 3.3). Moreover, the N/Mo p12 mutant 7 infectivity was 33-fold 
less than wild type, which is also considerably smaller than the infectivity defect of Mo-
MLV p12 mutant 7 (Figure 5.3 and Figure 3.3). Therefore, despite the infectivity of 
N/Mo p12 mutant 5 and 7 not being elevated to the levels seen for these mutants in the 
N-MLV background, the changes in CA have increased their relative infectivity by a 
small but significant degree. 
 
As would be expected, the CA changes have made the wild type N/Mo sensitive to 
human TRIM5alpha and the infectivity was reduced by 13.8-fold compared to Mo-
MLV (Figure 5.3, TE671 cells, red bar with black stripes versus red bar). Thus, these 
N/Mo p12 mutants can be used in the abrogation assay with cells expressing human 
TRIM5alpha. 
 
N/Mo VLPs with or without mutations in p12 were used as tester viruses in the 
TRIM5alpha abrogation assay. Wild type N/Mo was able to abrogate TRIM5alpha, 
albeit with a ~three-fold reduction in abrogation ability when compared to N-MLV 
(Figure 5.4, black line with triangles versus black line with rings). The N/Mo C-
terminal p12 mutants, 13 and 15, were able to abrogate as well as wild type N/Mo 
(Figure 5.4, pink and magenta lines), consistent with what was seen for the C-terminal 
p12 mutants in the N-MLV background (Figure 5.1B). All of the N/Mo N-terminal p12 
mutants were unable to abrogate TRIM5alpha restriction (Figure 5.4, light and dark 
green and blue lines). Therefore, alterations to the N-terminal domain of Mo-MLV p12 
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affect the ability of restriction factors to interact with the CA core, immediately after its 
release into the cytoplasm. 
 
Figure 5.3: Infectivity of Mo-MLV with genetically altered restriction factor tropism. 
Three mutations were introduced into Mo-MLV CA (D82N, A110R and H117L) in the Mo-
MLV Gag-Pol vector to make the resulting VLPs sensitive to Fv1 (called N/Mo). D17 cells (left 
side) and TE671 cells (right side) were infected with equal RT-units of VLPs and the infectivity 
quantified after at least 48 hours. The infectivity is displayed as the percentage of the wild type 
Mo-MLV infectivity for each cell type. The graphs are representative of multiple independent 
experiments. 
 
Figure 5.4: Abrogation of human TRIM5alpha restriction factor activity by N/Mo-MLV 
VLPs carrying mutations in p12. TE671 cells, expressing human TRIM5alpha, were infected 
with a two-fold dilution series of the tester VLPs (see key). Four hours later, cells received a 
second infection with a fixed volume of GFP-encoding N-MLV. The percentage of GFP+ cells 
is plotted for each volume of tester virus. The graph is representative of at least three 
independent experiments. 
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One possible explanation for the failure of the N-terminal p12 mutants to abrogate 
restriction, is that mutation in p12 affects the processing and/or function of CA from the 
Gag polyprotein. To test if mutation in the N-terminal domain of p12 affects the 
processing of CA from Gag, mixed particles were synthesised from N-MLV Gag-Pol 
and B-MLV Gag-Pol, with or without the p12 mutant 6 (Figure 5.5A). All of these 
mixed particles contain 10% of wild type p12 and were as infectious as wild type N- or 
B-MLV (data not shown).  
 
When only 10% of the CA in the mixed particle was N-tropic, TRIM5alpha could not 
recognise the core and its activity was not abrogated (Figure 5.5B, B6/N, golden brown 
line). When all of the CA in the mixed particle was N-tropic, and 90% of the Gag 
contained the upstream N-terminal p12 mutation, it was able to be recognised by 
TRIM5alpha and could abrogate restriction (Figure 5.5B, N6/N, maroon line). Finally, 
when all of the N-tropic CA in the mixed particle came from Gag that contained the 
upstream N-terminal p12 mutation, it was also able to abrogate restriction by 
TRIM5alpha (Figure 5.5B, N6/B, orange line). Therefore, when the gag sequence 
contained an N-terminal p12 mutation upstream to the CA sequence, it did not affect the 
processing or function of CA from the resulting Gag polyprotein with regards to 
forming a mature core recognised by TRIM5alpha. 
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Figure 5.5: The effect of p12 mutation in gag on the ability of human TRIM5alpha to 
recognise CA in the abrogation assay. (A) Schematic detailing the Gag-Pol plasmids used to 
construct the mixed particles tested in this assay. The percentage of each plasmid transfected is 
shown on the left. (B) TE671 cells, expressing human TRIM5alpha, were infected with a two-
fold dilution series of the tester VLPs (see key and A). Four hours later, cells received a second 
infection with a fixed volume of GFP-encoding N-MLV. The percentage of GFP+ cells is 
plotted for each volume of tester virus. The graph is representative of at least three independent 
experiments. 
 
 
5.1.3 Further investigations into the role of the N-terminal domain of p12 in 
restriction factor saturation 
To assess if the affect of the p12 N-terminal domain on abrogation ability is 
independent of the C-terminal domain, the abrogation ability of mixed particles 
composed of an N- and C-terminal p12 mutant were tested. All the compositions of 
these mixed mutant particles are non-infectious, as was shown in chapter 3 (Figure 3.9). 
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All N-MLV mixed mutant particles were able to abrogate TRIM5alpha restriction when 
they contained as little as 10% of p12 with an active N-terminal domain (10% of a p12 
C-terminal mutant) (Figure 5.6 A, B and C). Thus the affect of the N-terminal domain 
of p12 on abrogation ability was entirely independent of the C-terminal domain. 
 
Some of the alanine point mutations in the N-terminal domain of Mo-MLV p12 only 
reduced the infectivity of the virus by 2-10-fold (Figure 3.15). The most significant 
reductions in infectivity were seen when leucines and aspartic acids were mutated to 
alanines (Figure 3.15). To see if the L16A point mutant, in the N-terminal domain of 
p12 was also unable to abrogate restriction, N/Mo VLPs containing this mutation were 
generated and used in the TRIM5alpha abrogation assay. 
 
Both the L16A p12 mutant and the double domain mutant LR(16,66)AA, displayed the 
same phenotype. Both were able to partly abrogate human TRIM5alpha activity, which 
resulted in ~2-3-fold reduced abrogation ability compared to the controls (Figure 5.7A, 
grey dotted line with green rings and black dotted line with yellow rings).  
 
N/Mo wild type appeared to have the same abrogation ability as these two mutants in 
this experiment, but when the percentage of GFP positive cells was plotted against the 
RT activity of each dilution of virus, it could be seen that this was due to less wild type 
N/Mo VLPs synthesised for use in this assay (Figure 5.7 A and B, compare black lines 
with black rings). As the RT activity is quantified retrospectively (the tester virus is 
used immediately after harvest), this check was used to ensure the phenotype observed 
in the abrogation assay was not due to reduced production of tester virus. Therefore, 
when the N-terminal domain of p12 was inactivated by a point mutation (L16A) the 
virus was able to partly abrogate restriction by TRIM5alpha.  
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Figure 5.6: Abrogation of human TRIM5alpha restriction factor activity by VLPs 
containing a mixture of N- and C- terminal p12 mutants. TE671 cells, expressing human 
TRIM5alpha, were infected with a two-fold dilution series of (A) mutant 13, (B) mutant 14 or 
(C) mutant 15 tester mixed VLPs and controls (see key). (Note- The percentage of C-terminal 
p12 mutant in the N-MLV mixed particles is indicated in brackets). Four hours later, cells 
received a second infection with a fixed volume of GFP-encoding N-MLV. The percentage of 
GFP+ cells is plotted for each dilution of tester virus. The graphs are representative of at least 
three independent experiments. 
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Figure 5.7: Abrogation of human TRIM5alpha restriction factor activity by N-tropic 
MLV with point mutations in the N- or C- terminal domains of p12. TE671 cells, 
expressing human TRIM5alpha, were infected with a two-fold dilution series of the tester VLPs 
(see legend) immediately after harvest. Four hours later, cells received a second infection with a 
fixed volume of GFP-encoding N-MLV. The percentage of GFP+ cells are plotted against the 
volume of tester virus (A) or the RT activity of each virus dilution (B) from one experiment. 
The graphs are representative of two independent experiments. 
 
Table 5.1: Summary of abrogation assay data. 
Virus Restriction factor Abrogation ability Figure 
N-MLV HuTRIM5alpha +++ 5.1 
N-MLV 5 HuTRIM5alpha +++ 
N-MLV 6 HuTRIM5alpha - 
N-MLV 7 HuTRIM5alpha +++ 
N-MLV 8 HuTRIM5alpha - 
N-MLV 13 HuTRIM5alpha +++ 
N-MLV 15 HuTRIM5alpha +++ 
N-MLV Fv1b +++ 5.1 
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N-MLV 5 Fv1b + 
N-MLV 6 Fv1b - 
N-MLV 7 Fv1b +++ 
N-MLV 8 Fv1b - 
N-MLV 13 Fv1b +++ 
N-MLV 15 Fv1b +++ 
Mo-MLV HuTRIM5alpha - 5.4 
N/Mo HuTRIM5alpha +++ 
N/Mo 5 HuTRIM5alpha - 
N/Mo 6 HuTRIM5alpha - 
N/Mo 7 HuTRIM5alpha - 
N/Mo 8 HuTRIM5alpha - 
N/Mo 13 HuTRIM5alpha +++ 
N/Mo 14 HuTRIM5alpha +++ 
N/Mo 15 HuTRIM5alpha +++ 
N/Mo L16A HuTRIM5alpha + 5.7 
N/Mo R66A HuTRIM5alpha +++ 
N/Mo LR(16,66)AA HuTRIM5alpha + 
N6/N HuTRIM5alpha +++ 5.5 
N6/B HuTRIM5alpha +++ 
B6/N HuTRIM5alpha - 
N13/N6 (0.9:0.1) HuTRIM5alpha +++ 5.6 
N13/N6 (0.8:0.2) HuTRIM5alpha +++ 
N13/N6 (0.2:0.8) HuTRIM5alpha +++ 
N13/N6 (0.1:0.9) HuTRIM5alpha +++ 
N14/N6 (0.9:0.1) HuTRIM5alpha +++ 
N14/N6 (0.8:0.2) HuTRIM5alpha +++ 
N14/N6 (0.2:0.8) HuTRIM5alpha +++ 
N14/N6 (0.1:0.9) HuTRIM5alpha +++ 
N15/N6 (0.9:0.1) HuTRIM5alpha +++ 
N15/N6 (0.8:0.2) HuTRIM5alpha +++ 
N15/N6 (0.2:0.8) HuTRIM5alpha +++ 
N15/N6 (0.1:0.9) HuTRIM5alpha +++ 
+++ = 8-fold greater abrogation than negative control   
+ = 3-8-fold greater abrogation than control   
- = Less than 3-fold greater abrogation than control   
 
5.2 Investigations into the state of the virion CA core before entry to the 
cytoplasm 
All of the data compiled so far are consistent with the possibility that the mutations in 
the N-terminus of p12 have an effect on the very final stages of retroviral replication 
(maturation). Maturation is a complex process of rearrangement within the virion, 
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triggered by the cleavage of the Gag and Pol precursors into the mature proteins 
(Yoshinaka and Luftig, 1977). This rearrangement is vital for infectivity of the virus, 
and virions that cannot undergo this process are not infectious (Crawford and Goff, 
1985; Katoh et al., 1985; Kohl et al., 1988). It has been shown so far that Mo-MLV N-
terminal p12 mutants all bud from the cell and contain the processed Gag proteins, but 
they are unable to infect cells. As all of the N-terminal Mo-MLV p12 mutants (barring 
mutant 6) can reverse transcribe in infected cells, but cannot abrogate restriction factors, 
it is possible that the core is unstable or malformed. The experiments described in this 
next section will detail investigations aimed to assess the formation and stability of the 
pre-entry CA core from Mo-MLV p12 mutants. 
 
5.2.1 Investigations into the effect of Gag processing on the early function of p12 
In wild type Mo-MLV, a sizable proportion of p12 in the particle remains fused to MA 
(Figure 3.2). This indicated, that the processing between MA and p12 is inefficient, 
consistent with previous reports (Oshima et al., 2004). Consequently, it is possible that 
the active p12 molecule, during the early stages of infection, is the MA-p12 fusion. To 
assess this, a mutation was made at the end of MA (Y131D) in the Mo-MLV Gag-Pol 
expression vector to block the MA-p12 cleavage (Oshima et al., 2004). 
 
To assess the liberation of free p12 from MA in VLPs containing the MA Y131D 
mutation, immunoblotting analysis was performed using a p12 polyclonal and MA 
antibodies (Figure 5.8A). This cleavage mutation blocked the majority of MA-p12 
cleavage, as was seen by a loss of mature MA signal in the MA immunoblot (Figure 
5.8A, bottom panel) plus an increase of MA-p12 and a significant reduction of free p12 
in the p12 immunoblot (Figure 5.8A, middle panel). 
 
The infectivity of p12 mutants, with and without the MA Y131D mutation, was 
quantified. Consistent with previous reports, the MA-p12 processing mutation had a 
minor (3.6-fold) effect on infectivity of wild type Mo-MLV (Figure 5.8B, red bar versus 
red/black checked bar) (Oshima et al., 2004). As expected, the addition of the MA 
Y131D mutation did not have an effect on the infectivity phenotype of the Mo-MLV 
p12 mutants (Figure 5.8B).  
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Figure 5.8: Gag processing and infectivity of Mo-MLV MA Y131D MA-p12 processing 
mutant. (A) Equal RT-units of VLPs containing Y or D at position 131 of MA, with or without 
p12 mutations, were analysed by immunoblotting with anti-CA (top panel), anti-p12 polyclonal 
(middle panel) or anti-MA (bottom panel) antibodies. (B) D17 cells were infected with equal 
RT-units of VLPs and infectivity was quantified. The graph indicates the mean and range 
infectivity of the VLPs, as a percentage of wild type, from three independent experiments. 
 
To completely block MA-p12 cleavage, two additional mutations were introduced into 
p12, PA(1,2)DE. This changed the sequence at the MA-p12 border from YPA to DDE 
(called 'DDE' mutant). The processing of Gag in this mutant was assessed by 
immunoblotting with a panel of MLV antibodies (Figure 5.9 A and B). No mature MA 
protein was detected for the Mo-MLV DDE mutant, as was observed for the MA 
Y131D mutant (Figure 5.9A). A weak mature p12 band could be observed for the MA 
Y131D mutant but no band was detected for the Mo-MLV DDE mutant (Figure 5.9B), 
indicating the DDE mutant had completely blocked MA-p12 processing. The infectivity 
of the DDE mutant was, surprisingly, as infectious as the MA Y131D mutant (Figure 
5.9C). Therefore, it is possible that p12 can function as the uncleaved MA-p12 fusion. 
139 
 
However, an increase in p12-containing Gag processing intermediates could be seen for 
the MA-p12 cleavage mutants (Figure 5.9B, marked by asterisks). These were smaller 
than MA-p12 and potentially could function relatively efficiently as the 'active' p12 
species during the early stages of infection. As MA is anchored to the virion membrane, 
it would be assumed that the majority remains with the virion membrane after fusion 
and not travel with the PIC. Thus, as p12 is a component of the PIC, the latter scenario 
seems more plausible, where blocking MA-p12 gave rise to alternatively processed 
forms of p12 which could function in the place of mature p12. 
 
Figure 5.9: The ability of extra mutations at the MA-p12 border to further inhibit MA-p12 
processing during maturation. (A) Equal volumes or (B) equal RT-units of VLPs were 
analysed by immunoblotting with anti-CA (A, top panel), anti-MA (A, bottom panel) or p12 
monoclonal (B) antibodies. p12-containing Gag processing intermediates are represented by 
asterisks (*). (C) D17 cells were infected with equal RT-units of VLPs and infectivity was 
quantified after at least 48 hours. The graph indicates the mean and range infectivity of the 
VLPs, as a percentage of wild type, from three independent experiments. 
 
Mo-MLV C-terminal p12 mutants in mixed particles display a dominant negative effect 
on infectivity (Figure 3.8). To test if fusing the C-terminal p12 mutants to MA 
abolished this activity, mixed particles were made where the Gag-Pol vector containing 
the p12 mutation also contained the MA Y131D MA-p12 processing mutation. Firstly, 
the N-terminal p12 mutants 6 and 7 were tested. Addition of the processing mutation 
had no effect on the infectivity phenotype of the mixed particles (Figure 5.10, green line 
and blue line versus green dashed line and blue dashed line, respectively). Interestingly, 
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when the Gag-Pol with the C-terminal p12 mutant contained the processing mutation, 
they lost their dominant negative effect on infectivity (Figure 5.11 A, B and C, compare 
solid coloured lines versus coloured dashed lines with black squares). Furthermore, 
when both the wild type and the C-terminal p12 mutant Gag-Pol vectors contained the 
processing mutation, the dominant negative effect was restored (Figure 5.11, A, B and 
C, coloured dot-dashed lines with black triangles). 
  
This interesting result could highlight some important information regarding the N-
terminal domain interaction. However due to the lack of some experimental evidence, 
the following assumptions will have to be made: (i) the functional p12 in the MA 
Y131D mutants is the alternatively processed forms of p12 and not MA-p12 and (ii) the 
alternatively processed forms of p12 are cleaved from Gag with slower kinetics than 
mature p12. Thus if these assumptions are correct and bearing in mind that the dominant 
negative effect requires an active N-terminal domain. Removal of the dominant negative 
effect of C-terminal p12 mutants by blocking the MA-p12 processing could indicate the 
following: (i) the N-terminal domain interaction occurs after cleavage of p12 from MA, 
(ii) either mature p12 is more adapted at making the N-terminal domain interaction, or 
has a kinetic advantage over the alternatively processed forms of p12 (mentioned 
above). Finally, the fact that the C-terminal mutants act as a dominant negative as long 
as the wild type p12 contains the same MA-p12 processing, suggests that the C-terminal 
p12 mutants are somehow more efficient at making the N-terminal interaction than wild 
type p12 molecules. 
 
Figure 5.10: Infectivity of Mo-MLV mixed particles containing a mixture of wild type and 
N-terminal mutant p12 with a MA-p12 processing mutation. D17 cells were infected with 
equal RT-units of mixed VLPs (see key) and productive infection was quantified after at least 
48 hours. Infectivity is plotted as a percentage of wild type Mo-MLV infectivity and the data is 
representative of at least two independent experiments. 
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Figure 5.11: Infectivity of Mo-MLV mixed particles containing a mixture of wild type and 
C-terminal mutant p12 with a MA-p12 processing mutation. Mo-MLV mixed particles, 
containing wild type p12 and: (A) p12 mutant 13, (B) p12 mutant 14 or (C) p12 mutant 15, with 
or without the MA Y131D mutation (see key), were synthesised. An additional set of mixed 
particles were synthesised for each p12 mutant, where the wild type Gag-Pol also contained the 
MA Y131D mutation (A, B and C, 'both MA Y131D' triangle points with dot-dash lines). The 
infectivity was quantified and is plotted as a percentage of wild type Mo-MLV infectivity. The 
data is representative of at least three independent experiments. 
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5.2.2 Assessing the stability of the Mo-MLV CA core before entry to the cell 
HIV-1 cores have been successful isolated from virions by centrifuging through a non-
ionic detergent onto a sucrose gradient (Kotov et al., 1999). Early studies were able to 
isolate MLV cores at a sucrose density of about 1.28g/ml (Bolognesi, Luftig, and 
Shaper, 1973; Durbin and Manning, 1982). In contrast in a more recent study, mature 
MLV CA cores could never be isolated at the calculated density for the MLV core 
(1.25g/ml) (Fassati and Goff, 1999). Therefore a method to isolate Mo-MLV cores 
similar to that employed for MLV and HIV-1 was devised (shown in Figure 5.12A) 
(Bolognesi, Luftig, and Shaper, 1973; Durbin and Manning, 1982; Kotov et al., 1999). 
The gradient was fractioned from the top down using a syringe pump driven gradient 
fractionator (fraction 1= the top). The method used for forming the gradient and 
collecting the fractions displayed a relatively good linear gradient, which was consistent 
between experiments (Figure 5.12B).  
 
Mo-MLV VLPs were run in gradients with and without Triton. The fractions were 
collected and analysed by immunoblotting with an anti-CA antibody. A peak of mature 
CA was detected in the gradient for both whole VLPs and the detergent stripped VLPs 
(Figure 5.12C). The peak of mature CA for whole VLPs migrated to a sucrose density 
of 1.148g/ml, whereas the detergent stripped VLPs migrated to a lower sucrose density 
of 1.113g/ml. It should be noted that the majority of the CA was seen in the pre-gradient 
and layers and the very top of the gradient (fraction 2) when VLPs were spun through 
detergent consistent with previous studies (Figure 5.12 C, fractions 1-3, note-these were 
diluted further to reduce the intensity of the bands) (Bolognesi, Luftig, and Shaper, 
1973; Durbin and Manning, 1982; Fassati and Goff, 1999; Kotov et al., 1999). For 
detergent-stripped wild type Mo-MLV, the average sucrose density of the peak CA 
fraction from multiple experiments was 1.115g/ml (n=5) (Figure 5.12C, fraction 7). 
This sucrose density was significantly less than the sucrose density at which un-lysed 
MLV virions migrated to on the gradients (Figure 5.12C, 'No Triton' immunoblot). 
Thus, it was unlikely that this mature CA peak represented un-lysed virions. However, 
due to the low sucrose density of the fractions that contained the mature CA material 
compared with the published density of isolated MLV cores (Bolognesi, Luftig, and 
Shaper, 1973; Durbin and Manning, 1982), it was unlikely that the CA species isolated 
in these experiments represented whole cores and more likely represented partial cores. 
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Figure 5.12: Attempted isolation of the MLV CA core from virions. To isolate MLV CA 
cores, virus was centrifuged through a layer of detergent onto a sucrose gradient. (A) Diagram 
showing preparation of gradients. For VLP analysis, triton was omitted. (B) Following 
centrifugation, the density of each fraction was measured using a refractometer and is plotted 
against the fraction number (fraction 1 = top of the gradient). (C) Wild type Mo-MLV VLPs 
were run on gradients with (bottom panel) or without Triton (top panel) and samples from each 
fraction were analysed by immunoblotting with an anti-CA antibody. The number below each 
fraction indicates the percentage of the total fraction loaded on the gel. 
 
To test if the amount of virus loaded onto the detergent layer gradients affected the 
position of the CA peak, three gradients were run with increasing amounts of virus 
loaded (2 plates of virus, 4 plates of virus or 6 plates of virus). The fractions were 
analysed by immunoblotting with an anti-CA antibody (Figure 5.13). Loading twice the 
normal amount of virus (normal = two 10cm plates of virus) on the detergent layer 
gradient did not affect the position of the mature CA peak in the gradient (Figure 5.13A, 
middle panel fraction 7). Interestingly, when three times as much virus was loaded, the 
peak also remained at a similar sucrose density but an increase in CA material was seen 
further down the gradient (Figure 5.13A, bottom panel). Therefore if too much virus 
was loaded on the detergent layer gradient, further spreading of the CA material was 
observed, but importantly the peak CA fraction remained at the same sucrose density. 
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Figure 5.13: The effect of loading more virus onto the detergent layer gradient. Twelve 
10cm plates of wild type Mo-MLV were produced by transient transfection of 293T cells, 
pooled together and concentrated over a 20% (w/v) sucrose cushion. Volumes equivalent to two 
10cm plates (black circles), four 10cm plates (black squares) or six 10cm plates (black triangles) 
of virus were loaded onto separate detergent layer gradients. (A) The gradients were run and the 
fractions analysed by immunoblotting with an anti-CA antibody. Note- fractions 1-3 are diluted 
more to reduce the high signal from the 'free' CA monomers at the top of the gradient. (B) 
Graph displaying the density profile of the gradients from (A). 
 
To establish if the viral RNA genome co-sediments with the CA peaks in this assay, 
RNA was isolated, reverse transcribed and the relative amount of viral genome was 
quantified using qPCR. Viral RNA could be detected in the wild type Mo-MLV 
detergent layer gradient in two peaks at fraction 4 (1.085g/ml) and fraction 11 
(1.190g/ml) (Figure 5.14A). Fraction 4 and 11, contained little and no mature CA, 
respectively (Figure 5.14B). These peaks are relatively close to the where the 35S 
(~fraction 7) and 70S (~fraction 10) gRNA would be expected to migrate and possibly 
reflect partially NC-coated gRNA (based on the approximate calculated S-values for 
each fraction). Thus, the mature CA peak detected in the gradients did not co-migrate 
with the gRNA, suggesting they are not whole cores. 
 
As it was possible to isolate some higher order form of mature CA from the core, using 
this assay, it seemed pertinent to assess if the p12 mutants also contained this CA core 
structure. The sucrose density of the fractions containing the peak of mature CA for the 
p12 N-terminal mutants was shifted to a lower sucrose density, when compared to wild 
type (Figure 5.15A). In contrast, the opposite was true for the C-terminal p12 mutants, 
where the peak was shifted to a higher sucrose density for mutants 14 and 15, although 
mutant 13 was similar to wild type (Figure 5.15A). The sucrose density profiles of the 
gradients, shown in Figure 5.15A, were plotted to emphasise their comparability (Figure 
5.15B). 
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Figure 5.14: Position of the genomic viral RNA in detergent layer gradients. Mo-MLV 
VLPs were synthesised and spun through detergent into a gradient. (A) RNA isolated from each 
fraction by phenol-chloroform extraction was reverse transcribed and cDNA was quantified 
using qPCR. The RNA was used as a template control. (B) Protein from each fraction was 
analysed by immunoblotting using an anti-CA antibody. 
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Figure 5.15: The effect of p12 mutations on the CA sedimentation profile in the triton spin 
through assay. Concentrated wild type or p12 mutant VLPs were layered onto triton spin 
through gradients. (A) Proteins were analysed by immunoblotting with an anti-CA antibody. 
Films were scanned with an Epson V700 scanner and representative western blots for wild type 
Mo-MLV and all the p12 mutants are shown. (B) A sample from each fraction was used to 
measure the refractive index to determine the sucrose densities. The graph shows the density 
profile of the all the gradients from (A). * input band missing due to over dilution of the sample. 
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To quantify the data from multiple experiments, the change in sucrose density of the 
mature CA peak fraction, between the p12 mutants and wild type, was calculated 
(Figure 5.16). This method standardises the difference observed for the p12 mutants in 
every experiment to the internal wild type Mo-MLV control. As could be seen in the 
representative blots (Figure 5.15A), the N-terminal p12 mutants have a sedimentation 
profile that was shifted to a lower sucrose density than wild type (Figure 5.16, light and 
dark, green and blue bars). Whereas, the C-terminal p12 mutants (barring mutant 13), 
all had a sedimentation profile that was shifted to a higher sucrose density (Figure 5.16, 
pink, purple and magenta bars).  
 
Therefore, this assay showed that the N- and C-terminal p12 mutants had differing 
phenotypes. The lower sedimentation profile of the mature CA peak for the N-terminal 
p12 mutants suggested either: (i) they lacked a mature core within the virion or (ii) a 
less stable core was formed, which broke into smaller parts after removal of the virion 
membrane. Interestingly, two of the C-terminal mutants showed the opposite effect 
(mutant 14 and 15), indicating that the core could be more stable in these viruses.  
 
 
Figure 5.16: Quantification of the effect of p12 mutations on the CA sedimentation profile 
in the detergent layer gradient. The sucrose density of the CA peak, after fraction 4, was 
determined for each p12 mutant and compared to that of the wild type control run in the same 
experiment. The mean density difference between each p12 mutant and wild type are shown in 
the graph. The error bars indicate the range. 
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5.2.3 Ultrastructure of the Mo-MLV core within the virion 
One reason why mutation of the N-terminal domain of p12 could result in a lack of 
abrogation of restriction factors, and cause the sedimentation profile of the partial cores 
to change, is if a mature CA core was not formed. To visualise if mutation of the N-
terminus of p12 resulted in formation of an aberrant core, cell-free virus was prepared 
for thin-section transmission electron microscopy (TEM). The p12 mutant 6 was chosen 
as it displays the most severe form of the N-terminal domain defect (reduced reverse 
transcription in vivo). Wild type and p12 mutant 6 VLP preparations, used for TEM, 
displayed the expected phenotypes (Figure 5.17). 
 
 
Figure 5.17: Characterisation of Mo-MLV VLPs for thin-section transmission electron 
microscopy. Sixty 10cm plates of 293T cells were transfected to produce either wild type or 
p12 mutant 6 Mo-MLV VLPs. The harvested VLPs were pooled and concentrated by pelleting 
in an ultracentrifuge. (A) Viral release was quantified using the RT-ELISA and is displayed as 
the RT activity mU/ml. (B) Viral proteins were separated by SDS-PAGE and the proteins 
stained with SimplyBlue stain. The gel was scanned using an Epson V700 scanner. (C) D17 
cells were infected with equal RT-units of the VLPs and the infectivity was quantified. The 
infectivity is shown as the percentage of wild type. 
 
 
VLP pellets were fixed, embedded in agar and thin 50nm sections were cut and stained 
on grids. Micrographs were taken at 20,000x magnification using a JOEL 1200EX TEM 
equipped with a CCD camera. Representative electron micrographs from wild type and 
p12 mutant 6 VLPs are shown adjacent to each other for comparison (Figure 5.18 A and 
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B). Looking at the wild type micrographs, an array of heterogeneity in VLP size and 
shapes were seen (Figure 5.18A). Importantly, the majority of the particles seen in these 
micrographs contained the characteristic electron dense core of a mature retroviral 
particle (Figure 5.18A) (Auerbach, Brown, and Kaplan, 2006; Auerbach, Brown, and 
Singh, 2007; Muriaux et al., 2004). In the micrographs of p12 mutant 6 VLPs, a few 
particles were seen containing a mature core (examples with green arrowheads), while 
the vast majority either lacked a core (examples with pink arrowheads) or contained 
some electron dense material that did not constitute an immature or mature core 
(examples with yellow arrowheads) (Figure 5.18B). This striking result highlighted p12 
mutant 6 has a defect in the formation of a mature core. 
 
To quantify this defect, the diameter of particles was measured and particles between 
80-120nm in diameter were assigned a core morphology using a set of examples (Figure 
5.19A). For wild type Mo-MLV particles, the majority (78.26%) displayed a mature 
core morphology, whereas only 12.50%, of the p12 mutant 6 virions contained a mature 
core phenotype (Figure 5.19B, green bars). The majority (56.85%) of the p12 mutant 6 
virions displayed an aberrant core morphology (Figure 5.19B, red bar). Only a few wild 
type virions containing aberrant cores could be observed (9.13%) (Figure 5.19B, red 
bar). Similarly, for virions lacking a core, wild type had a minor proportion in this 
category (11.74%), whereas p12 mutant 6 had significantly more virions without a 
visible core (28.23%) (Figure 5.19B, orange bars). The remaining virions were scored 
as containing an immature core morphology (Figure 5.19B, blue bar). Therefore, the 
defect with p12 mutant 6 results in the inability to form a mature core, with 85.08% of 
the virions either lacking a core or displaying some type of aberrant core morphology. 
Thus, the N-terminal domain of p12 was involved in, but possibly not limited to, the 
efficient assembly of the mature CA core within the virion. 
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Figure 5.18: Ultrastructure of p12 mutant Mo-MLV VLPs by thin-section transmission 
electron microscopy. Wild type or p12 mutant 6 VLPs were concentrated and prepared for thin 
section electron microscopy. Micrographs were taken at 20,000x magnification using a JOEL 
1200EX TEM equipped with a Gatan Orius CCD camera. Four representative micrographs of 
(A) wild type VLPs or (B) p12 mutant 6 VLPs are shown. Arrowheads indicate examples of: 
wild type-like VLPs in p12 mutant 6 micrographs (green arrowheads), VLPs lacking an 
identifiable core (pink arrowheads) or an aberrant core (yellow arrowheads). Scale bars are 
50nm. 
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Figure 5.19: Quantification of p12 mutant Mo-MLV VLP core morphology by thin-section 
transmission electron microscopy. Micrographs of wild type or p12 mutant 6 VLPs were 
analysed and the core morphology of the virions (between 80-120nm in diameter) categorised. 
(A) Representative images showing the core morphology from each morphological category. 
(B) Quantification of the core morphology data from wild type and p12 mutant 6 virions. 
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5.3 Investigations into the function of the C-terminal domain of p12 
As mutation of the C-terminal domain of p12 does not affect the ability of the virus to 
abrogate restriction, it can be assumed that the Mo-MLV core in these mutants is 
correctly formed. The intracellular PICs from cells infected with Mo-MLV containing 
p12 mutant 14 were biochemically similar to wild type, when analysed by equilibrium 
and velocity sedimentation (Yuan et al., 2002). Additionally, a later study using 
immunofluorescence, has highlighted that p12 could be seen on the condensed mitotic 
chromosomes during infection, a phenomenon that was not seen for p12 mutant 14 
(Prizan-Ravid et al., 2010). Thus, genetic assays aimed at rescuing the C-terminal p12 
mutant defect were performed. 
 
 
5.3.1 The effect of nuclear localisation motifs in p12 on Mo-MLV viability 
A few retroviral proteins have been described to have karyophilic motifs, essential for 
replication. One type of karyophilic motif is the nuclear (NLS) and nucleolar 
localisation motifs (NoLS), which are highly basic motifs directing nuclear trafficking 
of many proteins (Emmott and Hiscox, 2009; Lange et al., 2007). It has been shown that 
a motif based around essential arginines in the C-terminus of p12 was necessary for 
function. Could this motif in p12 have a role in nuclear localisation? However, barring a 
few examples, simple retroviruses like the gammaretroviruses only access the 
chromosomes during mitosis, thus if p12 does contain a karyophilic signal it is unlikely 
to direct active transport into the nucleus. (Jarrosson-Wuilleme et al., 2006; Liu et al., 
2011; Roe et al., 1993).  
 
To test if the C-terminal domain of p12 plays a karyophilic role during the early stages 
of infection, using the AscI cloned into p12 (described in Chapter 3) an NLS and two 
NoLS were cloned into p12 of the Mo-MLV Gag-Pol vector. The release of wild type 
Mo-MLV VLPs, with or without the modifications, were quantified by the level of RT 
activity released (Figure 5.20A). Addition of the prototypic NLS from the simian 
vacuolating virus 40 (SV40) large T-antigen was significantly detrimental to wild type 
virus release, resulting in a 44-fold reduction in release (Figure 5.20A). The angiogenin 
NoLS and NF-kB inducing kinase (NIK) NoLS motifs in wild type Mo-MLV p12 also 
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had an effect on VLP release, but to a smaller degree than the SV40 T-antigen NLS 
(2.4-fold and 4.6-fold reductions, respectively) (Figure 5.20A). The infectivity of p12 
mutant VLPs carrying these NoLS motifs in p12 was assessed. Insertion of the 
angiogenin NoLS into wild type p12 had only a minor, 1.8-fold, effect on infectivity 
(Figure 5.20B). Whereas, the NIK NoLS reduced the infectivity of wild type Mo-MLV 
by 145-fold (Figure 5.20B). The angiogenin NoLS had little effect on the infectivity of 
the p12 mutants, with no effect seen on the infectivity of the two N-terminal p12 
mutants (Figure 5.20B). The C-terminal p12 mutant 14, had a further reduction in 
infectivity when carrying the angiogenin NoLS of 8.3-fold compared to p12 mutant 14 
without this NoLS (Figure 5.20B). This infectivity was almost down to background 
levels, suggesting that this motif was actively taking p12 (and the PIC) away from 
where it needed to go during the early stages of infection. The fact that it did not affect 
wild type Mo-MLV infectivity, suggested that the motif in the C-terminal domain of 
p12 was dominant over this NoLS motif. 
 
Interestingly, the NIK NoLS in p12 had the opposite effect on the infectivity of Mo-
MLV. It reduced the infectivity of wild type Mo-MLV (145-fold), p12 mutant 6 (24-
fold) and mutant 7 (22-fold), but increased the infectivity of p12 mutant 14 by 18-fold 
(Figure 5.20B). Therefore the effect of this motif was dominant over the C-terminal 
domain of p12, directing wild type Mo-MLV to a location not ideally suited for 
productive infection. However, this nuclear/nucleolar location could improve the 
chances of mutant 14 to integrate (up to the infectivity of wild type with the NIK 
NoLS). Thus, localisation of p12 to the nucleolus, while detrimental to wild type p12 
function, could enhance the chances that p12 mutant 14 would integrate its viral DNA 
into the host cell chromosomes. However, it should be noted that the nuclear 
localisation of these viruses has not yet been tested.    
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Figure 5.20: The effect of p12 containing different nuclear localisation signals on VLP 
release and infectivity. Using the AscI restriction site introduced into p12 of the Mo-MLV 
Gag-Pol expression vector (p12-AscI), different nuclear localisation motifs were cloned into 
p12. (A) RT activity was measured using the RT-ELISA and VLP release is shown as a 
percentage of the wild type VLP RT activity. The bars show the mean and range of three 
independent experiments. (B) The infectivity was quantified and is expressed as a percentage of 
wild type infectivity. The bars indicate the mean and range of three independent experiments. 
Ang NoLS = Angiogenin nucleolar localisation signal (IMRRRGL), NIK NoLS = NF-kB 
inducing kinase nucleolar localisation signal (RKKRKKK) and SV40 NLS = simian vacuolating 
virus 40 large T-antigen nuclear localisation signal (PKKKRRV). 
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5.3.2 The chromatin tethering function of the C-terminus of p12 
The HIV-1 PIC is tethered to the host chromosomes by interactions with lens 
epithelium-derived growth factor (LEDGF) through IN (Cherepanov et al., 2003; 
Maertens et al., 2003). This interaction is essential for efficient HIV-1 integration. 
Based on the fact that p12 mutant 14 could not localise to condensed chromatin in 
infected cells (Prizan-Ravid et al., 2010), and a minor infectivity rescue could be 
achieved by addition of an NoLS, it was possible that p12 could be a LEDGF-like 
chromatin tether molecule for MLV. 
 
A portion of the prototypic foamy virus (PFV) Gag, in the glycine-arginine-rich box II 
(GRII), is responsible for chromatin tethering of expressed PFV Gag, and of the 
incoming PFV PICs (Mullers et al., 2011; Tobaly-Tapiero et al., 2008). To see if the C-
terminal domain of Mo-MLV p12 has a chromatin tethering function, the PFV 
chromatin binding sequence (CBS) was cloned into p12. Wild type and p12 mutant Mo-
MLV VLPs, with or without the PFV CBS in p12, all produced similar levels of VLPs 
(none had greater than a two-fold defect in VLP production) (Figure 5.21A). Inclusion 
of the PFV CBS in wild type p12 did, however, reduce the infectivity of Mo-MLV by 
16-fold (Figure 5.21B). Therefore, the PFV CBS targeted p12 (and the PIC) to the 
chromatin in a manner that was sub-optimal for integration. Inclusion of the PFV CBS 
in the N-terminal p12 mutants, mutant 6 or 7, did not have an effect on infectivity 
(Figure 5.21B). However, when the PFV CBS was inserted into any of the C-terminal 
p12 mutants, the infectivity was increased by greater than 100-fold (Figure 5.21B). In 
conclusion, this represented a significant rescue of the defect imposed by the mutation, 
indicating the C-terminal domain of p12 has a chromatin tethering function for the 
incoming PICs. 
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Figure 5.21: The effect on Mo-MLV of p12 containing the PFV CBS. Using the AscI 
restriction site introduced into p12 of the Mo-MLV Gag-Pol expression vector (p12-AscI), the 
PFV CBS (NQGGYNLRPRTYQP) was cloned into p12 (p12-PFV CBS). (A) RT activity was 
measured using the RT-ELISA and VLP release is shown as a percentage of the wild type VLP 
RT activity. The bars show the mean and range of three independent experiments. (B) The 
infectivity was quantified and is expressed as a percentage of wild type infectivity. The bars 
indicate the mean and range of three independent experiments. 
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5.3.3 The effect of p12 on viral DNA integration site selection 
In addition to chromatin binding, LEDGF influences integration targeting for 
lentiviruses (Cherepanov, 2007; Ciuffi et al., 2005; Llano et al., 2006). MLV, similar to 
HIV-1, does not integrate randomly into the genome and MLV has a preference for 
transcriptional start sites (Mitchell et al., 2004). However, unlike HIV-1, no factors 
involved in integration targeting for simple retroviruses have been described. 
 
To assess if p12 influences the integration targeting of MLV through p12's chromatin 
tethering function a panel of modified Mo-MLVs were synthesised, and titrated on 
HeLa cells (Figure 5.22A). HeLa cells were infected with a MOI~1.5 (less for p12 
mutant 6 and 14) and the total DNA was isolated. The integration sites were then 
sequenced in the Bushman laboratory. After filtering out sequences that were non-
unique and too short for annotation the unique integration sites (Figure 5.22B) were 
aligned to the human genome.  
 
Using the genome annotation RefGene, the distance of the integration sites to the 
nearest gene were analysed (Figure 5.22C). For wild type Mo-MLV an enrichment of 
integration sites, located close to the start site of genes was found, as previously 
reported (Figure 5.22C) (Cattoglio et al., 2010; Mitchell et al., 2004). The same 
integration pattern was also seen for the Mo-MLV/Ga-Cp12 chimera and the Mo-MLV 
with the p12-PFV-CBS, with and without the p12 mutation 14 (Figure 5.22C). While 
p12 mutant 6 also followed the same pattern as wild type, p12 mutant 14 did not. 
Mutant 14 displayed a wider integration selection pattern, with some integration sites a 
considerable distance from a transcriptional start site (Figure 5.22C). Similarly, another 
genomic feature favoured for integration by Mo-MLV are CpG islands (Cattoglio et al., 
2010). All of the viruses tested had a similar tendency to integrate near CpG islands, 
with the exception of p12 mutant 14, which displayed a slightly reduced tendency to 
integrate near CpG island midpoints (Figure 5.22D).  
 
Therefore, targeting the Mo-MLV PIC to chromatin using MLV p12, the C-terminus of 
GaLV p12 or the PFV CBS did not influence the integration pattern of Mo-MLV. 
However interestingly, this data has suggested the loss of the C-terminus of p12 does 
have an influence on integration site selection, although the number of integration sites 
analysed for the p12 mutants is extremely low (due to their infectivity defect).  
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Figure 5.22: The influence of p12 on integration site selection of Mo-MLV. (A) Infectious 
titre of viruses in HeLa cells (note- all VLPs except wild type were concentrated ten times). 
HeLa cells were infected at an approximate MOI~1.5, total DNA was isolated and sent to the 
Bushman laboratory for integration site sequencing. (B) Number of unique integration sites 
sequenced from the infected HeLa cells. (C) Distance of the integration sites for each virus to 
the 5' end of genes (determined using the RefGene annotation). (D) Distance of the integration 
sites for each virus to the nearest CpG island midpoint. Integration site sequencing and 
annotation was performed in the Bushman laboratory. Wt- wild type Mo-MLV, Mut 6- Mo-
MLV p12 mutant 6 and Mut 14- Mo-MLV p12 mutant 14. 
 
5.4 Summary 
5.4.1 The function of the N-terminal domain of p12 
Mutations in the N-terminal domain of p12 affected the ability of Fv1 and TRIM5alpha 
to interact with the CA core during infection. This implied that the CA core of the N-
terminal p12 mutants was either (i) blocked from the restriction factor by the mutant 
p12 (ii) mislocalised within the infected cell, (iii) processed incorrectly and thus not 
recognisable by the restriction factors, (iv) unstable or (v) no recognisable core was 
present to be acted on by the restriction factors. 
 
Firstly, it is unlikely that the N-terminal p12 mutants block restriction factor binding to 
the core, as it would be hard to explain why this would cause an infectivity defect. 
Secondly, it is also unlikely that the CA core of these p12 mutants are mislocalised 
within infected cells, as no specific sub-cellular localisation of retroviruses or restriction 
factors have been described.  
 
Using mixed particles it was shown that the CA from gag that contained an N-terminal 
p12 mutation was correctly processed and could be identified by restriction factors. This 
indicated that p12 mutations in cis to CA did not alter CA processing or inclusion as 
part of the mature core. To assess the stability of the Mo-MLV p12 mutant core, 
isolation of MLV cores was attempted by centrifugation of VLPs through detergent 
onto a sucrose gradient. This method has allowed isolation of HIV-1 cores and the 
stability of CA mutant cores to be analysed (Forshey et al., 2002; Kotov et al., 1999). 
Unfortunately, whole cores were not isolated by this method, but a species of partial 
core, devoid of the genomic RNA, was isolated in the gradient. Importantly, the position 
of these partial cores within the gradient was reproducible between experiments, and 
were more buoyant than un-lysed VLPs. The N-terminal p12 mutants all migrated to a 
lower sucrose density than wild type, indicating that the core was either less stable or 
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poorly formed in these mutants. Interestingly, two of the C-terminal mutants (14 and 
15) migrated to a sucrose density that was higher than wild type.  
 
To assess the morphology of the mature core inside the N-terminal p12 mutants, thin 
section TEM was performed on purified mutant 6 virions. Perhaps surprisingly, only a 
minor proportion of p12 mutant 6 virions contained a morphologically mature core. The 
majority had aberrant core morphologies, and a sizeable proportion contained no visible 
cores. This hinted towards the involvement of p12 in the efficient formation of the 
mature CA core during maturation. 
 
For p12 to have an effect on the CA core through its N-terminal domain, it would be 
expected to bind to some core-associated factor. No long-range interactions were 
reported between MLV p12 and the N-terminus of CA in an expressed fusion protein, 
but p12 and CA have been functionally linked using chimeric viruses (Kyere, Joseph, 
and Summers, 2008; Lee and Nagashima, 2005). Taken together with the chimeric data 
from chapter 4, it is possible that the N-terminal domain of p12 actually interacts, 
directly or indirectly, with the forming CA core within the virion.  
 
Another point to consider is that the point mutant L16A, which significantly knocked 
down the infectivity of Mo-MLV, could partially abrogate restriction. This implied that 
the CA core of this p12 point mutant is actually present in the infected cells. The L16A 
mutant was 2.8-fold more infectious than p12 mutant 6 and the partial abrogation could 
reflect an increase in virions with mature cores formed by the L16A mutant. However, 
the abrogation and infectivity defects do not match, indicating that mutation of the N-
terminus of p12 may cause another defect in addition to malformation of the mature 
core. 
 
Finally, completely blocking the cleavage of p12 from MA had a very minor effect on 
infectivity of Mo-MLV, consistent with previous reports (Oshima et al., 2004). This 
suggested that either MA-p12 or more likely one of the Gag processing intermediates 
could carry out the early function of p12. In mixed particles, the dominant negative 
effect of the C-terminal p12 mutants was lost by blocking the processing of the 
dominant negative p12 molecule from MA. This showed that in the wild type virion the 
cleaved form of p12 was better suited to carry out the N-terminal domain interaction, 
and that this interaction occurred or was activated after MA-p12 cleavage. 
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5.4.2 The function of the C-terminal domain of p12 
Localisation of p12 (and the PIC) to the nucleus via the NIK NoLS motif increased the 
infectivity of p12 mutant 14 by greater than 10-fold, with the caveat that this motif was 
toxic to wild type p12 function. Another NoLS, from angiogenin, was unable to 
partially rescue the p12 mutant 14 infectivity defect. The difference between the NIK 
NoLS and the angiogenin NoLS, is that the former is composed of two components, an 
NLS and an NoLS (Birbach et al., 2004). Therefore the NIK NoLS can shuttle between 
the nuclear and nucleolar compartments, potentially increasing the chances that the 
MLV PIC will interact with the chromosomes. The angiogenin NoLS is likely inactive 
in the context of the MLV PIC as it is unable to confer nucleolar localisation to β-
galactosidase, but it can localise the smaller GFP molecule to the nucleolar 
compartment (Lixin et al., 2001). 
  
Addition of a chromatin binding sequence, from PFV, into the C-terminal p12 mutants 
was able to significantly rescue the infectivity of Mo-MLV by at least 100-fold. This 
motif also had an effect on the infectivity of wild type Mo-MLV (>10-fold reduction), 
indicating that the location of the chromatin binding is sub-optimal for integration of 
Mo-MLV. Live imaging experiments have shown that the Kaposi's sarcoma-associated 
herpes virus (KSHV) LANA CBS rescues the chromatin binding of p12 mutant 14 (and 
partly rescues the infectivity defect) in infected mitotic cells, although it remains more 
tightly associated with the chromatin than wild type p12 after mitosis (Elis et al., 2012).  
The use of the PFV chromatin binding sequence or the C-terminal domain of GaLV p12 
was unable to change the integration targeting of Mo-MLV, showing that p12-
chromatin binding is not targeting Mo-MLV integration site selection. This has also 
recently been reported using a panel of heterologous CBS motifs in Mo-MLV p12 
(Schneider et al., 2013). However, loss of the C-terminus of p12 reduced the integration 
tendency towards transcriptional start sites, something not seen for the N-terminal p12 
mutant 6. However, it should be noted that the number of integration sites analysed 
were too small to make this observation statistically significant but it does warrant 
further investigation. If this trend remains after further experiments it means that p12 
mediated docking does exert an effect on integration site selection, and that binding to 
the chromatin (by the motif in p12 or another CBS) allows the integration machinery to 
contact a co-factor that then determines site selection. This fits with the fact that wild 
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type Mo-MLV is 10-fold less infectious when p12 contains the PFV-CBS, indicating 
that the PFV-CBS could bind to the chromatin where less of the site selection co-factor 
exist.  
 
The data I have shown here, together with data from Monica Roth's laboratory and the 
elegant experiments performed in Eran Bacharach's laboratory, indicate that p12 has a 
LEDGF-like chromatin tethering function for Mo-MLV. However, unlike the LEDGF-
chromatin interaction for lentiviruses, the p12-chromatin interaction is not directly 
determining the site of Mo-MLV integration. 
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Chapter 6.  
Investigations into the movements of the 
retroviral PIC during the early stages of infection 
 
Work in the previous chapters has highlighted that p12 contains two domains, both 
which function during the early stages of infection. Genetic and biochemical assays 
have revealed that the N-terminal domain has a role in formation and/or stability of the 
retroviral core, while the C-terminus is required later in the life cycle, to bind the PIC to 
mitotic chromatin. To compliment the genetic and biochemical data compiled so far, the 
sub-cellular localisation of p12 and the CA core were investigated using fluorescence 
microscopy. 
  
Studying the movements of the PIC in infected cells with fluorescence microscopy 
presents many problems. Of most significance is the non-productive uptake of virus 
particles into cells (Marechal et al., 1998; McDonald et al., 2002). Methods to exclude 
these defective particles from analysis were assessed. While the role of the C-terminal 
domain of p12 during the early stages of infection has been investigated thoroughly 
using microscopy, the phenotype of the N-terminal p12 mutants have not been assessed 
(Elis et al., 2012; Prizan-Ravid et al., 2010). During a collaborative stay at Tel Aviv 
University, the effect of the N-terminal p12 mutants on Mo-MLV PIC movements were 
studied using a combination of live cell imaging and fixed immunofluorescence.    
 
6.1 Expression of p12 in mammalian cells 
The only structural data on p12 comes from a fusion of p12 with the NTD of CA, and 
suggests that p12 displays a high degree of flexibility (Kyere, Joseph, and Summers, 
2008). Thus p12 does not form a defined structure in vitro. Indeed, when untagged p12 
was expressed in mammalian cells it was only weakly detectable by immunoblotting 
after transfection (Boucherit, V. unpublished data). This is likely due to its unstructured 
nature, when not part of the PIC, and subsequent degradation by the proteasome. Thus, 
analysis of the localisation of native p12 in mammalian cells by immunofluorescence 
was not an option. In order to stabilise p12 and to study its sub-cellular localisation, p12 
was fused to a fluorescent protein. 
167 
 
 
6.1.1 The sub-cellular localisation of an mCherry-p12 fusion expressed in 
mammalian cells 
The Mo-MLV p12 coding region of gag was amplified by PCR and cloned 3' to 
mCherry in a mammalian expression vector, resulting in a p12 fusion protein N-
terminally tagged with mCherry, via a short linker (Figure 6.1A, mCherry-p12). A stop 
codon was introduced after the PPPY to produce an mCherry fusion to the N-terminus 
of p12 (Figure 6.1A, mCherry-Np12). To produce an mCherry fusion to the C-terminus 
of p12, an EcoRI restriction site was introduced into the central portion of p12 and the 
N-terminus of p12 was excised by digesting with this restriction enzyme (Figure 6.1A, 
mCherry-Cp12). 
 
HeLa cells were transfected with the mCherry-p12 fusions or an mCherry molecule 
containing just the linker and were analysed by immunoblotting, 20 hours after 
transfection (using the p12 polyclonal antibody) (Figure 6.1B). As a control for p12 
cleavage from mCherry, Mo-MLV VLPs were included. All three mCherry-p12 fusion 
proteins were expressed and displayed a molecular weight, by SDS-PAGE, similar to 
the calculated theoretical molecular weight. The mCherry-p12 transfected cells 
contained a prominent band at ~43kDa, slightly higher than the theoretical size of 
36.5kDa. As p12 migrates as a 12kDa protein when separated by SDS-PAGE, despite 
its theoretical size of 8.7kDa, this slight discrepancy was to be expected (Figure 6.1B). 
Similarly, the prominent band in the cells transfected with the fusion proteins mCherry-
Np12 or mCherry-Cp12 migrated at ~37kDa, slightly higher than the calculated 
molecular mass of 31.2kDa (Figure 6.1B). A non-specific band could be seen migrating 
at ~12kDa, the same size as mature p12, in all the HeLa cell samples (Figure 6.1B). 
Importantly, this band was not increased in the cells transfected with the mCherry-p12 
fusion indicating that p12 was not specifically cleaved from the fusion protein. 
  
Degradation products of the mCherry-p12 fusion proteins could be seen below the 
bands corresponding to the full-length fusion protein, and one was particularly 
prominent (~10kDa less that the fusion proteins) (Figure 6.1B, asterisks). This band 
likely represented a rate-limiting intermediate during the breakdown of the fusions 
proteins in mammalian cells. Unfortunately, despite our best efforts, the mCherry could 
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not be detected with an antibody that should cross-react to the mCherry protein (data 
not shown). Importantly, all p12 fusion proteins were expressed in mammalian cells, 
were approximately the expected sizes by SDS-PAGE, and p12 was not preferentially 
cleaved from mCherry. 
 
Figure 6.1: Expression of mCherry-p12 fusion proteins in mammalian cells. (A) Diagrams 
displaying the regions of p12 fused to mCherry. The molecular mass of the fusion proteins are 
displayed in brackets, adjacent to the name of the fusion protein. (B) HeLa cells were 
transfected with or without the fusion proteins, and the cell lysate analysed by immunoblotting 
with an anti-p12 polyclonal antibody. Viral lysate of wild type Mo-MLV was used as a control 
for cleavage of p12 from mCherry. UT- untransfected. *- specific degradation product 
 
HeLa cells transfected with the mCherry-p12 fusion proteins were analysed by 
fluorescence microscopy to determine if p12 contains any karyophilic sequences 
determining sub-cellular localisation. Cells were fixed 20 hours post-transfection and 
treated with DAPI to stain the nuclear DNA (Figure 6.2). 
  
Due to the relatively small size of mCherry it does not require active transport into the 
nucleus and could be seen throughout the cytoplasm and nuclear compartment (Figure 
6.2B). Similarly mCherry-p12, mCherry-Np12 and mCherry-Cp12 were all distributed 
throughout the cytoplasm and nucleus (Figure 6.2 C, D and E, respectively). 
Interestingly, a few cells expressing the mCherry-Cp12 displayed some nucleolar 
accumulation of mCherry signal (Figure 6.2E, magenta box). However, this observation 
was relatively rare, indicating it may be due to overloading the cells with fusion protein. 
Therefore, p12 did not harbour significant karyophilic activity to direct the fusion 
proteins to specific sub-cellular compartments in these experiments. 
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Figure 6.2: Sub-cellular localisation of mCherry-p12 fusions expressed in mammalian 
cells. HeLa cells were transfected with or without the mCherry-p12 fusion proteins. 20 hours 
after transfection the cells were fixed and analysed by fluorescent microscopy. Representative 
images of HeLa cells transfected with: (A) no plasmid, (B) mCherry, (C) mCherry-p12, (D) 
mCherry-Np12 and (E) mCherry-Cp12 are shown. Exposure settings were kept constant during 
acquisition and the fluorescence intensity of the mCherry signal has been scaled by the same 
values for each sample. The nucleolar accumulation of mCherry-Cp12 is highlighted in the 
magenta box. 
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6.1.2 The sub-cellular localisation of mCherry-p12 in mitotic cells 
Unfortunately, no HeLa cells transfected with the fusion proteins were observed in 
mitosis when imaged using fluorescence microscopy. Therefore to observe transfected 
cells during mitosis, live imaging experiments were performed. M.dunni cells were 
transfected with the mCherry-p12 fusion constructs and the cells imaged over a ~24 
hour time course. The M.dunni cells were chosen as they divide very rapidly and thus 
increase the number of mitotic events occurring. Cells were treated with Hoechst 33342, 
a membrane permeable DNA dye, so the chromosomes could be visualised. 
Representative movies can be seen in Appendix C. Unfortunately, no transfected mitotic 
cells could be seen during the time course. The temporal constraints of visiting multiple 
points (to record multiple cells) during the time-course precluded recording of enough 
cells, thus another approach was needed.  
 
An array of drugs are available that bock the cell cycle at certain stages, nocodazole 
depolymerises microtubules and blocks cells in mitosis. 293T cells were transfected 
with the fusion proteins followed by incubation with nocodazole. This approach enabled 
the analysis of cells expressing the fusion proteins during mitosis (Figure 6.3). The 
control cells expressing mCherry did not show an accumulation of the cherry signal on 
the condensed chromosomes (Figure 6.3B). The histograms, on the right, display the 
fluorescent signal intensities along the line annotated in the images and have been 
scaled to emphasise the DAPI (DNA) and mCherry signal in the area around the 
condensed chromosomes (Figure 6.3). The chromosomes can be seen as the DAPI 
peaks in the histogram. The histogram of the mCherry control clearly showed that the 
mCherry signal did not peak in the proximity of the DAPI (chromosomal) peaks (Figure 
6.3B). Similarly, for mCherry-p12 and mCherry-Cp12 no strong accumulation of 
mCherry signal could be detected on the chromosomes (Figure 6.3 C and D, 
respectively). However, avoidance of the DAPI peaks in the histograms displaying the 
mCherry-p12 and mCherry-Cp12 signal was not seen, in contrast to the mCherry 
control (Figure 6.3, histograms in C and D versus B). Therefore the mCherry-p12 was 
not excluded from the chromosomes, but due to the high signal in the space between the 
chromosomes, it is difficult to judge if p12 is driving a slight accumulation of the fusion 
proteins onto the chromosomes.  
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Figure 6.3: Sub-cellular localisation of mCherry-p12 fusions expressed in mammalian cells 
arrested in mitosis. 293T cells were transfected with the fusion proteins or controls and then 
arrested in mitosis using nocodazole. Representative images of 293T cells transfected with: (A) 
no plasmid, (B) mCherry, (C) mCherry-p12 and (D) mCherry-Cp12 are shown. The intensity 
profile of the mCherry and DAPI signal along the lines (left-to-right), drawn in the images, are 
displayed in the histograms on the right. Exposure settings were kept constant during 
acquisition and the fluorescence intensity of the mCherry signal has been scaled by the same 
values for each sample. 
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6.2 Visualising Mo-MLV p12 during infection 
The use of fluorescence microscopy to follow viral proteins during different stages of 
infection has provided powerful insights into many aspects of the host-retrovirus 
interaction. Immunofluorescence has also been applied to study p12 and the Mo-MLV 
PIC during infection. The association of myc-tagged p12 with CA and the viral DNA 
during the early stages of infection has highlighted that p12 is part of the MLV PIC 
(Prizan-Ravid et al., 2010). As mentioned in Chapter 5, the interaction of the MLV PIC 
with condensed chromatin during infection in a p12-dependant manner has been 
elegantly shown using both fixed and live imaging fluorescence microscopy (Elis et al., 
2012; Prizan-Ravid et al., 2010). Thus, application of microscopy techniques to study 
the movements of the Mo-MLV PIC bearing N-terminal p12 mutations may reveal 
more information regarding the defect in these mutants.  
 
 
6.2.1 Non-specific uptake of Mo-MLV into cells via an Env-independent 
mechanism 
It has been widely noted in the literature that in addition to viruses entering via a 
productive Env-mediated pathway, intact viral particles are taken up non-specifically 
into cells (Marechal et al., 1998; McDonald et al., 2002). These particles are not on an 
infectious pathway and can be considered as dead-end products, although their presence 
complicates the analysis of microscopy data. 
 
To assess the magnitude of this problem with Mo-MLV VLPs, D17 cells were infected 
using equal RT-units of VLPs with or without VSV-G. After 12 hours, cells were fixed 
and immunostained with anti-p12 monoclonal and anti-CA antibodies, followed by 
secondary antibodies conjugated with alexafluor 594 and 488, respectively. No signal 
could be seen in the uninfected cells as expected (Figure 6.4A). However, cells infected 
with Mo-MLV VLPs with or without Env proteins looked remarkably similar (Figure 
6.4 B and C). Large amounts of CA and p12 staining could be seen in the cytoplasm (in 
endosomes for VLPs lacking Env) for both, indicating Mo-MLV VLPs lacking Env 
proteins were efficiently taken up into cells in a non-specific manner. 
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Figure 6.4:  Non-specific uptake of Mo-MLV into D17 cells. 12 hours post-infection (A) 
uninfected D17 cells or D17 cells infected with equal RT-units of Mo-MLV with (B) the VSV-
G envelope or (C) no envelope were analysed by indirect immunofluorescence using CA and 
p12 monoclonal antibodies. For each viral protein detected, the exposure settings were kept 
constant during acquisition and the fluorescence intensity has been scaled using the same values 
for each sample. 
 
Prizan-Ravid et al. utilised cells (U/R) that stably express the ecotropic MLV receptor, 
mCAT-1, and viruses with the ecotropic envelope (Prizan-Ravid et al., 2010; Wang et 
al., 1991). Therefore, the non-specific uptake control in these experiments was infection 
of the parental U20S cells, which lack the mCAT-1 receptor. Remarkably, despite the 
large amount of internalised p12 puncta in the infected U/R cells, the non-specific 
uptake control had very few p12 puncta (Prizan-Ravid et al., 2010). Therefore it was 
possible that the Env protein somehow reduces non-specific uptake of virions into cells. 
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To test this, U20S cells were infected for two hours with equal RT-units of Mo-MLV 
containing either the ecotropic Env or no Env. Cells were washed thoroughly after 
infection, returned to the incubator for a further two hours, fixed and immunostained 
using the anti-CA antibody. Z-stacks of randomly chosen interphasic cells (picked 
based on the DAPI staining) were imaged and the Z-stacks projected into a 2D 
representation of the volume of the cell (Figure 6.5A, examples of the projected Z-
stacks). The number of CA puncta per cell was much higher (four-fold increase) for 
Mo-MLV VLPs with no Env than VLPs that contained an Env complex that does not 
permit access to the cell (Figure 6.5B). Thus, it appears that in U20S cells, VLPs 
containing no Env were more readily taken up in an receptor-independent manner than 
VLPs bearing an Env complex that did not permit entry to U20S cells. 
 
 
Figure 6.5: Non-specific uptake of ecotropic Mo-MLV into human U20S cells. Human 
U20S cells were infected with equal RT-units of Mo-MLV VLPs with an ecotropic envelope or 
Mo-MLV VLPs lacking an envelope. Cells were fixed two hours post-infection and analysed by 
indirect immunofluorescence using the anti-CA antibody. (A) Representative images of a 
compressed Z-stack of the infected U20S cells. (B) Two independent experiments were 
performed and a Z-stack of images through randomly chosen cells recorded. The total number 
of CA puncta per cell (over a fluorescence threshold) were counted. The mean of the two 
independent experiments are shown with the range. Note- the low green auto-fluorescence of 
cells was used to determine the cell borders. 
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6.2.2 Visualising PICs on a productive infection pathway in infected cells 
As was shown in the previous section, Mo-MLV VLPs are non-specifically taken up 
into cells in an receptor-independent manner. While this problem is likely over-
estimated by using VLPs containing no Env, it is evident that a significant number of 
VLPs enter the cell in a non-productive manner. Indeed, cells infected by a given 
infectious MOI of virus contain significantly higher numbers of discrete viral puncta 
than predicted from the MOI, suggesting that the replication of many particles must fail 
during the early steps of infection. Two separate methods were attempted to rule out the 
analysis of non-productive 'infections'.  
 
Synthesis of viral DNA is an essential step before integration, thus, identification of 
PICs that contain viral DNA are more likely on a productive infection pathway. Viral 
DNA and proteins can be detected by using fluorescent in situ hybridisation (FISH) 
combined with immunofluorescence in infected cells (Prizan-Ravid et al., 2010; Roe et 
al., 1993). As all the N-terminal mutants, barring mutant 6, reverse transcribe in D17 
cells a combined viral DNA FISH and immunofluorescence could be utilised during the 
early stages of infection. D17 cells were infected with a high MOI of Mo-MLV VLPs 
(MOI >10) and were stained with the anti-CA antibody followed by FISH against the 
viral DNA at 10 hours post-infection. A strong signal could be seen for the CA 
immunofluorescence in the cytoplasm but no viral DNA FISH signal could be seen 
through the high fluorescence background (Figure 6.6A). Indeed, uninfected D17 cells 
treated with the biotin labelled probe and the Streptavidin-FITC displayed a high level 
of background, which was most intense in the perinuclear region (Figure 6.6B). 
 
As the background from the FISH staining appeared primarily in the cytoplasm and the 
perinuclear region, it was thought that the background may be due to binding of the 
Streptavidin-FITC to biotin-like molecules. To block this, cells were pre-treated with 
1mg/ml avidin before FISH. Unfortunately, this did not reduce the background and no 
punctate signal for the viral DNA, co-localising with the p12 signal could be seen 
(Figure 6.6A). Hence, due to a high background, caused by non-specific binding of the 
Streptavidin-FITC, the viral DNA could not be detected in D17 cells infected with Mo-
MLV VLPs. 
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Figure 6.6: Attempted detection of the Mo-MLV PIC by fluorescent in situ hybridisation 
(FISH). (A) D17 cells were infected with a high MOI of Mo-MLV and were analysed by 
indirect immunofluorescence against CA, followed by FISH with a probe against the Mo-MLV 
LTR and LacZ genome of the VLPs. (B) Uninfected D17 cells were processed for FISH as in 
(A) without the immunofluorescence against CA. The exposure settings were kept constant for 
the FISH images. 
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Figure 6.7: Reducing the background of fluorescent in situ hybridisation (FISH) of the 
Mo-MLV PIC in infected cells. (A) D17 cells were infected with a high MOI of Mo-MLV and 
were analysed by indirect immunofluorescence against p12, followed by FISH with a probe 
against the Mo-MLV LTR and LacZ genome of the VLPs. Before processing for FISH, cells 
were treated with 1mg/ml avidin. (B) Uninfected D17 cells were processed for FISH as in (A) 
without the immunofluorescence against p12. The exposure settings were kept constant for the 
FISH images. 
 
 
A second approach to reduce the amount of non-specifically endocytosed virions 
analysed in microscopy has been done by labelling the HIV-1 virion membrane with 
GFP/mCherry fused to the 15 N-terminal membrane targeting amino acids of p60c-Src 
(Campbell et al., 2007). This method has allowed virions inside cells, containing the 
virion membrane, to be excluded from analysis. Therefore, this labelling method was 
applied to Mo-MLV. To assess the effect of co-transfection of the S15-mCherry 
plasmid on VLP assembly and release, VLP plasmids were transfected (1μg of each) 
with increasing amounts of the pS15-mCherry expression plasmid. More pS15-mCherry 
plasmid transfected dramatically reduced the amount of VLP released, as assessed by 
the RT activity in the supernatant (Figure 6.8A). Thus, excess S15-mCherry plasmid 
potently competed with the viral plasmids for transcription and translation. As lower 
doses of transfected S15-mCherry permitted synthesis of reasonable levels of virus 
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(Figure 6.8A), the infectivity of these 'labelled' viruses was tested. A 3.6-fold reduction 
in infectivity was seen for VLPs synthesised when co-transfected with 0.25μg of pS15-
mCherry (Figure 6.8B). This effect was exacerbated when greater amounts of pS15-
mCherry were transfected, which reduced the infectivity by 8-fold compared to wild 
type (Figure 6.8B). Therefore, transfection (and likely expression) of larger amounts of 
S15-mCherry during VLP synthesis was detrimental to Mo-MLV VLP release and 
infectivity. 
 
 
Figure 6.8: The effect of co-transfecting pS15-mCherry while synthesising Mo-MLV 
VLPs. Mo-MLV VLPs were synthesised with increasing amounts of co-transfected pS15-
mCherry. (A) VLP release is shown as the level of RT-activity released from the transfected 
cells. (B) D17 cells were infected with equal RT-units of VLPs, infectivity was quantified and 
expressed as a percentage of Mo-MLV VLP infectivity without co-transfected pS15-mCherry. 
(C) VLP release of Mo-MLV co-transfected with lower levels of pS15-mCherry. (D) D17 cells 
infected with equal RT-units of VLPs, were quantified and expressed as a percentage of Mo-
MLV VLP infectivity without co-transfected pS15-mCherry. 
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As Mo-MLV VLP production and infectivity was compromised using this labelling 
technique I was advised that transfecting very low levels of the S15mCherry plasmid 
was sufficient for HIV-1 labelling (Eleanor Gray, personal communication). Labelling 
Mo-MLV with 0.05μg of pS15-mCherry did not have an effect on VLP release (Figure 
6.8C) and the infectivity was reduced by less than two-fold compared to un-labelled 
Mo-MLV (Figure 6.8D). Thus low levels of the pS15-mCherry plasmid were required 
to preserve Mo-MLV VLP viability. 
 
HIV-1 VLPs released from the cells at early time points are the most efficiently labelled 
after transfection with the S15-mCherry plasmid (Ed Campbell, personal 
communication). Therefore to test how much Mo-MLV was labelled with the S15-
mCherry, VLPs were harvested at different times post-transfection (media changed 24 
hours post-transfection). As a control, HIV-1 VLPs were also labelled with S15-
mCherry and harvested at the same time points.  
 
VLP release was quantified by measuring the RT-activity (Figure 6.9 A and B). 
Labelling Mo-MLV by transfecting with 100ng or 50ng S15-mCherry had no 
discernible effect on the release of Mo-MLV when compared to the controls (Figure 
6.9A, CON versus S15). When HIV-1 was labelled by transfecting 50ng of S15-
mCherry a noticeable drop in VLP release was seen (Figure 6.9B, red and black solid 
lines with squares). Addition of 100ng of the control plasmid (pcDNA3.1) into the 
transfection also reduced the amount of HIV-1 VLP released (Figure 6.9B, black dashed 
line with triangles). When 100ng of S15-mCherry was transfected with the HIV-1 VLP 
plasmids, as time progressed less VLPs were produced. This suggested that larger 
quantities of S15mCherry plasmid were interfering with the synthesis/assembly/release 
of HIV-1 (Figure 6.9B, red dashed line with triangles).  
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Figure 6.9: Mo-MLV and HIV-1 VLP release when co-transfected with pS15-mCherry. 
Mo-MLV and HIV-1 VLPs were synthesised co-transfected with pS15-mCherry (S15) or 
pcDNA3.1 (CON). (A) Time course of MLV VLP release (measured by RT-activity) when co-
transfected with the pS15-mCherry or control plasmids (media change 24 hours post-
transfection) (B) Time course of HIV-1 VLP release (measured by RT-activity, assay performed 
by Harriet Groom) when co-transfected with the pS15-mCherry or control plasmids (media 
change 24 hours post-transfection). 
 
To test the efficiency of labelling, VLPs were spun onto coverslips, fixed and 
immunostained with an anti-p12 monoclonal antibody (Mo-MLV) or an anti-CA 
antibody (HIV-1). The control, HIV-1, was optimally labelled with the lower quantity 
of S15mCherry plasmid transfected when harvested 7 hours after the media change 
(Figure 6.10A, maroon line with squares). Using more of the S15mCherry plasmid 
resulted in two-fold decrease in labelling at this time point (Figure 6.10A, maroon 
dashed line and triangles). HIV-1 VLPs harvested very early (5 hours) and later (9 
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hours) had much less VLPs labelled with S15mCherry (Figure 6.10A, maroon solid and 
dashed lines). Mo-MLV was poorly labelled by S15mCherry using either quantity of 
plasmid DNA (Figure 6.10A, red solid and dashed lines). Unfortunately, these data 
preclude the use of this approach for identifying un-fused MLV virions. 
 
 
 
Figure 6.10: Labelling efficiency of Mo-MLV VLPs with S15-mCherry. Mo-MLV or HIV-1 
VLPs co-transfected with 50ng or 100ng of pS15-mCherry during synthesis, were spun onto 
coverslips and analysed by indirect immunofluorescence with antibodies against p12 (for Mo-
MLV) or CA (for HIV-1). (A) The percentage of p12+ Mo-MLV VLPs and CA+ HIV-1 VLPs 
labelled with S15-mCherry were calculated and plotted against the time of VLP harvest. At least 
100 puncta were analysed for each virus/conditions and time point. 
 
6.3 Construction of a system to follow the intracellular movements of the 
Mo-MLV PIC in real-time 
Labelling of retroviral proteins, using a genetically encoded fluorescent protein, can 
provide a wealth of information about replication in real-time. HIV-1 Vpr is packaged 
into the virus through interactions with the p6 portion of the Gag precursor protein 
(Paxton, Connor, and Landau, 1993). Fusion of GFP to Vpr and expression of this 
fusion in HIV-1 producer cells labels a significant proportion of the viruses with GFP 
(McDonald et al., 2002). This labelling procedure has been widely used in the field to 
study the movements of HIV-1 during the early stages of infection. As MLV does not 
contain a trans-packaged accessory protein, like Vpr, fluorescent labelling methods for 
p12 and the MLV core were sought to study the early stages of MLV replication using 
real-time fluorescence microscopy. 
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6.3.1 Labelling p12 with the tetracysteine-specific dye ReAsH 
Instead of tagging proteins with the relatively large eGFP (~27kDa), which can have 
detrimental effects to protein function, a smaller tag containing four cystienes can be 
cloned into the protein of interest. The biarsenical dyes, FlAsH or ReAsH, specifically 
bind to this tetracysteine motif (TC) and become fluorescent (Griffin and Adams, 1998). 
The ReAsH dye is particularly exciting as it is capable of photoconverting 3,3'-
Diaminobenzidine (DAB) into a localised precipitate visible by electron microscopy 
(Lanman et al., 2008). 
  
The smallest active TC-tag was inserted in the central portion of p12 (45DGNGGE50 > 
45CCPGCC50) of the Mo-MLV Gag-Pol vector using site directed mutagenesis. VLPs 
containing p12-TC, no p12-TC or a mixture of p12-TC and wild type p12 were 
generated and VLP release quantified (Figure 6.11A). VLPs containing only p12-TC 
could efficiently bud from the cell, indicating that the TC-tag in p12 did not affect VLP 
release (Figure 6.11A, black bars). VLP recovery, after the staining protocol (from 
Arhel et al. (Arhel and Charneau, 2009)), was good. This indicated that VLPs were not 
lost during the centrifugation and re-suspension step (Figure 6.11A, grey bars). Mo-
MLV containing 100% p12-TC did, however, have a defect in infectivity, which 
resulted in a 3.8-fold reduction compared to wild type infectivity (Figure 6.11B, black 
bars). This infectivity defect was negligible when only 50% of p12 in the VLP 
contained the TC-tag (Figure 6.11B, black bars). Therefore the TC tag in the central 
portion of p12 had a small but significant impact on p12 function.  
 
When the Mo-MLV VLPs were subject to the in vitro ReAsH labelling procedure, the 
infectivity of the VLPs was reduced. Even VLPs containing no p12-TC had a reduction 
in infectivity (1.7-fold reduction), indicating that the centrifugation step to remove 
unbound dye likely had a detrimental effect on viral infectivity (Figure 6.11B, grey 
bars). Interestingly, the VLPs that contained higher amounts of p12-TC had a greater 
loss of infectivity (Figure 6.11B, grey bars). Therefore, the in vitro staining protocol 
was detrimental to Mo-MLV infectivity, which was worse when more p12-TC was in 
the VLP. 
183 
 
 
Figure 6.11: The effect of labelling p12-TC in Mo-MLV with ReAsH in vitro. Mo-MLV 
mixed particle VLPs, containing wild type p12 and p12 with a tetracysteine motif (p12-TC 
[CCPGCC]) inserted in the central portion of p12, were synthesised. (A) VLP release was 
measured by the level of RT activity produced (black bars, 'Before ReAsH'). After staining the 
amount of recovered VLP was quantified by the amount of RT activity (grey bars, 'After 
ReAsH'). (B) D17 cells were infected with equal RT-units of VLPs from before (black bars, 
'Before ReAsH') and after (grey bars, 'After ReAsH') in vitro labelling with ReAsH. The 
infectivity is displayed as a percentage of unlabelled wild type Mo-MLV. 
 
The efficiency of ReAsH labelling in vitro was assessed by immunostaining of VLPs 
bound to coverslips with the anti-p12 antibody. No specific (Figure 6.12, bottom 
panels), or non-specific ReAsH signal (Figure 6.12, top panels) could be seen for the 
VLPs stained with anti-p12. This suggested that the ReAsH dye was poorly bound to 
the TC motif in p12 using the in vitro labelling procedure. Large clumps of virus could 
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be seen, which was likely caused by the centrifugation step, and is probably part of the 
infectivity issue for viruses treated according to  this protocol. 
 
 
Figure 6.12: ReAsH labelling efficiency of p12-TC in Mo-MLV VLPs using an in vitro 
labelling protocol. Mixed Mo-MLV VLPs, with a 50/50 mixture of TC-tagged p12 to wild type 
p12, or wild type Mo-MLV VLP controls were stained with ReAsH in vitro. VLPs were 
analysed by indirect immunofluorescence with the p12 monoclonal antibody. A representative 
image of each VLP sample is shown. Exposure settings were kept constant for each fluorescent 
dye during acquisition and the fluorescence intensity of the signals have been scaled using the 
same intensity values. 
 
 
Labelling the matrix protein (M-protein) from vesicular stomatitis virus with a 
biarsenical dye, for studying the early stages of infection, has been achieved by staining 
the virus in the producer cell, during assembly (Mire et al., 2009; Whitt and Mire, 
2011). As the in vitro labelling technique was unsuccessful for ReAsH labelling of p12-
TC in Mo-MLV, an in vivo labelling of the Mo-MLV p12-TC VLPs was attempted. 
Producer cells were treated with 2.5μM of ReAsH in serum-free media for 16 hours 
before VLP harvest. VLPs were concentrated, stuck to coverslips and analysed by 
immunofluorescence with a monoclonal antibody against p12. 
 
Wild type Mo-MLV produced in the presence of ReAsH did not take up the dye non-
specifically (Figure 6.13A, top panels). A few puncta of ReAsH material could be seen 
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in this control which likely represent aggregates of ReAsH, as they do not co-stain with 
the p12 antibody. Mo-MLV VLPs, containing 50% p12-TC, displayed a significant 
portion of VLPs labelled with ReAsH (Figure 6.13A, bottom panels), indicating that the 
in vivo technique labels p12-TC in Mo-MLV efficiently. Unfortunately, the infectivity 
of the labelled particles (Mo-MLV 50% p12-TC) was significantly reduced compared to 
Mo-MLV wild type (Figure 6.13B). This suggested that the binding of the ReAsH dye 
to the central region of p12 had a detrimental effect to p12 function. 
 
Figure 6.13: ReAsH labelling efficiency of p12-TC in Mo-MLV VLPs using an in vivo 
labelling protocol. Mo-MLV containing wild type p12 or a 50/50 mixture of wild type p12 and 
p12-TC were synthesised in the presence of 2.5μM ReAsH-EDT2. (A) VLPs were harvested, 
concentrated, spun onto coverslips and analysed by indirect immunofluorescence with a p12 
monoclonal antibody. A representative image of each sample is shown. (B) A two-fold dilution 
series (based on the RT activity) of the VLPs was used to infect D17 cells. The infectivity is 
displayed as the luminescence counts per second against the RT activity of the VLPs. 
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6.3.2 Labelling CA with a fluorescent protein to follow the PIC during infection 
As labelling p12 using a TC tag based method did not work well, labelling of the core 
using a CA-YFP fusion protein was attempted. An expression vector coding for a 
modified B-tropic MLV Gag protein, where the last four amino acids of CA and the 
whole of NC have been replaced with YFP, was utilised. Mo-MLV particles were 
labelled with increasing amounts of this modified fluorescently labelled Gag. VLP 
release was quantified by measuring the RT activity of the labelled viruses (Figure 
6.14A). Labelling with a small amount of the CA-YFP protein (5% transfected), did not 
grossly affect Mo-MLV VLP release (Figure 6.14A). When more of the Gag in the 
mixed VLP came from the modified CA-YFP plasmid, the release of VLPs was 
significantly reduced (Figure 6.14A, greater than 10%). This reduction in RT activity is 
probably in part due to less Gag-Pol being present, as the modified Gag plasmid does 
not encode pol. As CA is required for Gag-Gag association in MLV, which helps to 
drive assembly, the Gag-Gag interactions are likely disturbed to some degree when 
higher proportions of the CA molecules are fused to YFP. The infectivity of the labelled 
VLPs was assessed and remained high until 50% of the Gag came from the CA-YFP 
plasmid (Figure 6.14B). Thus, the released VLPs produced using this labelling method 
were viable. 
 
To test the percentage of Mo-MLV VLPs labelled with CA-YFP, they were spun onto 
coverslips and analysed by immunofluorescence with the anti-p12 monoclonal 
antibody. The amount of p12 positive and YFP positive puncta were scored and 
displayed as the percentage of the total p12 positive puncta (Figure 6.14C). The optimal 
labelling of Mo-MLV VLPs occurred when 10% of the Gag transfected came from the 
CA-YFP modified Gag vector (Figure 6.14C). The percentage of puncta with co-
localised p12 and YFP was high for all the mixed VLPs, when at least 10% of the 
transfected Gag was from the CA-YFP plasmid (Figure 6.14C). The slight caveat of this 
analysis is that all CA-YFP puncta should stain for p12, as the CA-YFP modified Gag 
contains p12. Thus some of the co-localised puncta will likely represent non-infectious 
particles. Importantly, VLPs containing no CA-YFP can be discerned by this method. 
Therefore the Mo-MLV VLPs were labelled efficiently with CA-YFP even when low 
levels of the labelling plasmid were co-transfected. 
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Figure 6.14: The effect of labelling Mo-MLV with a B-tropic CA-YFP fusion protein. Mo-
MLV VLPs were labelled with CA-YFP by co-transfecting with the B-tropic CA-YFP modified 
Gag plasmid (pB30Y) during VLP synthesis. (A) VLP release is shown as the amount of RT 
activity released from producer cells for increasing amounts of CA-YFP gag transfected. (B) 
D17 cells were infected with equal RT-units of VLPs and the infectivity quantified. The 
infectivity is plotted as a percentage of Mo-MLV with no CA-YFP. (C) VLPs were spun onto 
coverslips and analysed by indirect immunofluorescence using a p12 monoclonal antibody. The 
percentage of p12 puncta positive for YFP was quantified and is displayed in the graph. The 
percentage of CA-YFP modified Gag transfected (along the x-axis), is expressed as a percentage 
of the total mass of the Gag containing plasmids transfected. 
 
6.3.3 Labelling p12 with GFP to follow the PIC during infection 
A previous attempt to label p12 by cloning the 16 amino acid fragment of the split GFP 
system (Cabantous, Terwilliger, and Waldo, 2005) into the central portion of p12 lead 
to significantly reduced infectivity (Chapter 3). However, the full length GFP molecule 
has been successfully attached to the N-terminus of p12, preserving the protease 
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cleavage site, in a modified Mo-MLV Gag expression vector (Elis et al., 2012). This 
GFP-p12 fusion has been used to label an infectious clone of Mo-MLV and visualise 
the incoming PIC in real-time during infection (Elis et al., 2012). Increasing amounts of 
this modified GFP-p12 Gag plasmid were used to label the Mo-MLV VLPs with GFP-
p12.  
 
 
Figure 6.15: The effect of labelling Mo-MLV with eGFP-p12. Mo-MLV VLPs were labelled 
with eGFP-12 by co-transfecting with the MLV eGFP-p12 modified Gag plasmid during VLP 
synthesis. (A) VLP release is shown as the amount of RT activity released from producer cells 
for increasing amounts of GFP-p12 modified Gag transfected. (B) D17 cells were infected with 
equal RT-units of VLPs and the infectivity quantified. The infectivity is plotted as a percentage 
of Mo-MLV with no eGFP-p12. (C) VLPs were spun onto coverslips and analysed by indirect 
immunofluorescence using a p12 monoclonal antibody. The percentage of p12 puncta positive 
for GFP were quantified and displayed in the graph. The percentage of GFP-p12 modified Gag 
transfected (along the x-axis), is expressed as a percentage of the total mass of the Gag 
containing plasmids transfected. 
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The release of VLPs decreased in a linear fashion as the amount of the modified GFP-
p12 Gag transfected was increased (Figure 6.15A). As with the CA-YFP modified Gag, 
this will be in part due to less Gag-Pol present in the VLPs, as the modified Gag does 
not encode pol. Labelled VLPs were as infectious as wild type even when 70% of the 
Gag came from the GFP-p12 plasmid (Figure 6.15B). Thus, while too much GFP-p12 
Gag in the VLP appeared to have an effect on VLP synthesis/release, the produced 
VLPs were viable. 
 
The efficiency of labelling VLPs, with the GFP-p12 modified Gag, was assessed by 
immunofluorescence with an anti-p12 monoclonal antibody on the VLPs. This analysis 
also suffers from the drawback that all GFP positive puncta will stain for p12, although 
some of these puncta may be solely composed of the modified Gag and are not viable 
VLPs. Regardless, when 30-40% of the Gag transfected came from the GFP-p12 
modified Gag, the majority of VLPs contained measurable GFP-p12 signal (Figure 
6.15C). Thus, this method could efficiently label Mo-MLV VLPs using GFP-p12, with 
minimal effect on virus viability. 
 
6.4 The movements of Mo-MLV p12 and the PIC during the early stages of 
replication 
To establish if any defect could be seen with the N-terminal p12 mutants, I set out to 
study the movements of the Mo-MLV PIC immediately after entry to the cell. I initiated 
this work during my visit to Eran Bacharach's laboratory in Israel. Using their expertise 
on following the movements of the Mo-MLV PIC in infected cells (Elis et al., 2012; 
Prizan-Ravid et al., 2010), two experimental approaches were attempted to analyse the 
N-terminal p12 mutants. One used synchronised infections of cells combined with 
immunofluorescence and the other using live imaging of GFP-p12 or CA-YFP labelled 
Mo-MLV in infected cells.  
 
6.4.1 Following p12 labelled with GFP during the early stages of infection 
GFP-labelled p12 in Mo-MLV has been successfully utilised to document the docking 
of p12 to chromatin in infected mitotic cells (Elis et al., 2012). Thus, attempts were 
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made to observe the movements of the N-terminal p12 mutants immediately after the 
release of the Mo-MLV cores into the cytoplasm, using live fluorescence microscopy. 
Wild type and N-terminal p12 mutant Mo-MLV VLPs labelled with GFP-p12 and 
containing an ecotropic Env were synthesised for use in these experiments. U/R-H2A-
RFP cells, expressing histone 2A fused to RFP and the ecotropic MLV receptor 
(mCAT-1), were transfected with S15-mCherry to mark out the cell membrane. After 16 
hours, cells were placed on the microscope and infected with GFP-p12 VLPs (MOI ~8, 
the wild type and p12 mutant 5 infections were MOI ~5). The imaging began 
immediately, looking for cells that contain GFP-p12 puncta in the cytoplasm.  
 
Three types of intracellular movement were seen (i) direct movements, (ii) fast 
uncoordinated movements and (iii) still, shaky movements (Figure 6.16 and appendix 
D1). When the N-terminal p12 mutants were analysed, the same movements could be 
seen for all of them, although there appeared to be an increase in the amount of 
stationary puncta observed for p12 mutant 5 and 6 compared to wild type (appendix D2 
versus D4, D6 and D8). Virtually all Mo-MLV GFP-p12 VLPs lacking an envelope 
protein (non-specifically taken up in vesicles) were stationary with occasional direct 
movements (appendix D10).  
 
After imaging, cells were returned to the incubator and imaged the next day to see if a 
defect had become apparent for the p12 mutants. Interestingly, the N-terminal p12 
mutants 5 and 6 displayed much less GFP-p12 puncta per cell when imaged between 
20-25 hours post infection, and appeared to be less mobile when compared to wild type 
Mo-MLV (appendix D3 versus D5 and D7). However, p12 mutant 7 looked more like 
wild type than p12 mutant 5 or 6 (appendix D3 versus D9). VLPs non-specifically taken 
up into cells had formed large GFP aggregates in the perinuclear region (appendix D11), 
and were likely in the process of being degraded by the proteasome. In conclusion, this 
preliminary analysis showed that the p12 signal for the N-terminal mutants 5 and 6 
appeared to diminish faster in infected cells than wild type. However, the phenotype 
appears quite subtle and would require analysis of a large number of cells to make the 
observation significant.  
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Figure 6.16: Intracellular Movements of Mo-MLV GFP-p12 puncta immediately after 
infection. U/R-H2A-RFP cells, transfected with S15mCherry, were infected with Mo-MLV 
GFP-p12 at an MOI ~5. Images were taken on a spinning-disk confocal microscope equipped 
with an EMCCD and scaled to highlight the signal and remove background noise. Displayed are 
movie frames showing the three typical intracellular movements of the GFP-p12 puncta 
(highlighted by a coloured box in the first frame): direct movements (top panels, red highlight), 
fast uncoordinated movements (middle panels, blue highlight) and still shaky movements 
(bottom panels, magenta highlight). The coloured dot in each frame indicates the starting 
position of the puncta in the first frame for comparison. The time (s) is displayed in the top left-
hand corner. Scale bars- 5μm. 
 
 
Interestingly, the infectivity of p12 mutant 5 and 7 was higher when the virus contained 
GFP-p12 (with the corresponding p12 mutation) compared to the untagged mutants 
(Figure 6.17), indicating that the fusion of GFP to p12 partly rescued the infectivity 
defect observed. This was not observed for p12 mutant 6, 8 or 14 (Figure 6.17). 
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Figure 6.17: Infectivity of Mo-MLV p12 mutants containing GFP-p12. U/R cells were 
infected with p12 mutants with (GFP-p12) and without (unmodified) GFP-p12 and the 
infectivity was quantified. The infectivity of VLPs are shown as a percentage of the infectivity 
of wild type Mo-MLV without GFP-p12. 
 
6.4.2 Following the Mo-MLV PIC labelled with CA-YFP during the early stages of 
infection 
To validate the use of the CA-YFP for labelling the Mo-MLV PIC (from section 6.3.2), 
cells were infected on the microscope as above. Imaging of Mo-MLV labelled with CA-
YFP revealed particles internalised in cells that displayed similar movements to the Mo-
MLV particles labelled by GFP-p12 (appendix E1 versus D1 and D2). This indicated 
that the CA-YFP labelling technique did indeed label cores that enter the cell. 
Interestingly, and surprisingly, in mitotic cells, CA-YFP was seen docked on the 
chromosomes early after infection (Figure 6.18A and appendix E2). This was 
unexpected, as it had been assumed that little CA remains with the MLV PIC that 
associates with the chromatin. When the infection was observed again, after 18 hours, 
CA-YFP could again be seen attached to the condensed chromatin in mitotic cells 
(appendix E3).  
 
GFP-p12 from Mo-MLV was shown to dock on condensed chromatin in mitotic cells 
after 12 hours, but has not been investigated at such an early time post-infection (Elis et 
al., 2012). Therefore, GFP-p12 labelled Mo-MLV VLPs were used to infect U/R-H2A-
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RFP cells on the microscope and mitotic cells were imaged immediately after infection. 
As was seen for Mo-MLV labelled with CA-YFP, GFP-p12 was observed docked onto 
the condensed chromatin in mitotic cells at an early time point (Figure 6.18B and 
appendix E4). When p12 contained the mutation 14, neither the CA-YFP nor the GFP-
p12 puncta associated with the condensed chromatin in infected cells, as previously 
reported (data not shown) (Elis et al., 2012). Thus, this early chromatin binding of the 
Mo-MLV PIC labelled with GFP-p12 or CA-YFP was mediated by p12 and some CA 
may remain with the nuclear associated PIC. 
 
 
Figure 6.18: Docking of Mo-MLV GFP-p12 and CA-YFP on mitotic chromosomes early 
after infection. U/R-H2A-RFP cells were infected on the microscope with (A) Mo-MLV CA-
YFP and (B) Mo-MLV GFP-p12 VLPs and mitotic cells were imaged. Displayed are time 
frames from representative infected cells. The docked puncta are marked out by red boxes and 
the tracks are progressively coloured with green, blue or red lines. The time (s) is displayed in 
the top left-hand corner. Scale bars- 5μm. 
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6.4.3 Early post-entry movements of the MLV PIC in infected cells analysed using 
immunofluorescence 
Tagging proteins with fluorescent proteins can significantly alter their behaviour 
especially with regards to the their turnover in cells. Indeed, the infectivities of p12 
mutants 5 and 7 tagged with GFP-p12 were higher than the untagged p12 mutants 
(Figure 6.17), indicating that the attachment of GFP to these p12 N-terminal mutants 
restored some p12 function. As the N-terminal p12 mutants had a defect in formation of 
the mature core (Chapter 5), indirect immunofluorescence was used to analyse the 
movements of p12 and CA immediately after core release into the cytoplasm. To 
normalise the detection of p12, a myc-tagged p12 (described previously, (Prizan-Ravid 
et al., 2010)) was cloned into the Mo-MLV Gag-Pol vectors and ecotropic Mo-MLV 
VLPs were synthesised. U/R cells were infected (MOI~3) at 4oC using spinoculation 
(O'Doherty, Swiggard, and Malim, 2000) (to synchronise the infection), fixed and 
stained for p12 (myc) and CA using indirect immunofluorescence at various times post 
infection. 
  
It should be noted that the immunostaining with the anti-CA antibody utilised in this set 
of experiments had a lot of non-specific background, and thus a false positive rate in 
uninfected cells of 1-2 CA puncta could be seen (data not shown). However this rate 
was not uniform and many uninfected cells contained no false positive CA signal. The 
highest background signal was seen around the nucleus (Figure 6.19A, top panels).  
Cells infected with wild type Mo-MLV, at an early time point, contained mostly p12-
myc puncta co-localised with the CA puncta (Figure 6.19A, top panels). As time 
progressed, less puncta were seen in the cells but most of the puncta remained both p12-
myc and CA positive (Figure 6.19 B and C, top panels). In stark contrast, the N-terminal 
p12 mutants all contained very little p12-myc signal, despite the presence of CA signal 
even at the very early time points (Figure 6.19A). As time progressed this worsened 
until only a few CA puncta remained (Figure 6.19 B and C). Viruses attached to the 
coverslips could be found for the p12 mutants and these stained with both the p12-myc 
and CA antibodies, indicating the p12 mutations did not alter the antigenic properties of 
the myc tag (Figure 6.19B, Mut 6 yellow box). Thus, mutation of the N-terminus of p12 
resulted in the loss of p12 from the internalised core (or aggregates of CA in the case of 
p12 mutant 6) very early after release into the cytoplasm. 
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Figure 6.19: Movements N-terminal p12 mutants PICs in infected cells. Cells were infected 
with p12-myc Mo-MLV VLPs (MOI~3) at 4oC to synchronise the infection. Cells were fixed 
after (A) 20 minutes, (B) 1 hour and (C) 7 hours post-infection and immunostained with 
antibodies against the myc-tag (p12) and CA. Cells were imaged using a spinning disk confocal 
microscope with the same exposure settings for each staining. Representative images are shown 
with the fluorescence intensity scaled by the same values. The yellow box in (B) indicates a p12 
mutant 6 VLP bound to the coverslip. ** Mutant 5 was fixed after 3 hours in this example. A 
trace of the nucleus is shown (blue lines) for mutant 7 in (C) as the dapi staining was weak 
causing a high background from the dapi channel, due to technical problems with the UV lamp.  
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6.5 Summary 
In this chapter, the localisation of p12 expressed in cells and in cells infected with Mo-
MLV was investigated. Expression of mCherry-p12, or the N- or C-terminal regions of 
p12 fused to mCherry, produced a stable fusion protein in mammalian cells but had no 
specific sub-cellular localisation, indicating that p12 does not confer a strong 
karyophilic influence on mCherry. As p12 has been shown to bind to condensed 
chromatin in mitotic cells, as part of the Mo-MLV PIC (Elis et al., 2012; Prizan-Ravid 
et al., 2010), the influence of the cell cycle on the localisation of mCherry-p12 was 
investigated. In contrast to a very recent report (Schneider et al., 2013), significant 
accumulation of mCherry-p12 was not seen on the mitotic chromatin. The discrepancy 
between the findings of Schneider et al. and those presented here is likely down to 
technical differences, which will be discussed in Chapter 7. 
 
Unfortunately a high level of non-specific uptake (via Env-independent mechanisms) 
was seen in cells infected with Mo-MLV VLPs. This non-specific uptake has been 
widely documented and is a significant problem for the analysis of microscopy data 
(Marechal et al., 1998; McDonald et al., 2002). Interestingly, the non-specific uptake of 
Mo-MLV virus into cells lacking the appropriate receptor appeared low for Prizan-
Ravid et al (Prizan-Ravid et al., 2010). Indeed, non-specific uptake of Mo-MLV VLPs 
with no envelope into cells was significantly higher than VLPs that contain an envelope 
protein, with no receptor present on the cells. Therefore the presence of an Env protein 
on the surface of the virion renders it less likely to be non-specifically taken up into 
cells. Whether this is a cell/Env type-specific phenomenon will require investigations 
with more combinations of cells and different Env proteins. Nevertheless, a large 
number of particles remain non-specifically taken up into cells, even if the use of an 
Env negative control over estimates the problem. Thus, methods to rule out Mo-MLV 
on a non-productive infection pathway were assessed.  
 
Firstly, the detection of viral DNA and viral proteins in infected cells using combined 
immunofluorescence and FISH was attempted. Unfortunately, detection of the viral 
DNA using FISH was never successful due to a high background that resulted from 
non-specific binding of the avidin-fluorophore to some abundant biotin-like molecule in 
the cell. Blocking the cells with avidin did not reduce this background. Due to the 
unsuccessful nature of the preliminary experiments, and the time required to perform a 
single FISH experiment, further attempts were not pursued. A protocol using a 
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digoxigenin (DIG) labelled probe to detect the MLV viral DNA in infected cells has 
been more successful and could potentially be used in future studies (Sada Ohkura, 
personal communication). 
  
Secondly, labelling of the Mo-MLV viral membrane with S15mCherry was attempted. 
This method has been used to distinguish viral particles that have undergone fusion and 
lost their viral membrane from particles non-specifically taken up into cells (Campbell 
et al., 2007). Unfortunately, co-expression of the S15mCherry plasmid with the Mo-
MLV VLP plasmids caused a dramatic reduction in VLP release and affected the 
infectivity of any particles that were produced. Using very low levels of the 
S15mCherry plasmid resulted in wild type-like release and infectivity of Mo-MLV, but 
very few S15mCherry labelled particles could be detected by microscopy. Only HIV-1 
control VLPs contained a significant number of labelled particles, although the labelling 
efficiency was lower than previously reported (Campbell et al., 2007). Consequently, 
Mo-MLV could not be successfully labelled with the S15mCherry molecule, indicating 
that Mo-MLV may bud from subtly different microdomains in the membrane compared 
to HIV-1, which have lower levels of the S15mCherry protein. 
 
A small tetracysteine motif was cloned into p12 for labelling with a fluorescent dye 
(FlAsH or ReAsH) to follow the movements of the Mo-MLV PIC during infection. The 
in vitro labelling method described by Arhel et al. for labelling HIV-1 IN (Arhel and 
Charneau, 2009) was unsuccessful for labelling Mo-MLV containing the p12-TC, but a 
high level of labelling could be achieved when the VLPs were synthesised in the 
presence of ReAsH (in vivo labelling). Unfortunately, loading the dye onto p12 reduced 
infectivity by 10-fold compared to control Mo-MLV VLPs without p12-TC. Thus, 
similar to the result seen with the split GFP motif in p12 (Chapter 3) the ReAsH dye in 
the central 'linker' region of p12 significantly reduced infectivity. The binding of FlAsH 
or ReAsH to the TC motif induces the formation of a kink to allow disulphide bonds 
between the dye and the cystienes to form, hinting that structural alteration to the 'linker' 
region in p12 is not compatible with p12 function. 
 
Labelling of Mo-MLV VLPs using either the GFP-p12, used by Elis et al. (Elis et al., 
2012), or a CA-YFP molecule, was much more successful, with no significant effect on 
VLP release or infectivity at levels sufficient for labelling. These labelled VLPs were 
then used in live imaging experiments with our collaborators in Israel (Eran Bacharach's 
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laboratory). Live imaging of cells infected with GFP-p12 VLPs displayed three types of 
intracellular movements (i) direct movements, (ii) fast uncoordinated movements and 
(iii) still, shaky movements. Particles displaying movements of type (i) and (iii) could 
change between the two and frequently did, whereas GFP-p12 particles showing type 
(ii) movements always displayed this type of movement over the window of 
observation. Non-specifically endocytosed virus had a phenotype that was almost 
entirely of type (iii) based movements with occasional type (i) movements from some 
particles. I would suggest that the very fast uncoordinated movements (type ii) arise 
from free aggregates of protein including GFP-p12, which are small enough to pass 
about by diffusion within the cell, as their velocities were greater than fast microtubule 
based transport. In contrast, the slower and direct movements are likely microtubule 
based transport, which have been reported for HIV-1 (Arhel et al., 2006; McDonald et 
al., 2002). While lots of these type (ii) movements could be seen for wild type Mo-
MLV GFP-p12 20 hours post-infection, little could be seen in the cells infected with 
p12 mutant 5 and 6 at the later time points. This suggested for these mutants that the 
majority of GFP-p12 that had entered the cells had been degraded by the later time 
point. Due to the small difference in phenotype observed with the Mo-MLV GFP-p12 
mutants using live imaging, it is unlikely that this approach will shed new light on the 
N-terminal p12 mutant defect. Strangely, p12 mutants 5 and 7 had a higher infectivity 
when the VLPs contained the GFP-p12 and I will discuss this further in Chapter 7. 
 
Unexpectedly, the live imaging of CA-YFP labelled Mo-MLV revealed it to be bound 
to condensed chromatin in a p12-dependant manner. This tethering could be visualised 
even at very early time points when Mo-MLV PICs were labelled using either GFP-p12 
or CA-YFP. These early bound puncta, if they do represent PICs, will not likely have 
had time to reverse transcribe their genome, indicating that reverse transcription is not 
important for chromatin tethering. Indeed, p12-mediated chromatin tethering does not 
require packaging of the viral genome (Efrat Elis, personal communication). Thus, 
surprisingly, the data shown here suggests that a significant proportion of CA may 
remain with the MLV nuclear-associated PIC, although whether the CA-YFP fusion 
stabilises CA and causes an exaggerated phenotype will require further investigation. 
 
Finally, indirect immunofluorescence was used to study the movements of p12 and CA 
within infected cells over a time course, and strikingly the signal for p12-myc was 
found to diminish rapidly after infection for the N-terminal p12 mutants (mutant 5, 6 
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and 7) compared to wild type Mo-MLV. However, the CA signal for the p12 mutants 
appeared to persist longer. This striking phenotype indicates that the observations with 
the GFP-p12 labelled PICs were indeed somewhat artifactual, in that the GFP-p12 
signal could persist much longer inside infected cells than the 'native' p12 species (with 
a small tag). While this analysis should be regarded as preliminary, and quantification is 
required to make a solid conclusion, it looks as though mutation of the N-terminus of 
p12 does indeed result in the loss of p12 from the PIC early after infection. This 
suggests that the interaction at the N-terminus of p12 keeps p12 with CA and the PIC 
during the early steps of replication. 
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Chapter 7.  
Discussion 
 
Mo-MLV p12 has been shown to be an essential Gag protein. It is required at both early 
and late stages of the viral life cycle (Yuan, Li, and Goff, 1999), although the function 
of p12 during the early infection steps has remained enigmatic. The work presented in 
this thesis, and recently published data, have highlighted functions of p12 essential for 
progression through the early stage of infection. Two domains have been described in 
Mo-MLV p12, which are both required to be active on a single p12 molecule for 
infection. All gammaretroviruses analysed have a conserved requirement for p12 
function during the early stages of infection, indicating that p12 function has been fixed 
in the gammaretroviral lineage. Importantly, using a combination of genetic and 
biochemical techniques, the N-terminal domain of p12 has been shown to function in 
formation of the mature CA core during viral maturation before entry to the target cell. 
Genetic approaches have shown that the C-terminus of p12 is vital for tethering the 
nuclear-associated MLV PIC to condensed chromatin. This chapter will discuss these 
findings in more detail, with an emphasis on their wider implications on the replication 
of retroviruses.  
 
While the findings presented here have assigned important roles to p12 during infection 
the mechanism of p12 action remains ill defined. I will, therefore, finish by highlighting 
my model for p12 function and some key experimental approaches that will validate and 
expand on this model. 
   
7.1  p12 N-terminal domain function during the early stages of infection 
In Chapter 5, key experiments were described that triggered the investigation into the 
effect of p12 mutations on the structure/stability of the mature CA core. These 
experiments utilised CA-core sensing restriction factors (Fv1 and TRIM5alpha) to 
detect the incoming CA core from p12 mutants (Section 5.1). Surprisingly, this revealed 
that mutation of the N-terminus of p12 caused an inability to abrogate restriction 
factors. A few possible explanations exist as to why these p12 mutant cores failed to 
abrogate restriction: (i) inhibition of restriction factor binding to the CA core by mutant 
p12, (ii) incorrect localisation of the core within infected cells, (iii) the CA monomers in 
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the core were not processed correctly so that restriction factors could not recognise the 
core, (iv) the mature CA core was unstable, or (v) no mature CA core was formed inside 
the virion. These possibilities will be discussed in the following section. 
 
7.1.1 Towards the cause of the p12 mutant abrogation defect 
A mechanism where the N-terminal p12 mutants could inhibit restriction factor 
interaction with the CA core would be relatively complex. How this inhibition would 
also cause the infectivity defect for Mo-MLV is also unclear. It would, therefore, seem 
improbable that the N-terminal p12 mutants could block restriction factor interaction 
with the CA core and is unlikely the cause of the abrogation defect. Mislocalisation of 
the p12 mutant core within infected cells also seems less likely. Indeed, MLV that 
enters the cell using different entry pathways is restricted by Fv1 (Yap and Stoye, 
2003). Thus, bypassing fusion at the plasma membrane (and fusing through endosomes 
in the cytosol) does not permit escape from restriction factors, suggesting a certain level 
of plasticity in their ability to 'locate' incoming CA cores. I have also shown that the CA 
monomers liberated from a Gag molecule containing a p12 mutation in cis, can be 
incorporated into a mature core recognised by restriction factors (Figure 5.5). Thus, p12 
mutations upstream in Gag did not alter processing of CA from the Gag polyprotein, or 
the subsequent conformational changes required to form the mature core. 
  
This leaves two possible causes for the abrogation defect: either the core is unstable or it 
is poorly formed/absent. In vitro disassembly assays have been used to assess the 
stability HIV cores with mutations in CA (Forshey et al., 2002). This assay requires 
isolation of cores from virions, by detergent removal of the membrane. The success of 
this purification for HIV-1 has a low yield (~16%) of cores, and cores from MLV 
appear to be less amenable to isolation by this method (Fassati and Goff, 1999). Cores 
isolated from Friend murine leukaemia virus and Rauscher murine leukaemia virus have 
been reported in the past, but more recent attempts to isolate cores from Mo-MLV using 
a range of detergents were unsuccessful (Bolognesi, Luftig, and Shaper, 1973; Durbin 
and Manning, 1982; Fassati and Goff, 1999) The work described in Chapter 5 also 
documented an inability to isolate whole cores from Mo-MLV virions (Section 5.2.2). 
However, partial cores could be isolated, migrating to a higher sucrose density than the 
free CA protein and a lower sucrose density than un-lysed virions (Figure 5.12). The 
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composition of these partial cores (i.e. how much CA they contain, etc) remains to be 
determined. This assay was used to test all the p12 mutants, and revealed that the N-
terminal p12 mutants' partial cores had a lower apparent S-value than the wild type 
partial cores (Figure 5.15). Moreover, when Mo-MLV N-terminal p12 mutant RTCs 
were isolated from infected cells and analysed by velocity sedimentation they also had a 
lower apparent S-value than wild type RTCs (Boucherit, V. unpublished data). 
Interestingly, the C-terminal p12 mutants displayed the opposite phenotype, migrating 
to higher sucrose density fractions than wild type. Thus, either no mature core (but 
some aggregated form of CA) was present within the N-terminal p12 mutant virions or 
the core was less stable than wild type cores. 
  
Strikingly, thin-section TEM of purified p12 mutant 6 virions found that relatively few 
mutant virions showed a recognisable mature core morphology (Section 5.2.3). Many of 
the particles displayed a smaller punctate mass in place of a mature core, indicating the 
N-terminal domain of p12 is required for the efficient formation of the mature CA core. 
This leads to the question: How does p12 aid in the formation of the mature core? 
Currently no co-factor molecules have been described required in the formation of a 
retroviral CA core. However, evidence does exist that alteration of CA molecules or 
addition of small molecules that interact with the CA core can affect core morphology. 
Auerbach et al. have described a similar aberrant core morphology, to the one observed 
for p12 mutant 6, for an insertion mutant in the second alpha helix of MLV CA-NTD 
(Auerbach, Brown, and Singh, 2007). From the hexameric structure of MLV CA-NTD, 
intermolecular interactions occur between alpha helix 2 and 3, and helix 2 and 1, 
indicating that the mutation described by Auerbach et al. may affect hexamer stability 
(Mortuza et al., 2004). It has also been shown that formation of the mature HIV-1 CA 
core is disrupted when virus is synthesised in the presence of a CA-targeting drug (PF-
3450074) (Blair et al., 2010). The initial study found that the drug was able to promote 
CA multimerisation (Blair et al., 2010), however, a later report described that the drug 
destabilised the HIV-1 CA core (Shi et al., 2011). Thus currently, its precise mode of 
action remains controversial, but it has been shown to bind a pocket in the HIV-1 CA 
NTD (Blair et al., 2010). 
  
Some mutations have also been described which do not affect CA directly but have an 
effect on the morphology of the CA core. One such mutation is blocking the PR 
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processing between NC and p6, which causes an aberrant core morphology despite no 
alteration to the liberation of mature CA (de Marco et al., 2012). Many explanations 
exist to the cause of this defect but it does highlight that altering the processing of Gag 
can have downstream effects on the formation of the mature core. It is quite unlikely 
that this is the cause of the p12 mutant 6 phenotype as no alteration to the cleaved Gag 
products is observed (Section 3.1.1). Indeed, completely blocking MA-p12 cleavage 
only had a minor effect on infectivity suggesting efficient cleavage of p12 from MA is 
not essential (Section 5.2.1). 
  
Whether the p12 mutant 6 core phenotype is shared with the other N-terminal p12 
mutants will required more TEM analysis. Mutant 6 is the only p12 mutant that could 
not efficiently reverse transcribe in vivo (Section 3.1.3), so the defect in core 
morphology may be more striking for this mutant. However, the biochemical data on 
the mutant partial cores from sucrose gradients would suggest that all the N-terminal 
mutants have altered cores. Whether this is due to an equivalent phenotype to p12 
mutant 6 or an altered morphology making the cores less stable remains to be 
established.  
 
7.1.2 The N-terminus of p12 retains p12 within the PIC 
Both domains of p12 need to be active on a single p12 molecule for MLV to be 
infectious. It is known that the C-terminal domain is required for a late stage, tethering 
the PIC to the chromatin (discussed in Section 7.3), and that the N-terminal domain is 
required for the formation of the mature core. However, mixed particles containing a 
mixture of N- and C- terminal p12 mutants can abrogate restriction factors (indicating 
the CA core is correctly formed) but are non-infectious (Figure 3.9 and Figure 5.6). This 
implies that the N-terminal domain of p12 has a dual function, and it is this second 
function that needs to be in cis with an active C-terminal domain for MoMLV 
infectivity. I propose that this second function is in retaining p12 with the PIC and it is 
likely to be caused by the same interaction that the aids in the formation of the CA core. 
This notion is supported by fixed immunofluorescence studies of infected cells showing 
that p12 signal was lost very rapidly from the CA signal for p12 mutant 5, 6 and 7 when 
inside cells (Section 6.4.3), indicating these p12 mutants could not stay with the core (or 
malformed mutant core). 
206 
 
 
7.1.3 Sequence requirements in the N-terminal domain of p12 
Individual alanine mutagenesis was performed on p12 from two gammaretroviruses, 
Mo-MLV and GaLV (Figure 3.15 and Figure 4.6). The N-terminal domains of both Mo-
MLV and GaLV p12 contained essential leucine residues. Additionally, aspartic acid 
residues in the N-terminus of Mo-MLV p12 were also important for p12 function (one 
in the N-terminus of GaLV p12 also had a minor effect on infectivity when mutated). 
For both viruses, mutation of larger regions (5-6 alanine substitutions) had a more 
dramatic effect on infectivity than many point mutants, indicating the combined amino 
acid composition in the domain is likely important. This is exemplified by Mo-MLV 
p12 mutant 5, where three individual mutations (K10A, K12A and Q14A) have a minor 
effect on infectivity, but mutation of the whole region, or all three residues at once, 
cause a much bigger infectivity defect (Figure 3.15). Moreover, this was also seen with 
GaLV mutant N, where the D5A only caused a minor infectivity defect but the larger 
mutation N caused a much greater defect. 
 
Certain regions of p12 were less sensitive to mutation in some gammaretroviruses 
(Figure 4.3), demonstrating the whole N-terminus is not essential for all 
gammaretroviruses. The regions that were less sensitive are covered by either p12 
mutant 5 or 7 and, interestingly, Mo-MLV containing GFP-p12 with mutant 5 or 7 were 
more infectious than p12 mutant 5 or 7 without GFP (Figure 6.17). This was not seen 
for p12 mutant 6, 8 or 14. There are a couple of logical possibilities to the function of 
GFP in this minor rescue of infectivity: (i) GFP increased p12 (or the N-terminal 
domain) stability or (ii) the GFP molecule trapped the p12 mutant in the core. It seems 
unlikely that an added GFP molecule would trap p12 in the PIC as when a big enough 
gap in the core is formed, during infection, GFP-p12 would be expected to diffuse. 
Based on the fact that p12 mutant 5 and 7 are dispensable for some retroviruses and that 
the larger mutations have a bigger effect on infectivity than the point mutants, I would 
suggest that the residues in these region of p12 help to stabilise the N-terminal domain 
interaction. However, whether this stabilising action is through making weak contacts 
with the interacting factor or maintaining an optimal conformation of the domain will 
require more investigation. 
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7.1.4 Towards an interacting partner for the N-terminus of p12 
It was shown that the N-terminal domain of p12 has an influence on the formation and, 
possibly, the stability of the CA core. The mechanism behind this effect on the CA core 
remains unknown, but it likely involves interaction of the N-terminus of p12 with 
another viral factor. No long range interactions between p12 and CA of MLV have been 
reported, when they were expressed as a fusion protein (Kyere, Joseph, and Summers, 
2008). Indeed, work in our laboratory has found little evidence to suggest that p12 
interacts with monomeric CA in vitro (Nader, M. unpublished data). However, studying 
the viability of SNV and MLV chimeras has provided genetic evidence linking p12 and 
CA function during the early stages of infection (Lee and Nagashima, 2005). A panel of 
chimeras between Mo-MLV and GaLV, analysed here, have also suggested a link 
between the N-terminal domain of p12 and another viral factor (Section 4.3). These 
chimeras, however, do not rule out the possibility of a link between p12 and a factor 
other than CA, but based on the data from Lee et al (Lee and Nagashima, 2005), it 
would seem reasonable that the functional link is with CA.  
 
What does p12 interact with and could p12 interact with the CA lattice directly? 
Limited biochemical evidence exists suggesting an interaction between p12 and CA. 
Immunoprecipitation of p12 from infected cells co-precipitated CA, although only a 
very small proportion of the total CA in the cells (Prizan-Ravid et al., 2010). Viral DNA 
was also found to be immunoprecipitated with an antibody to p12, indicating p12 is in a 
complex with the viral DNA and CA during infection (Prizan-Ravid et al., 2010). Low 
levels of CA present in the pull down may indicate the interaction between p12 and the 
PIC is weak, being easily disrupted by the isolation protocols. Interestingly, when the 
restriction factor tropism of Mo-MLV was altered by making changes in CA (D82N, 
A110R and H117L) the infectivity of p12 mutant 5 and 7 increased (Section 5.1.2). This 
observation again suggests a link between p12 and CA. As p12 mutants 5 and 7 are 
infectious in the N- and B- MLV background, could further changes to Mo-MLV CA 
(making it even more similar to N- or B- MLV CA) increase the infectivity of p12 
mutant 5 and 7 further? More experiments are required to determine if this is the case, 
but if further alterations to CA could rescue the infectivity defect of the p12 mutants this 
would imply an interaction between CA and p12. 
 
A specific interaction between p12 and viral gRNA has been previously reported (Sen, 
Sherr, and Todaro, 1976; Sen, Sherr, and Todaro, 1977; Sen and Todaro, 1977). It was 
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shown that the affinity of p12 for RNA was determined by the level of phosphorylation, 
where too much or no phosphorylation reduced p12 affinity for gRNA (Sen, Sherr, and 
Todaro, 1977). If mutation of the N-terminus of p12 were to abolish p12 binding to 
RNA it is hard to imagine how this would cause the defect observed for the N-terminal 
p12 mutants, as in the wild type scenario RNA would be converted to DNA in the 
infected cell and likely result in the loss of p12 from the PIC. Unless, however, p12 
were also to have an affinity for DNA, which has not been investigated. Either way, it 
seems unlikely that a lack of p12 binding to the gRNA in the virion would result in 
aberrant core morphologies. 
 
Lastly, as p12 is required in the nucleus for chromatin tethering (Section 5.3.2), other 
viral factors that enter the nucleus could be prime binding targets for p12. One such 
factor is IN. IN is absolutely required for the formation of the provirus and as such is an 
essential component of the PIC. Recently, small molecule inhibitors of the HIV-1 IN-
LEDGF interaction (LEDGINs) have been described (Christ et al., 2010). One of these 
compounds (CX05045) showed dramatic effects on the morphology of the HIV-1 core 
when viruses were synthesised in the presence of the drug (Desimmie et al., 2013). 
Many of the viral cores were 'empty' and the RNP was outside the core (Desimmie et 
al., 2013). The authors showed that this LEDGIN was increasing the multimerisation of 
IN both in vitro and in viral particles (Desimmie et al., 2013). Interestingly, mutations 
in IN causing these aberrant core morphologies have previously been described, 
although there is a significant reduction in the level of Pol incorporated into these IN 
mutant particles (Engelman et al., 1995). Instead of interacting with the CA core, p12 
could potentially bind to MLV IN,  and loss of this binding could result in premature IN 
multimerisation that is detrimental to the formation of the CA core. Identification of 
interacting partners for p12 is essential to establish a mechanism by which Mo-MLV 
p12 aids in the formation of the CA core. 
 
7.2 Clathrin and the N-terminus of p12 
One interaction between a host factor and p12 has been reported. Clathrin is 
incorporated into Mo-MLV via interactions with a 'DLL' motif in p12 (Zhang et al., 
2011). These three amino acids are situated in the p12 mutant 8 region, and mutation of 
any of these amino acids reduces the infectivity by greater than 10-fold (Chapter 3). The 
biggest infectivity defect is seen with the D25A mutant (>100-fold decrease in 
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infectivity, Figure 3.15), which is far greater than the infectivity defect reported upon 
depletion of clathrin from the producer cell (although it should be noted that the 
depletion of clathrin was not complete) (Zhang et al., 2011). Furthermore, the reported 
loss of mature p12 from virions described by Zhang et al., was artifactual due to the 
antibody utilised, as shown in Figure 3.2. However, as I have shown for mutant 8, the 
authors did find a morphological defect of the core, based on the reduced abrogation of 
TRIM5alpha with p12 D25A mutant (Zhang et al., 2011). Work in our laboratory has 
found that p12 mutant 6 can incorporate clathrin but has the same infectivity and 
abrogation defect as p12 mutant 8 (Nader, M. unpublished data). Due to the relatively 
small infectivity defect imposed by clathrin depletion and the fact that other mutations 
in the N-terminus of p12 do not affect clathrin incorporation yet still inhibit infectivity, 
it seems unlikely that reduced clathrin incorporation explains the defect in the N-
terminal p12 mutants.  
 
So what is the function of clathrin incorporation? It has now been shown that clathrin is 
incorporated into a wide range of retroviruses (HIV-1, HIV-2, SIVmac, MPMV and 
MLV) (Popov et al., 2011; Zhang et al., 2011). Motifs responsible for clathrin 
incorporation are situated in varying positions within Gag and Pol, in different viruses 
(Popov et al., 2011; Zhang et al., 2011), implying that the positional recruitment of 
clathrin is not necessary for clathrin function in the virion. One of the functions of 
clathrin in endocytosis is stabilisation of the curved structure of clathrin-coated pits, by 
forming a lattice-like structure (Ford et al., 2002; Kirchhausen, 2000). It is possible that 
clathrin could act as a scaffold during assembly aiding in the efficient formation and 
stabilisation of the virion bud. Indeed mutation of the SIVmac DLL motif, responsible 
for clathrin incorporation, and the late domain (PTAP), both in p6, resulted in wider 
non-spherical protrusions from producer cells (Zhang et al., 2011). This suggested that, 
in SIVmac, clathrin does indeed have a role in the stabilising the virion bud at the 
assembly sites (Zhang et al., 2011). A three-fold infectivity defect was also seen for 
SIVmac synthesised in cells depleted of clathrin, indicating a similar phenomenon could 
be occurring for MLV. While the incorporation of clathrin is potentially involved in the 
morphogenesis of the virion bud during assembly, the mechanism behind this effect 
remain to be established. It is also not clear why virus produced in cells with depleted 
clathrin have a reduced infectivity in target cells. 
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7.3 p12 C-terminal domain function during the early stages of infection 
p12 has been shown to be part of the MLV PIC by co-localisation with the viral DNA 
and CA during the early stages of infection (Prizan-Ravid et al., 2010). Interestingly, 
mutation of the C-terminus of MoMLV p12 (mutant 14) resulted in PICs incapable of 
chromatin accumulation during mitosis (Elis et al., 2012; Prizan-Ravid et al., 2010). The 
PFV CBS, inserted in p12, was able to rescue the infectivity defect of C-terminal p12 
mutants, and has shown that the C-terminus of Mo-MLV p12 has an essential chromatin 
tethering function (Section 5.3.2). Additionally, chromatin tethering of p12 mutant 14 
could be rescued by addition of the LANA CBS from Karposis's sarcoma-associated 
herpes virus (KSHV) (Elis et al., 2012). Both these CBS motifs did not completely 
rescue the infectivity defect, indicating the targeting to the chromatin is sub optimal for 
MLV integration. Furthermore, Mo-MLV PICs were more rigidly bound to chromatin 
when p12 contained the LANA CBS, and the PICs remained associated with the 
chromatin after mitosis (not seen for wild type Mo-MLV) (Elis et al., 2012). Moreover, 
docked wild type GFP-p12 puncta on chromosomes appeared to wobble, indicating the 
p12-mediated tethering is dynamic and the PICs are not tightly bound (Section 6.4.2).  
 
Very recently, a report has shown that the ability of a heterologous CBS to rescue the 
p12 mutant 14 infectivity defect correlates relatively well with the affinity for mitotic 
chromatin of GFP proteins containing the p12-CBS motifs (Schneider et al., 2013). In 
contrast to this recent report, no strong indication of mCherry-tagged p12 binding to 
mitotic chromatin was observed in this study (Section 6.1.2). Likely reasons for this 
discrepancy are as follows: (i) The chromatin accumulation via p12 binding is very 
weak, meaning that the amount of mCherry-p12 expressed in cells will likely have a 
great effect on the ratio of mitotic-to-cytoplasmic mCherry signal. (ii) In my 
experiments, widefield microscopy had to be used due to the higher sensitivity required 
to visualise the mCherry-tagged p12 molecules in cells. The widefield system utilises an 
electron multiplying charged coupled device (EMCCD) to record information whereas 
the available confocal systems use photon multiplier tubes (PMT), which have a very 
low quantum efficiency compared to EMCCDs (i.e. they cannot record low 
fluorescence signals). (iii) Widefield microscopy, in contrast to confocal, also records 
fluorescence from above and below the plane of focus, and thus subtle differences in 
signal between the cytoplasm and the mitotic chromatin would not be exposed. (iv) 
Schneider et al. used GFP to tag their proteins, which has a higher quantum efficiency 
than mCherry (Shaner, Steinbach, and Tsien, 2005), and the confocal microscope they 
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utilised potentially had an EMCCD detector or one of the new high sensitivity PMTs for 
data recording ((Schneider et al., 2013) not specified in the methods). Thus, it seems 
likely their experimental set up was primed for better detection of smaller differences in 
fluorescent signal between the cytoplasm and the chromatin.  
 
Unfortunately, despite knowing the subcellular location of the p12 C-terminal 
interaction, to date, no interacting partners have been found (Schneider et al., 2013) 
(and Nader, M. and Efrat, E. unpublished data). Similar methodologies to those utilised 
so far for p12, have managed to show interactions between GFP tagged with either the 
PFV CBS or the KSHV LANA CBS and histones H2A and H2B (Tobaly-Tapiero et al., 
2008). As the chromatin affinity of the PFV-CBS and LANA CBS is much stronger 
than that seen for p12, it is likely that either the interaction of p12 with the chromatin 
factor is weaker, or less of the p12-chromatin factor exists to interact with p12. Due to 
the transient affinity of p12 for mitotic chromatin, it is entirely possible that the C-
terminus of p12 may interact with a modified histone protein only present during 
mitosis.  
 
7.3.1 Integration site targeting 
A better understanding of integration targeting is thought vital to the design of better 
and safer retroviral-based gene therapy vectors. HIV-1 is targeted to chromatin via 
interaction with LEDGF, which acts as an IN-to-chromatin link (Busschots et al., 2005; 
Cherepanov et al., 2003; Ciuffi et al., 2005; Maertens et al., 2003; Marshall et al., 
2007). LEDGF is not merely a tether, but has a direct influence on the integration site 
selection by HIV-1 (Ciuffi et al., 2005; Llano et al., 2006). HIV-1 tends to integrate into 
the body of transcriptionally active genes (Berry et al., 2006; Lewinski et al., 2006; 
Mitchell et al., 2004), whereas MLV has a tendency to integrate close to the 
transcriptional start sites near CpG islands (Mitchell et al., 2004; Wu et al., 2003). Cells 
depleted of LEDGF, by RNAi knock down, change the integration pattern observed for 
HIV-1 (Ciuffi et al., 2005).  
 
Whether p12 had a LEDGF-like function with regards to integration site selection was 
investigated (Section 5.3.3). In line with a very recent report (Schneider et al., 2013), 
targeting p12 to the chromatin using another chromatin binding motif did not alter the 
integration site selection for Mo-MLV. Interestingly, the residual integration events 
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seen for p12 mutant 14 displayed an intriguing integration pattern that appeared less 
favourable to transcriptional start sites, although it should be noted that the number of 
sites sequenced was very low. Encouragingly however, the N-terminal p12 mutant 6, 
which also had a very low number of integration events, displayed an integration pattern 
similar to wild type Mo-MLV. Thus, the reduced affinity for transcriptional start sites 
with p12 mutant 14 hints that the chromatin tethering of p12 (regardless of the specific 
CBS motif utilised) does influence integration site selection. I would hypothesise that 
targeting to the chromatin allows interaction of IN with a host co-factor that then 
influences the integration site selection. This hypothesis would fit with the data 
suggesting the factor targeting integration site selection for MLV is IN with a small but 
significant contribution from Gag (Lewinski et al., 2006).  
 
7.3.2 Composition of the chromatin-associated PIC 
The composition of the retroviral core undergoes many changes on its way to the host 
chromatin. On the path to the nucleus, the poorly understood process of uncoating 
occurs. The timing and extent of the CA loss from the cores remains ill defined, but 
appears to occur at different rates between retroviruses (Arfi et al., 2009; Fassati and 
Goff, 1999; Fassati and Goff, 2001; Hulme, Perez, and Hope, 2011). For MLV and 
simple retroviruses, nuclear envelope breakdown is required for access to the host 
chromosomes. The composition of the PIC in the nucleus is likely significantly different 
from the one present in the cytoplasm and, as a minimal requirement for tethering and 
integration, it must contain the following viral components: viral DNA, IN and p12. 
Little CA is seen in the nucleus of cells infected with MLV, using biochemical analysis 
(Fassati and Goff, 1999) and immunofluorescence (Elis et al., 2012). Surprisingly, when 
Mo-MLV was labelled with the CA-YFP fusion protein, CA-YFP could be seen docked 
on the mitotic chromatin as had been seen for GFP-p12 (Section 6.4.2). This implied 
that some fraction of CA remained with the nuclear-associated PIC.  N-terminal p12 
mutants labelled with GFP-p12 were more stable inside infected cells than native p12 
(with a myc tag). This was also observed with mCherry-p12 expressed in cells, where 
expression of p12 with a small tag was unstable and was quickly degraded in stark 
contrast to mCherry-tagged p12. Therefore it is likely that, as with p12, the attachment 
of a YFP molecule to CA also has a stabilising effect on the protein and the presence of 
CA-YFP on the condensed chromatin could be an artefact of altered protein behaviour.   
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Curiously, attachment of the PIC to the chromatin could occur very rapidly after entry 
of the core into the infected cells. GFP-p12 was seen docked on the condensed 
chromatin less than one hour post infection (Section 6.4.2), meaning that reverse 
transcription is unlikely to have occurred before docking. Indeed, VLPs lacking the 
viral genome were also able to dock onto condensed chromatin (Efrat Elis, personal 
communication). Therefore, the presence of the viral DNA is not a requirement for p12 
mediated docking on the chromatin. However, it is entirely possible that these early-
docked PICs are not on a productive infection pathway and constitute dead end 
products. 
 
7.4 Non-specific uptake of virus particles into cells 
Viruses on non-productive infection pathways are a significant problem, especially in 
microscopy studies of infection (McDonald et al., 2002). Investigations into the amount 
non-specific uptake of virus into cells, in this thesis, have revealed that the amount of 
virus taken up into U20S cells was greater when virus contained no envelope protein 
compared to a redundant envelope protein (Section 6.2.1). This indicates that the use of 
VLPs without envelope proteins likely overestimates the number of non-specifically 
endocytosed particles. In agreement with this observation, a similar phenomenon has 
also been seen for HeLa cells incubated with NL43 HIV-1 and a ΔEnv version of this 
virus, where less NL43, containing a redundant Env, was non-specifically taken up into 
the HeLa cells than the ΔEnv virus (Marechal et al., 1998). Interestingly, when less of 
the ΔEnv HIV-1 was applied to the cells, the amount of internalised p24 (CA) dropped 
down to the level seen for viruses containing a redundant Env protein, indicating that it 
may have a dose-dependent effect (Marechal et al., 1998). However, more work is 
required with other cell/Env combinations to assess whether this is a common 
phenomenon or restricted to certain cell types. Additionally, investigations using a 
range of MOIs will help to determine if there is a dose-dependent effect to this non-
specific virus uptake. 
 
7.5 Conservation of p12 function in retroviruses 
Many retroviruses contain Gag cleavage products between MA and CA. The early 
function of p12 was required for all the gammaretroviruses analysed, although not all 
gammaretroviruses required the whole of the N-terminus for function (Section 4.1.3). 
The alpharetrovirus, RSV, codes for three proteins between MA and CA: p10, p2a and 
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p2b. The p2b protein carries the 'PPPY' late-domain essential for the late stages of 
replication (Xiang et al., 1996). The p10 protein is interesting in that it determines the 
shape of in vitro formed particles (CA-NC) from tubes to spheres (Campbell and Vogt, 
1997). This is also true in vivo, as RSV with mutations in the C-terminus of p10 
(L219A) produce less virus (due to impaired nuclear export) but the viruses that are 
released contain aberrant core morphologies (Scheifele et al., 2007). Therefore, p10, 
while different from gammaretroviral p12 molecules, also has a role to play in 
formation of the CA core. MMTV is a betaretrovirus and contains four cleaved proteins 
between MA and CA, named: p21, p8, p3 and n (Hizi et al., 1989). Interestingly, 
deletion of the n domain of MMTV Gag results in the formation of tube-like structures 
assembling in the cytoplasm and released from cells (Zabransky et al., 2010). These two 
examples highlight other Gag cleavage products originating between MA and CA that 
have an effect on the formation/morphology of the CA core. 
 
RfRV, an endogenous retrovirus from the greater horseshoe bat (Rhinolophus 
ferrumequinum), contains a p12-like sequence before the CA domain in Gag (Cui et al., 
2012). The potential RfRV p12 sequence is considerably larger than Mo-MLV p12 (121 
amino acids versus 84), although both sequences contained a similar proportion of 
prolines, 20.2% for Mo-MLV p12 and 26.4% for RfRV p12 (Figure 7.1). While the 
sequence identity was low (only 28.9%) this was similar to the identity of Mo-MLV p12 
with GaLV p12. The 'PPPY' motif found in all gammaretroviral p12 proteins was also 
present in the potential RfRV p12 molecule. Interestingly, the N-terminus of the 
potential RfRV p12 contained conserved residues that were shown to be essential for 
Mo-MLV and GaLV p12 function (leucines and aspartic acids). After the 'PPPY' motif 
little sequence identity was shared between RfRV and Mo-MLV p12 until the start of 
the 'SPM' motif that was essential for Mo-MLV p12 function. This central 'linker' 
region in p12 displayed the largest sequence divergence between distantly related 
gammaretroviruses, indicating its composition is not under significant selective 
pressure. In additionally to the 'SPM' motif, many arginine residues are situated in the 
C-terminus of the RfRV p12 protein, which were essential for Mo-MLV and GaLV p12 
function.  
 
Sequence alignments of RfRV Gag and Pol with other gammaretroviruses showed 
RfRV to be ancestral to the exogenous MLVs (Cui et al., 2012). This suggests the 
possibility that the function of p12 has been preserved in gammaretroviruses before the 
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emergence of the exogenous MLVs. To test this experimentally, the Gag (or parts of 
Gag) of this ancient gammaretrovirus could be resurrected, as has been done for the 
endogenous lentiviral CAs from the rabbit endogenous lentivirus type K (RELIK) and 
prosimian immunodeficiency virus (PSIV) (Goldstone et al., 2010). This approach 
could test if the early function of p12 has actually been preserved in the 
gammaretroviral lineage. 
 
 
Figure 7.1: Alignment of Mo-MLV p12 with RfRV p12 sequence. The Mo-MLV p12 amino 
acid sequence (GenBank: J02255.1) was aligned with that of RfRV (JQ303225.1) using Clustal 
X2 (Larkin M. A. et al. 2007). Numbers highlight the amino acid numbering from Mo-MLV 
p12. 
 
7.6 A model for p12 function during the early stages of infection 
Based on the findings presented in this thesis and the recent work published by others I 
would like to propose a model for the function of p12 during the early stages of 
infection (Figure 7.2). In a wild type context (Figure 7.2A), p12 is liberated from the 
Gag polyprotein by the viral protease and a proportion of the mature p12 molecules 
make essential interactions with a factor within the virion, through their N-terminal 
domain. The identity of this target and the nature of the interaction currently remain 
unknown. Interaction between p12 and its interacting partner aids in the formation of 
the mature core. After release of the viral core into the cytoplasm, p12 remains bound to 
the PIC (through the N-terminal domain interaction) and travels to the nucleus. At 
mitosis, the PIC reaches the proximity of the chromosomes and interaction of the C-
terminus of p12 with host chromatin occurs. After mitosis, p12 releases from the 
chromatin and the integration complex is trafficked to the site of integration by host 
factors recruited during p12-mediated chromatin tethering. 
 
In Mo-MLV with p12 mutant 6 (Figure 7.2B), p12 cannot make the N-terminal 
interaction at all, and thus the mature core is formed with a poor efficiency. This means 
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that upon infection, only a small fraction of viruses will contain correctly formed cores 
that can support reverse transcription (based on the reduced accumulation of viral DNA 
products with this mutant in vivo). Due to no interaction between p12 and PIC 
components, p12 will be lost from the PIC and no chromatin tethering can occur. For N-
terminal p12 mutants 5, 7 and 8 (Figure 7.2C), the state of the CA core is currently 
unknown. Based on the ability of these p12 mutants to reverse transcribe, I would 
assume that they contain some aberrant core which can support reverse transcription but 
it is somewhat grossly malformed or unstable so that restriction factors cannot 
recognise/interact with it. Again when these mutant cores are released into the 
cytoplasm, a lack of interaction between p12 and the PIC results in the loss of p12 and 
no chromatin tethering. 
 
Finally, when the C-terminal domain of p12 is mutated (Figure 7.2D), infection 
proceeds as wild type until nuclear envelope breakdown when p12 is unable to tether 
the nuclear-associated PIC to chromatin. Thus, the residual integration seen for this 
mutant likely represents chance interactions with an accessible region of the chromatin 
conducive to integration. 
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Figure 7.2: A model for the function of gammaretroviral p12 during maturation and the 
early stages of infection. Diagrams representing the stages of retroviral infection from cleavage 
of Gag and Pol to attachment of the PIC to the chromatin for Mo-MLV containing: (A) wild 
type p12, (B) mutant 6 p12, (C) mutant 5, 7 or 8 p12, or (D) C-terminal mutant p12. CA is 
coloured in blue, p12 in red, viral RNA in orange and the viral DNA in light purple.  
 
218 
 
7.7 Future work 
One key question really needs to be answered to establish mechanisms for the action of 
p12:  
 What are the viral and host factors that p12 interacts with? 
A few experimental approaches are described below which may help to answer this 
question. 
 
7.7.1 State of the CA core in the other p12 mutants 
In order to determine the function of the N-terminus of p12, it is imperative that the 
state of the CA core is assessed in the other p12 mutants. Therefore, the same thin-
section TEM analysis should be applied to N-terminal p12 mutants 5, 7 and 8 to analyse 
the morphology of the CA core in these mutants.  
 
None of the work here has directly assessed the effect of the p12 mutations on the state 
of the immature Gag lattice. It is possible that the mutations in p12 cause a defect at a 
step before formation of the mature core. Mo-MLV p12 mutants, with an inactivate PR, 
could be used to analyse the immature cores by cryo-EM. Due to a greater degree of 
homogeneity in the morphology of immature viral particles, cryo-EM averaging 
techniques are more accurate, which will allow electron densities of the Gag molecules 
to be created for analysis. How much insight this approach would give is debatable and 
would really depend on the magnitude of any observed defect.   
 
7.7.2 The composition of the isolated 'partial' cores 
Partial Mo-MLV CA cores (devoid of the gRNA) were isolated in sucrose gradients by 
centrifugation of virions through a Triton layer. The sedimentation profile of these 
partial cores was different from free CA protein and un-lysed virions. However, the 
composition of these partial cores remain unknown. Detection of p12 and NC was 
unsuccessful due to low levels of protein present in the partial core fractions (data not 
shown). Concentration of protein from the fractions could be performed by 
trichloroacetic acid or methanol/chloroform precipitation. This would concentrate the 
proteins and potentially enable the detection of p12 and NC by immunoblotting. 
Determination of the amount of CA contained in the partial cores is a more complex 
problem. Samples could be run on non-denaturing gels to obtain some information 
about size of the CA complex, although this would work best if the partial cores are 
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smaller complexes (i.e. CA hexamers). If they are much larger than CA hexamers, then 
potentially dynamic light scattering (DLS) or cryo-EM of the partial cores may produce 
a better estimate on the size of these complexes. However these second methods may 
suffer due to the low concentration of partial cores isolated, in addition to the likely 
unstable nature of the cores. It is possible that the use of cross-linking reagents may 
help to stabilise the partial cores if they prove too unstable for analysis. 
 
7.7.3 Identification of interacting partners for the N-terminus of p12 
To establish a mechanism for the action of p12, identification of interacting partners for 
the N- and C-terminus of p12 is vital. Interactions of p12 with monomeric CA have 
been hard to detect in vitro (Nader, M. unpublished data). CA-interacting molecules can 
often have a low affinity for monomeric CA, especially if the interaction actually occurs 
with oligomeric forms of CA (eg. hexamers). Indeed, the CA-binding portion of CPSF6 
binds monomeric CA with a very low affinity (Price et al., 2012). Thus, using 
oligomeric CA structures to probe for p12-CA interactions may be more fruitful. An 
ordered core-like structure of MLV CA on lipid-coated nanotubes has been reported 
(Hilditch et al., 2011). If p12 does indeed interact with CA, these assemblies may serve 
as better targets for assessment of p12 and CA-core interactions. CA-coated lipid 
nanotubes could be incubated with purified p12 and pelleted by centrifugation to see if 
p12 can bind. If the binding is disrupted by the centrifugal force required to pellet the 
CA-coated tubes, binding of GFP-p12 on the CA-coated tubes could be assessed by a 
fluorescence recovery after photobleaching (FRAP) technique, similar in principle to 
experiments performed by Schneider et al. to show immobilisation of GFP-p12 on 
condensed chromatin. Instead of transfecting cells, purified GFP-p12 could be applied 
to immobilised CA nanotubes and analysed by FRAP. If there is a delay in the 
fluorescent recovery, it suggests that the bleached GFP-p12 has remained bound to the 
CA-nanotube, indicating an interaction. 
 
If these results indicate an interaction between p12 and CA core-like structures can 
occur, more advanced in vitro techniques could be used to establish the sites of binding. 
Hexamers of the N-terminal domain of N- and B-tropic MLV CA have been solved by 
X-ray crystallography (Mortuza et al., 2008; Mortuza et al., 2004). These N-MLV CA 
hexamer crystals could be used as a target for co-crystallisation of p12 with its binding 
surface. If crystallisation is not possible, p12 bound to the CA-coated nanotubes could 
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be investigated using cryo-electron microscopy (cryo-EM) in an attempt to localise the 
area of p12 core interaction. However, p12 may be too small for visualisation on the 
nanotubes by cryo-EM. Therefore, addition of a large protein to p12, like GFP, may 
make for easier identification of p12 on the nanotubes. 
 
7.7.4 Identification of interacting partners for the C-terminus of p12 
In an attempt to find an interacting partner for the C-terminal domain of p12, 
immunoprecipitation of cellular factors from mitotic cells should be attempted. Using 
cells arrested in mitosis may enrich lysates with the p12-chromatin interacting factor if 
the factor is only present during mitosis. It remains entirely possible that p12 tethers to 
the chromatin by actually interacting with the host DNA, thus chromatin 
immunoprecipitation (ChIP) may prove valuable in this investigation. Thus, if p12 binds 
to specific regions of DNA or DNA-associated host proteins this may be revealed. 
 
7.7.5 The mechanism of integration site selection 
Adding heterologous chromatin binding motifs in Mo-MLV p12 did not alter the 
targeting of Mo-MLV integration (Schneider et al., 2013). However, our preliminary 
data highlights an altered integration pattern for Mo-MLV C-terminal p12 mutant 14. 
The first thing that must be done is to confirm the phenotype by sequencing more 
integration sites. Due to the inefficiency of the p12-independant integration this will 
require a large volume of virus to be produced, to enhance the number of integration 
events. VLPs encoding GFP could be utilised which will allow fluorescent activated cell 
sorting to be used and enrich a population of infected cells for integration site analysis. 
 
7.7.6 Position of p12 within the PIC and the composition of the nuclear-associated 
PIC 
Fluorescence microscopy has undergone some significant advances over the past decade 
and a host of super resolution fluorescence microscopy techniques have been 
established. Theses technique use either physical or mathematical manipulation to 
surpass the diffraction limit of light, producing impressive spatial resolutions in the 
order of tens of nanometres. Using these super resolution techniques, I aim to test the 
localisation of p12 with respect to the PIC at various times leading up to docking on the 
chromatin. Potentially, whether p12 is located inside or outside of the PIC could be 
tested as well as any localised affinity of p12 with the CA core. From mixed particles, 
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little wild type p12 is needed in a particle for full infectivity, thus mixed VLPs with 
myc-tagged wild type p12 and an N-terminal p12 mutant could be studied, then only the 
'functional' p12 will be analysed by microscopy using an anti-myc antibody. If a 
chromatin interacting partner for Mo-MLV p12 can be isolated, super resolution 
microscopy could be used to show an intimate association between the factors during 
infection, implicating a physiological significance to the interaction.  
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Appendix A: Mutagenesis Primers 
Plasmid 
name 
Plasmid 
details 
Mutant 
name/ 
descriptio
n 
Mutation in p12 
(unless 
otherwise 
stated) 
Forward 
primer 
(5'-3') 
Reverse 
primer 
(5'-3') 
pCI G3-N and 
pCI G3-B 
N-MLV and B-MLV 
Gag-Pol 
mammalian 
expression 
constructs 
5 
RPSKPQ(10-
15)AAAAAA 
gctcttaccccct
ctataaaacccg
cagctgctgcag
ctgcggttctctcc
gataatggcg 
cgccattatcgg
agagaaccgca
gctgcagcagct
gcgggttttatag
agggggtaaga
gc 
6 VLSDN(16-20)AAAAA 
gaccttctaaacc
tcaggctgccgc
cgctgctggcgg
acctctcattgac 
gtcaatgagag
gtccgccagca
gcggcggcagc
ctgaggtttaga
aggtc 
7 GGPLI(21-25)AAAAA 
acctcaggttctct
ccgataatgccg
cagctgccgctg
accttctctcaga
agaccct 
agggtcttctgag
agaaggtcagc
ggcagctgcgg
cattatcggaga
gaacctgaggt 
8 
DLLSED(26-
31)AAAAAA 
ggcggacctctc
attgccgctgccg
cagcagcccctc
cgccgtacggag 
ctccgtacggcg
gaggggctgctg
cggcagcggca
atgagaggtccg
cc 
13 PSPIV(61-65)AAAAA 
gagattcctgccg
ccgctgccgcag
cgtctcgcctgcg
gg 
cccgcaggcga
gacgctgcggc
agcggcggcag
gaatctc 
14 SRLRG(66-70)AAAAA 
cctgccccctctc
ccatagtggctgc
cgcggcggcca
aaagagacccg
cccgcg 
cgcgggcgggt
ctcttttggccgc
cgcggcagcca
ctatgggagag
ggggcagg 
15 KRDPP(71-75)AAAAA 
cgcctgcggggc
gcagcagccgc
cgccgcggcag
attcc 
ggaatctgccgc
ggcggcggctg
ctgcgccccgca
ggcg 
pHG1 
XMRV Gag-Pol 
mammalian 
expression 
construct 
5 
KPPKPQ(10-
15)AAAAAA 
cttaccccctctat
aaagtccgcagc
tgctgcggccgc
ggttctccctgata
gcggcgga 
tccgccgctatc
agggagaaccg
cggccgcagca
gctgcggacttta
tagagggggta
ag 
6 VLPDS(16-20)AAAAA 
cctcctaagccc
caggctgccgct
gctgccggcgga
cctctcat 
atgagaggtccg
ccggcagcagc
ggcagcctggg
gcttaggagg 
7 GGPLI(21-25)AAAAA 
cccaggttctccc
tgatagcgccgc
agctgccgctga
ccttctcacagag
gatcc 
ggatcctctgtga
gaaggtcagcg
gcagctgcggc
gctatcagggag
aacctggg 
13 PSPMV(60-64)AAAAA 
tccgaggtttccc
ccgctgctgccg
cggcgtctcgact
gcgggga 
tccccgcagtcg
agacgccgcgg
cagcagcgggg
gaaacctcgga 
14 SRLRG(65-69)AAAAA 
tcccccccttctcc
catggtggctgc
agcggcggcaa
ggagagaccctc
ccgcagcg 
cgctgcgggag
ggtctctccttgc
cgccgctgcag
ccaccatggga
gaaggggggg
a 
15 RRDPP(70-74)AAAAA 
tctcgactgcggg
gagcggcagcc
gctgccgcagcg
gactccacc 
ggtggagtccgc
tgcggcagcgg
ctgccgctcccc
gcagtcgaga 
pFeLVdw 
FeLV Gag-Pol 
mammalian 
expression 
construct 
5 
DPPKPP(7-
12)AAAAAA 
cgttctccccaag
ccagccgccgc
cgcagcggctgt
gttaccgcctgat 
atcaggcggtaa
cacagccgctg
cggcggcggct
ggcttggggag
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aacg 
6 
VLPPDP(13-
18)AAAAAA 
cagaccccccc
aaaccgcctgcg
gcagcggctgct
gcttcctccccttt
aattgatc 
gatcaattaaag
gggaggaagc
agcagccgctg
ccgcaggcggtt
tgggagggtctg 
7 SSPLI(19-23)AAAAA 
aaccgcctgtgtt
accgcctgatcct
gctgccgctgca
gctgatctcttaac
agaagagccac 
gtggctcttctgtt
aagagatcagct
gcagcggcagc
aggatcaggcg
gtaacacaggc
ggtt 
8 
DLLTEE(24-
29)AAAAAA 
accgcctgatcct
tcttcccctttaatt
gctgccgcagca
gcagcgccacct
ccctatccgggg 
ccccggatagg
gaggtggcgctg
ctgctgcggcag
caattaaaggg
gaagaaggatc
aggcggt 
13 SPI(51-53)AAA 
aggaccccaac
cgctgccgcggc
tgcaagccggct
a 
tagccggcttgc
agccgcggcag
cggttggggtcct 
14 SRLRE(55-59)AAAAA 
cccaaccgcttc
cccgattgccgc
cgcggcagcgg
cacgacgagaa
aaccctgctgaa 
ttcagcagggtttt
ctcgtcgtgccg
ctgccgcggcg
gcaatcgggga
agcggttggg 
15 RRENP(60-64)AAAAA 
ccccgattgcca
gccggctaagg
gaagcagcagc
agccgctgctga
agaatctcaagc
c 
ggcttgagattctt
cagcagcggct
gctgctgcttccc
ttagccggctgg
caatcgggg 
pcGaLVgp 
GaLV Gag-Pol 
mammalian 
expression 
construct 
N TDDLL(3-7)AAAAA 
ccccccatctacc
cggcagcagcc
gccgcagccctc
ctctctgaaccca
cg 
cgtgggttcaga
gaggagggctg
cggcggctgctg
ccgggtagatgg
gggg 
8 
LLSEPT(8-
13)AAAAAA 
gcaacagacga
cttactcgccgcc
gctgcagccgcg
cccccgccctatc
cggcggca 
tgccgccggata
gggcgggggcg
cggctgcagcg
gcggcgagtaa
gtcgtctgttgc 
13 EGP(44-46)AAA 
agcgatcctgcg
gcggcagccgct
gggaccaggag
t 
actcctggtccc
agcggctgccg
ccgcaggatcg
ct 
14 GTRSR(49-53)AAAAA 
cctgaggggcca
gccgctgcggcc
gcggctgcccgt
gcccgcagtcca
gca 
tgctggactgcg
ggcacgggcag
ccgcggccgca
gcggctggccc
ctcagg 
15 RARSP(54-58)AAAAA 
gctgggaccag
gagtcgcgctgc
cgccgctgcagc
agacaactcgg
gt 
acccgagttgtct
gctgcagcggc
ggcagcgcgac
tcctggtcccag
c 
pKB4 
Mo-MLV Gag-Pol 
mammalian 
expression 
construct 
K10A K10A 
cactccttctctag
gcgccgcaccta
aacctcaagttctt 
aagaacttgag
gtttaggtgcggc
gcctagagaag
gagtg 
P11A P11A 
cttctctaggcgc
caaagctaaacc
tcaagttcttt 
aaagaacttga
ggtttagctttggc
gcctagagaag 
K12A K12A 
tccttctctaggcg
ccaaacctgcac
ctcaagttctttct 
agaaagaactt
gaggtgcaggtt
tggcgcctagag
aagga 
P13A P13A 
tctaggcgccaa
acctaaagctca
agttctttctg 
cagaaagaactt
gagctttaggttt
ggcgcctaga 
Q14A Q14A 
ctaggcgccaaa
cctaaacctgca
gttctttctgacag
tgg 
ccactgtcagaa
agaactgcaggt
ttaggtttggcgc
ctag 
KKQ(10,12,14) KKQ(10,12,14)AAA ctcactccttctct cccccactgtca
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AAA aggcgccgcac
ctgcacctgcagt
tctttctgacagtg
gggg 
gaaagaactgc
aggtgcaggtgc
ggcgcctagag
aaggagtgag 
V15A V15A 
caaacctaaacc
tcaagctctttctg
acagtgggg 
ccccactgtcag
aaagagcttga
ggtttaggtttg 
L16A L16A 
gccaaacctaaa
cctcaagttgcttc
tgacagtggggg
gc 
gccccccactgt
cagaagcaactt
gaggtttaggttt
ggc 
S17A S17A 
caaacctaaacc
tcaagttcttgctg
acagtgggg 
ccccactgtcag
caagaacttgag
gtttaggtttg 
D18A D18A 
cctaaacctcaa
gttctttctgctagt
ggggggccgctc
atcgac 
gtcgatgagcgg
ccccccactagc
agaaagaactt
gaggtttagg 
S19A S19A 
ctcaagttctttctg
acgctgggggg
ccgctc 
gagcggccccc
cagcgtcagaa
agaacttgag 
G20A G20A 
ctttctgacagtgc
ggggccgctcat
c 
gatgagcggcc
ccgcactgtcag
aaag 
G21A G21A 
ctgacagtgggg
cgccgctcatcg
a 
tcgatgagcggc
gccccactgtca
g 
P22A P22A 
gacagtggggg
agcgctcatcga
cc 
ggtcgatgagcg
ctcccccactgtc 
L23A L23A 
gacagtggggg
gccggccatcga
cctacttac 
gtaagtaggtcg
atggccggccc
cccactgtc 
I24A I24A 
gtggggggccg
ctcgccgaccta
cttacaga 
tctgtaagtaggt
cggcgagcggc
cccccac 
D25A D25A 
ggggccgctcat
cgccctacttaca
gaag 
cttctgtaagtag
ggcgatgagcg
gcccc 
L26A L26A 
gggccgctcatc
gacgcacttaca
gaagaccc 
gccgctcatcga
cctagctacaga
agacccccc 
L27A L27A 
gccgctcatcga
cctagctacaga
agacccccc 
ggggggtcttctg
tagctaggtcgat
gagcggc 
T28A T28A 
gccgctcatcga
cctacttgcagaa
gacccc 
ggggtcttctgca
agtaggtcgatg
agcggc 
E29A E29A 
catcgacctactt
acagcagaccc
cccgccttatagg
g 
ccctataaggcg
gggggtctgctgt
aagtaggtcgat
g 
D30A D30A 
atcgacctactta
cagaagcccca
ccgccttataggg
acc 
ggtccctataag
gcggtggggctt
ctgtaagtaggtc
gat 
P60A P60A 
gaggcaccgga
cgcctccccaat
gg 
ccattggggagg
cgtccggtgcct
c 
S61A S61A 
gcaccggaccc
cgccccaatggc
at 
atgccattgggg
cggggtccggtg
c 
P62A P62A 
ccggacccctcc
gcaatggcatctc 
gagatgccattg
cggaggggtcc
gg 
M63A M63A 
ccggacccctcc
ccagcggcatct
cgcc 
ggcgagatgcc
gctggggaggg
gtccgg 
S65A S65A 
ctccccaatggc
agctcgcctacgt
gg 
ccacgtaggcg
agctgccattgg
ggag 
R66A R66A 
ccctccccaatg
gcatctgccctac
gtggg 
cccacgtaggg
cagatgccattg
gggaggg 
L67A L67A 
caatggcatctcg
cgcacgtggga
gacggg 
cccgtctcccac
gtgcgcgagatg
ccattg 
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R68A R68A 
cccaatggcatct
cgcctagctggg
agacggg 
cccgtctcccag
ctaggcgagatg
ccattggg 
G69A G69A 
ctcgcctacgtgc
gagacgggagc
c 
ggctcccgtctc
gcacgtaggcg
ag 
R70A R70A 
cgcctacgtggg
gcacgggagcc
ccc 
gggggctcccgt
gccccacgtag
gcg 
R71A R71A 
ctcgcctacgtgg
gagagcggagc
cccc 
gggggctccgct
ctcccacgtagg
cgag 
E72A E72A 
tgggagacggg
cgccccctgtgg 
ccacagggggc
gcccgtctccca 
P73A P73A 
ggagacgggag
gcccctgtggcc 
ggccacagggg
cctcccgtctcc 
P74A P74A 
gacgggagccc
gctgtggccgac 
gtcggccacag
cgggctcccgtc 
p12-TC 
DGNGGE(45-
50)CCPGCC 
ccacccccttccg
acaggtgctgcc
ctggttgctgcgc
gacccctgcggg
agag 
ctctcccgcagg
ggtcgcgcagc
aaccagggcag
cacctgtcggaa
gggggtgg 
p12-AscI GGE(48-50)GAP 
cgacagggacg
gaaatggcgcg
ccagcgacccct
gcgggag 
ctcccgcaggg
gtcgctggcgcg
ccatttccgtccct
gtcg 
L16D L16D 
gccaaacctaaa
cctcaagttgattc
tgacagtggggg
gc 
gccccccactgt
cagaatcaactt
gaggtttaggttt
ggc 
L16F L16F 
aacctaaacctc
aagttttttctgac
agtgggggg 
ccccccactgtc
agaaaaaactt
gaggtttaggtt 
L16K L16K 
gccaaacctaaa
cctcaagttaagt
ctgacagtgggg
ggccg 
cggccccccact
gtcagacttaact
tgaggtttaggttt
ggc 
L16Q L16Q 
acctaaacctca
agttcagtctgac
agtggggggcc 
ggccccccactg
tcagactgaactt
gaggtttaggt 
L16V L16V 
aacctaaacctc
aagttgtttctgac
agtgggggg 
ccccccactgtc
agaaacaacttg
aggtttaggtt 
S17D S17D 
acctaaacctca
agttcttgatgac
agtggggggcc
g 
cggccccccact
gtcatcaagaac
ttgaggtttaggt 
S17K S17K 
gcgccaaaccta
aacctcaagttctt
aaggacagtgg
ggggcc 
ggccccccactg
tccttaagaactt
gaggtttaggttt
ggcgc 
S17Q S17Q 
gcgccaaaccta
aacctcaagttctt
caggacagtgg
ggggcc 
ggccccccactg
tcctgaagaactt
gaggtttaggttt
ggcgc 
D18E D18E 
taaacctcaagtt
ctttctgagagtg
gggggcc 
ggccccccactc
tcagaaagaact
tgaggttta 
S71T S71T 
gcaccggaccc
caccccaatggc
at 
atgccattggggt
ggggtccggtgc 
R66H R66H 
cccaatggcatct
cacctacgtggg
agac 
gtctcccacgta
ggtgagatgcca
ttggg 
R70H R70H 
tctcgcctacgtg
ggcatcgggag
ccccctgtg 
cacagggggct
cccgatgcccac
gtaggcgaga 
S17 F/V S17 F/V 
aaacctaaacct
caagttcttnnkg
acagtgggggg
ccgctc 
gagcggccccc
cactgtcmnna
agaacttgaggt
ttaggttt 
D18 F/K/Q/L D18 F/K/Q/L 
gtcgatgagcgg
ccccccactmn
nagaaagaactt
gaggtttagg 
cctaaacctcaa
gttctttctnnkag
tggggggccgct
catcgac 
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Del Sm deletion 
p12  
D43-P53 del 
ccacccccttccg
cgggagaggca 
tgcctctcccgcg
gaagggggtgg 
Del Lrg deletion 
p12  
P37-A57 del 
gccttataggga
cccggacccctc
cc 
gggaggggtcc
gggtccctataa
ggc 
Changing 
tropism of Mo-
MLV CA to N-
tropic like 
CA D82N 
gcggtgcgggg
caatgatgggcg
cccc 
ggggcgcccat
cattgccccgca
ccgc 
CA A110R 
gggattacacca
cccagcgaggta
ggaaccacctag
t 
actaggtggttcc
tacctcgctgggt
ggtgtaatccc 
CA H117L 
ggtaggaacca
cctagtcttgtatc
gccagttgctcct
agc 
gctaggagcaa
ctggcgatacaa
gactaggtggttc
ctacc 
Insert L 
between p12 
A2 and T3 of 
Mo-MLV/Ga-
p12 or Ga-
Np12 chimeras 
PA>L<T 
cctccctttatccg
gcactcacagac
gacttactc 
gagtaagtcgtct
gtgagtgccgga
taaagggagg 
MA-p12 
cleavage 
MA Y131D 
ccgcctcgatcct
cccttgatccagc
cct 
agggctggatca
agggaggatcg
aggcgg 
pKB4 p12AscI 
Mo-MLV Gag-Pol 
mammalian 
expression 
construct with p12-
AscI 
AscI insert oligo alanine insert (smaller) 
gcgccgggcgc
gccagcggcgg
cggcggcagcg
gcggcagctgcg
gccgcagctgca
gcgggcgcgcc
gcgccg 
cggcgcggcgc
gcccgctgcag
ctgcggccgca
gctgccgccgct
gccgccgccgc
cgctggcgcgc
ccggcgc 
AscI insert oligo 
Angiogenin NoLS 
insert 
gcgccgggcgc
gccaatcatgag
gaggaggggcc
ttgcgggcgcgc
cgcgccg 
cggcgcggcgc
gcccgcaaggc
ccctcctcctcat
gattggcgcgcc
cggcgc 
AscI insert oligo sGFP11 inset 
gccgggcgcgc
cacgtgaccaca
tggtccttcatga
gtacgtaaatgct
gctgggattaca
gcgggcgcgcc
gcg 
cgcggcgcgcc
cgctgtaatccc
agcagcatttac
gtactcatgaag
gaccatgtggtc
acgtggcgcgc
ccggc 
AscI insert oligo NIK NoLS 
gcgccgggcgc
gccaaggaaga
agaggaaaaag
aaggcgggcgc
gccgcgccg 
cggcgcggcgc
gcccgccttctttt
tcctcttcttccttg
gcgcgcccggc
gc 
AscI insert oligo SV40 T-antigen NLS 
gcgccgggcgc
gccaaagaaga
aaaggagggtc
gcgggcgcgcc
gcgccg 
cggcgcggcgc
gcccgcgaccct
ccttttcttctttgg
cgcgcccggcg
c 
AscI insert oligo PFV CBS 
gcgccgggcgc
gccaaatcaag
gaggatataatct
tcgaccccgtact
taccaacctgcg
ggcgcgccgcg
ccg 
cggcgcggcgc
gcccgcaggttg
gtaagtacggg
gtcgaagattat
atcctccttgattt
ggcgcgcccgg
cgc 
AscI insert oligo alanine insert (large) 
gcgccgggcgc
gccagcggcgg
cggcggcagcg
gcggcagctgcg
gccgcagctgcg
gcggcggcggc
agcggcggcag
ctgcggccgcag
ctgcggccgcag
cgggcgcgccg
cgccg 
cggcgcggcgc
gcccgctgcgg
ccgcagctgcg
gccgcagctgc
cgccgctgccgc
cgccgccgcag
ctgcggccgca
gctgccgccgct
gccgccgccgc
cgctggcgcgc
ccggcgc 
pKB4 MA 
Y131D 
Mo-MLV Gag-Pol 
mammalian 
expression 
construct 
MA-p12 
cleavage 
MA Y131D  p12 
PA(1,2)DE 
ccgcctcgatcct
cccttgatgatga
gctcactccttctc
taggc 
gcctagagaag
gagtgagctcat
catcaagggag
gatcgaggcgg 
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pKB5 myc 
pKB p12-myc 
plasmids 
Mut 5 p12-myc KPKPQ(10-14)AAAAA 
ccctcactccttct
ctaggcgccgca
gctgcagctgca
gttctttctgacag
tggggggc 
gccccccactgt
cagaaagaact
gcagctgcagct
gcggcgcctag
agaaggagtga
ggg 
pKB6 myc 
Mut 6 p12- Myc 
and Mut 6 
eGFP-p12 
VLSDS(15-19)AAAA 
gccaaacctaaa
cctcaagctgctg
ctgccgctgggg
ggccgctcatcg
a 
tcgatgagcggc
cccccagcggc
agcagcagcttg
aggtttaggtttg
gc 
pKB7 myc 
Mut 7 p12- Myc 
and Mut 7 
eGFP-p12 
GGPLI(20-24)AAAAA 
cctcaagttctttct
gacagtgcggc
ggcggccgccg
acctacttacaga
agacccc 
ggggtcttctgta
agtaggtcggcg
gccgccgccgc
actgtcagaaag
aacttgagg 
pKB8 myc 
Mut 8 p12- Myc 
and Mut 8 
eGFP-p12 
DLLTED(25-
30)AAAAAA 
ggggggccgctc
atcgccgcagct
gcagcagcacc
cccgccttatagg
gacccaaga 
tcttgggtccctat
aaggcgggggt
gctgctgcagct
gcggcgatgag
cggcccccc 
pcDNACherry-
p12 Cherry p12 
expression 
plasmids 
EcoRI removal 
in p12 
A51F 
agggacggaaa
tggtggagaattc
acccctgcggg 
cccgcaggggt
gaattctccacc
atttccgtccct 
pcDNACherry-
p12 
Stop codon in 
p12 
R35stop 
gaagacccccc
gccttattgagac
ccaagaccac 
gtggtcttgggtct
caataaggcgg
ggggtcttc 
pcGaLVgp 
GaLV Gag-Pol 
mammalian 
expression 
construct 
T3A T3A 
cccatctacccg
gcagcagacga
cttactcc 
ggagtaagtcgt
ctgctgccgggt
agatggg 
D4A D4A 
ctacccggcaac
agccgacttactc
ctcc 
ggaggagtaag
tcggctgttgccg
ggtag 
D5A D5A 
cccggcaacag
acgccttactcct
cctct 
agaggaggagt
aaggcgtctgttg
ccggg 
L6A L6A 
cccggcaacag
acgacgcactcc
tcctctctgaa 
ttcagagagga
ggagtgcgtcgt
ctgttgccggg 
L7A L7A 
acccggcaaca
gacgacttagcc
ctcctctctg 
cagagaggag
ggctaagtcgtct
gttgccgggt 
L8A L8A 
gcaacagacga
cttactcgccctct
ctgaacccacgc
cc 
gggcgtgggttc
agagagggcg
agtaagtcgtctg
ttgc 
L9A L9A 
gacgacttactcc
tcgcctctgaacc
cacgccc 
gggcgtgggttc
agaggcgagg
agtaagtcgtc 
E44A E44A 
gatagtagcgat
cctgcggggcca
gccgctggg 
cccagcggctg
gccccgcagga
tcgctactatc 
G45A G45A 
agtagcgatcct
gaggcgccagc
cgctgggacc 
ggtcccagcgg
ctggcgcctcag
gatcgctact 
P46A P46A 
agcgatcctgag
ggggcagccgct
gggaccagg 
cctggtcccagc
ggctgccccctc
aggatcgct 
G49A G49A 
gaggggccagc
cgctgcgaccag
gagtcgccgt 
acggcgactcct
ggtcgcagcgg
ctggcccctc 
T50A T50A 
gggccagccgct
ggggccaggag
tcgccgtgcc 
ggcacggcgac
tcctggccccag
cggctggccc 
R51A R51A 
ccagccgctggg
accgcgagtcgc
cgtgcccgc 
gcgggcacggc
gactcgcggtcc
cagcggctgg 
S52A S52A 
gccgctgggacc
agggctcgccgt
gcccgcagt 
actgcgggcac
ggcgagccctg
gtcccagcggc 
R53A R53A 
gctgggaccag
gagtgcccgtgc
ccgcagtcca 
tggactgcgggc
acgggcactcct
ggtcccagc 
R54A R54A 
gggaccaggag
tcgcgctgcccg
cagtccagca 
tgctggactgcg
ggcagcgcgac
tcctggtccc 
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R56A R56A 
aggagtcgccgt
gccgccagtcca
gcagacaac 
gttgtctgctgga
ctggcggcacg
gcgactcct 
S57A S57A 
agtcgccgtgcc
cgcgctccagca
gacaactcg 
cgagttgtctgct
ggagcgcgggc
acggcgact 
P58A P58A 
cgccgtgcccgc
agtgcagcaga
caactcgggt 
acccgagttgtct
gctgcactgcgg
gcacggcg 
Introduce BsrGI 
site 5' to GaLV 
gag 
  
ccccacccctcact
gtacatctccccgc
aggagaattc 
gaattctcctgcgg
ggagatgtacagt
gaggggtgggg 
Remove XhoI 
site 3' of pol 
  
gcaaaataagcgg
ccgctaaagtctag
agggcccgt 
acgggccctctag
actttagcggccgc
ttattttgc 
pczGaLV/Mo-
p12 chimeras 
GaLV Gag-Pol  
chimera 
mammalian 
expression 
construct 
Remove 
introduced 
BsrGI site 5' of 
GaLV Gag 
  
ccccacccctcact
ctgcttctccccgca
ggagaattc 
gaattctcctgcgg
ggagaagcagagt
gaggggtgggg 
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Appendix B: Plasmid List 
Plasmid name Description Synthesis 
pKB4 Mo-MLV Gag-Pol expression vector 
Mo-MLV Gag-Pol from pMD-MLV 
cloned into pcDNA3.1 
pKB5 
Mo-MLV Gag-Pol expression vector with 
p12 mutant 5 
BsrGI/XhoI fragment from pNCS 
PM5 cloned in pKB4 
pKB6 
Mo-MLV Gag-Pol expression vector with 
p12 mutant 6 
BsrGI/XhoI fragment from pNCS 
PM6 cloned in pKB4 
pKB7 
Mo-MLV Gag-Pol expression vector with 
p12 mutant 7 
BsrGI/XhoI fragment from pNCS 
PM7 cloned in pKB4 
pKB8 
Mo-MLV Gag-Pol expression vector with 
p12 mutant 8 
BsrGI/XhoI fragment from pNCS 
PM8 cloned in pKB4 
pKB13 
Mo-MLV Gag-Pol expression vector with 
p12 mutant 13 
BsrGI/XhoI fragment from pNCS 
PM13 cloned in pKB4 
pKB14 
Mo-MLV Gag-Pol expression vector with 
p12 mutant 14 
BsrGI/XhoI fragment from pNCS 
PM14 cloned in pKB4 
pKB15 
Mo-MLV Gag-Pol expression vector with 
p12 mutant 15 
BsrGI/XhoI fragment from pNCS 
PM15 cloned in pKB4 
pKB16 
Mo-MLV Gag-Pol expression vector with 
FLAG-tagged wild type p12 
BsrGI/XhoI fragment from pNCS 
FLAG cloned in pKB4 
pKB17 
Mo-MLV Gag-Pol expression vector with 
p12 late domain mutant 
BsrGI/XhoI fragment from pNCS L-
domain cloned in pKB4 
pKB4 K10A 
Mo-MLV Gag-Pol expression vector with 
p12 mutant 
Site directed mutagenesis of pKB4 
pKB4 P11A 
Mo-MLV Gag-Pol expression vector with 
p12 mutant 
Site directed mutagenesis of pKB4 
pKB4 K12A 
Mo-MLV Gag-Pol expression vector with 
p12 mutant 
Site directed mutagenesis of pKB4 
pKB4 P13A 
Mo-MLV Gag-Pol expression vector with 
p12 mutant 
Site directed mutagenesis of pKB4 
pKB4 Q14A 
Mo-MLV Gag-Pol expression vector with 
p12 mutant 
Site directed mutagenesis of pKB4 
pKB4 KKQ(10,12,14)AAA 
Mo-MLV Gag-Pol expression vector with 
p12 mutant 
Site directed mutagenesis of pKB4 
pKB4 V15A 
Mo-MLV Gag-Pol expression vector with 
p12 mutant 
Site directed mutagenesis of pKB4 
pKB4 L16A 
Mo-MLV Gag-Pol expression vector with 
p12 mutant 
Site directed mutagenesis of pKB4 
pKB4 S17A 
Mo-MLV Gag-Pol expression vector with 
p12 mutant 
Site directed mutagenesis of pKB4 
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pKB4 D18A 
Mo-MLV Gag-Pol expression vector with 
p12 mutant 
Site directed mutagenesis of pKB4 
pKB4 S19A 
Mo-MLV Gag-Pol expression vector with 
p12 mutant 
Site directed mutagenesis of pKB4 
pKB4 G20A 
Mo-MLV Gag-Pol expression vector with 
p12 mutant 
Site directed mutagenesis of pKB4 
pKB4 G21A 
Mo-MLV Gag-Pol expression vector with 
p12 mutant 
Site directed mutagenesis of pKB4 
pKB4 P22A 
Mo-MLV Gag-Pol expression vector with 
p12 mutant 
Site directed mutagenesis of pKB4 
pKB4 L23A 
Mo-MLV Gag-Pol expression vector with 
p12 mutant 
Site directed mutagenesis of pKB4 
pKB4 I24A 
Mo-MLV Gag-Pol expression vector with 
p12 mutant 
Site directed mutagenesis of pKB4 
pKB4 D25A 
Mo-MLV Gag-Pol expression vector with 
p12 mutant 
Site directed mutagenesis of pKB4 
pKB4 L26A 
Mo-MLV Gag-Pol expression vector with 
p12 mutant 
Site directed mutagenesis of pKB4 
pKB4 L27A 
Mo-MLV Gag-Pol expression vector with 
p12 mutant 
Site directed mutagenesis of pKB4 
pKB4 T28A 
Mo-MLV Gag-Pol expression vector with 
p12 mutant 
Site directed mutagenesis of pKB4 
pKB4 E29A 
Mo-MLV Gag-Pol expression vector with 
p12 mutant 
Site directed mutagenesis of pKB4 
pKB4 D30A 
Mo-MLV Gag-Pol expression vector with 
p12 mutant 
Site directed mutagenesis of pKB4 
pKB4 P60A 
Mo-MLV Gag-Pol expression vector with 
p12 mutant 
Site directed mutagenesis of pKB4 
pKB4 S61A 
Mo-MLV Gag-Pol expression vector with 
p12 mutant 
Site directed mutagenesis of pKB4 
pKB4 P62A 
Mo-MLV Gag-Pol expression vector with 
p12 mutant 
Site directed mutagenesis of pKB4 
pKB4 M63A 
Mo-MLV Gag-Pol expression vector with 
p12 mutant 
Site directed mutagenesis of pKB4 
pKB4 S65A 
Mo-MLV Gag-Pol expression vector with 
p12 mutant 
Site directed mutagenesis of pKB4 
pKB4 R66A 
Mo-MLV Gag-Pol expression vector with 
p12 mutant 
Site directed mutagenesis of pKB4 
pKB4 L67A 
Mo-MLV Gag-Pol expression vector with 
p12 mutant 
Site directed mutagenesis of pKB4 
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pKB4 R68A 
Mo-MLV Gag-Pol expression vector with 
p12 mutant 
Site directed mutagenesis of pKB4 
pKB4 G69A 
Mo-MLV Gag-Pol expression vector with 
p12 mutant 
Site directed mutagenesis of pKB4 
pKB4 R70A 
Mo-MLV Gag-Pol expression vector with 
p12 mutant 
Site directed mutagenesis of pKB4 
pKB4 R71A 
Mo-MLV Gag-Pol expression vector with 
p12 mutant 
Site directed mutagenesis of pKB4 
pKB4 E72A 
Mo-MLV Gag-Pol expression vector with 
p12 mutant 
Site directed mutagenesis of pKB4 
pKB4 P73A 
Mo-MLV Gag-Pol expression vector with 
p12 mutant 
Site directed mutagenesis of pKB4 
pKB4 P74A 
Mo-MLV Gag-Pol expression vector with 
p12 mutant 
Site directed mutagenesis of pKB4 
pKB4 LR(16,66)AA) 
Mo-MLV Gag-Pol expression vector with 
p12 mutant 
Site directed mutagenesis of pKB4 
L16A 
pKB4 L16D 
Mo-MLV Gag-Pol expression vector with 
p12 mutant 
Site directed mutagenesis of pKB4 
pKB4 L16F 
Mo-MLV Gag-Pol expression vector with 
p12 mutant 
Site directed mutagenesis of pKB4 
pKB4 L16K 
Mo-MLV Gag-Pol expression vector with 
p12 mutant 
Site directed mutagenesis of pKB4 
pKB4 L16Q 
Mo-MLV Gag-Pol expression vector with 
p12 mutant 
Site directed mutagenesis of pKB4 
pKB4 L16V 
Mo-MLV Gag-Pol expression vector with 
p12 mutant 
Site directed mutagenesis of pKB4 
pKB4 S17D 
Mo-MLV Gag-Pol expression vector with 
p12 mutant 
Site directed mutagenesis of pKB4 
pKB4 S17K 
Mo-MLV Gag-Pol expression vector with 
p12 mutant 
Site directed mutagenesis of pKB4 
pKB4 S17Q 
Mo-MLV Gag-Pol expression vector with 
p12 mutant 
Site directed mutagenesis of pKB4 
pKB4 S17V 
Mo-MLV Gag-Pol expression vector with 
p12 mutant 
Site directed mutagenesis of pKB4 
pKB4 S61T 
Mo-MLV Gag-Pol expression vector with 
p12 mutant 
Site directed mutagenesis of pKB4 
pKB4 R66H 
Mo-MLV Gag-Pol expression vector with 
p12 mutant 
Site directed mutagenesis of pKB4 
pKB4 R70H 
Mo-MLV Gag-Pol expression vector with 
p12 mutant 
Site directed mutagenesis of pKB4 
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pKB4 S17F 
Mo-MLV Gag-Pol expression vector with 
p12 mutant 
Site directed mutagenesis of pKB4 
pKB4 D18F 
Mo-MLV Gag-Pol expression vector with 
p12 mutant 
Site directed mutagenesis of pKB4 
pKB4 D18K 
Mo-MLV Gag-Pol expression vector with 
p12 mutant 
Site directed mutagenesis of pKB4 
pKB4 D18Q 
Mo-MLV Gag-Pol expression vector with 
p12 mutant 
Site directed mutagenesis of pKB4 
pKB4 D18L 
Mo-MLV Gag-Pol expression vector with 
p12 mutant 
Site directed mutagenesis of pKB4 
pKB4 D18E 
Mo-MLV Gag-Pol expression vector with 
p12 mutant 
Site directed mutagenesis of pKB4 
pKB4 p12-TC 
Mo-MLV Gag-Pol expression vector with 
tetracysteine motif in p12 
Site directed mutagenesis of pKB4 
pKB4 p12-AscI 
Mo-MLV Gag-Pol expression vector with 
AscI site in p12 
Site directed mutagenesis of pKB4 
pKB4 p12 DelSm 
Mo-MLV Gag-Pol expression vector with 
D43-P53 p12 deletion 
Site directed mutagenesis of pKB4 
pKB4 p12 DelLrg 
Mo-MLV Gag-Pol expression vector with 
P37-A57 p12 deletion 
Site directed mutagenesis of pKB4 
pKB4 MA-D 
Mo-MLV Gag-Pol expression vector with 
MA Y131D mutation 
Site directed mutagenesis of pKB4 
pKB4 DDE 
Mo-MLV Gag-Pol expression vector with 
MA Y131D + p12 PA(1,2)DE mutations 
Site directed mutagenesis of pKB4 
MA-D 
pKB4 sGFPp12 
Mo-MLV Gag-Pol expression vector with 
sGFP11 motif in p12 
AscI flanked oligos digested and 
cloned into pKB4 p12-AscI 
pKB4 p12-SV40 
Mo-MLV Gag-Pol expression vector with 
SV40 T-antigen NLS in p12 
AscI flanked oligos digested and 
cloned into pKB4 p12-AscI 
pKB4 p12Ang NoLS 
Mo-MLV Gag-Pol expression vector with 
angiogenin NoLS motif in p12 
AscI flanked oligos digested and 
cloned into pKB4 p12-AscI 
pKB6 p12Ang NoLS 
Mo-MLV Gag-Pol expression vector with 
angiogenin NoLS motif in p12 mutant 6 
AscI flanked oligos digested and 
cloned into pKB4 p12-AscI 
pKB7 p12Ang NoLS 
Mo-MLV Gag-Pol expression vector with 
angiogenin NoLS motif in p12 mutant 7 
AscI flanked oligos digested and 
cloned into pKB4 p12-AscI 
pKB14 p12Ang NoLS 
Mo-MLV Gag-Pol expression vector with 
angiogenin NoLS motif in p12 mutant 14 
AscI flanked oligos digested and 
cloned into pKB4 p12-AscI 
pKB4 p12NIK NoLS 
Mo-MLV Gag-Pol expression vector with 
NIK NoLS motif in p12 
AscI flanked oligos digested and 
cloned into pKB4 p12-AscI 
pKB6 p12NIK NoLS 
Mo-MLV Gag-Pol expression vector with 
NIK NoLS motif in p12 mutant 6 
AscI flanked oligos digested and 
cloned into pKB4 p12-AscI 
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pKB7 p12NIK NoLS 
Mo-MLV Gag-Pol expression vector with 
NIK NoLS motif in p12 mutant 7 
AscI flanked oligos digested and 
cloned into pKB4 p12-AscI 
pKB14 p12NIK NoLS 
Mo-MLV Gag-Pol expression vector with 
NIK NoLS motif in p12 mutant 14 
AscI flanked oligos digested and 
cloned into pKB4 p12-AscI 
pKB4 p12CBS 
Mo-MLV Gag-Pol expression vector with 
PFV CBS motif in p12 
AscI flanked oligos digested and 
cloned into pKB4 p12-AscI 
pKB6 p12CBS 
Mo-MLV Gag-Pol expression vector with 
PFV CBS motif in p12 mutant 6 
AscI flanked oligos digested and 
cloned into pKB4 p12-AscI 
pKB7 p12CBS 
Mo-MLV Gag-Pol expression vector with 
PFV CBS motif in p12 mutant 7 
AscI flanked oligos digested and 
cloned into pKB4 p12-AscI 
pKB13 p12CBS 
Mo-MLV Gag-Pol expression vector with 
PFV CBS motif in p12 mutant 13 
AscI flanked oligos digested and 
cloned into pKB4 p12-AscI 
pKB14 p12CBS 
Mo-MLV Gag-Pol expression vector with 
PFV CBS motif in p12 mutant 14 
AscI flanked oligos digested and 
cloned into pKB4 p12-AscI 
pKB15 p12CBS 
Mo-MLV Gag-Pol expression vector with 
PFV CBS motif in p12 mutant 15 
AscI flanked oligos digested and 
cloned into pKB4 p12-AscI 
pKB4 p12mycE 
Mo-MLV Gag-Pol expression vector with 
myc motif in p12 
BsrGI/XhoI fragment cloned from 
pNCS p12-1xMycR (gift from Eran 
Bacharach) 
pKB5 p12mycE 
Mo-MLV Gag-Pol expression vector with 
sGFP11 motif in p12 mutant 5 
BsrGI/XhoI fragment cloned from  
pNCS p12-1xMycR PM5 (gift from 
Eran Bacharach) 
pKB6 p12mycE 
Mo-MLV Gag-Pol expression vector with 
sGFP11 motif in p12 mutant 6 
Site directed mutagenesis of pKB4 
p12mycE 
pKB7 p12mycE 
Mo-MLV Gag-Pol expression vector with 
sGFP11 motif in p12 mutant 7 
Site directed mutagenesis of pKB4 
p12mycE 
pKB8 p12mycE 
Mo-MLV Gag-Pol expression vector with 
sGFP11 motif in p12 mutant 8 
Site directed mutagenesis of pKB4 
p12mycE 
pKB14 p12mycE 
Mo-MLV Gag-Pol expression vector with 
sGFP11 motif in p12 mutant 14 
BsrGI/XhoI fragment cloned from 
pNCS p12-1xMycR PM14 (gift from 
Eran Bacharach) 
pMo/N 
Mo-MLV Gag-Pol expression vector with 
CA mutations DAH(82,110,117)NRL 
Site directed mutagenesis of pKB4 
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pMo/N Mut 5 
Mo-MLV Gag-Pol expression vector with 
CA mutations DAH(82,110,117)NRL and 
p12 mutant 5 
Site directed mutagenesis of pKB5 
pMo/N Mut 6 
Mo-MLV Gag-Pol expression vector with 
CA mutations DAH(82,110,117)NRL and 
p12 mutant 6 
Site directed mutagenesis of pKB6 
pMo/N Mut 7 
Mo-MLV Gag-Pol expression vector with 
CA mutations DAH(82,110,117)NRL and 
p12 mutant 7 
Site directed mutagenesis of pKB7 
pMo/N Mut 8 
Mo-MLV Gag-Pol expression vector with 
CA mutations DAH(82,110,117)NRL and 
p12 mutant 8 
Site directed mutagenesis of pKB8 
pMo/N Mut 13 
Mo-MLV Gag-Pol expression vector with 
CA mutations DAH(82,110,117)NRL and 
p12 mutant 13 
Site directed mutagenesis of pKB13 
pMo/N Mut 15 
Mo-MLV Gag-Pol expression vector with 
CA mutations DAH(82,110,117)NRL and 
p12 mutant 15 
Site directed mutagenesis of pKB14 
pMo/N L16A 
Mo-MLV Gag-Pol expression vector with 
CA mutations DAH(82,110,117)NRL and 
p12 mutant L16A 
Site directed mutagenesis of L16A 
pMo/N R66A 
Mo-MLV Gag-Pol expression vector with 
CA mutations DAH(82,110,117)NRL and 
p12 mutant R66A 
Site directed mutagenesis of R66A 
pMo/N LR(16,66)AA 
Mo-MLV Gag-Pol expression vector with 
CA mutations DAH(82,110,117)NRL and 
p12 mutant LR(16,66)AA 
Site directed mutagenesis of 
LR(16,66)AA 
pcDNA3.1(A)p12eGFP 
Mo-MLV modified Gag expression vector 
containing eGFP-p12 
Gift from Eran Bacharach 
pcDNA3.1(A)p12eGFP PM5 
Mo-MLV modified Gag expression vector 
containing eGFP-p12 mutant 5 
Gift from Eran Bacharach 
pcDNA3.1(A)p12eGFP PM6 
Mo-MLV modified Gag expression vector 
containing eGFP-p12 mutant 6 
Site directed mutagenesis 
pcDNA3.1(A)p12eGFP PM7 
Mo-MLV modified Gag expression vector 
containing eGFP-p12 mutant 7 
Site directed mutagenesis 
pcDNA3.1(A)p12eGFP PM8 
Mo-MLV modified Gag expression vector 
containing eGFP-p12 mutant 8 
Site directed mutagenesis 
pcDNA3.1(A)p12eGFP PM14 
Mo-MLV modified Gag expression vector 
containing eGFP-p12 mutant 14 
Gift from Eran Bacharach 
pCIG3N N-tropic MLV Gag-Pol expression vector Gift from Jonathan Stoye 
pCIG3N Mut 5 
N-tropic MLV Gag-Pol expression vector 
with p12 mutant 5 
Site directed mutagenesis of 
pCIG3N 
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pCIG3N Mut 6 
N-tropic MLV Gag-Pol expression vector 
with p12 mutant 6 
Site directed mutagenesis of 
pCIG3N 
pCIG3N Mut 7 
N-tropic MLV Gag-Pol expression vector 
with p12 mutant 7 
Site directed mutagenesis of 
pCIG3N 
pCIG3N Mut 8 
N-tropic MLV Gag-Pol expression vector 
with p12 mutant 8 
Site directed mutagenesis of 
pCIG3N 
pCIG3N Mut 13 
N-tropic MLV Gag-Pol expression vector 
with p12 mutant 13 
Site directed mutagenesis of 
pCIG3N 
pCIG3N Mut 14 
N-tropic MLV Gag-Pol expression vector 
with p12 mutant 14 
Site directed mutagenesis of 
pCIG3N 
pCIG3N Mut 15 
N-tropic MLV Gag-Pol expression vector 
with p12 mutant 15 
Site directed mutagenesis of 
pCIG3N 
pCIG3B B-tropic MLV Gag-Pol expression vector Gift from Jonathan Stoye 
pCIG3B Mut 5 
B-tropic MLV Gag-Pol expression vector 
with p12 mutant 5 
Site directed mutagenesis of 
pCIG3B 
pCIG3B Mut 6 
B-tropic MLV Gag-Pol expression vector 
with p12 mutant 6 
Site directed mutagenesis of 
pCIG3B 
pCIG3B Mut 7 
B-tropic MLV Gag-Pol expression vector 
with p12 mutant 7 
Site directed mutagenesis of 
pCIG3B 
pCIG3B Mut 8 
B-tropic MLV Gag-Pol expression vector 
with p12 mutant 8 
Site directed mutagenesis of 
pCIG3B 
pCIG3B Mut 13 
B-tropic MLV Gag-Pol expression vector 
with p12 mutant 13 
Site directed mutagenesis of 
pCIG3B 
pCIG3B Mut 14 
B-tropic MLV Gag-Pol expression vector 
with p12 mutant 14 
Site directed mutagenesis of 
pCIG3B 
pCIG3B Mut 15 
B-tropic MLV Gag-Pol expression vector 
with p12 mutant 15 
Site directed mutagenesis of 
pCIG3B 
pB30Y 
B-tropic MLV modified Gag expression 
vector CA-YFP fusion (del of last 4 a.a. of 
CA and all of NC) 
Gift from Melvyn Yap 
pcFeLVgp FeLV Gag-Pol expression vector Gift from Jonathan Stoye 
pFeLVdw FeLV Gag-Pol expression vector 
FeLV Gag-Pol cloned from 
pcFeLVgp into pcDNA3.1 
pFeLV Mut 5 
FeLV Gag-Pol expression vector with p12 
mutant 5 
Site directed mutagenesis of 
pFeLVdw 
pFeLV Mut 6 
FeLV Gag-Pol expression vector with p12 
mutant 6 
Site directed mutagenesis of 
pFeLVdw 
pFeLV Mut 7 
FeLV Gag-Pol expression vector with p12 
mutant 7 
Site directed mutagenesis of 
pFeLVdw 
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pFeLV Mut 8 
FeLV Gag-Pol expression vector with p12 
mutant 8 
Site directed mutagenesis of 
pFeLVdw 
pFeLV Mut 13 
FeLV Gag-Pol expression vector with p12 
mutant 13 
Site directed mutagenesis of 
pFeLVdw 
pFeLV Mut 14 
FeLV Gag-Pol expression vector with p12 
mutant 14 
Site directed mutagenesis of 
pFeLVdw 
pFeLV Mut 15 
FeLV Gag-Pol expression vector with p12 
mutant 15 
Site directed mutagenesis of 
pFeLVdw 
pcGaLVgp GaLV Gag-Pol expression vector Gift from Jonathan Stoye 
pcGaLVgp Mut 5 
GaLV Gag-Pol expression vector with p12 
mutant 5 
Site directed mutagenesis of 
pcGaLVgp 
pcGaLVgp Mut 6 
GaLV Gag-Pol expression vector with p12 
mutant 6 
Site directed mutagenesis of 
pcGaLVgp 
pcGaLVgp Mut 7 
GaLV Gag-Pol expression vector with p12 
mutant 7 
Site directed mutagenesis of 
pcGaLVgp 
pcGaLVgp Mut 8 
GaLV Gag-Pol expression vector with p12 
mutant 8 
Site directed mutagenesis of 
pcGaLVgp 
pcGaLVgp Mut 13 
GaLV Gag-Pol expression vector with p12 
mutant 13 
Site directed mutagenesis of 
pcGaLVgp 
pcGaLVgp Mut 14 
GaLV Gag-Pol expression vector with p12 
mutant 14 
Site directed mutagenesis of 
pcGaLVgp 
pcGaLVgp Mut 15 
GaLV Gag-Pol expression vector with p12 
mutant 15 
Site directed mutagenesis of 
pcGaLVgp 
pcGaLVgp T3A 
GaLV Gag-Pol expression vector with p12 
mutant 
Site directed mutagenesis of 
pcGaLVgp 
pcGaLVgp D4A 
GaLV Gag-Pol expression vector with p12 
mutant 
Site directed mutagenesis of 
pcGaLVgp 
pcGaLVgp D5A 
GaLV Gag-Pol expression vector with p12 
mutant 
Site directed mutagenesis of 
pcGaLVgp 
pcGaLVgp L6A 
GaLV Gag-Pol expression vector with p12 
mutant 
Site directed mutagenesis of 
pcGaLVgp 
pcGaLVgp L7A 
GaLV Gag-Pol expression vector with p12 
mutant 
Site directed mutagenesis of 
pcGaLVgp 
pcGaLVgp L8A 
GaLV Gag-Pol expression vector with p12 
mutant 
Site directed mutagenesis of 
pcGaLVgp 
pcGaLVgp L9A 
GaLV Gag-Pol expression vector with p12 
mutant 
Site directed mutagenesis of 
pcGaLVgp 
pcGaLVgp E44A 
GaLV Gag-Pol expression vector with p12 
mutant 
Site directed mutagenesis of 
pcGaLVgp 
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pcGaLVgp G45A 
GaLV Gag-Pol expression vector with p12 
mutant 
Site directed mutagenesis of 
pcGaLVgp 
pcGaLVgp P46A 
GaLV Gag-Pol expression vector with p12 
mutant 
Site directed mutagenesis of 
pcGaLVgp 
pcGaLVgp G49A 
GaLV Gag-Pol expression vector with p12 
mutant 
Site directed mutagenesis of 
pcGaLVgp 
pcGaLVgp T50A 
GaLV Gag-Pol expression vector with p12 
mutant 
Site directed mutagenesis of 
pcGaLVgp 
pcGaLVgp R51A 
GaLV Gag-Pol expression vector with p12 
mutant 
Site directed mutagenesis of 
pcGaLVgp 
pcGaLVgp S52A 
GaLV Gag-Pol expression vector with p12 
mutant 
Site directed mutagenesis of 
pcGaLVgp 
pcGaLVgp R53A 
GaLV Gag-Pol expression vector with p12 
mutant 
Site directed mutagenesis of 
pcGaLVgp 
pcGaLVgp R54A 
GaLV Gag-Pol expression vector with p12 
mutant 
Site directed mutagenesis of 
pcGaLVgp 
pcGaLVgp R56A 
GaLV Gag-Pol expression vector with p12 
mutant 
Site directed mutagenesis of 
pcGaLVgp 
pcGaLVgp S57A 
GaLV Gag-Pol expression vector with p12 
mutant 
Site directed mutagenesis of 
pcGaLVgp 
pcGaLVgp P58A 
GaLV Gag-Pol expression vector with p12 
mutant 
Site directed mutagenesis of 
pcGaLVgp 
pHG1-env XMRV Gag-Pol expression vector Gift from Harriet Groom 
pHG1-env p12 mutant 5 
XMRV Gag-Pol expression vector with p12 
mutant 5 
Site directed mutagenesis of pHG1-
env 
pHG1-env p12 mutant 6 
XMRV Gag-Pol expression vector with p12 
mutant 6 
Site directed mutagenesis of pHG1-
env 
pHG1-env p12 mutant 7 
XMRV Gag-Pol expression vector with p12 
mutant 7 
Site directed mutagenesis of pHG1-
env 
pHG1-env p12 mutant 13 
XMRV Gag-Pol expression vector with p12 
mutant 13 
Site directed mutagenesis of pHG1-
env 
pHG1-env p12 mutant 14 
XMRV Gag-Pol expression vector with p12 
mutant 14 
Site directed mutagenesis of pHG1-
env 
pHG1-env p12 mutant 15 
XMRV Gag-Pol expression vector with p12 
mutant 15 
Site directed mutagenesis of pHG1-
env 
pczLacZ-LTR 
MLV LTR-driven LacZ reporter expression 
vector 
Gift from Kate Bishop 
pLNCG 
MLV LTR-driven GFP reporter expression 
vector 
Gift from Jonathan Stoye 
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pczVSV-G 
Vesicular stomatitis virus glycoprotein 
expression vector 
Gift from Jonathan Stoye 
pMoSAF MLV ecotropic Env expression vector Gift from Harriet Groom 
pS15-mCherry 
Mammalian expression vector for the first 
15 amino acids of c-src fused to mCherry 
Gift from Ed Campbell 
pCMVTagcherryPaisy 
mCherry-paisy fusion mammalian 
expression vector 
Gift from Kate Bishop 
pCMVTagcherry 
mCherry-linker fusion mammalian 
expression vector 
Gift from Kate Bishop 
pCMVcherry-p12 
mCherry-p12 fusion mammalian 
expression vector 
p12 PCR amplified from pKB4 using 
primers oKB130-p12 for (5'-
CTGAATTCccagccctcactccttctctag) 
and oKB131-p12 rev (5'-
CTACTCGAGtcagaatgcctgcgaggtagt
g). Digested with EcoRI and XhoI 
and ligated into pCMVcherry-paisy 
pCMVcherry-Np12 
mCherry-Np12 fusion mammalian 
expression vector 
Site directed mutagenesis of 
pCMVcherry-p12 
pCMVcherry-Cp12 
mCherry-Cp12 fusion mammalian 
expression vector 
Site directed mutagenesis of 
pCMVcherry-p12 to insert EcoRI site 
in p12. Digested out 5' p12 
sequence with EcoRI digest 
pKB4/Ga-p12 
Mo-MLV Gag-Pol expression vector with 
GaLV p12 in place of MLV p12 
Overlapping extension PCR 
pKB4/Ga-p12-CL 
Mo-MLV Gag-Pol expression vector with 
GaLV p12 in place of MLV p12 and 
insertion L between A2 and L3 
Site directed mutagenesis of pKB4/Ga-
p12 
pKB4/Ga-Np12 
Mo-MLV Gag-Pol expression vector with 
GaLV p12 N-terminus of in place of MLV 
p12 N-terminus 
Overlapping extension PCR 
pKB4/Ga-Np12-CL 
Mo-MLV Gag-Pol expression vector with 
GaLV p12 N-terminus of in place of MLV 
p12 N-terminus and insertion L between A2 
and L3 
Site directed mutagenesis of pKB4/Ga-
Np12 
pKB4/Ga-Cp12 
Mo-MLV Gag-Pol expression vector with 
GaLV p12 C-terminus of in place of MLV 
p12 N-terminus 
Overlapping extension PCR 
pczGaLVgp BsX 
GaLV Gag-Pol expression vector with 
BsrGI site 5' to gag introduced and XhoI 3' 
to pol removed 
Site directed mutagenesis of pczGaLVgp 
pczGaLV/Mo-p12 
GaLV Gag-Pol expression vector with Mo-
MLV p12 in place of MLV p12 
Overlapping extension PCR 
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pczGaLV/Mo-Np12 
GaLV Gag-Pol expression vector with Mo-
MLV p12 N-terminus in place of GaLV p12 
N-terminus 
Overlapping extension PCR 
pczGaLV/Mo-Cp12 
GaLV Gag-Pol expression vector with Mo-
MLV p12 C-terminus in place of GaLV p12 
C-terminus 
Overlapping extension PCR 
pczGaLV/Mo-p12 
GaLV Gag-Pol expression vector with Mo-
MLV p12 in place of MLV p12 with 5' BsrGI 
removed 
Site directed mutagenesis of 
pczGaLV/Mo-p12 
pczGaLV/Mo-Np12 
GaLV Gag-Pol expression vector with Mo-
MLV p12 N-terminus in place of GaLV p12 
N-terminus with 5' BsrGI removed 
Site directed mutagenesis of 
pczGaLV/Mo-Np12 
pczGaLV/Mo-Cp12 
GaLV Gag-Pol expression vector with Mo-
MLV p12 C-terminus in place of GaLV p12 
C-terminus with 5' BsrGI removed 
Site directed mutagenesis of 
pczGaLV/Mo-Cp12 
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Appendix C-E: Legends 
 
Appendix C: Live imaging of mCherry and mCherry-p12 expressed in mammalian cells. 
M.dunni cells were transfected with (C1) mock, (C2) mCherry or (C3) mCherry-p12 expression 
constructs and imaged from 12 hours post-transfection every 5 minutes for over 21 hours. 
Representative movies are shown. The fluorescent intensities of the mCherry signal are scaled 
by the same values between movies. 
 
Appendix D: Live imaging of cells infected with GFP-p12 labelled Mo-MLV VLPs. U/R 
cells expressing H2A-RFP were transfected with S15mCherry (to mark the membrane) and 
infected with Mo-MLV VLPs labelled with GFP-p12. Movie (D1) shows the three types of 
GFP-p12 movements. In the red box- direct movements, the blue box- fast uncoordinated 
movements and the magenta box- still, shaky movements. Representative movies of early 
infections (20 minutes to 1 hour post-infection) and late infections (20-26 hours post-infection) 
with Mo-MLV containing: (D2 and D3) wild type p12; (D4 and D5) p12 mutant 5; (D6 and D7) 
p12 mutant 6; (D8 and D9) p12 mutant 7 and (D10 and D11) wild type p12 but no Env are 
shown. All fluorescent intensities were scaled by values to highlight signal over noise but are 
not equal between samples. 
 
Appendix E: Live imaging of CA-YFP labelled Mo-MLV. U/R cells expressing H2A-RFP 
were infected with Mo-MLV labelled with CA-YFP. In (E1) movements of wild type Mo-MLV 
CA-YFP at 1 hour post-infection are shown. Note- the nucleus has been drawn in this movie 
from an image of H2A-RFP signal before the movie was recorded. (E2) shows a representative 
movie of wild type Mo-MLV CA-YFP docked on the mitotic chromatin early after infection. 
(E3) shows a representative movie of wild type Mo-MLV CA-YFP docked on the mitotic 
chromatin 18 hours post infection. (E4) shows a representative movie of wild type Mo-MLV 
GFP-p12 docked on the mitotic chromatin early after infection. All fluorescent intensities were 
scaled by values to highlight the signal over background noise but are not equal between 
samples. 
 
 
 
